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ABSTRACT
The human cytomegalovirus (CMV) can cause significant morbidity and mortality in 
haematopoietic stem cell transplant (HSCT) patients. The immunosuppressed state of 
the hosts facilitates dissemination of the virus and disease. In contrast, CD8^ T cells in 
healthy individuals control viral dissemination and maintain a balance between antiviral 
host defence and replication of the virus that leads to viral latency with sporadic, 
harmless reactivations.
Current pharmacological intervention in the HSCT setting is associated with 
significant toxicity and is counteracted by the occurrence of resistant viral strains. 
Alternative approaches, such as adoptive therapy of CMV specific CD8^ T cells are of 
great interest in the field. So far, levels of such cells correlating with protection against 
CMV disease in patients were only shown for cells targeting two different viral 
epitopes.
The project described in this thesis investigates CD8^ T cell responses to several 
common CMV targets presented by different human leukocyte antigens in the HSCT 
setting. Results demonstrate significant differences between the numbers of different 
CMV specific CD8^ T cells that, in the presence of CD4^ T cell help, inversely correlate 
with the ability to detect CMV reactivation. Findings also demonstrate significant 
differences in the diversity of T cell receptors (TCRs) used by the different CMV 
specific CD8^ T cells isolated from HSCT patients.
These findings are clinically relevant in that the quantity of cells shown to 
correlate with protection against CMV could be used as a marker for monitoring 
patients' immune status towards CMV. This may aid clinical decision making to limit 
pharmacological intervention to those patients at highest risk for the development of 
CMV disease. It may also aid the monitoring of the effectiveness of adoptive therapy 
trials. Therapeutic use of cells with high TCR diversity may be advantageous over other 
cells in that they may impede the development of CMV immune escape in patients.
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CHAPTER 1 INTRODUCTION
The English scientist Dr. James Ephraim Lovelock once said “An inefficient virus kills 
its host. A clever virus stays with i t”. The human cytomegalovirus (CMV) is an ancient 
virus, which is well adapted to its host. It has evolved strategies to avoid its elimination 
and can exist in a latent form in individuals. Nevertheless it is not adapted to artificial 
circumstances brought by recent medical advances and can cause significant morbidity 
and, in some cases, mortality in patients who received immunosuppressive conditioning 
prior to haematopoietic stem cell transplantation (HSCT).
The project described in this thesis investigates immune responses to CMV in 
the HSCT setting, where clinical intervention is needed to restore the balance between 
virus and host. This chapter will introduce background information on some features of 
CMV, the human immune response to the virus and particularly its cellular 
compartment, immune evasion strategies evolved by CMV, HSCT and the role of CMV 
in the transplant setting as well as other information directly relevant to this 
investigation. Attention is focused on CMV specific CD8^ T cells that may be used for 
adoptive immunotherapy and whose monitoring may be clinically advantageous during 
periods of immunodeficiency in HSCT patients. This chapter will also explain the 
choice of CD8^ T cells that were studied within this project.
1-1 Cytomegalovirus infection
The human Cytomegalovirus is also called human herpesvirus 5 (HHV-5). It is a 
ubiquitous B-herpesvirus (genus Cytomegalovirus (CMV), family Herpesviridae, 
subfamily Betaherpesvirinae) with a diameter of about 200 nm. It is a deoxyribonucleic 
acid (DNA) virus with the typical herpes virion structure as illustrated in Figure 1-1.
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Figure 1-1 Structure of Cytomegalovirus
Left: m odel o f  C M V  virion  adapted w ith perm ission  from Dr. M R eschke
(h ttp ://w w w .b iografix .de); right: Electron m icroscop ic im age o f  a herpes virion (c: capsid , t: 
tegum ent; e: lipid en velope; bar =  100 nm ) adapted from (M cG eoch  et  a l ,  2 0 0 6 ) w ith  
perm ission from  the author.
Its double stranded DNA ranks amongst the largest of all DNA virus genomes 
containing more than 200 open reading frames (Chee et a l,  1990). The genome size 
varies in different strains. The low passage strain Merlin is 236 kilobase (kb) in size 
(Dolan et a l,  2004) whereas high passage strains have smaller genomes with AD 169 
and Towne containing 230 kb (Murphy et a l,  2003). The genome structure consists of 
two separate regions, the unique short and unique long sequences (US and UL 
respectively), which are flanked by terminal and internal repeats. In some laboratory 
strains repeats consist of the terminal repeat long (TRL), the terminal repeat short (TRS) 
and the two internal, inverted repeats (IRL and 1RS), which allow viral progeny to 
contain four isomers, each differing in the orientation of the UL and US components to 
one another (Kilpatrick and Huang, 1977). Clinical isolates contain an additional DNA 
segment (UL133 - 151) and lack an IRL repeat (Murphy et a l,  2003). The CMV DNA 
is surrounded by a capsid consisting of 162 capsomeres (Wright et al, 1964) arranged 
in an icosahedral structure (a polyhedron having 20 faces, usually regular: with 
equilateral triangles as faces). This nucleocapsid is surrounded by the tegument 
composed of phosphoproteins, which is enclosed by a host derived lipid bi-layer 
envelope spiked with viral proteins that are usually glycosylated and can be categorised 
into three families, the glycoprotein complexes (gC) 1, gCll and gClll. The envelope is 
acquired during the life cycle of the virus as illustrated in Figure 1-2.
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Figure 1-2 CMV lytic cycle
CM V attaches by tethering (1 ) to cell surface heparan sulfate proteoglycans (H S P G ) via its 
glycoproteins (Com pton et  a l ,  1993) resulting in clustering with other receptors o f  w hich  
suggested  candidates are am inopeptidase N  (C D 13) (Soderberg et  a l ,  1993) and epiderm al 
growth factor receptor (E G FR ) (W ang et  a l ,  2003). Post attachm ent integrin interaction (Feire  
et  a l ,  2 0 0 4 ) (2) helps the viral en velop e to fuse with the plasm a m em brane o f  the cell (3). The 
binding o f  C M V  also  triggers an inflam m atory response via T o ll-lik e  receptor (T L R ) 2 and 
C D 14 (Com pton et  a l ,  20 0 3 ). T he viral capsid containing the gen om e and tegum ent proteins 
enters the cytoplasm . The capsid  then travels along m icrotubules (4 ) towards the nucleus, 
where uncoated viral D N A  enters through nuclear pores (5 ) and circularises (6 ). Viral D N A  is 
transcribed in the nucleus, m essenger ribonucleic acid (m R N A ) is transported to the cytoplasm  
for translation o f  proteins that then travel back to the nucleus or are delivered  from  the 
endoplasm atic reticulum  (ER ) to the G olgi apparatus. Transcription occurs in a cascade w ith  
im m ediate-early (IE) transcripts (7 ) triggering transcription o f  early (E ) gen es ( 8 ), w hich  
am ongst other functions participate in viral D N A  replication (9 ) and trigger transcription o f  
late (L ) gen es (10 ), w hich am ongst other functions provide capsid proteins. Encapsidation o f  
D N A  and assem bly o f  n ucleocapsids in the nucleus (11 ) are fo llow ed  by primary envelopm en t 
in the perinuclear space (12), w hich expands into the ER. The temporary en velop e acquired  
during budding into the inner nuclear en velop e is lost by fusion  with the outer nuclear 
en velope. N aked capsid  subsequently progresses through the cytoplasm  and buds into G olgi 
vesic les laden with viral proteins. This process provides the d evelop in g  virion w ith tegum ent 
proteins ( • ) ,  an en velop e (--)  and surface g lycoproteins ( •  • )  (13). The G olgi ves ic le  
delivers the new  virion to the ce ll surface, w here it fuses w ith the cell m em brane releasing new  
in fectious virus (14). This figure w as created based on inform ation from  (B oeh m e, 2 0 0 6 , 
M ocarski, 2 006 , M ocarski, 2007 ).
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Virus penetration can occur in permissive and non-permissive cells alike but viral gene 
expression only occurs in permissive cells. After infection, the viral genome expresses 
genes in three overlapping phases including immediate early (IE, within the first two 
hours), early (E, within less than 24 hours) and late (L, after 24 hours) genes in host 
cells (Stinski, 1978). IE (or alpha) gene products are required for the trans-activation of 
E (or beta) gene. E (beta) gene-encoded proteins, in turn, are necessary for viral DNA 
replication. L (gamma) genes are primarily expressed following the onset of viral DNA 
replication and include genes encoding structural components of the virion. DNA 
replication in herpesviruses is thought to proceed as a biphasic process. Origin-specific 
initiation on a circularized input genome leads to an early, theta mechanism that results 
in the production of circular episomes. Replication later undergoes a switch to a rolling- 
circle form of replication. This results in the production of linear concatemeric 
genomes, which are cleaved and incorporated into virions. This form of replication is 
responsible for the bulk of viral DNA produced during infection. (Lehman and 
Boehmer, 1999)
The phosphoprotein 65 (pp65) is one of the late expressed tegument proteins but 
is already transferred into cells with the CMV virion at the onset of infection before 
viral gene expression is initiated (Greffe et a l,  1992, Riddell et a l,  1991a). The protein 
is therefore widely used in the diagnosis of CMV infection and is thought to be one of 
the main targets of the CDS^ T cell response against CMV, which will be described in 
more detail later.
CMV infected cells appear round and enlarged with intracellular inclusion 
bodies (Albrecht and Weller, 1980) as shown in Figure 1-3. These features were 
initially described as cytomegalic inclusion disease. The name cytomegalovirus was 
later used to reflect the cellular changes caused by the virus.
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Figure 1-3 Characteristic appearance of CMV infected cells
H aem atoxylin  and eosin  (H & E) stain o f  lung section  (4 8 0 x ) adapted w ith perm ission  from  
Dr. D . L. W iedbrauk (h ttp://w w w .m icrobelibrary.org). This stain dem onstrates b lue colouring  
o f  basophilic structures such as nucleic acids by haem atoxylin  and pink co louring o f  
eosin op h ilic  structures such as proteins by eosin  (red b lood  ce lls  are stained red). An enlarged  
C M V  infected cell can be seen  at the right part o f  the figure. The stain sh ow s the form ation o f  
characteristic intranuclear in clu sion s (called  o w l’s ey e s)  in the infected cell as w ell as capsids  
form ed in the cytoplasm .
Cytomegaloviruses are highly species specific, which is indicative of a long co­
evolution with its host. Human CMV productively infects a number of human cell types 
including fibroblasts, endothelial cells, epithelial cell and smooth muscle cells (Plachter 
et a l,  1996). After a lytic cycle (Figure 1-2), it usually establishes lifelong latency 
(Sissons et a l,  2002) during which CMV is kept firmly under control by persisting 
humoral and cell-mediated immune responses (Zanghellini et a l,  1999). Latency is a 
typical characteristic of all herpesviruses, during which the viral genome persists in 
specific host cells in the absence of any detectable production of infectious virus but 
with the ability to reactivate under specific stimuli. Along with infection of immune 
privileged sites such as retinal pigment epithelium (Scholz et al,  2003) latency is one of 
a vast variety of immune evasion strategies (compare section 1-6 and 1-9.3) ensuring 
virus survival within the host. Host cells latently infected with CMV demonstrate 
altered expression of genes affecting functions such as immunity, cell growth, 
signalling and transcriptional regulation that may confer a survival advantage to the 
virus during latency or during the initial steps of virus reactivation (Slobedman and
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Mocarski, 1999). CMV latency is established in bone marrow derived myeloid 
precursors and the virus persists as a circular plasmid in CD34^ bone marrow 
progenitors, peripheral blood monocytes (Bolovan-Fritts et a l,  1999, Hahn et a l ,  1998, 
Mendelson et a l ,  1996, Taylor-Wiedeman et a l ,  1991) and possibly endothelial cells 
(Jarvis and Nelson, 2002). Since CMV can persist in myeloid progenitor cells, these can 
serve as a renewable primary reservoir for latent virus. It has been shown that once the 
myeloid cells differentiate into macrophages they reactivate viral IE gene expression 
(Taylor-Wiedeman et a l ,  1994). Differentiation of CD34^ bone marrow progenitors 
into mature dendritic cells (DC) also results in reactivation of IE genes and production 
of infectious CMV (Reeves et a l,  2005).
Latency is regulated by the CMV major immediate-early promoter (MIEP), 
which is repressed by binding of cellular transcriptional repressors that recruit enzymes 
modifying histones bound to the MIEP. Reactivation of CMV is concomitant with 
chromatin remodelling of the MIEP into a transcriptionally active state (reviewed in 
(Sinclair and Sissons, 2006)). Reactivation of CMV from latency and replication of 
CMV can be triggered by an inflammatory environment induced by cytokines (Kline et 
a l,  1998) or allogeneic stimulation (Soderberg-Naucler et a l,  1997).
It results in production of infectious virions, which are shed from mucosal 
surfaces and ensure spread of the virus between different hosts. CMV can be 
transmitted from mother to foetus or from person to person by saliva, sexual contact, 
breast-feeding, blood transfusion or transplantation of solid organs or haematopoietic 
stem cells. The virus is present in 40 - 100 % of individuals depending on different 
socio-economic regions ranging from highly developed areas to developing countries 
(Krech, 1973). In Europe and the USA previous CMV infection can be demonstrated in 
up to 80 % of healthy individuals by persisting titres of CMV specific Immunoglobulin 
(Ig) G (Gershon AA, 1997, Ho, 1991). The equilibrium between viral immune escape 
strategies and effective immune responses in healthy hosts results in generally 
asymptomatic infection with periodic chronic low-grade reactivation linked to stress 
events (Docke et a l,  1994, Toro and Ossa, 1996). The host’s cytotoxic T cell response 
acts efficiently to clear productively infected cells thereby maintaining viral latency in 
immunocompetent hosts. However, uncontrolled CMV replication in the absence of an 
effective immune response fosters viral dissemination resulting in disease.
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Accordingly CMV is one of the leading infectious causes of birth defects and a major 
opportunistic pathogen in patients with acquired immune deficiency syndrome (AIDS) 
as well as in otherwise immunosuppressed individuals such as recipients of organ and 
haematopoietic stem cell transplantations (HSCT).
1-2 Haematopoietic stem ceii transpiantation (HSCT)
HSCT has been established as an important treatment modality for patients with 
haematological diseases. It is based on destruction or significant reduction of 
haematopoietic cells using cytotoxic drugs and/or total body irradiation (conditioning) 
followed by haematological reconstitution from donor haematopoietic stem cells (HSC).
Reconstitution of the T cell compartment occurs through two main pathways. In 
addition to thymus dependent generation of new T cells derived from stem cells, 
reconstitution can also occur through thymus independent expansion of mature T cells 
(Fry and Mackall, 2005). Although homeostatic proliferation of T cells is tightly 
regulated under normal conditions, under conditions of lymphopenia, cells can divide 
until the cellularity of the T cell compartment has been restored (Crooks et a l , 2006, 
Goldrath et a l , 2000).
With the exception of memory lymphocytes that can persist for several years, 
most mature blood cells are short lived. They develop from pluripotent stem cells that 
have the capacity for self-renewal and can give rise to multilineage progenitors. 
Multilineage progenitors in turn produce progenitor cells that are committed to produce 
blood cells of individual haematopoietic lineages. Therefore HSC can differentiate to all 
blood cell lineages (reviewed in (Orkin and Zon, 2008)). HSC and their capacity to 
renew lethally damaged blood cells were first experimentally explored after the first 
atomic bomb explosions in 1945 (reviewed in (Little and Storb, 2002)). E. D. Thomas 
pioneered the application of the results from early animal studies to the transfer of stem 
cells to cancer patients with malignant stem cells (which are quiescent and therefore 
insensitive to conventional chemotherapy) from the 1950s onwards (Thomas et a l ,  
1957).
Today the transplantation of HSC is used as a therapy for life threatening 
congenital or acquired disorders of the haematopoietic system including various 
malignant and non-malignant diseases. Many if not most of these transplantations are 
performed for haematologic and lymphoid cancers. HSC can be harvested from three 
sources. Traditionally, HSC are located in the bone marrow (BM) and can be harvested
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from the centre of a bone, typically the pelvis. Since HSC circulate between BM and 
blood in a circadian pattern (Mendez-Ferrer et a l ,  2008) and granulocyte colony 
stimulating factor (G-CSF) treatment can mobilise HSC into the blood stream, 
peripheral blood stem cells (PBSC) can also be directly harvested from withdrawn 
blood. Transplants with PBSC are more convenient and have replaced BM 
transplantation in many instances. Alternatively umbilical cord and placenta can be used 
to harvest cord blood (CB) stem cells. CB transplants were demonstrated to require less 
stringent HLA matching with low incidences of graft versus host disease (GvHD, this 
term will be explained in detail later) but they result in slower reconstitution and are 
often limited in pluripotent stem cell dose (Rocha and Gluckman, 2006, Wagner et a l , 
2002). Therefore the use of additional grafts can be beneficial for successful 
engraftment (Barker et a l,  2005). HSC can be used for autologous (from the patient’s 
own HSC that may be purged of residual diseased cells, for example by antibody 
treatment) or allogeneic (from another person’s HSC) HSCT. (reviewed in (Copelan, 
2006))
Allogeneic donors include related donors (including syngeneic donor, that is an 
identical twin) or unrelated volunteers from donor registries such as the Anthony Nolan 
Trust. The match of the major histocompatibility complex (MHC) (which is called 
Human leukocyte antigen (HLA) in human cells) in donor and recipient 
(histocompatibility) greatly influences the risk of the transplantation (Flomenberg et a l , 
2004). As will be described in more detail in section 1-6, T cells recognise antigen in 
form of peptides presented on HLA molecules. HSCT recipient T cells may recognise 
foreign donor antigens and reject grafts. Donor T cells may recognise recipient antigens, 
which can result in graft versus tumour effects in leukaemic patients but also graft 
versus host disease. To keep the risk of an allogeneic HSCT at minimum, the HLA 
tissue types of donors and patients are matched as closely as possible. Therefore 
sensitive HLA typing of major HLA class I (HLA-A, HLA-B and HLA-C) and major 
HLA class II (HLA-DR, HLA-DQ and HLA-DP) is usually performed at the molecular 
level. HLA are polymorphic proteins. The loci encoding these major HLA have each up 
to several hundred variants in their DNA sequence, which are called HLA alleles. A 
series of these HLA alleles on a chromosome is called HLA haplotype of which each 
individual has two (passed from their mother and father respectively) that make up their 
HLA tissue type. Known HLA alleles are updated by the Anthony Nolan Research 
Institute in the IMGT/HLA database, which is part of the international 
ImMunoGeneTics (IMGT) project (http://imgt.cines.fr). Data on known HLA alleles are
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integrated into software tools that allow assessment of histocompatibility between any 
of the HLA class I and II alleles (Eisner et al., 2004).
However, GvHD or graft rejection also occurs in patients that receive HSCT 
from donors who (according to current standards) are fully HLA matched and can be 
caused by minor histocompatibility antigens. These are proteins other than the MHC, 
which are nevertheless also polymorphic and can therefore be different in patient and 
donor. Y chromosome encoded minor histocompatibility antigens are the cause for 
observations of higher incidences of GvHD in men receiving an HSCT from female 
donors than those receiving it from male donors (Vogt et a i,  2002). The potential 
exposure to fetal antigens during pregnancy may additionally increase the risk of GvHD 
in HSCT recipients receiving grafts from a female donor that had been pregnant 
previously. Polymorphic genes encoding killer-immunoglobulin-like receptor (KIR) 
ligands (Miller et a l ,  2007) or others involved in immune responses and particularly 
cytokines can impact upon GvHD (Cavet et a l,  2001).
GvHD can occur following transfer of viable donor lymphocytes into 
immunocompromised or closely HLA-matched recipients and is commonest following 
allogeneic HSCT. It involves the attack of recipient tissue cells by donor derived T cells 
that recognise antigenic disparities between donor and recipient.
Acute GvHD (aGvHD) occurs within the first 100 days after transplantation. It 
is initiated (first phase) by the pre-transplant conditioning, which damages host tissues 
and results in activation of antigen presenting cells (AFC) and their subsequent release 
of inflammatory cytokines (Xun et a l,  1994). These include interleukin 1 (ILl), IL6, 
interferon Y (IFNy) and tumour necrosis factor a  (TNFa), which can result in up- 
regulation of adhesion molecules and host major histocompatibility complex (MHC) 
antigens, thereby enhancing the recognition of host tissue by donor T cells. The pre­
transplant conditioning additionally causes damage to endothelial and epithelial cells 
such as the intestinal mucosa (Eissner et a l , 1995), which enables bacterial products to 
translocate from the intestines, which in turn results in release of additional ILl and 
TNFa (Nestel et a l,  1992).
This first phase of aGvHD is self-limited in autologous HSCT but in allogeneic 
HSCT it can be followed by a second phase, in which donor T cells, which are 
stimulated by the inflammatory environment, recognise alloantigens. This can be 
achieved via two different pathways. The direct pathway involves recipient antigen
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presentation by recipient APC (Shlomchik et a l,  1999) whereas the indirect pathway 
involves recipient antigen presentation by donor APC (Matte et a l , 2004).
Alloantigen recognition, in turn, results in the third phase of aGvHD comprising 
T cell secretion of IL2 and IFNy, which can result in the recruitment of more T cells, 
natural killer (NK) cells, monocytes and macrophages. Primed mononuclear cells 
finally secrete more ILl and TNFa leading to a new inflammatory cycle (cytokine 
storm) and contributing directly to cellular damage or apoptosis. (reviewed in (Antin 
and Ferrara, 1992, Krenger et a l,  1997))
Chronic GvHD (cGvHD) is defined as occurring later than 100 days post HSCT 
either after acute GvHD or without previous aGvHD symptoms. At this time 100 % 
chimaerism of skin APC has been demonstrated suggesting that cGvHD involves 
indirect recipient antigen presentation by donor APC (Shlomchik et a l,  1999). Chronic 
GvHD is a multi-organ disease, which can be graded according to its severity. In its 
severe form it carries a high risk of death due to infectious complications, bone marrow 
and multi-organ failure.
The risk of GvHD is influenced by the type of transplant and genetic differences 
between patient and donor as described earlier. It is also greatly influenced by the 
conditioning regimen received by patients. Traditionally conditioning was 
myeloablative (destructing the recipients bone marrow activity). Regimens included 
high dose total body irradiation (TBI) or fractionated (less toxic) TBI in combination 
with cyclophosphamide (an alkylating agent, whose metabolite forms DNA crosslinks 
leading to cell death), cyclophosphamide combined with busulfan (alkylating agent) or 
BEAM (consisting of the carmustine 1,3-bis (2-chloroethyl)-1 -nitroso-urea (BCNU, 
alkylating agent), etoposide (inhibitor of the enzyme topoisomerase II that is involved in 
DNA replication, its cytotoxic effect results from inhibiting or altering DNA synthesis), 
cytarabine (a synthetic pyrimidine nucleoside, whose metabolite can inhibit DNA 
polymerase via competition with deoxycytidine triphosphate, incorporation into DNA 
and RNA may also contribute to the cytotoxic effect) and melphalan (alkylating agent)). 
Since the 1990s HSCT was also performed with non-myeloablative regimens (reviewed 
in (Mackinnon et a l ,  2004)). This reduced intensity conditioning (RIC) is less toxic and 
primarily immunosuppressive. HSCT performed with RIC enables the treatment of 
patients, including those with myeloma (Peggs et a l,  2003a), myeloid leukaemia and 
myelodysplastic syndrome (Tauro et a l ,  2005), Hodgkin’s Disease (Thomson et a l ,  
2008) and Non-Hodgkin’s lymphoma (Peggs et a l ,  2005b), some of whom were too
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unfit to endure the toxicity of myeloablative conditioning and therefore could not be 
treated with HSCT previously. They use lower doses of chemo-radiotherapy within 
conditioning regimens aimed at achieving a mixed chimaerism in the patients’ 
haematopoietic cells and rely on eradication of tumours by the graft versus tumour 
effect of donor T cells from the graft or additional donor lymphocyte infusions (DLI) 
(Bloor et a l,  2008, Peggs et a l ,  2005a, Peggs et a l ,  2007) (reviewed in (Peggs and 
Mackinnon, 2001b, Peggs and Mackinnon, 2001a)). Conditioning included the 
immunosuppressive agent fludarabine (adenine analogue) given before low dose TBI or 
different combinations of fludarabine, cyclophosphamide and melphalan (Einsele et a l , 
2003, Peggs et a l ,  2004, Perez-Simon et al,  2003). The choice of conditioning in 
recent HSCT depends on the type of underlying disease as well as the age and co­
morbidity and therefore tolerance to toxicity by the patients, (reviewed in (Copelan,
2006) and (Hart and Peggs, 2007))
GvHD prophylaxis can be achieved by administration of immunosuppressive 
drugs. Most commonly used are methotrexate (MTX), which inhibits cellular 
proliferation; cyclosporine A (CSA), which suppresses antigen induced transcription of 
the IL2 gene and corticosteroids, such as prednisolone, which can reduce several 
immune responses involved in GvHD pathogenesis.
More specifically, MTX is a folic acid antagonist that inhibits the enzyme 
amidophosphoribosyltransferase that is involved in purine ribonucleotide synthesis. Its 
action as a decoy substrate inhibits critical biochemical reactions, thereby exhibiting a 
cytostatic effect on proliferating cells but also inducing renal, hepatic and 
gastrointestinal toxicity (Fairbanks et a l,  1999).
CSA is a cyclic peptide composed of 11 amino acids, which can be extracted 
from fungi. It binds to cyclophilin and thereby inhibits calcium-induced activation of 
the enzyme calcineurin. Calcineurin is a key enzyme involved in the signal transduction 
pathway resulting in IL2 expression for the activation of several immune cells such as 
T cells (Wiederrecht et a l,  1993).
Prednisolone and its pro-drug prednisone are steroid hormones, more 
specifically glucocorticoids, which are involved in a wide range of physiologic systems. 
Steroid hormones are characterised by their three hexane and one pentane ring. The 
principal naturally occurring glucocorticoid is cortisol, which is derived from 
cholesterol, synthesised and secreted by cells in the adrenal gland and regulated by 
negative feedback mediated via the hypothalamic-pituitary-adrenal (HPA) axis by
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occupancy of its receptor. Although activity via membrane receptors is possible 
(Bartholome et a l ,  2004), the glucocorticoids mostly act via cytosolic receptors. The 
hormone can passively diffuse across cell membranes, where it activates its main 
receptor, the glucocorticoid receptor (GR), which upon dimérisation translocates to the 
nucleus where it can bind to specific glucocorticoid response elements (GRE) and 
regulate transcription of a number of genes. GR is expressed at different levels in all 
cell types. The synthetic glucocorticoid prednisolone is four times more potent in its 
anti-inflammatory effect than cortisol. This anti-inflammatory effect is achieved by 
blocking synthesis of proinflammatory cytokines and their effects such as the Janus 
kinases - Signal Transducers and Activators of Transcription (Jak-STAT) signalling 
pathway, inhibition of proliferation or apoptosis of immune cells, inhibition of antigen 
processing and reduction of adhesion molecules as well as repressing transcription 
factors such as the nuclear factor-kappa B (NF-kB), which explains their effect on 
genes without GRE in their promoters (reviewed in (Cole, 2006) and (Webster et a l , 
2002)) However, the broad range of effects mediated by glucocorticoids also results in a 
variety of adverse effects including cutaneous side effects, wound healing disorders, 
growth failure, osteoporosis, adverse effects on the eyes such as cataract or glaucoma, 
diabetes, cardiovascular effects such as hypertension, weight gain and neuropsychatic 
symptoms (Schacke et a l ,  2002).
In addition to MTX, CSA and corticoids, GvHD prophylaxis or treatment can 
also be achieved by administration of alternative immunosuppressive drugs. These 
supplementary pharmaceuticals include tacrolimus (FK506), which is structurally 
different but acts in a similar way as CSA (Peters et a l ,  1993); sicrolimus (rapamycin), 
which is a structural analogue of FK506 binding to the same immunophilin but acting at 
a later stage in T cell cycle progression by blocking cytokine-mediated signal 
transduction pathways (Sehgal, 1995); and mycophenolate mofetil (MMF). The latter 
inhibits de novo synthesis of guanosine monophosphate (Allison et a l,  1993). This, in 
turn leads to decreased levels of guanosine triphosphate and hence deoxyguanosine 
triphosphate (Allison and Eugui, 2000). This results in a cytostatic effect on cells, which 
is most pronounced in T cells as they require de novo synthesis of purine nucleotides 
(Allison and Eugui, 2005). Other treatments tested for steroid refractory GvHD include 
daclizumab (a humanised monoclonal antibody to the IL2 receptor) (Perales et a l,
2007), extracorporeal photopheresis (EPE) (Setterblad et a l,  2008), infliximab (anti- 
TNFa monoclonal antibody) (Sleight et a l,  2007), thalidomide (Kulkami et a l ,  2003) 
and clofazimine (Rzepecki et a l , 2007).
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All of the pharmaceuticals mentioned above are associated with severe adverse effects 
(such as effecting the thymus) and morbidity. The most effective means of reducing 
GvHD development is T cell depletion (TCD) of the graft but TCD may also lead to 
increased graft failure, Epstein-Barr virus associated lymphoproliferative disorders and 
disease recurrence after bone marrow transplantation (relapse) due to the elimination of 
the graft versus tumour response. TCD can be achieved by ex vivo or in vivo 
administration of a humanised monoclonal antibody directed against cluster of 
differentiation 52 (CD52), also called Alemtuzumab or Campath-IH (Kottaridis et a l,  
2000, Kottaridis et a l,  2001) or antithymocyte globulin (ATG) (Kroger et a l,  2005). 
An indirect form of TCD is graft selection for CD34 expressing progenitor cells.
Immunosuppression resulting from the conditioning or post transplant 
immunosuppressive treatment employed for the prevention or treatment of GvHD give 
rise to a high risk of infectious complications after HSCT. Bacterial sepsis can occur 
early in the course of transplantation whereas viral infections such as those caused by 
CMV usually occur after engraftment. Fungal infections such as those caused by 
aspergillus may occur after the onset of neutropenia until engraftment. Early recognition 
and treatment of these infections are vital. Following engraftment, the ongoing risk of 
infection relates to the degree of immunosuppression.
1-3 The role of CMV in HSCT
Latent CMV infection is frequently reactivated post HSCT. In 1999 the risk of CMV 
antigenaemia (which is a measure of CMV replication, see section 1-5) at 1 year post 
HSCT from sibling donors was reported to be between 61 % and 69 % with antiviral 
prophylaxis using aciclovir or foscamet (compare section 1-4) respectively (Bacigalupo 
et a l ,  1999). In comparison, 4 0 - 4 5 %  (depending on whether grafts were T cell 
depleted or not) of recipients of autologous HSCT experience episodes of CMV 
infections as measured by DNAemia (Peggs et a l,  2003d). The most serious of the 
manifestations of CMV is pneumonia, which is more frequent post allogeneic than 
autologous HSCT (Enright et al,  1993). Despite treatment 6.3 % of allogeneic HSCT 
patients still developed CMV pneumonia at a mean of 188 days after transplantation and 
with an associated mortality rate of 76%  (Nguyen et a l,  1999). Overall, similar 
percentages (24 % and 25 %) of CMV seropositive (and thereby high-risk) patients 
undergoing either reduced-intensity or myeloablative HSCT may still develop CMV 
disease by one year post transplantation despite preventative measures (Junghanss et a l ,
2002). Therefore potential HSCT donors and recipients are typed for their CMV status.
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In cases where only a CMV seropositive donor can be found for a CMV seronegative 
patient, the exclusive use of blood products that have been leukocyte depleted 
diminishes the risk of primary infection.
Inflammation induced by the conditioning prior to HSCT (described above) can 
activate transcription factors such as NFkB, which stimulate the CMV MIEP and allow 
viral reactivation from latency (Fietze et a l,  1994).
Immunological impairment due to conditioning for HSCT upsets the balance 
between viral immune escape strategies and effective immune responses in the 
transplant recipient (compare sections 1-6 and 1-9). During the first months post 
allogeneic HSCT two thirds of patients fail to develop a protective CD8^ T cell 
response against CMV. They are at risk of CMV reactivation. Dissemination of CMV in 
the blood and subsequent infection of multiple organs contribute to CMV pathogenesis 
and can cause fatal pneumonia, myelosuppression, gastroenteritis, retinitis, myelitis and 
occasionally graft failure (Sissons and Carmichael, 2002). A large number of autograft 
transplant recipients restore CMV specific T cell responses during the first 3 months 
and are therefore susceptible to infection for a shorter time period after transplantation 
than allograft recipients (Reusser et a l,  1997).
CMV pathology occurs through a number of direct and indirect effects. It has 
been implicated in allograft rejection secondary to up-regulation of adhesion molecule 
expression and cytokine secretion in response to CMV infection. Up-regulation of the 
intercellular adhesion molecule 1 (ICAM-1) and the lymphocyte function-associated 
antigen 3 (LFA-3) by CMV has been demonstrated and is accentuated rather than 
abrogated by the antivirals ganciclovir and foscarnet (Craigen and Grundy, 1996). Up- 
regulated secretion of proinflammatory cytokines such as IL6 by CMV infection was 
also demonstrated (Carlquist et a l,  1999). This can result in further up-regulation of 
adhesion molecules and MHC antigens, thereby enhancing the recognition of host tissue 
by donor T cells.
During prolonged immunosuppression, lytic CMV infection can lead to loss of 
tissue function resulting in interstitial pneumonitis, hepatitis or gastrointestinal disease 
(Peggs and Mackinnon, 2004b). This pathogeneicity can be further enhanced by viral 
induced inflammation. CMV disease can also result in retinitis (Crippa et a l,  2001) and 
rarely encephalitis (Stroup et a l,  2007).
Given the proinflammatory properties of CMV described earlier, it is not 
surprising that an association between pre-transplant CMV seropositivity and an
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increased risk of GvHD was demonstrated (Bostrom et a l ,  1990). A study by Broers 
and colleagues showed that CMV seropositivity of either HSCT recipient or donor 
proved an independent risk factor for developing acute GvHD suggesting that CMV 
seropositivity affects transplantation outcome by increasing the incidence of acute 
GvHD (Broers et a l ,  2000). CMV has been shown to prolong and increase graft 
inflammation (Lautenschlager et a l ,  1997). CMV infection-induced cytokine 
production in recipient endothelium is likely to worsen the cytokine storm observed 
during aGvHD (described earlier). Endothelial cells are known to produce inflammatory 
cytokines such as IL6 after infection with CMV, which can increase leukocyte adhesion 
(Grefte et a l,  1993). Consistent with that IL6, amongst other cytokines such as ILl and 
TNFa, was shown to be important during the initial phase of T cell activation before T 
cells are specifically activated by recipient alloantigens (Lichtman A, 1997). The 
association between pre-transplant CMV seropositivity and an increased risk of GvHD 
may also be mediated by viral peptides cross-reacting with minor antigens. Nachbaur 
and colleagues suggested that donor-derived HLA-A*0201 restricted CMV specific 
CD8  ^ T cells can cross-react with HLA-A*0201 restricted recipient minor 
histocompatibility antigen (Nachbaur et a l ,  2001). In accordance with that Cwynarski 
and colleagues (Cwynarski et a l ,  2001) reported detection of CMV specific CDS^ T 
cells in only one of seven CMV seronegative recipients receiving allogeneic HSCT 
from seropositive donors, with this recipient being the only one of the seven to 
experience aGvHD. Gandhi and colleagues later suggested, that CMV specific CDS^ T 
cells derived from a seropositive donor might persist in a seronegative recipient with 
severe GvHD due to alloreactivity (Gandhi et a l ,  2003a). CMV DNAemia in such a 
recipient was undetectable indicating absence of primary CMV infection in the study by 
Gandhi and colleagues. They had determined the origin of cells by analysis of DNA sex 
chromosome and single nucleotide polymorphism and demonstrated donor origin of all 
virus specific CD8^ T cell clones. Alloreactivity of CMV specific CD8^ T cells was also 
suspected in one of the patients of the study described here (section 3-2.1.3). A direct 
correlation of CMV specific immune responses with the development of GvHD has 
been demonstrated for aminopeptidase N, also called CD 13 (compare description of 
viral entry receptors in section 1-1). CMV particles contain host derived CD 13 
molecules and therefore CMV infection of HSCT patients can result in the development 
of autoantibodies against host CD13, which correlates with the development of chronic 
GvHD (Soderberg et a l , 1996).
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An influence in the opposite direction (that is the influence of CMV pathogeneicity by 
GvHD complications) is also apparent. The slow regeneration of the immune system 
after stem cell transplantation is often protracted by the presence of GvHD and its 
immunosuppressive prophylaxis and treatment. As a result recipients of T cell depleted 
stem cell grafts are at higher risk of reactivating CMV (Couriel et a l ,  1996). 
Accordingly investigations of CMV specific CD8^ T cell responses post HSCT must 
consider GvHD complications and any immunosuppressive regimen including TCD in 
patients. The source of transplant is another important factor contributing to CMV 
immune regeneration with more rapid reconstitution after transplantation of peripheral 
blood stem cells (PBMC) mobilised with granulocyte colony stimulating factor (G- 
CSF) from allogeneic donors than reconstitution after conventional bone marrow 
transplantation (BMT) (Korbling et a l,  1995). The development of non-myeloablative 
conditioning that enables wider application of HSCT has increased the rate of 
opportunistic infections. The increased use of immunosuppressive treatment such as 
Campath-IH in this setting is associated with prolonged T cell depletion (Morris et a l,
2003) and a high incidence of CMV infection (Chakrabarti et a l ,  2002). Nevertheless 
Campath-IH was shown to not adversely affect overall transplant-related mortality 
(Peggs, 2004c). High-risk (CMV seropositive) patients undergoing HSCT with reduced 
intensity conditioning develop CMV complications as late as 1 year post 
transplantation, which is much later than complications observed post myeloablative 
conditioning (Junghanss et a l,  2002). The study described here demonstrates CMV 
replication at even later time periods in patients who received reduced-intensity 
conditioning with Melphalan and Fludarabine in combination with T cell depletion by 
Campath-IH in vivo and who could be studied for longer than 500 days post HSCT 
(patients 3, 11, 21 and 30, refer to Figure 3-1/Figure 3-16, Figure 3-7, Figure 3-15 and 
Figure 3-22 respectively).
In summary CMV is thought to play a complex role in haematopoietic stem cell 
transplantation with a dual mechanism of pathogenesis. On the one hand the virus 
replicates and is cytolytic in infected tissue, which leads to loss of tissue function. On 
the other hand pathogeneicity in organs is indirectly enhanced by the inflammatory 
effect of CMV and its inhibition of engraftment of transplanted cells resulting in 
maintained immunodeficiency. This is supported by findings that bone marrow cells 
including CD34^ cells can be infected with CMV (Maciejewski et a l ,  1992) and that 
CMV is myelosuppressive (Sing and Ruscetti, 1990).
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1-4 Pharmacological interventions for the prevention and 
treatment of CMV in HSCT recipients
Pharmacologic intervention is highly efficient but since these drugs inhibit viral DNA 
replication or translation of viral ribonucleic acid (RNA) during primary or reactivated 
CMV infections, they have no impact on the latent phase of the viral life cycle and 
therefore cannot eradicate the infection. Long-term therapy is limited by drug resistance 
mutations and substantial toxicity of the drugs, which can lead to viral recurrence.
Drugs currently licensed for the treatment of CMV infection include ganciclovir, 
its oral pro-drug valganciclovir, foscamet, cidofovir and fomivirsen whereas 
(val) aciclovir is licensed for prophylaxis. Figure 1-4 depicts the molecular stmctures of 
these antivirals and their resemblance of components involved in DNA elongation. 
Fomivirsen’s mechanism of action is not involved in DNA replication. Therefore its 
structure is not shown in this figure but within the text later.
44
Chapter 1
(Val)AcicIovir
(Val'Ganciclovir
( ' ine 
(Pyrimidine)
primer strand 
O
Guanine
(Purine)
J ?  elongation by 
/ /  DNA polymerase
Ribose
Adenine
(Purine)
sugarl
phosphate
Thymine
(Pyrimidine)
Phosphate sugarlphosphate
O -
y
X .
3Na+
Foscamet
HpN
HO
Cidofovir
/ \
Figure 1-4 Antiviral pharmaceuticals
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Aciclovir (ACV) and Valaciclovir can be used prophylactically. They arc acyclic 
dcoxyguanosine analogues in which the sugar ring is replaced by an open-chain 
structure. Whereas aciclovir is rapidly metabolised within cells, valaciclovir -  the L- 
valyl ester of ACV - has a much higher bioavailability than ACV. Aciclovir is 
selectively monophosphorylated by viral thymidine kinases with several thousand times 
higher efficiency than can be achieved by cellular thymidine kinases. 
Monophosphorylated aciclovir is charged and so unable to diffuse out of the cell. It is 
subsequently further phosphorylated into its active triphosphate form by cellular 
kinases. It has a much higher affinity for herpesviral than cellular DNA polymerase. Its 
incorporation into DNA disrupts binding of nucleosides by formation of a phosphate 
ester bond to the 3’ hydroxyl (OH) group of previous nucleosides during normal DNA 
elongation (compare Figure 1-4) resulting in chain termination. ACV has a high effect 
on herpes simplex virus but only a moderate effect on CMV replication. Side effects 
include renal impairment due to crystallisation of the compound in the kidneys and 
virus resistance can result from mutations in viral thymidine kinase gene (UL97) and/or 
the viral DNA polymerase catalytic subunit gene (UL54) (Lowance et a l,  1999, Perry 
and Faulds, 1996, Smiley and Murray, 1996, Wagstaff et a l,  1994).
Ganciclovir (GCV) is another synthetic deoxy guanosine analogue. It is the most 
widely used drug and, like aciclovir, is monophosphorylated in infected cells by the 
viral enzyme encoded by the UL 97 gene of CMV (Sullivan et al, 1992). Cellular 
kinases produce ganciclovir-triphosphate, which accumulates to hundred-fold higher 
levels in viral infected than uninfected cells (Biron et a l,  1985). DNA polymerase then 
incorporates it into the viral DNA. In contrast to ACV, the incorporation of GCV does 
not lead to chain termination but rather to a slow down of DNA polymerisation. GCV 
contains a hydroxymethyl group resulting in an improved effect on CMV replication but 
also higher toxicity. It is used for pre-emptive therapy administered at the time of viral 
load detection as described later within this section. The drug has serious side effects 
including inhibition of growth of haematopoietic stem cells and neutropenia. Therefore 
G-CSF is used in combination with GCV to increase neutrophil numbers (Crumpacker, 
1996). The treatment with GCV has also been demonstrated to limit CMV specific 
immune reconstitution after HSCT (Li et a l,  1994). Extended ganciclovir therapy can 
lead to drug resistance mutations. These occur most frequently in the UL97 gene 
inhibiting anabolism of the drug or, to a lesser extent, in the DNA polymerase gene 
(UL54) inhibiting the incorporation of ganciclovir-triphosphate into the viral DNA 
(Smith et a l,  1997). Valganciclovir is the valyl ester pro-drug of GCV and is
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hydrolysed to ganciclovir by intestinal and hepatic esterases. It acts by the same 
mechanism as GCV but has an increased oral bioavailability (Jung and Dorr, 1999).
Foscamet (FCN, trisodium phosphonoformat) is an alternative treatment option 
to GCV. It is a pyrophosphate analogue acting as inhibitor of viral DNA polymerase by 
directly inhibiting its pyrophosphate binding site. It blocks the cleavage of the 
pyrophosphate group of the nucleoside triphosphate added to the growing DNA chain at 
concentrations that do not affect human DNA polymerases. This drug does not require 
cellular activation (Wagstaff and Bryson, 1994). Responses to FCN can result in 
resistance mutations in UL54. However, the compound is active against CMV variants 
expressing mutated UL97 proteins found in GCV resistant clinical isolates and can 
therefore be used in combination with GCV to reduce drug resistance (Sissons and 
Carmichael, 2002). Main adverse effects of FCN include high nephrotoxicity, 
electrolyte imbalances and poor bioavailability requiring intravenous administration 
(Nyberg et a l,  1989).
Cidofovir (CDV) is a cytosine analogue. It does not require a viral function for 
its activation. It is a phosphonate, stmcturally equivalent to nucleoside monophosphate 
but without the charge which would prevent the molecule crossing the plasma 
membrane. It only needs two phosphorylations by cellular enzymes to be converted to 
its active form. The diphosphorylated forms then act as a chain terminator of viral DNA 
synthesis and two consecutive incorporations efficiently terminate DNA elongation. 
They have a higher affinity for the viral than cellular DNA polymerases. CDV is active 
against CMV variants with UL97 mutations but UL54 mutations can result in 
resistance. It has a prolonged half-life in comparison to ganciclovir and foscamet, which 
enables less frequent administration (Reusser, 2000) but possesses low bioavailability 
that necessitates intravenous administration. Its severe renal toxicity necessitates 
administration with probenecid to prevent kidney damage (Lalezari, 1997) and renders 
it a second-line therapy for the treatment of CMV retinitis (De Clercq and Holy, 2005).
Fomivirsen is an oligodeoxynucleotide of the sequence 5’- 
GCGTTTGCTCTTCTTCTTGCG-3’ complementary to the major immediate early 2 
(IE2) mRNA of CMV blocking translation of IE2 encoding mRNA (Azad et a l ,  1993). 
Due to modified nucleosides and/or sugars it has a long half-life. Although not directly 
involved in viral genome replication, the crucial role of IE protein production in 
initiating the replication of CMV as described in section 1-1 make them an important 
target for antiviral intervention. Fomivirsen can be administered by intraocular injection
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and is highly efficient but due to adverse affects its use is restricted to the treatment of 
CMV retinitis (Biron, 2006) and so does not effect systemic CMV.
The role of intravenous immunoglobulin therapy is controversial. Some studies 
suggested a benefit for patients treated with immunoglobulin in combination with 
ganciclovir post HSCT (Reed et a l ,  1988), whereas others reported a limited value of 
this combined treatment for the outcome of established cytomegalovirus pneumonia 
after HSCT (Verdonck et al, 1989). A more recent randomised trial has shown no 
benefit from immunoglobulins used prophylactically (Ruutu et a l,  1997), but successful 
treatment of established CMV disease was reported in individual patients (Chow et a l , 
1992, Hiyoshi et a l,  1997, Koriyama et a l,  2004, Weng et a l,  2003).
Initial prophylactic interventions, usually with GCV, using continuous treatment 
during the first 100 days post HSCT led to prolonged neutropenia resulting in increased 
risk of bacterial and fungal infections and therefore no improved overall survival in 
patients. Subsequently, pre-emptive strategies were developed based on detection of 
CMV reactivation (compare section 1-5) prior to the development of disease and 
administration of antiviral treatment such as GCV until CMV becomes undetectable 
(Boeckh et a l ,  1996). The advantage of pre-emptive treatment over antiviral 
prophylaxis is that the former targets only those patients who are at maximum risk for 
developing CMV diseases and minimises exposure of others. Pre-emptive treatment 
reduces the incidence of CMV disease during the first 100 days post 
transplantation(Goodrich et a l,  1991). However, patients receiving antiviral treatment 
during this time as well as patients with high viral load and patients developing chronic 
GvHD are at increased risk for late-onset CMV disease, which is now the main CMV- 
related complication after allogeneic HSCT (Boeckh et a l ,  2003, Einsele et a l ,  2000, 
Zaia et a l ,  1997). Antiviral treatment early after HSCT is likely to block the 
development of protective immunity. Continued prophylaxis with GCV in combination 
with CMV viral load monitoring is not feasible because the association of GCV with 
neutropenia and opportunistic infections may offset its beneficial effects (Winston et 
a l,  1993). This may contribute to the risk of uncontrolled late-onset CMV reactivation 
in patients who are not actively monitored any more. Additional CMV preventative 
approaches are needed in the HSCT setting and non-pharmacological treatment 
alternatives such as adoptive CMV specific CD8^ T cell immunotherapy might prove 
beneficial.
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1-5 Monitoring CMV replication post HSCT
CMV disease (with the exception of retinitis) cannot be diagnosed based on clinical 
manifestations alone. Viral isolation from patient samples is diagnostic for CMV 
infection but diagnosis of CMV disease traditionally requires histopathology, cytology 
or culture based methods to provide evidence for presence of the virus in affected 
tissues (de la Hoz et a l , 2002) These methods are time consuming and place patients at 
risk of delayed treatment. Increasing CMV load in the blood is thought to precede 
clinical disease in the majority of HSCT patients (Gor et a l ,  1998). Thus, detection 
methods based on various viral parameters were developed in addition to traditional 
methods to identify patients at risk for CMV disease.
Viral parameters currently used for monitoring CMV replication are viraemia 
(isolation of infectious virus from peripheral blood leucocytes), antigenaemia 
(quantitative measurement of pp65 in peripheral blood leucocytes using 
immunofluorescence), DNAemia (quantitative measurement of CMV DNA or copy 
number in peripheral blood leucocytes, plasma or whole blood by either polymerase 
chain reaction (PCR) or hybridisation technique) and RNAemia (measurement of IE or 
L mRNA in peripheral blood leucocytes or whole blood by reverse transcriptase PCR or 
nucleic acid sequence based amplification).
Early tissue culture based methods were time consuming, poorly reproducible 
and of low sensitivity. In contrast, newer methods based on quantitative antigen 
detection or molecular amplification that are rapid, highly sensitive and reproducible are 
now available (reviewed in (Boeckh and Boivin, 1998)) and used routinely to monitor 
HSCT patients (Peggs, 2004a).
However, it should be noted that the inability to detect systemic CMV 
DNAemia or antigenaemia during routine monitoring does not preclude subclinical 
CMV reactivation at localised tissue sites in HSCT patients (discussed by (Gandhi et 
a l,  2003a)).
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1-6 Induction of CMV specific immune responses
A variety of natural immune defence mechanisms against viral intruders such as CMV 
exist in the human host. The epithelium is the first line of defence. Epithelial cells are 
joined by tight junctions providing a physical barrier against most microorganisms. 
CMV circumvents this first line of defence by infection through bodily fluids such as 
urine, saliva, blood, tears, semen or breast milk.
The first components of the immune system that will subsequently be 
encountered by the pathogen are the cells and molecules of the innate immune system. 
Innate recognition occurs by preformed receptors that recognise structures on a broad 
range of pathogens. This inherited arm of the immune system thereby enables an 
immediate response. Receptors can either recognise pathogens and their products 
directly or recognise host molecules that are upregulated by cells under conditions of 
stress. Viral double stranded RNA, which is generated during the life cycle of CMV and 
unmethylated cytosines in “cytosine and guanine separated by a phosphate” (CpG) 
dinucleotides can be recognised directly by Toll-like receptors (TLR) and a role for 
TLR3 and 9 was demonstrated for the innate immune defence against mouse 
cytomegalovirus infection (Tabeta et al, 2004). Indirect means of recognition include 
those via NKG2D ligands, of which several are known to exist (Eagle et a l ,  2006). 
Although CMV produces UL16 protein that can retain NKG2D ligands in the inside of 
infected cells as an immune evasion strategy, only some (MICB, ULBPl, and ULBP2 
but not MICA and ULBP3) of the NKG2D ligands are affected by this strategy (Dunn 
et a l,  2003, Welte et al,  2003). NKG2D ligands can activate receptor-bearing cells 
such as NK cells and trigger multiple signalling cascades (Sutherland et al,  2002). The 
importance of NK cells is demonstrated in patients with NK cell deficiencies, who are 
very susceptible to CMV infection and disease (Biron et a l,  1989). NK cells can 
recognise virus-infected cells by their failure to express self major HE A class I 
molecules as a result of the viral infection (missing-self hypothesis) (Ljunggren and 
Karre, 1990). On ligation with activating receptors mentioned above they are able to 
exert immediate action against infected cells. Innate immune responses can lead to 
direct killing of some infected cells, early production of inflammatory cytokines with 
antiviral activity and production of chemokines that recruit inflammatory cells into the 
infected tissue. The complement cascade plays an important role in this response. It 
involves C proteins that can bind to the Fc region of antigen-antibody complexes, 
thereby mediating antibody-dependent cytotoxicity. C proteins can also directly bind to
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viral proteins. Subsequent activation of a cascade of enzymatic events leads to 
deposition of complement complexes on the surface of virus-infected cells resulting in 
lysis. Furthermore complement fragments produced during the process of enzymatic 
cleavage induce soluble immune mediators and can opsonise virus, thereby initiating or 
amplifying immunological defence mechanisms that might normally only occur at low 
level (Hirsch, 1982). CMV has evolved strategies to escape immune control mediated 
by the complement cascade. The presence of C control proteins in virus particles 
reduces lysis mediated by deposition of complement complexes (Spear et a l ,  1995), and 
virus-encoded Fc receptor homologues may entice antibodies away (Keller et a l ,  1976). 
Interferon a  and p that are produced during viral infection (Goodboum et a l , 2000) are 
also important mediators of innate effector functions and were found to stimulate cross­
presentation (Le Bon et a l,  2003), which may play an important role for adaptive 
immune defence against CMV as will be described later within this section. Apoptotic 
infected cells and debris are delivered to regional lymph nodes by tissue derived DC or 
other APC priming the adaptive immune response mediated by lymphocytes (Steinman 
e ta l ,  1999).
In contrast to innate immune responses, immune cells of the adaptive arm of the 
immune response (lymphocytes) utilise an antigen receptor repertoire that is a result of 
developmental processes that vary between individuals (compare section 1-8.1). The 
variability of lymphocyte receptors increases the possibility of detecting any antigen 
that may be encountered throughout life. Lymphocytes originate from haematopoietic 
lymphoid progenitors in the bone marrow and can be distinguished into two main cell 
types. T lymphocytes (T cells) mature in the thymus and develop membrane bound T 
cell receptors whereas B lymphocytes (B cells) mature in the bone marrow and develop 
B cell receptors both in transmembrane and soluble form (the soluble form is 
alternatively called immunoglobulin or antibody). Upon first encounter of antigen, 
lymphocytes must first proliferate and differentiate before being effective against 
pathogens. The adaptive arm of the immune response is therefore slower to respond 
than the innate arm of the immune response. However, unlike the innate response, an 
adaptive response leaves behind a pool of memory lymphocytes and antibodies that can 
act immediately upon a subsequent encounter of the same pathogen. B-lymphocyte 
derived CMV immunoglobulin (Ig) might be beneficial when administered to transplant 
patients (compare section 1-4). However its beneficial effect is believed to be directed 
against indirect inflammatory effects of CMV (Kazatchkine and Kaveri, 2001) and to be 
tolerance inducing rather than directly antiviral (Hoetzenecker et a l,  2007). Maternal
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humoral immunity before conception is important for the prevention of damaging 
congenital CMV infection in the newborn (Fowler et a l ,  1992). In contrast, humoral 
immunity against CMV may not play an important role post HSCT (Munoz et a l,  
2001). In addition, individuals suffering from common variable immunodeficiency who 
lack the ability to produce sufficient antibodies in response to exposure to viral and 
other pathogens (Bayry et a l ,  2005) were demonstrated to have CMV specific T cell 
responses and no symptoms of CMV disease. This indicates that CMV replication can 
be controlled by T cells in the absence of B cells (Kopycinski, 2006).
T cells have been shown to be the main mediators of the immune defence 
against CMV and since their presence inversely correlates with infection and disease, 
adoptive therapy has been considered as potential therapy in immunocompromised 
patients (Greenberg et a l ,  1991, Quinnan et a l,  1984, Quinnan et a l ,  1982, Reusser et 
a l,  1991, Riddell et a l ,  1991b, Walter et a l,  1995). T cells are sub-classified according 
to the expression of either CD4 or CD8 co-receptors. Both CD4^ and CD8^ T cells are 
required for complete regeneration of CMV immunity (Foster et a l,  2002) and a 
hierarchy of immune control functions of CD8^ T cells, NK cells and CD4^ T cells has 
been suggested in mice (Polic et a l ,  1998). CD4^ T cells are thought to play a critical 
role in determining the fate of CD8^ T cells and it was demonstrated that in the absence 
of the former, CD8^ T cell mediated control of persistent herpesvirus is lost (Cardin et 
al,  1996). The probability for patients infected with human immunodeficiency virus 
(HIV) to develop CMV disease has been reported to be 13 %, 3 % and 0%  in the 
presence of CD4^ T cell counts of less than 50 cells/pl, 50-100 cells/pl and 100 cells/pl 
respectively (Gerard et a l,  1997). Spiegel and colleagues described the presence of 
CMV specific CD8^ T cells without effector function in the absence of low levels of 
CD4^ T cells in this patient group (Spiegel et a l ,  2000). In addition to CD4^ T cells 
with helper function, cytotoxic subsets of CD4^ T cells targeting CMV have recently 
been observed with properties and function similar to those of CMV specific CD8^ T 
cells (Crompton et al, 2008).
There are several lines of evidence that CD8^ T cells may play one of the most 
important roles in protective immunity against CMV. Delayed reconstitution of CD8^ T 
cells correlates with CMV disease in allogeneic bone marrow transplant patients (Li et 
a l,  1994) and a study by Reusser and colleagues demonstrated the association of CMV 
specific CD8^ T cells with protection from CMV disease in autologous transplant 
patients (Reusser et a l,  1997).
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Since CD8^ T cells play such an important role in protective immunity against CMV, 
this thesis focuses on investigating the fine specificity and of these cells and their 
correlation with protection against CMV in HSCT patients. CD8^ T cells exert their 
specificity to antigen through their T cell receptors. These molecules were demonstrated 
to bind antigen in the form of peptides presented by HLA molecules (compare section 
1-2) at the surface of antigen presenting cells (Zinkemagel and Doherty, 1974). The 
process by which CMV specific antigens are presented to and induce CD8^ T cells is 
reviewed below.
After viral infection of cells, CMV encoded proteins are digested into peptide 
fragments by the proteasome and other intracellular proteases (Coux et a l,  1996), which 
are thought to generate the final carboxy-terminal residues of HLA binding peptides. 
The resulting peptides are translocated into the lumen of the endoplasmatic reticulum 
(ER) by the transporter associated with antigen presentation (TAP) (Lankat-Buttgereit 
and Tampe, 2002), which spans the membrane of the ER. In the ER, peptides usually 
undergo additional trimming at the amino terminus that is mainly facilitated by ER 
associated aminopeptidase (ERAAP) (Serwold et a l , 2002) before associating with the 
heavy chains of HLA class I molecules. Noncovalent interaction results from sequence- 
dependent interaction between side chains of the peptide (anchors) and pockets of the 
peptide-binding groove of the HLA class I molecule on the one hand and a conserved 
hydrogen bond network formed by non-polymorphic amino acids at each end of the 
peptide-binding groove of the HLA and the peptide on the other hand. Thereby peptide- 
binding specificity is determined by the first mentioned interaction whereas the last 
mentioned interaction restricts the lengths of peptides to generally eight to ten residues, 
although larger peptides can bind by bulging in the middle. A series of chaperone 
proteins facilitate the partial folding of class I HLA and its association with B2 
microglobulin (132m) in the ER before it can interact with TAP. These chaperones 
include the TAP binding protein tapasin, the thiol oxidoreductase ERp57, calnexin and 
calreticulin, which all assist protein folding by promoting the formation of disulfide 
bonds, regulating the redox state during initial folding of proteins or retaining unfolded 
proteins in the ER. It also includes the immunoglobulin-binding protein (BiP) although 
its role is yet undetermined. Once the peptides are transported to the ER and are 
trimmed by ERAAP, peptide editing occurs. This involves peptide loading and 
exchange to achieve binding of high affinity peptides to the awaiting HLA, a process 
that is mediated by protein disulfide isomerase (PDI). The stabilised HLA/i32m/peptide
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complex can then be transported to the plasma membrane via the Golgi network, 
(reviewed by (Antoniou and Powis, 2008, Cresswell et al, 2005, Jensen, 2007))
The ER is an interconnected membrane network held together by the 
cytoskeleton. It is continuous with the outer layers of the nuclear envelope and proteins 
can be shuffled between the ER and the Golgi apparatus. The complexity of the ER is 
unaccounted for in Figure 1-5, which schematically illustrates the process of antigen 
processing for presentation of peptide fragments on HLA class I molecules on the 
surface of cells.
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Figure 1-5 Processing of CMV antigen for presentation by HLA class I
The processing o f  CM V peptides by APC is illustrated. The H LA class I heavy chain initially  
assem bles with the chaperon calnexin  that initiates fo ld ing. Subsequently 6 2 m and HLA  
associate with the peptide loading com p lex  in vo lv in g  calreticulin, TAP, tapasin and ER p57. 
BiP has been described to bind transiently but its role rem ains undeterm ined so  far. Peptides 
generated by the proteasom e and other intracellular proteinases are translocated into the ER. 
This is usually achieved via TAP. Peptide ed iting results in peptides o f  the appropriate 
sequence to bind to HLA. The stabilised  H L A /6 2 m /peptide com p lex then d issociates from  the 
peptide-loading com p lex  and is transported to the cell surface. Cross-presented peptides m ay 
bind by alternative TA P dependent or T A P  independent m echanism s. The graph w as created  
based in inform ation from (A ntoniou  and Pow is, 2 0 0 8 , C ressw ell et  a l ,  2005 , Jensen, 2007 , 
Pepperl et  a i ,  2 000 , Tabi et a i ,  2 0 0 1 , T op ilk o and M ich elson , 1994).
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In contrast to the endogenous pathway of antigen processing described above, 
exogenous proteins that a cell has endocytosed are usually processed by a different 
pathway leading to presentation by HLA class II molecules that can be recognised by 
CD4^ T cells. This is not further discussed here because this project focuses on CD8^ T 
cells recognising peptides presented via HLA class I molecules. However, CMV 
derived peptides taken up exogenously (cross-priming) or from subviral dense bodies 
(alternative loading) can also associate with HLA class I to induce a CD8^ T cell 
response and both of these pathways are illustrated along with the conventional pathway 
in Figure 1-5. Endocytosed exogenous antigens are believed to exit the endosomal 
pathway into the cytosol (before or after antigen processing) before entering the 
conventional pathway (Wilson and Villadangos, 2005).
Cross-presentation of viral antigens has been demonstrated (Tabi et a l,  2001) 
and provides an explanation for the presence of high frequencies of CMV specific CD8^ 
T cells in virus carriers despite the numerous viral evasion strategies that will be 
discussed later (sections 1-7 and 1-9.3). Tabi and colleagues demonstrated that dendritic 
cells can acquire viral antigen from CMV infected non-apoptotic fibroblasts regardless 
of the HLA type of the fibroblasts and present them through their HLA class I 
molecules to T cells. This was suggested to be a phagosome/endosome-to-cytosol 
pathway because of blockage by proteasome inhibitors (Kovacsovics-Bankowski and 
Rock, 1995). Cross presentation was shown to be restricted to immature DC whereas 
activation by systemic exposure to viral Toll-like receptor ligands and subsequent 
maturation of DC leads to less take up of exogenous antigen and less delivery of 
endocytosed antigen to the cytosol (Wilson et a l,  2006). This observation may help to 
explain immune exhaustion effects observed during systemic infection. The details of 
various TAP dependent and TAP independent pathways of cross-presentation are still 
being discovered. Delivery of peptides from virally infected cells to APC (compare 
Figure 1-5) may involve phagocytosis (Ackerman et a l ,  2003) or a direct gap-junction- 
mediated transfer (Neijssen et a l,  2005). Importantly, since cross-presentation results in 
presentation of viral antigen by non-infected cells, production of CMV encoded gene 
products with immunomodulatory function (as described in sections 1-7 and 1-9.3) is 
avoided.
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Dense bodies (DB) are enveloped spherical structures that lack viral capsid and DNA. 
In addition to properly assembled new virions (compare Figure 1-1 on page 29), 
infected cells were shown to also release these non-infectious defective particles 
(Craighead et a l,  1972) including DB and non-infectious enveloped particles (NIEP) 
that resemble virions but lack DNA. They consist mainly of glycoprotein and tegument 
protein with pp65 being its major component (Baldick and Shenk, 1996, Fiala et a l,  
1976). DB and NIEP were shown to be able to enter cells with the same kinetics (<60 
seconds after contact with cell membrane) and mode of penetration as complete virus 
particles enabling delivery of their protein components into the cell (Topilko and 
Michelson, 1994). Consistent with that the ability of DBs to induce significant CD8  ^T 
cell responses in the absence of infectious virus was recently demonstrated in mice 
(Pepperl et a l, 2000).
Activation of naïve CD8  ^ T cells involves stimulation through the T cell 
receptor, which recognises CMV derived peptides bound to MHC class I molecules on 
infected cells and requires costimulation by antigen presenting cells (compare Figure 
1-11 on page 71). Upon encounter of antigen, lymphocytes stop migrating and enlarge. 
Activated CMV specific CD8  ^T cells increase in size, thereby becoming lymphoblasts. 
Lymphoblast transformation was induced by short-term stimulation of T cells with 
phytohaemagglutinin (PHA) to induce mRNA levels throughout this project and is 
therefore described briefly. The generation of lymphoblasts results from an energetic 
event, during which metabolism increases and the production of new RNA and proteins 
is induced. Therefore ribosomes, which are necessary to synthesize proteins, associate 
with the ER resulting in a rough appearance of the latter, the cytoplasm increases and 
the plasma membrane increases its number of microvillus and its phagocytic activity. 
This process results in enlargement of the entire cell. An illustration of this 
transformation induced by PHA is shown in Figure 1-6.
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Figure 1-6 T cell lymphoblast formation
Surface m orphology (left: unstim ulated, right: PH A  stim ulated, both 8 ,0 0 0 x ) is show n,
adapted from H offm ann and co lleagu es (H offm ann e t  a i ,  1977).
Lymphoblasts undergo clonal proliferation and become effector CD8  ^ T cells that can 
produce cytokines such as IFNy or directly kill CMV infected cells via FAS or perforin 
dependent mechanisms (compare sections 1-9.1 and 1-9.2). In contrast to their naïve 
counterparts, antigen-experienced CDS^ T cells can recognise their target cells with 
little or no requirement of co-stimulation, thus enabling killing of virally infected cells 
other than APC (compare section 1-9). At this stage cells have changed their expression 
of adhesion molecules, which enables them to migrate between endothelial cells at the 
sites of infection (Masopust et a l, 2001). Effector CD8  ^ T cells are attracted to these 
sites by cytokines released by local inflammatory cells. After viral clearance, most 
virus-specific CDS^ T cells die by apoptosis but some survive as a population of 
memory cells which can become cytotoxic and proliferate upon restimulation with 
CMV antigen.
Naïve CD8  ^ T cells circulate in the lymphatic system between blood and 
secondary lymphoid organs via specialised post capillary vessels called high endothelial 
venules (HEV) that are only expressed on lymphoid tissue. Their migration involves 
interaction between L-selectins (CD62L), chemokine receptors (CCR7) and integrins 
(LFAl) with their ligand counterparts expressed on HEV. These are the peripheral 
lymph node addressin (PNAd), CCL21 and ICAMl respectively (Masopust et a l.
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2001). In contrast, memory T cells can be classified into central memory T cells (T c m )  
and effector memory T cells (T em ) according to their expression of lymph node homing 
molecules and immediate effector function. Whereas T cm  (CD62L^CCR7^) are thought 
to reside preferentially in secondary lymphoid organs, T em  (CD62L'CCR7') and short­
lived effector T cells can migrate directly into non-lymphoid tissue to exhibit immediate 
effector function (Lewis et a l, 2007, Mora and von Andrian, 2006). This was shown to 
involve tissue specific receptor interaction (Picker et a l, 1993) that may be conferred by 
activation with tissue specific APC or by the local environment, in which a naïve T cell 
becomes activated. As an example, interaction of T em  with the endothelium of small 
intestinal blood vessels was shown to involve the integrin « 4^7 (Berlin et a l, 1993), 
chemokine receptor CCR9 (Zabel et a l,  1999) and a higher affinity LFA-1 with the 
ligands mucosal addressin cell adhesion molecule (MAdCAM) (Nakache et a l,  1989), 
CCL25 (Hosoe et a l,  2004) and ICAM-1 respectively. Evidence of naïve CDS^ T cells 
accessing non-lymphoid environment in some circumstances, however, is growing and 
awaits further studies on the potential functionalities of these cells (Lewis et a l, 2007).
1-7 CMV strategies to limit the priming of an immune defence
Probably to facilitate persistence in the host, and thereby enhancing the chance for 
transmission to a new host, human CMV devised several strategies for avoiding 
immune detection. One of these is the limitation of gene expression to the minimum 
during latency. A second strategy involves the replication in tissues that have less 
stringent immune surveillance. Epithelial cells of the salivary gland do not express 
sufficient HLA class I molecules to mediate virus clearance by CDS^ T cells and 
thereby allow virus shedding into body fluids for viral transmission between individuals 
(Hengel et a l,  1998). As a third strategy, the virus does express several factors designed 
to silence host defence mechanisms. Some examples of those are mentioned later in this 
section and other factors directly influencing CD8  ^ T cell effector functions are 
mentioned in section 1-9.3.
CMV prevents virions from being exposed to the host immune defence by 
reducing apoptosis through the action of lE l and IE2 genes (Zhu et a l, 1995). In 
addition to that CMV encodes gene products with immunomodulatory function that can 
thwart recognition by host effector cells. These include some US proteins, which 
decrease cell surface expression of MHC class I molecules in CMV infected fibroblasts 
in vitro (Jones et a l, 1995) and are therefore thought to interfere with cytotoxic CD8  ^T 
cell immune surveillance. The product of US3 is expressed rapidly but transiently and
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prevents egress of MHC class I proteins from the ER to the Golgi apparatus (Lee et a l , 
2000). In addition, US 10 can delay the trafficking of MHC class I molecules through 
the ER to the cell surface (Furman et a l, 2002). The products of the genes US2 and 
US 11 are expressed in the E phase and act in a similar way to redirect MHC class I 
from the ER into the cytosol leading to their ubiquitin-dependent proteasome-mediated 
degradation (Gewurz et a l, 2001, Shamu et a l,  2001). Both products appear to use 
different dislocation complexes (reviewed in (Antoniou and Powis, 2008)). US2 and 
US3 were also shown to result in downregulation of HLA class II (Hegde and Johnson, 
2003, Hegde et a l, 2002). The product of US6 is expressed in the L phase and prevents 
peptide loading by binding to TAP and thereby retaining it in the lumen of the ER 
(Hewitt et a l,  2001). CMV carries an abundance of genes involved in immune 
modulation of the host other than those interfering with peptide presentation, which will 
be described in section 1-9.3.
Interference of CMV with peptide presentation would be most efficient if  the 
virus would selectively down-regulate viral antigen presenting alleles, while at the same 
time preserving other alleles to act as inhibitors of NK cell activation. A varying 
efficiency of immune evasion proteins depending on the HLA allele targeted has been 
observed and may explain the predominance of CD8^ T cells targeting peptides 
presented by resistant HLA alleles rather than non-resistant alleles. Several HLA-B 
alleles including HLA-B*0702 were found to be resistant to effects of the US2 protein 
whereas others such as HLA-A*0201 are not (Barel et a l, 2003). Consistent with that 
Lacey and colleagues demonstrated a relative dominance of HLA-B*0702 restricted 
CDS^ T cells to CMV pp65 in individuals sharing HLA-A*0201 and HLA-B*0702 
alleles (Lacey et a l, 2003), which may hold true for other responses as well.
The strategies used by CMV to evade immune responses of the host is likely to 
play a role in shaping the host T cell response and may partly explain the 
immunodominance of CD8^ T cells directed to antigens like pp65 that can be presented 
by infected cells before expression of the US genes (compare Figure 1-5 on page 54). 
Although the sequential expression of US proteins targets the efficiency of cell 
mediated immunity of the host, CD8^ T cells remain critical in the control of CMV 
replication and it has been shown that infected cells remain targets throughout the 
replicative cycle in vitro despite the expression of viral genes that downregulate class I 
MHC expression (Riddell and Greenberg, 1997). Specific cytokines can limit the 
immune evasion potential of CMV from CD8^ T cell control (compare section 1-9.3)
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showing that there exists a highly balanced relationship between host and pathogen 
(Hengel et a l,  1995). Manley and colleagues demonstrated that the immune evasion 
proteins do not prevent the development of a diverse CMV specific CD8^ T cell 
response in vivo. Interferon gamma (IFNy) production of CD8^ T cells from healthy 
CMV seropositive donors was greater towards fibroblasts infected with US gene 
deletion mutant RV798 than towards the wild type AD 169 CMV strain (Manley et a l,
2004). It is unknown whether CD8^ T cells specific for CMV antigens that are not 
presented by permissively infected fibroblasts in vitro are activated and maintained at 
relatively high frequency in vivo but several explanations seem possible. It may be 
possible that the US proteins do not impair antigen presentation in fibroblasts or non­
fibroblasts in vivo as efficiently as they do in fibroblasts in vitro. This may be due to 
different kinetics of the US expression in different cell types leading to incomplete 
antigen presentation impairment (Manley et a l, 2004). It was shown that deletion of 
genes expressing products with immunomodulatory function greatly affects antigen 
presentation in vitro but has little effect on the magnitude of the overall murine anti 
CMV CD8^ T cell response in vivo (Gold et a l,  2002). Sylwester and colleagues 
recently demonstrated immunogenicity of 33 different open reading frames, which were 
recognised by CD8^ T cells in several CMV carriers each (Sylwester et a l,  2005). 
These findings suggest that part of the CD8  ^ T cell response is induced by cross 
presentation (compare section 1-6) because genes expressing products with 
immunomodulatory function should act only in cells that express them and therefore 
should effect only direct priming of T cells by APC that present endogenous antigen. 
Indeed induction of CD8^ T cells targeting structural and non-structural CMV proteins 
by crosspriming was demonstrated (Tabi et a l, 2001).
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1-8 CD8* T cell specificity
Specific CD8^ T cell recognition of virus-infected cells is accomplished by the 
interaction of T cell receptors (TCR) on the effector cells with HLA/viral peptide 
complexes on infected cells. All human nucleated cells express up to six different major 
class I HLA molecules (compare section 1-2) and up to 250,000 of each of the HLA 
class I molecules were estimated to present peptides on the surface of a cell (Parham 
and Ohta, 1996).
TCRs are highly variable antigen-recognition structures. Conventional CD8^ T 
cells express approximately 10"^  identical TCRs on their surface (reviewed in (Mazza 
and Malissen, 2007)). They are disulfide-linked, membrane-bound heterodimers 
consisting of a  and P chains for most mature T cells (yb T cells are not considered in 
this chapter). Each chain is the result of rearrangement of multiple copies of variable 
(V), joining (J) and, in the case of the B-chain, diversity (D) segments (compare Figure 
1-9 on page 67) during T cell maturation and subsequent joining to one of the constant 
(C) regions. The a  and B chains of mature T cell receptors then contain an amino- 
terminal variable (V) region and a constant (C) region, followed by a short hinge region 
(where a  and B chain are linked by a disulfide bond), a transmembrane region and the 
cytoplasmic tail.
1-8.11 cell receptor rearrangement during I  cell developm ent
The TCRa chain is encoded on chromosome 14. Its V region is encoded by two DNA 
segments, the V gene segment and the J gene segment, with the latter located closely to 
the C region. During developmental gene rearrangement of T cells in the thymus, the V 
and J gene segments are joined. This enzymatic process is guided by conserved, 
noncoding DNA sequences called recombination signal sequences (RSS). The newly 
formed exon is joined to the C region sequence by RNA splicing after transcription. The 
TCRB chain V region is encoded in three gene segments on chromosome 7 (compare 
Figure 1-9). In addition to the V and J gene segments, there is a third gene segment, the 
D gene segment, lying between them. During rearrangement, D and J segments are 
joined first before joining with V. During the process of gene rearrangement, the 
sequences between rearranging genes are deleted in the form of circular excision 
products called TCR excision circles (TREC). Multiple copies of all gene segments 
exist. The combination of randomly selected gene segments of each type results in great 
diversity of the TCR V regions. Figure 1-7 illustrates the TCR VB gene rearrangement
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The T cell development described above occurs from common lymphoid progenitors 
expressing CD34 that have migrated from the bone marrow to the thymus. There, 
cytokine signalling and interaction with cells present in the thymus guides the different 
stages of thymocyte differentiation. TCRp rearrangement occurs first followed by 
rearrangement of TCRa. Once a productive B chain gene rearrangement has occurred, it 
pairs with an invariant pre-a chain. Subsequent expression of a pre-TCR triggers 
phosphorylation and degradation of RAG (product of the recombination activating gene, 
the main enzyme complex involved in the rearrangement of TCR genes). This stops 
further B chain rearrangement and ensures allelic exclusion. Cell proliferation and 
expression of co receptor are induced. Only after proliferation has ceased, RAG-1 and 
RAG-2 are transcribed again and the TCRa chain can be rearranged. It then pairs with 
the B chain to produce the final T cell receptor, (refer to (Kuklina, 2006) for a review)
Resulting thymocytes express low levels of TCRa/B receptors and undergo 
selection depending on their recognition of self-MHC/peptide complexes. TCR 
recognition of MHC/peptide ligands results in thymocytes receiving signals for survival 
and further differentiation into either CD4^ or CD8^ single positive thymocytes 
(positive selection). Subsequently high avidity interactions elicit signals that result in 
deletion of thymocytes. This process of negative selection contributes to the clonal 
deletion of self-reactive cells thereby avoiding autoimmunity. Only about 3 - 5 % of 
developing thymocytes with TCR recognising MHC/peptide ligands with low avidity 
are thought to survive the selection in the thymus (Egerton et a l, 1990, Goldrath and 
Bevan, 1999). This selection process enriches cells that are potentially reactive to 
foreign antigen, but not to self-antigen, presented by self-MHC. (reviewed in (Huseby et 
a l, 2008))
In addition to the diversity created by the joining of different gene segments, 
further diversity of the TCR between gene segments of the V-D-J (TCRP) or V-J 
(TCRa) junction results from random incorporation and deletion of nucleotides during 
the enzymatic process of gene rearrangement (N- and P-nucleotides). This alters the 
junctional regions in lengths (compare section 1-8.2), thereby creating regions not 
encoded in the germline DNA, and results in the high variability of V regions necessary 
for the recognition of many potentially encountered antigens. The potential diversity 
created for TCR heterodimers has been calculated to be approximately 10*^  (Davis and 
Bjorkman, 1988). The TCR repertoire following thymic selection is between 10  ^ and 
10* (Arstilagra/., 1999).
63
___________________________________________________________________ Chapter 1
The variability of the resulting TCR V region is not distributed evenly. When a  and B 
chains are paired in the TCR molecule hypervariable sequences form loops in the 
resulting protein structure leading to three complementarity-determining regions (CDR) 
of the antigen-binding site amongst less variable framework regions. CDRl and CDR2 
are thought to interact primarily with the HLA and are encoded in the germline V 
segment genes, whereas CDR3 encompasses the V-J, or in case of the B-chain, the 
V-D-J junction (Wilson et a l, 1988), is located in the centre of the TCR-HLA/peptide 
interaction region and is thought to interact primarily with the peptide ligand. A 
structural model for the interaction between TCR and MHC/peptide (determined by 
crystallography) is shown in Figure 1-8.
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Figure 1-8 Model of the structure of an MHC class I/peptide-TCR complex
This figure sh ow s a backbone tube representation o f  the interaction o f  a T cell receptor (TC R ) 
with a major h istocom patib ility  com p lex  (M H C ) class I/peptide. The M H C, con sistin g  o f  its 
three a  dom ains associated with 6 2 -m icroglobu lin  (6 2 m ), is on the bottom  with the peptide 
show n as large tube in ye llow . The TCR is above with the C D R  a l  and a 2  coloured pink, 
CDR 61 and 62 coloured blue and the C D R 3 coloured y e llo w  (adapted from (G arcia et  a i ,  
1996)).
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The CDR3 of the B-chain is the most diverse part of the TCR and TCR diversity can 
therefore be experimentally estimated by analysing the length of this region. The 
method for distinguishing VB transcripts according to CDR3 length was initially 
described by Cochet et a l (Cochet et a l,  1992). It has been called spectratyping by 
Gorski et a l (Gorski et a l, 1994) and immunoscope by Pannetier et a l (Pannetier et a l, 
1995) and is briefly explained below.
1-8.2 Estimation of I  cell receptor diversity
Junctional diversity generated during somatic recombination as described above results 
in CDR3 regions differing in size by multiples of 3 nucleotides whereas rearrangements 
that would be out-of-frame are rarely detected in PBMC (Gorski et a l, 1994). VB 
CDR3 size variation is limited. Seven to 12 amino acid residues account for more than 
80 % of all functional rearrangements (Liu et a l, 1995a). VB spectratyping involves the 
generation of complementary DNA (cDNA) followed by amplification of a segment of 
the T cell receptor B chain that spans the CDR3 region with a fluorescently labelled 
primer specific for the CB region and primers specific for VB. As it is not possible to 
design a single primer that can anneal to all VB segments of the 24 families that exist, 
multiple PCR reactions with different primers need to be performed. Figure 1-9 
illustrates the location of functional TCR VB genes.
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Figure 1-9 TCR VB locus at 7q34
This figures illustrates the location o f  TCR VB (T R B V ) gen es designated according to the 
nom enclature by R ow en  and co lleagu es (R ow en  et  a i ,  1996). O f the total number o f  91 -94  
TRB genes that ex ist per haploid gene, 82-85  (6 4 -6 7  T R B V , 2 T R B D , 14 TRBJ and 2 TR B C ) 
are localised  on chrom osom e 7 at 7q34 (show n ) and 9 orphans are localised  on chrom osom e 9 
(not show n). O f these 82-85  TRB genes, 56-65 genes are functional (4 0 -4 8  T R B V , 2 T R B D , 
12-13 TRBJ and 2 TR B C ) and T R B V  genes can be allocated to 21-23  subgroups depending on 
the nom enclature used. Adapted from (Lefranc, 2001b ) (h ttp://im gt.cines.fr).
A multiplex PCR approach using 7 reactions each with a mix of differentially labelled 
VB family specific primers and one CB primer was used in the project described here 
(compare Table 2-7 on page 165). The PCR products of different length can be resolved 
by denaturing gel electrophoresis. The ratio of transcripts per cell has been 
demonstrated to be fairly constant. Therefore the amount of PCR product as measured 
by fluorescence intensity in each size peak indicates the number of clonotypes and 
therefore TCR diversity. The deletion and addition of nucleotides during the 
rearrangement of T cell receptors is random. Therefore the CDR3 lengths in cord blood 
approximate to a Gaussian distribution (Garderet et al., 1998). Clonal expansions such 
as those of CMV specific CD8^ T cells (Weekes et al., 1999a, Weekes et a i, 1999b, 
Weekes et a l, 1999c) result in changes in the relative peak heights. Antigenic 
stimulation results in skewing of the Gaussian distribution in CDR3 lengths of
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peripheral T cells from adults with increasing age. Predominance of only a few size 
classes in a spectratype indicates oligoclonality.
The thymic selection shapes the preimmune TCR repertoire from which antigen 
can drive the selective expansion of T cell clones with preferred TCR that subsequently 
dominate the T cell response to an antigen (McHeyzer-Williams et a l, 1999). The TCR 
repertoire used for the recognition of some peptide-MHC complexes may vary widely 
between individuals reflecting a private TCR usage. Some viral infections, however, are 
known to induce presentation of peptide-MHC complexes, which generate T cell 
subsets expressing similar CDR3 B loops in different individuals. This public TCR 
usage can for example be observed in HLA-B8 expressing individuals after Epstein- 
Barr virus (EBV) infection by generation of a prominent Epstein-Barr nuclear antigen 3 
(EBNA-3) specific T cell responses with a dominant TCR (Argaet et a l, 1994). Another 
example for public TCR usage can be found for HLA-A2 restricted T cell responses 
towards influenza virus (Moss et a l, 1991). It has recently been suggested that 
structurally dominant versus absent peptide features may determine the selection of a 
diverse versus limited TCR repertoire of CDS^ T cell responses to influenza A virus 
infection in mice respectively (Turner et a l, 2005). In contrast, peptides bound to HLA 
in a bulged form, which are likely to be rare, may only be accommodated by a few 
TCRs. CD8^ T cell responses with such extremely restricted TCR sequences have been 
reported for bulged 1 Imer and 13mer target structures (Tynan et a l,  2005, Miles et a l,
2005). Alternatively, prevalence of virus specific T cell clones with public TCR usage 
may be due to a functional advantage conferred by the CDR3 motifs. A competitive 
advantage due to superior CD8^ T cell avidity was demonstrated for influenza A 
specific CD8^ T cells in HLA-A2 expressing individuals, in whom a dominant public 
TCR VB17 amino acid sequence was up to 10,000-fold more avid than subdominant 
clones that were expanded in vitro after removal of VB17^ cells (Lawson et a l, 2001). 
Subdominant clones were also shown to occur in vivo during HLA-B8 restricted EBV 
specific CD8^ T cell responses (Argaet et a l, 1994). The selective expansion of CD8^ T 
cells expressing high affinity TCRs may allow for more rapid destruction of virus- 
infected cells whereas the persistence of subdominant CD8^ T cell clones with 
heterogeneous (low affinity) TCRs may provide a mechanism to cope with pathogen 
mutation.
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TCR usage of CMV specific T cells has been investigated previously demonstrating 
public TCRs with expansions in V61 and other VB families in the context of HLA- 
A*0201 when using spectratyping (Peggs et a l, 2003c). The knowledge of TCRs used 
in the T cell response to different CMV antigens may be useful for enhancing the 
detection during the monitoring of CMV responses in high-risk immunodeficient 
patients or for the development of treatment modalities using TCR gene transfer. 
Besides their role in protection from CMV dissemination and disease, CD8^ T cell 
responses to CMV can have an adverse effect on the immune fitness of infected 
individuals by contributing towards shaping the overall CD8^ T cell repertoire. Ouyang 
and colleagues demonstrated that a large fraction of the entire CD8^ T cell population in 
individuals more than 85 years old consists of T cells specific for a single CMV epitope. 
The fraction of these cells secreting IFNy upon antigen stimulation is lower than in 
younger individuals and may additionally result in increased susceptibility to infectious 
disease by limiting the T cell repertoire available for responses to other antigens in the 
elderly (Ouyang et a l,  2003). Therefore the diversity of TCRs used by CMV specific 
CD8^ T cells has important implications for patients beyond their protection from 
CMV.
1-8.31 cell receptor excision circles (TRECs)
TCR gene recombination as described in section 1-8.1 results in formation of T cell 
receptors, whereby TRECs are formed as by-products (compare Figure 1-7, page 62). 
TRECs can be used experimentally to estimate the number of naïve T cells. This is 
based on the fact that these extrachromosomal DNA fragments are stable within cells 
(Livak and Schatz, 1996). TREC content is therefore high in naïve T cells that have 
recently rearranged their TCR genes and did exit the thymus. Since TRECs are not 
duplicated during mitosis, they are diluted with every cell division (Takeshita et a l, 
1989) and therefore TREC content is low in activated proliferating T cells.
In a p  T cells, TRECs are produced during the rearrangement of both, TCRa 
encoding and TCRp encoding, genes. Many potential gene recombinations bring about 
different potential TRECs. However, 67 % of all a p  T cells produce similar signal and 
coding joint TRECs during the deletion of the TCRD locus when the TCRa genes are 
rearranged (Douek et a l,  1998). This is illustrated in Figure 1-10. Accordingly these 
TRECs can be used to estimate the number of naïve T cells amongst peripheral cells.
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Figure 1-10 Signal joint and coding joint TREC
T his figure illustrates the T C R D  locus em bedded w ithin  the TC R A  locus and form ation o f  the 
signal jo int (sj) TREC by ligation  o f  recom bination signal sequences flanking the ô-rec locus  
and T|)-Ja locus on the top. The cod in g  jo in t (cj) then b ecom es part o f  a second  TREC when  
recom bination o f  T C R A V  to TCRAJ occurs (illustrated on the bottom ). Adapted from  (D ou ek  
e t a l ,  1998).
Reconstitution of T cells post HSCT depends on the expansion of memory T cells and 
the generation of new T cells from progenitors (Bomberger et a l, 1998). The 
measurement of TRECs amongst peripheral cells is useful to determine if reconstituted 
cells stem are either newly generated (high TREC content) or did expand from mature T 
cells (low TREC content). In comparison, determination of thymopoietic capacity on 
the basis of CD45RA^ phenotyping of naïve T cells is of limited value as these cells 
may very rapidly convert into memory T cells of CD45RO^ phenotype (Picker et a l, 
1993) and memory T cells can also convert back into CD45RA^ expressing T cells 
(compare section 1 -9).
1-9 CD8"^  T cell differentiation, effector function & CMV 
immune evasion
T cells that completed their development in the thymus including rearrangement of their 
TCR (refer to section 1-8.1 for details) circulate between blood and peripheral lymphoid 
organs. These cells that have not yet encountered their specific antigen are termed naïve 
T cells. The engagement of the TCR of a CD8^ T cell recognising a CMV derived 
peptide bound to HLA class I molecule on the surface of an antigen presenting cell in 
combination with co stimulatory signals results in activation (compare section 1-6) and 
subsequent clonal proliferation with the development of daughter cells bearing the same 
TCR. Activation and subsequent signalling is complex. A simplified illustration is 
provided in Figure 1-11. It involves molecular clustering that leads to formation of an
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immunological synapse and interaction of an ever-growing list of signalling molecules 
(reviewed in (Razzaq et a l, 2004)).
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Figure 1-11 CD8 T cell activation
This figure illustrates how  triggering o f  the TC R /C D 3 com p lex  that bound to sp ec ific  
H L A/peptide on target ce lls  is com bined  with various other signals received v ia  costim ulators, 
coinhibitors and integrins. An early effect o f  TCR engagem ent is the activation o f  m em bers o f  
the Src tyrosine kinase fam ily (C D 3 associated  Fyn and CDS associated  L ck) via  
dephosphorylation by the phosphotyrosine phosphatase C D 45. A ctivated leu k ocyte-sp ecific  
protein tyrosine k inase (L ck) and Fyn are instrumental for phosphorylation o f  im m unoreceptor 
tyrosine-based activation m otifs (IT A M ) in the cytop lasm ic dom ains o f  CD 3 chains. This, in 
turn, creates b inding sites for further proteins w ith S rc-hom ology type 2 dom ains (S H 2). O ne 
o f  these is the tyrosine kinase Z ap-70, w hich  b ecom es then activated by phosphorylation by 
one o f  the Src-like kinases, w hich, together with Z ap-70, phosphorylate several downstream  
substrates and initiate further sign alling  cascades. A ctivation  o f  transcriptions factors for 
several genes (w ith  one o f  the m ost important being IL2 and IL2 receptor) in com bination with  
com p lex  m odifications including m obilisation  o f  calcium , release o f  retained preform ed  
receptors and granules and internalisation o f  surface receptor finally results in d ifferentiation, 
proliferation and effector functions o f  T ce lls . TCR sign a llin g  can be tuned by the affin ity for 
its ligand. High affinity peptide b inding results in phosphorylation o f  all ITAM s o f  receptors 
o f  the CD3 com p lex  that can lead to full T cell activation. In contrast, low  affin ity peptide 
binding can result in incom plete phosphorylations and thereby may for exam ple induce  
cy to lysis  but not proliferation. TCR sign als on ly  result in T cell activation o f  naive CD8"  ^ T 
ce lls  when com bined with costim ulatory sign als (for exam p le C D 28, N K G 2D , C D 40L  and 4- 
IB B  with the latter being expressed on activated T ce lls). T hese signals are further tuned by 
inhibitory signals (for exam ple KIR, C T L A -4 and Fas, being expressed or sen sitive  only after 
T cell activation), integrins and cytok ines. N a ïve CD8"  ^ T ce lls  do not express IL2 and its 
receptor. These are induced upon TCR engagem ent and costim ulation, resulting in stim ulation  
o f  growth, d ifferentiation and survival o f  antigen-selected  CD8^ T ce lls . IL2 production  
triggered by TCR and costim ulation, how ever, m ay not be su fficien t for full activation and 
CD4^ T ce lls can provide additional cytok ines. This figure was created based on inform ation  
m ainly from (Andersen et  a l ,  20 0 6 , M edem a and Borst, 1999, V iv ier and M alissen, 2 0 0 5 ).
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Recognition of target cells by CD8^ T cells results in oligomerisation of TCR molecules 
that triggers a complex cascade of downstream intracellular signalling events. Signals 
originating from TCR triggering can be tuned by co-stimulators, integrins and co­
inhibitors and, if positive signalling outbalances the negative signalling, it eventually 
leads to killing of target cells by the release of effector molecules by effector CD8^ T 
cells. Effector function of CD8^ T cells is primarily achieved by direct cytotoxicity 
(mediated by cell-cell contact) or release of cytokines such as IFNy (Andersen et a l,
2006) as will be described in sections 1-9.1 and 1-9.2.
The developing cells differentiate into antigen-experienced CD8^ T cells. These 
cells leave the lymphoid tissue via the lymphatic duct and enter the blood to find target 
cells displaying the HLA/peptide complexes they recognise. Differentiation brings 
about cell surface changes that enable some of the mature CD8^ T cells to enter other 
tissues. Inflammation causes a change in the expression of adhesion molecules on 
endothelial cells of local blood vessels, which together with chemokines attracts CD8^
T cells.
Differentiation is accompanied by expression of different surface molecules and 
mediators of cytotoxicity. Discrimination of different T cell subsets according to their 
differentiation stage has been defined using different markers by different investigating 
groups (amongst others including CD45 isoforms, CCR7, CD28, CDl lb, CD57, CD27, 
CD7, CD62L, granzyme and perforin content, ability to proliferate and/or secrete 
cytokines and activation markers such as HLA-DR and CD38), which makes 
comparisons difficult. However the consensus reached is that CMV specific CD8^ T 
cells are present in heterogeneous phenotypes in vivo (Gillespie et a l , 2000).
The expression of distinct isoforms of CD45 enables antigen-experienced T cells 
to respond to TCR mediated signals with little or no co-stimulation. The isomers 
CD45RA and CD45RO are generated by alternative splicing of mRNA transcripts with 
the resulting CD45RO proteins exhibiting stronger association with the TCR signalling 
complex than CD45RA. Both molecules catalyse dephosphorylation of protein tyrosine 
kinases (Lck, Fyn) triggering subsequent steps of T cell activation (Figure 1-11).
Naïve CD8^ T cells express the costimulatory molecule CD27 and CD45RA (as 
well as other markers such as the costimulatory molecule CD28 and the lymph node 
homing receptor CCR7), whereas memory T cells lose the expression of CD45RA. 
Recently primed virus-specific T cells are mainly of the CD45RO^ CD27^ phenotype 
with cytolytic activity only after restimulation (Hamann et a l, 1997). These CD27^ T
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cells irreversibly switch off CD27 expression after stimulation for prolonged periods 
(Hintzen et a l, 1993) followed by additional loss of CD28 expression. Differentiating T 
cells eventually revert back to expression of CD45RA^ (Hamann et a l, 1999, Wills et 
a l, 1999). The readily detectable effector functions of CD27' T cells, such as high 
granzyme B expression and direct cytolytic activity (described below), would predict 
these cells to be critical in the control of virus replication (Bachmann et a l, 1999). 
Accordingly, the majority of CMV specific CD8^ T cells display a CD45ROVCD28’ 
/CCR7' phenotype with varying expression of CD27 during acute primary infection and 
most of these cells switch to a CD45RAVCD287CD277CCR7‘ late differentiation 
phenotype after recovery (Wills et a l, 2002b). Identical T cell clones were found to 
express either isoform of the CD45 molecules suggesting a common origin of antigen 
experienced CD45RO and CD45RA expressing CMV specific T cells (Wills et a l,
1999). CMV specific CD8^ T cells are enriched for the CD277CD28' phenotype in 
HSCT patients (Gandhi et a l, 2003a). Furthermore CMV specific CD8^ T cells exposed 
to antigen for prolonged periods of time are found to express a CD57^CD27‘ or 
CD57^CD28' phenotype that was previously associated with terminally differentiated 
non-proliferating effector T cells (Kern et a l, 1999a, Kern et a l, 1996) but was more 
recently reported as a highly differentiated T cell subset of unique functionality 
(including the capability of proliferation) late after activation (Chong et a l,  2008). 
Several lines of evidence suggest that highly differentiated CMV specific CD8^ T cells 
of CD45RAVCD287CD277CCR7‘ phenotype are actually readily stimulated via 
alternative costimulatory molecules (Waller et a l,  2007) and have the capacity to 
provide immediate effector function as well as to migrate to draining lymph nodes 
(reviewed in (Waller et a l, 2008)). Following resolution of primary infection, CMV 
specific CD8^ T cells remain high in immunocompetent individuals, probably to hold 
the persisting virus in check (Gillespie et a l, 2000). They are thought to be periodically 
stimulated, thus undergoing expansion with each viral reactivation (Weekes et a l, 
1999a, Weekes et a l, 1999b, Weekes et a l, 1999c) resulting in memory inflation over 
time (Kern et a l, 1996).
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1-9.1 Direct cytotoxicity of CD8* T cells
The two main mechanisms of induction of direct cytotoxicity by effector CD8^ T cells 
(and NK cells alike) can be achieved by Fas (CD95) induced apoptosis or by the 
perforin pathway (Andersen et al., 2006).
The former mechanism involves engagement of the transmembrane protein Fas 
(CD95) on target cells. This receptor belongs to the tumour necrosis factor (TNF) 
family. FasL (expressed on activated CD8^ T cells) engagement triggers its homo- 
trimerisation and subsequent formation of the death inducing signalling complex 
(DISC) that induces apoptosis (programmed cells death). More specifically, 
trimérisation involves aggregation of death domains in the cytoplasmic tails of CD95. 
Subsequently the adaptor protein “Fas-associated protein with death domain” (FADD) 
binds the death domain of Fas through its own death domain. It also binds to caspase 8 
(via a death effector domain) and thereby bridges Fas to caspase 8. Activated caspase 8 
then triggers a cascade of caspases (cysteine proteases). It is released from the DISC 
into the cytosol, where it cleaves other effector caspases, eventually leading to 
degradation of chromosomal DNA into oligomers of 180 base pairs (bp) and other 
hallmarks of apoptosis, which is the degradation of cells into apoptotic bodies, which 
can be recognised and digested by phagocytes without the disruption of target cell 
membranes and induction of an inflammatory response. (Nagata, 1996)
The perforin pathway is the main mechanism of direct cytotoxicity exerted by 
effector CD8^ T cells, during which perforin and granzymes (serine proteases) are 
released into the intercellular space. Both of the mentioned molecules are pre­
synthesized and stored in lytic granules that mobilise to the cell surface upon contact 
with targets to secrete their content directly at the target cells. Perforin then inserts into 
the target cell membrane forming pores and these are believed to allow cellular uptake 
of granzymes (especially granzyme B) causing apoptosis of target cells in a caspase- 
dependent and caspase-independent manner, (reviewed in (Trapani and Smyth, 2002)) 
Some studies demonstrated that the uptake of granzymes into cells can be perforin- 
independent (mediated by receptor-mediated endocytosis) and that perforin 
subsequently mediates entry of granzyme B into the nucleus thereby initiating apoptosis 
(Shi e ta l,  1997).
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1-9.2 Cytokine secretion of CD8* T cells
Another antiviral response of effector CD8^ T cells and also innate natural killer (NK) 
cells encountering CMV infected target cells is the release of the cytokine IFNy. 
Binding of this secreted type II interferon results in binding to its cognate 
transmembrane IFNy receptor. The intracellular domains of the two chains of the 
receptor are associated with the janus kinases jak 1 and jak 2 respectively (reviewed in 
(Bach et a l, 1997)). Receptor triggering results in formation of a binding site for the 
signal transducer and activator of transcription (STAT) 1 and initiation of the Jak-STAT 
pathway. This pathway involves phosphorylation of STATl homodimers, which 
subsequently translocate to the nucleus and bind to y activated sequences (GAS) leading 
to transcription of IFNy inducible genes (reviewed in (Polic et a l, 1998)). Over 200 
genes are regulated by IFNy and these are implicated in antigen presentation, cell 
adhesion, chemotaxis and inflammation (reviewed in (Boehm et a l, 1997)). Main 
antiviral activity is believed to be mediated by alteration of proteasomes and MHC 
expression resulting in enhanced antigen processing and presentation. Furthermore INFy 
induces transcriptional activation of Fas in target cells resulting in increased Fas- 
mediated target cell lysis. Adoptive transfer studies have also demonstrated CD8^ T cell 
function to be dependent on INF y in vivo (Hengel et a l, 1994).
IFNy only moderately inhibits CMV replication in vitro (Torigoe et a l,  1993). 
However, its critical role in vivo was demonstrated by IFNy’s compensation for viral 
interference with antigen presentation (compare section 1-6). This was achieved by 
stimulation of synthesis, assembly and stability of HLA class I molecules resulting in 
restored antigen presentation in cells exposed to IFNy before CMV infection thereby 
limiting the immune evasion potential of CMV from CD8^ T cell control (Hengel et a l , 
1995).
Effector functions of CD8^ T cells are also mediated by other cytokines (for 
example TNFa can bind to TNF receptors triggering inflammation and events similar 
though weaker than to those described for FAS in section 1-9.1).
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1-9.3 CMV evasion of immune cell effector functions
Immune evasion allows CMV to increase the available time window for replication 
thereby facilitating virus shedding. The virus carries an abundance of genes involved in 
immune modulation of the host, some of which are involved in antigen recognition and 
were already mentioned earlier (section 1-7).
Important genes encoding products with immunomodulatory functions involving 
T cell effector functions are briefly described here. Examples of these are genes 
modulating the expression of MHC (compare section 1-7) and genes expressing MHC 
class I homologues (UL18 (Chapman et a l,  1999)). Additionally genes expressing 
cytokine homologues (UL111.5A encoding vILlO (Kotenko et a l, 2000)), inducing 
cytokine expression (UL144 (Atalay et a l,  2002)) or those expressing chemokine 
homologues (UL146 encoding vCXC-1 that mimics human IL8 (Penfold et a l,  1999)) 
and chemokine receptor homologues (US28 (Gao and Murphy, 1994), potentially 
UL27, UL33 and UL78 (Margulies et a l, 1996)) are capable of altering leukocyte 
behaviour. There is also evidence for viral immune evasion by the induction of TNPp 
and subsequent suppression of T cell responses (Michelson et a l, 1994). Furthermore 
CMV encodes genes whose products affect the cell cycle (UL69 (Lu and Shenk, 1999), 
UL82 encoding pp71 (Kalejta and Shenk, 2003)) and apoptosis (genes encoding 72 kilo 
Dalton (kDa) lEl and 80 kDa IE2 proteins (Hagemeier et a l,  1992), UL36 encoding 
vICA (Skaletskaya et a l,  2001) and UL37 encoding vMIA (McCormick et a l, 2003)). 
Genes preventing the killing of CMV infected cells by NK cells include UL40, UL18 
(both explained below), the HLA class I homologues UL142 (Wills et a l, 2005) and 
UL16 (compare section 1-6). HLA-E expression of cells depends on the binding of a 
peptide derived from other MHC class I molecules, which normally prevents NK cell 
recognition by binding to its inhibitory CD94/NKG2A receptor. MHC class I 
downregulation of virus infected cells would result in recognition by NK cells. CMV 
UL40 product, however, was shown to substitute for this peptide to protect infected 
cells (Tomasec et a l, 2000) although this was not confirmed in a subsequent study 
(Falk et a l, 2002). The product of UL18 mentioned earlier was also reported to inhibit 
NK cell lysis in some studies (Reybum et a l , 1997) but was shown to have a NK cell 
activating effect in others (Leong et a l, 1998). A more recent study demonstrated 
interaction of the UL83 encoded protein pp65 with an activating NK cell receptor that is 
thought to represent yet another strategy to reduce NK cell mediated killing (Amon et 
a l, 2005). Furthermore CMV was demonstrated to encode cellular receptors for the Fc
76
_____________   Chapter 1
domain of IgG (UL118/119 and TR L ll/IR L ll), the function of which is not yet 
determined (Atalay et a l, 2002) but may involve viral immune escape from 
complement (compare section 1-6). The protein pp65 was shown to decrease expression 
of HLA class II molecules in infected cells (Odeberg et a l, 2003) and phosphorylate the 
lE l encoded 72 kDa protein, thereby interfering with its processing and presentation for 
immunosurveillance by CD8^ T cells (Gilbert et a l,  1996).
There also exists circumstantial evidence for CMV escape from IFNy responses 
by the loss of infected cells to respond to IFNy. Lucin and colleagues found that in cells 
treated with the cytokine before CMV infection, IFNy, in synergism with TNFa, 
blocked late CMV gene transcription, reduced viral DNA replication and altered 
nucleocapsid formation. However, simultaneous infection and cytokine treatment did 
not result in a comparable effect (Lucin et a l, 1994). Similar observations were made 
during IFNy’s effect on antigen presentation in cells exposed to IFN y before CMV 
infection but not during simultaneous infection and cytokine treatment (Hengel et a l,
1995). Zimmermann and colleagues demonstrated that IFNy receptor signal 
transduction was affected by the product of the murine CMV m2 7 gene (Zimmermann 
et a l, 2005). Since a human gene homologous to m27 exists (Chee et a l, 1990), it may 
exert a similar function during human CMV infection.
Although immune evasion strategies of CMV ensure survival of the virus in its 
host, CMV specific CD8^ T cells remain critical in controlling viral replication and 
immunogenicity of several proteins has been demonstrated (Sylwester et a l,  2005). The 
principle of restoring the highly balanced relationship (that exists between CMV and 
immunocompetent individuals) in immunocompromised individuals by the transfer of 
CMV specific memory CD8^ T cells was proven (Walter et a l,  1995). For studies in 
that area accurate measurement of such cells in vivo is crucial.
77
 ________________________________________________________________ Chapter 1
1-10 Quantification of CMV specific CD8* T cells with 
HLA/peptide tetramers
Different viral CD8^ T cells can mediate control of virus infections. Clonal competition 
occurs (compare section 1-11.2), which is thought to differ substantially in a 
lymphopénie environment (such as in HSCT patients) from that in healthy individuals 
with normally balanced haematopoiesis (Goldrath and Sevan, 1999, Goldrath et al.,
2000). Approaches used for quantifying the different specific CD8^ T cells traditionally 
measure the function of those cells.
The limiting dilution assay (LDA) can be used to define an unknown frequency 
of effector T cells within PBMCs based on a functional read-out that is usually 
proliferation. It is a dose-response assay that allows detection of either positive or 
negative response to antigen in each individual culture within replicates. Several culture 
replicates that vary in the number of PBMC are tested. Entirely positive cultures are not 
informative because it is unknown whether one or more precursor cells in the culture 
responded. However cultures with negative responses in one or several replicates 
demonstrate that there are no precursors of the tested specificity in at least some 
replicates of that culture. Therefore it is possible to evaluate the effector T cell 
frequency in the original PBMC population by determining the number of cultures that 
are negative. To achieve this the fraction of negative cultures of replicates of a given 
number of PBMC can be used in suitable statistical tests including regression analysis 
and the least square method (Moretta et a l, 1983).
LDA can also be based on a chromium release assay used to determine the 
cytotoxic potential of CD8^ T cells. This assay uses the ^*Cr isotope of chromium for 
labelling of target cells and is based on the measurement of membrane disintegration 
through leakage of cytoplasm. CD8^ T cells are added and tested for their cytolytic 
function towards target cells whereby the amount of ^ ^Cr released into the supernatant is 
proportional to the number of targets killed (McCoy et a l,  1973). Alternatively LDA 
can be based on DNA fragmentation occurring early (before membrane disintegration) 
during apoptosis after CD8^ T cell induced cell death. Therefore target cells are labelled 
with the radiochemical tritiated thymidine ([^H] TdR) during growth phase. This results 
in incorporation of [^H] TdR into the DNA of target cells. They are then incubated with 
graded numbers of CD8^ T cells. Cells are harvested on glass filters whereby 
fragmented DNA from dead cells is washed through and the DNA retained by living 
cells is measured by radioactivity (Matzinger, 1991).
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The major drawback of the traditional LDA method (besides requiring large 
numbers of cells) is the failure to detect cells that are not functional in vitro, which can 
lead to underestimation of specific T cells (Goulder et a l,  2000, Moss et a l, 1995). 
CMV specific CD8^ T cell frequencies were measured directly using HLA/peptide 
tetramers in this project. Their functionality was tested secondarily by the detection of 
cytokine release upon stimulation with antigen. The basics underlying the measurement 
with HLA/peptide tetramers are briefly described below since they represent the 
platform for the main read-outs that will be described in the result chapters of this 
thesis.
The development of MHC class I tetramer/peptide tetramer complexes 
(tetramers) in 1996 represents the first direct method for measuring frequencies of 
antigen-specific CD8^ T cells (Altman et a l, 1996). Tetramers are multimeric forms of 
complexes of human leukocyte antigen (HLA) class I molecules and specific antigenic 
peptides conjugated to fluorochromes as illustrated in Figure 1-12.
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Figure 1-12 Model of an HLA/peptide tetramer complex
This figure represents a backbone tube representation o f  an H L A /peptide tetramer com p lex  
(com pare with M H C/peptide m onom er representation in Figure 1-8 on page 65). Streptavidin  
is shown in light blue, the fluorochrom e (here phycoerythrin) in red. HLA heavy chain is 
represented in dark blue, 132m in interm ediate b lue and peptide in purple (adapted from  
(M cM ichael and O'Callaghan, 1998)).
Binding of single HLA/peptide complexes with TCR is of low affinity and therefore has 
a fast dissociation rate (reviewed in (Davis et a l,  1998)). Boniface and colleagues 
demonstrated that ligand driven formation of TCR clusters is required and therefore 
three or more TCR need to be engaged to initiate effective activation of CD8^ T cells 
(Boniface et a l, 1998). HLA/peptide tetramers are produced by multimerisation with 
streptavidin. Since streptavidin has a tetrahedral symmetry it is likely that only three 
HLA/peptide complexes may engage TCR on the surface of a CD8^ T cell at any one 
time. Furthermore the most commonly used fluorochrome phycoerythrin is quite large 
(compare Figure 1-12) and likely to interfere with access of one HLA/peptide complex 
and therefore again binding is likely to be trimeric (reviewed in (McMichael and
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O'Callaghan, 1998)). The multimers provide multiple ligands for enhanced interaction 
with antigen specific CD8^ T cells. Therefore they have an increased overall avidity and 
a slower dissociation rate than monomers, which makes them more suitable for 
immunological staining of CD8^ T cells. The generation of HLA/peptide tetramers 
accounts for a major part of this project. It did involve the production of HLA heavy 
chain and him proteins from expression vectors, followed by refolding with peptide and 
multimerisation. Production steps were optimised for the different HLA/peptide 
combinations. Details on this will be described in section 2-11.
Binding of these complexes to the TCRa/B on CD8^ T cells (compare Figure 
1-8, page 65) is highly specific (Burrows et a l,  2000) provided that an optimum 
staining temperature is used (section 2-5.1). They can be used to directly visualise and 
enumerate antigen-specific CD8^ T cells by flow cytometry (section 2-5.3) without the 
requirement for in vitro stimulation and have made a major contribution towards the 
study of T cells demonstrating the importance of the CD8^ T cell immune defence 
against CMV.
It was suggested that the intensity of T cell staining obtained by TCR binding of 
tetramers is proportional to the avidity of the antigen specific T cells, which raises the 
possibility to use the technique to purify high avidity (and therefore highly reactive) 
antigen specific T cells (Yee et a l,  1999). High avidity antigen specific T cells from 
donors obtained by tetramers may then be transferred to patients for immunotherapy.
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1-11 Adoptive therapy with CMV specific T cells post HSCT
As described in detail in the earlier sections of this chapter, CMV infection is a major 
problem in HSCT patients. Conditioning regimens eliminate the recipient immune 
defence. T cell depletion, delayed T cell recovery in vivo and prolonged 
immunosuppressive treatments are associated with a significant risk of viral reactivation 
post HSCT. Vaccination approaches have been developed, which aim to evoke an 
immune response by administration of an immunogen to individuals. These initially 
made use of whole live virus but more recently involved the antibody target 
glycoprotein B as well as dense bodies and T cell targets, which are either pp65 and IE 
proteins administered in expression vectors or minimal epitopes derived from these 
proteins (reviewed in (Wills et a l, 2002a)). However, these vaccination approaches may 
not function optimally in immunocompromised hosts. Antiviral drugs inhibit productive 
virus replication in vivo. However, they appear to alter subsequent reactivations such 
that antiviral T cells recover less effectively. This can lead to late, chronic CMV 
reactivation, particularly in association with chronic GvHD (Junghanss et a l,  2002, 
Nguyen et a l, 1999). In addition, drug resistant escape mutants have been reported 
(Springer et a l, 2005) and the treatment itself is associated with significant toxicity in 
patients. Adoptive therapy of donor derived CMV specific CD8^ T cells is a promising 
treatment alternative (Gandhi et a l, 2003b).
Reusser and colleagues demonstrated that cytotoxic activity of CMV specific 
CD8^ T cells against infected fibroblasts correlates with resistance against CMV 
pneumonitis (Reusser et a l, 1991). A proof of principal for the feasibility of an 
adoptive immunotherapy approach against CMV in transplant patients has been 
established in a phase 1 clinical trial by Walter and colleagues (Walter et a l,  1995), 
who isolated and expanded CMV specific CD8^ T cell clones from the blood of HSCT 
donors and administered them to 14 patients prophylactically at weekly intervals in 
doses escalating from 3.3x10^ to IxlO^/kg beginning at 30 to 40 days post transplant. 
Their results strongly suggest a safe, protective effect against CMV reactivation. 
Neither CMV viraemia nor disease developed in any of the treated patients. CD8^ T cell 
responses declined over some weeks in patients who failed to recover endogenous CMV 
specific CD4^ T cell responses suggesting that CD4^ T cells are required for the 
persistence of transferred CD8^ T cells. However, it has to be noted that the respective 
patients had GvHD related treatment with cyclosporine and prednisolone. Therefore it is 
not known if the decline in transferred CD8^ T cells was due to CD4^ T cell deficiency
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or the immunosuppressive treatment. Einsele and colleagues (Einsele et a l, 2002) 
published a second immunotherapy trial. They infused polyclonal CMV specific T cell 
lines into eight HSCT recipients who had persisting or recurring CMV infection despite 
the prolonged used of antiviral treatment. Seven of these patients still received 
immunosuppressive GvHD prophylaxis at the time of first cell infusions. Cell lines 
were prepared by stimulation of PBMC vvdth CMV lysate and expanded with 
autologous, irradiated PBMC feeder cells for presentation of CMV lysate and IL2. They 
were predominately CD4^. A total dose of IxlO^/m^ was administered with no 
cytotoxicity observed. Viral load was subsequently reduced in 7/7 evaluable patients. 
This reduction was persistent in five and transient in two patients, who both had 
received intense immunosuppression for GvHD around the time of T cell therapy. A 
similar method was also successfully employed by Peggs and colleagues (Peggs and 
Mackinnon, 2004a, Peggs et a l, 2003c).
Despite the positive outcome of both these trials, there were some associated 
difficulties. The methodology by Walter and colleagues required skin biopsy for the 
generation of fibroblasts (that were used as APC) and live virus to stimulate T cells. The 
method by Einsele and colleagues required labour intensive in vitro expansion of cells. 
The feasibility of a more rapid expansion method using a 20-hour incubation period of 
donor PBMC with pp65 and subsequent isolation of IFNy producing T cells was 
demonstrated by Mackinnon and colleagues. Adoptive transfer of 1x10"^  cells/kg 
generated with this method either prophylactically (n=2) or pre-emptively (n=5) 
resulted in 700 to 5000 fold in vivo expansion and significant reduction of CMV 
reactivation periods in treated patients (Mackinnon et a l, 2007).
The correlation of CMV specific CD8^ T cells with protection against CMV 
disease in HSCT patients was subsequently confirmed by quantification using tetramers 
(Aubert et a l, 2001, Cwynarski et a l, 2001, Gratama et a l, 2004, Gratama et a l,
2001). Therefore CMV peptide specific CD8^ T cells that can be detected and sorted by 
tetramers could be used for an adoptive therapy in immunocompromised patients. This 
may result in highly specific protection against CMV without the use of live virus or 
usage of a highly labour intensive tissue culture based system. Direct tetramer based 
selection may be advantageous over the use of in vitro cultured T cells since it is 
unclear what effect the manipulations may have on their cellular function. Indeed, the 
direct application of such cells without prior in vitro expansion has been demonstrated 
in a phase 1 clinical trial (Cobbold et a l, 2005).
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For the development of an adaptive therapy approach, epitopes targeted by CD8^ T cells 
in an HLA dependent context as well as the number of specific T cells necessary for a 
protective response in vivo must be known. Initial CMV T cell studies addressing these 
questions focused primarily on frequency measurements of pp65 specific CD8^ T cells 
restricted by HLA-A* 02 and HLA-B*07 because these alleles are amongst the most 
common HLA types in Caucasoids and many other ethnic groups. The successful 
generation of HLA-A*0201 restricted CMV pp65 (495-503) specific CD8^ T cells 
under GMP conditions has already been demonstrated (Li Pira et a l, 2006) It is, 
however, desirable to develop reagents for an adoptive therapy approach directed 
towards different epitopes in the context of more than two HLA alleles, as this could 
benefit more patients.
1-11.1 T cell targets: HLA candidates and their frequency in the 
population
HLA/peptide tetramers are highly specific and their use is limited to individuals 
possessing T cells, which have been selected to react with peptides presented by 
relevant self-HLA molecules. Optimal therapeutic application may be achieved by the 
selection of tetramers comprising a wide variety of HLA alleles that are relatively 
common in most ethnic populations. Previous studies suggested that 90 % coverage of 
some ethnic groups might be attainable with as few as eleven CD8^ T cell epitopes 
(Longmate et a l, 2001).
According to Marsh, HLA-A2 has a gene frequency of 25 % in Caucasoids 
(Marsh, 2000). Longmate and colleagues estimated that the most common HLA-A2 
allele, HLA-A*0201, covers 45.8 % of European Caucasoids (Longmate et a l, 2001). 
To choose further HLA alleles that may allow the most possible coverage of 
Caucasoids, gene frequencies of the most common (>8 %) HLA genes within this ethnic 
group were compared and are shown in Table 1-1.
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HLA-A Gene Frequency
HLA-A2 25.0 %
HLA-Al 14.0 %
HLA-A3 11.9%
HLA-A24 10.4%
HLA-B Gene Frequency
HLA-B44 11.2%
HLA-B35 10.3 %
HLA-B7 8.7 %
Table 1-1 Average gene frequency of the most common HLA-A and HLA-B genes 
amongst Caucasoids
This table dem onstrates average gen e frequ en cies o f  H L A  g en es that are m ost com m on  
am ongst C aucasoids (M arsh, 2 0 0 0 ).
This table demonstrates that besides tetramers that incorporate the well-studied HLA- 
A2 or HLA-B7, it would be desirable to investigate CMV specific CD8^ T cell 
responses with tetramers that incorporate HLA-Al, HLA-A3, HLA-A24, HLA-B44 or 
HLA-B35. Accordingly efforts during this project were focused on the generation of 
tetramers comprising the most common alleles of these less well-studied HLA genes.
An HLA-A*0301 restricted CMV pp65 epitope was not known at the time of 
initiating this project. Enzyme-linked immunospot (ELISpot) based investigations of the 
HLA-A*0301 restricted CMV p p l50 (945-955) CD8^ T cell epitope defined by (La 
Rosa et a l, 2005) yielded very low or undetectable responses in healthy individuals. 
Therefore investigations of HLA-A*0301/CMV specific CD8^ T cells had to be halted 
to prioritise investigations with tetramers that showed more promising production 
developments first.
HLA-B *4402 encoded protein was successfully produced by cloning from 
homozygous cell lines and expression in Escherichia coli (E. coli). However, refolding 
(as is necessary for the production of HLA-B*4402/CMV tetramer) proved to be 
difficult and after lengthy, unsuccessful trials using alternative refolding strategies, 
investigations of HLA-B*4402/CMV specific CD8^ T cells had to be halted as well to 
prioritise investigations with tetramers that showed more promising production 
developments first.
Tetramers incorporating HLA-A*0101, HLA-A*2402 or HLA-B*3501 and 
relevant CMV peptides were produced successfully. This involved several optimisation 
strategies of the original method described by Altman and colleagues (Altman et a l ,
1996) and took up a major part of this project. Results obtained during the generation of
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these tetramers will be described in Chapter 2. Findings from the measurement of T cell 
responses obtained with these reagents will subsequently be shown in the result chapters 
of this thesis.
HLA-A*2402 is of particular interest regarding coverage of multiple ethnic 
populations because it is the most frequent HLA allele in the Japanese population. The 
allele frequencies of HLA-A*0201 and HLA-B*0702 in this population are only 11 % 
and 5 % respectively whereas the allele frequency of HLA-A*2402 is 32.7 % in the 
Japanese (Tokunaga et a l, 1997). Sette and Sidney estimated that the HLA-A*2402 
allele covers 58 % of the Japanese (Sette and Sidney, 1999). Longmate and colleagues 
estimate that successive addition of HLA-A*0201, HLA-A*2402 and HLA-A*0101 
already covers 75.7 % of the Caucasoid population. Accordingly adoptive transfer of 
CD8^ T cells targeting CMV peptides presented by the common HLA-A*0101, HLA- 
A*2402 and also HLA-B*3501 in addition to HLA-A*0201 and HLA-B*0702 may 
enable therapy of a majority of European Caucasoids and Asians. Consistent with that, 
this project aimed to further the knowledge on the less well-studied HLA-A*0101, 
HLA-A*0201, HLA-A*2402 and HLA-B*3501 restricted CMV specific CDS^ T cells, 
which may be most relevant for inclusion in future adoptive therapy trials.
1-11.2 T cell targets: CMV peptide candidates and their
immunogenicity
Of all the peptides encoded by a foreign antigen such as CMV that can potentially be 
presented to CDS^ T cells, only a small proportion induces measurable responses in 
association with any given HLA allele. This observation is known as 
immunodominance. Yewdell and Bennink reviewed that to be immunogenic; peptides 
must first be able to bind to an HLA class I allomorph (the product of an HLA class I 
allelic gene) with high enough affinity. This is estimated to narrow down the number of 
potential peptides by 1/200. Then limitations in the CDS^ T cell repertoire render 1/2 of 
the HLA binding peptides non immunogenic. Of these, limitations in the efficiency of 
antigen processing render a further 4/5 non immunogenic (Yewdell and Bennink, 1999). 
The competition for limited resources between CDS^ T cells responding to the 
remaining immunogenic peptides (0.2 % of peptides encoded by the foreign antigen) 
finally dictates the outcome of the overall T cell response in the host.
Kedl and colleagues reviewed that T cells may compete when the number of 
APC or antigen is limited and the T cells are present in numbers high enough to 
influence one another. Competition appears to primarily occur between CDS^ T cells
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responding to the same HLA/antigen (direct competition) rather than between CD8^ T 
cells responding to different HL A/antigens (cross competition) (Kedl et a l,  2003). 
Direct competition may result from either high affinity T cells removing HLA/antigen 
from the APC (shown in Drosophila (Huang et a l,  1999)), thereby decreasing the 
chance of lower affinity T cells to detect it or from killing of APC (demonstrated for 
infection with Listeria monocytogenes (Wong and Pamer, 2003)). These mechanisms 
can explain affinity maturation of CD8^ T cells. Internalisation of HLA/peptides by T 
cells in turn results in themselves becoming sensitive to lysis by T cells specific for the 
peptides and may serve to down-regulate immune responses (Huang et a l,  1999). 
Indirect competition likely results from the limitations of the space surrounding APC 
and plays a role in driving epitope dominance (reviewed in (Kedl et a l, 2003)).
The CMV genome contains more than 200 open reading frames (Chee et a l, 
1990). At the time of initiating this project, evidence suggested that the major tegument 
protein pp65 and the immediate early protein lE l are the main immunodominant targets 
for CD4^ and CD8^ T cells (Beninga et a l,  1995, Boppana and Britt, 1996, Davignon et 
a l, 1995, Kern et a l, 2002, Kern et a l, 1999b, Wills et a l, 1996). Since the quantity of 
pp65 specific CD8^ T cells correlating with protection from CMV disease were 
previously determined in the context of HLA-A*0201, this study aimed to compare 
CD8^ T cell responses recognising pp65 presented by this and other common HLA 
alleles (initially HLA-B*3501 and HLA-A*2402) and to investigate the correlation of 
those cells with CMV replication in HSCT patients.
During the development of this project, a peptide derived from pp50 was shown 
to induce HLA-A*0101 restricted CD8^ T cell responses of a magnitude similar to those 
observed for pp65 and lE l for the first time (Elkington et a l, 2003). At this time the 
panel of CMV specific CD8^ T cell responses to be investigated was expanded to 
include HLA-A*0101 restricted CD8^ T cell responses targeting pp65 and also the new 
pp50 epitope.
High magnitudes of a focused response targeting mainly two proteins seem 
surprising considering pp65 is one amongst a large number of proteins encoded by the 
CMV genome. Accordingly a recent report demonstrated new data revealing a much 
broader specificity of CD8^ T cell responses (Sylwester et a l, 2005). Knowledge on the 
two protein targets, pp65 and pp50, which were investigated in this study, is 
summarised below.
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The CMV tegument phosphoprotein, pp65, is considered one of the most important 
antigens for cellular immunity in CMV infection (McLaughlin-T ay lor et a l,  1994, 
Walter et a l, 1995). This structural protein is introduced into the cell after viral 
penetration. Therefore recognition can occur in the absence of de novo viral gene 
expression. CD8^ T cells targeting pp65 are thought to lyse infected cells before viral 
assembly and may provide a biological advantage for limiting the spread of infection 
after CMV reactivation (Riddell et a l,  1991a). Dense bodies were shown to consist 
mainly of pp65 (Irmiere and Gibson, 1983) and to enter cells efficiently, delivering 
protein into the cells and eliciting CD8^ T cell responses in the absence of de novo 
protein synthesis (Pepperl et a l, 2000). The inhibition of protein presentation due to 
downregulation of class I MHC as one of the immune escape strategies of CMV might 
further explain why the specificity of the CD8^ T cell responses seems to be focused on 
pp65 (Beersma et a l, 1993, Gilbert et a l,  1993, Gilbert et a l,  1996, Spaete et a l, 1994, 
Warren et a l, 1994). Wills and colleagues demonstrated that the CD8^ T cell response 
to CMV is dominated by pp65 irrespective of major histocompatibility complex 
haplotype. The group used a pp65 gene deletion mutant of CMV to show that CD8^ T 
cells targeting this protein contribute to 70 to 90 % of all CD8^ T cells recognising 
CMV infected cells (Wills et a l, 1996). Kem and colleagues found that over 80 % of 
normal healthy donors have CD8^ T cell responses to peptides derived from pp65 (Kem 
et a l, 2002).
The importance of CMV antigens such as pp50 may have been underestimated 
prior to 2003. Profiling of CD8^ T cell responses to a large panel of CMV antigens 
during that year revealed, for the first time, that more than 40 % of CD8^ T cell 
responses to CMV are directed towards antigens other than pp65 or the immediate early 
protein 1 (Elkington et a l, 2003).
In contrast to pp65, pp50 is a non-stmctural protein. Alternative names of this 
phosphoprotein are pUL44 and p52. At present the knowledge on this protein is much 
more limited than that on pp65. It is known, together with pUL54, to form the viral- 
encoded DNA polymerase complex that mediates replication of CMV in the nucleus of 
infected cells. More recently it was demonstrated to also form disulfide-linked 
homopolymers in the cytoplasm of cells (Alvisi et a l, 2006). It was reported to be 
released from cells upon cell lysis of infected cells and to aid cell adhesion during viral 
entry by binding to integrins on target cells in mice (Loh et a l, 2000). It is one of the 
most immunogenic CMV proteins that can induce a humoral response (Gergely et a l ,
88
___________________________________________________________________ Chapter 1
1988). The promoter of the gene encoding CMV pp50 was shown to use three 
transcriptional start sites that were expressed differentially throughout infection (Leach 
and Mocarski, 1989). Therefore translation starts early (4 hours post infection) but 
maximal synthesis occurs late (48 hours) after infections (Geballe et a l,  1986). Since 
viral immunomodulating proteins are known to block endogenous antigen presentation 
by CMV infected cells, CMV pp50 specific CD8^ T cells may also be induced primarily 
by cross priming (compare section 1-6). In comparison, it was demonstrated that for 
many EBV-encoded antigens, which are poorly processed by infected cells, CD8^ T 
cells are generated through the cross-priming pathway (Blake et a l , 2000, Blake et a l ,
1997).
Amino acid sequences of pp65 and pp50 derived epitopes, which were targets of 
CMV specific CD8^ T cells studied during this project, are summarised in Table 2-5 on 
page 129. Relevant publications on details and immunological significance of these 
epitopes are introduced during the relevant sections in Chapter 3.
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1-12 Aims of this thesis
Current limitations of antiviral therapies identify a need for alternative approaches, such 
as an adoptive therapy, to combat the development of potentially fatal CMV related 
complications in HSCT patients. Tetramers are a valuable tool for highly specific 
selection and thereby therapeutic use of antigen specific T cells and for monitoring of 
those cells ex vivo.
The study described in this thesis aims to further the knowledge firstly on the 
quantity of CMV specific CD8^ T cells that correlate with protection from CMV 
replication in vivo and secondly on the fine specificity of those cells.
The aim of this project was to investigate CMV specific CD8^ T cell responses 
restricted by common HLA types other than the well studied HLA-A2 and HLA-B7 
types. Investigations covered responses to CMV peptides restricted by some of the most 
frequent HLA alleles amongst Caucasoid and Asian ethnic groups. This involved the 
development of corresponding tetramers to enumerate CD8^ T cells that target CMV in 
patients who reconstituted these responses after severe immunosuppression due to 
conditioning for HSCT. Longitudinal measurement of CMV specific CD8^ T cells was 
correlated with clinical data. The cells investigated were not studied with the same 
frequency and confirmed functionality in this patient group before, and this was the first 
study to address the question of which number of these cells (inversely) correlated with 
the ability to detect CMV replication in vivo. The results have direct implications for the 
development of CMV specific adoptive therapy in this patient group.
The different CMV specific CD8^ T cells were analysed for their TCR diversity 
directly ex vivo. This study represents the first to describe TCR diversity of CD8^ T 
cells targeting a CMV pp50 epitope in comparison to different CMV pp65 epitopes. 
This analysis may aid to determine which CMV specific CD8^ T cells are most likely to 
efficiently protect and benefit patients from amongst those targeting different CMV 
epitopes. CMV specific CD8^ T cells with high T cell receptor diversity may counter 
immune escape mechanisms and contribute only minimally to CMV associated 
immunosenescence, thereby providing an advantage over epitope specific CD8^ T cells 
with less T cell receptor diversity.
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CHAPTER 2 MATERIALS AND METHODS 
2-1 Introduction
The study described in this thesis primarily focuses on investigations involving the use 
of different tetrameric complexes and spectratyping analysis. Especially the generation 
of tetramers needed for the measurement of T cell responses accounts for a major part 
of the PhD project. Consistent with that the description of materials and methods in this 
chapter contains a main section that describes details of how the different tetramers 
were generated, including cloning of expression vectors, followed by expression, 
refolding and tetramerisation of proteins. Results obtained during the generation of 
tetramer reagents are included within this chapter rather than in the results chapters to 
draw the reader’s attention to the measurement of patient T cell responses rather than to 
preliminary experiments in the result chapters. In contrast, optimisation of spectratyping 
methods is described in the relevant result chapter to highlight new settings that were 
developed to enable spectratyping of small numbers of ex vivo PBMC.
All materials and methods used to perform the work mentioned throughout this 
thesis are described in this chapter. Buffer and solutions were prepared using chemicals 
purchased from BDH or Sigma if not mentioned otherwise. These were filter sterilised 
using 0.2 pm filters or autoclaved if their properties allowed so.
2-2 Patients & healthy donors
Patients and healthy donors were recruited for this study if they expressed the HLA 
types HLA-A*0101, HLA-A*0201, HLA-A*2402 or HLA-B*3501 (subsequently 
abbreviated as HLA-A 1 /A2/A24/B35) and they and/or their donors were CMV 
seropositive. A minority of healthy donors, some of them with unknown HLA type 
and/or CMV serology, were recruited for control experiments. All subjects gave 
informed consent (see section 2-2.2).
2-2.1 Determination of HLA type and CMV serology
The majority of DNA-based HLA typing assays for patients and healthy donors were 
performed at the Histocompatibility Laboratories at the Anthony Nolan Research 
Institute (ANRI). HLA class I genotyping was performed using sequence-specific 
oligonucleotides (PCR-SSO), sequence-specific primers (PCR-SSP), or nucleotide 
sequencing. PCR-SSO involves an HLA locus specific polymerase chain reaction
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(PGR). The product is denatured and hybridised against a panel of immobilised 
oligonucleotide probes that have sequence complementary to stretches of 
polymorphisms within HLA alleles. The presence of bound amplicon is measured in a 
colour reaction. The PCR-SSO methodology provides low to medium resolution results 
usually at the two-digit level. PCR-SSP and nucleotide sequencing analysis can provide 
high-resolution allelic level typing results represented by four digits. PCR-SSP involves 
multiple PCRs targeting the presence and absence of polymorphisms within HLA 
genes. Protocols usually also include internal controls from constitutive genes and 
products are analysed by agarose gel electrophoresis and staining. Depending on the 
primers used PCR-SSP can initially provide low to medium resolution typing. 
Additional testing after the low-resolution tissue type is known, can give a high- 
resolution result. PCR-SSP is the quickest DNA based method. However, it is not used 
for large scale HLA typing because of the rate-limiting step of agarose gel 
electrophoresis. Therefore the Histocompatibility Laboratories at the ANRI use a 
combination of both methods and nucleotide sequencing to discover novel mutations.
Patients that had not been HLA typed routinely at the high-resolution level 
before transplantation (for example patients scheduled for autologous transplantation) 
and healthy donors were typed for the major HLA antigens (HLA-A and HLA-B, HLA- 
C, HLA-DR, HLA-DQ and HLA-DP, compare section 1-2) at the allelic level at the 
Histocompatibility Laboratories at the ANRI.
Previous CMV infection was detected by the presence of specific G isotype Ig in 
the serum. The additional presence of specific M isotype Ig was also tested for and will 
be described later. The majority of CMV serology assays for patients and healthy 
donors were performed at the Histocompatibility Laboratories at the ANRI using the 
Bioelisa CMV IgG kit (Biokit Ltd).
This enzyme-linked immunosorbent assay (ELISA) test was used for detection 
of IgG antibodies to CMV in heat-inactivated serum. Briefly, serum was incubated in 
microplate wells (U 69 Maxisorb Immunoplate, Nunc) coated with CMV antigen. CMV 
antibodies, if present, then bound to the antigens attached to the well. The well was 
washed to remove residual serum and enzyme-labelled antibodies that bind to human 
IgG (rabbit anti-human IgG conjugated with peroxidase) were added. After another 
wash to eliminate unbound material, an enzyme substrate solution (citrate-acetate buffer 
containing hydrogen peroxide) containing a chromogen (3,3', 5,5'-Tetramethylbenzidine 
dissolved in dimethylsulfoxide) was added and developed a blue colour if the serum
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contained anti-CMV IgG. The blue colour was converted to yellow by addition of 
sulphuric acid stop solution. The intensity of the colour was proportional to the amount 
of anti-CMV IgG in the test serum and was estimated by measurement at 450 nm along 
with a calibration curve.
Early infection resulting in the presence of IgM but not IgG antibodies to CMV 
would be missed by the Bioelisa CMV IgG kit. Therefore CMV IgM serology was 
additionally tested using the Bioelisa CMV Colour (Biokit Ltd). In comparison to the 
IgG kit, this is a qualitative assay using a conjugate that is based on a mixture of anti­
human IgG and anti-human IgM. It should be noted that CMV IgM antibody can be 
present in patients with reactivation of latent CMV (Pass et a l,  1983) and therefore 
cannot be used to characterise primary infection (Subramanian, 2008).
Patients 10 and 15 were HLA typed (PCR-SSO in both cases) and tested for 
CMV (by fluorescent anti-pp65 and anti-pp67 antibody, and ELISA respectively) 
serology locally at the Universidad Autonoma de Madrid (UAdM) in Madrid, Spain and 
the Universidade Federal do Parana (UFdP) in Curitiba, Brazil respectively.
2-2.2 Ethical approval
Recruited patients gave informed written consent to participate in the study that was 
ethically approved by local authorities at the Royal Free Hospital (RFH) in London, and 
for consultation of their clinical data.
Patients were approached individually by the treating hospital’s medical staff, 
who informed them about the objectives and protocol of the study. Each patient was 
given an information sheet, which was translated into the patient’s native language 
when necessary. Patients who decided to enter the study were asked to sign a consent 
form.
2-2.3 Blood sample collection
Blood was collected from patients at the Haematology Day Unit (which was initially 
located at Crowley Ward and later at GACS (Oaks Ambulatory Care Suite)) at the RFH, 
London; the UAdM (in case of patient 10); the UFdP (in case of patient 15) or from 
healthy volunteers working at laboratories at the ANRI or at the Haematology and 
Virology Departments of the RFH after informed consent. Additional blood samples 
from patient 2 were also obtained from the Royal Devon & Exeter Hospital when the 
patient had moved away from London.
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For patients, 20 ml of peripheral blood samples were drawn in parallel with blood being 
taken for routine tests required for assessment of the progress of patients at visits to the 
clinic and therefore did not require additional venipuncture.
Blood samples obtained from the RFH were drawn into tubes containing 20 pi 
of Heparin (Monoparin 1000 U/ml, CP Pharmaceuticals) to prevent coagulation and 
were processed the same day. Blood samples obtained from the UAdM were drawn into 
tubes containing transport medium of a volume equal to that of the blood sample. 
Transport medium consisted of sterile filtered Roswell Park Memorial Institute (RPMI) 
1640 cell culture medium (BioWhittaker) supplemented with trisodium citrate at a final 
concentration of 3.3 % (w/v) and B-mercaptoethanol (BDH Biochemicals) at a final 
concentration of 5 pM. Blood samples preserved in that way were shipped by overnight 
delivery service and process at the ANRI the following day. Blood samples obtained 
from the UFdP were processed locally. Frozen PBMC were brought by collaborators on 
their way to London and stored in liquid nitrogen until used for experiments at the 
ANRI.
2-2.4 Consultation of clinical data including CMV PCR
Clinical data was consulted with the help of medical staff at the treating hospitals. This 
included general patient information, type of transplant received, conditioning regimens 
and potential T cell depletion of the grafts, T cell counts determined at the time of 
sampling, CMV DNAemia/antigenaemia results, antiviral treatment, GvHD 
prophylaxis, GvHD episodes and administration of immunosuppressive treatments. 
Complete information on the last three mentioned parameters could not be obtained for 
patients 1 and 19 because clinical data from these private patients had been removed 
from the RFH and access was not provided at the new location.
CMV DNAemia was assessed from whole blood by quantitative PCR performed 
at the Virology Department of the RFH as described in (Mattes et a l, 2005) or, in case 
of patient 10, at the UAdM. For patient 15, CMV was detected by antigenaemia using 
perinuclear staining of leukocytes indicating the number of CMV infected cells per 
200,000 PBMC (van der Bij et a l, 1988) stained during routine viral monitoring by the 
Virology Department of the UFdP.
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2-2.5 Patient’s  and healthy donor’s  characteristics
All patients were undergoing haematopoietic stem cell transplantation (HSCT) for 
haematological conditions and had been HLA typed at the allelic level by molecular 
techniques.
Patients from whom samples were collected from earlier than 100 days post 
transplantation onwards with at least 4 collections post transplantation were included in 
the follow-up cohort to establish a threshold of cell levels correlating with protection 
from CMV. Characteristics of these patients are demonstrated in Table 2-1. They were 
monitored weekly from engraftment on until discharge from hospital and at visits to the 
clinic thereafter.
Most patients that were scheduled for allogeneic HSCT (all allogeneic patients 
shown in Table 2-1 except patients 6, 10, 17, 22, 24 and 26, who did not receive CMV 
prophylaxis and patient 15 described later) received antiviral prophylaxis in form of 
intravenous aciclovir at 10 mg/kg of body weight, 3 times a day, during the in-patient 
stay and were given 2 g/kg of body weight oral valaciclovir, four times a day, thereafter. 
Aciclovir or valaciclovir were also given prophylactically to these patients between 
courses of antiviral treatment and continued until at least five months post 
transplantation. Patient 15, who was transplanted at the UFdP, received intravenous 
aciclovir at 250 mg/m^ (height = 1,66 m, weight = 63,8 kg, total corporal 
surface = 1,71 m^), 3 times a day from day -1 to +28 post transplantation. GvHD 
prophylaxis, usually in form of Cyclosporine A alone or with Methotrexate, that was 
given to patients are listed in Table 2-1. Most patients that were scheduled for 
autologous HSCT (all autologous patients shown in Table 2-1 except patients 14, who 
did not receive CMV prophylaxis) received the same CMV prophylaxis as that 
described above as in-patients, which was then stopped on discharge. Patients 
transplanted after renewal of these prophylaxis guidelines at the RFH (patients 6, 14, 
17, 22, 24 and 26) or patient 10, who was transplanted at the UAdM did not receive 
CMV prophylaxis.
Antiviral and immunosuppressive treatment received in addition to prophylaxis 
by the patients is shown in the follow-up graphs in the result chapters. Antiviral 
treatment usually consisted of intravenous ganciclovir at 5 mg/kg of body weight twice 
a day (simultaneously with subcutaneous intravenous granulocyte colony-stimulating 
factor (G-CSF) at 300 mg/kg of body weight once daily or on alternate days to 
counteract its myelosuppressive effect) or intravenous foscamet at 90 mg/kg of body
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weight twice a day. Patients transplanted after renewal of these treatment guidelines (all 
patients shown in Table 2-1 except patients 1, 9, 10, 15, 16 and 19) were also eligible 
for alternative treatment with oral Valganciclovir at 900 mg/kg of body weight twice a 
day. Doses were reduced if patients suffered renal impairment. Pre-emptive treatment in 
patients 1, 9, 16 and 19 was initiated after two consecutive positive CMV PCR results 
and until two consecutive negative CMV PCR were observed. In patients transplanted 
after renewal of these treatment guidelines (all patients shown in Table 2-1 except 
patients 1, 9, 10, 15, 16 and 19) treatment was warranted if the viral load was 
>3,000 genomes/ml. Patients were randomised to be treated either until two consecutive 
negative CMV PCR were observed (all patients except patients 10, 15 and 23) or until 
the viral load was <3,000 genomes/ml on two consecutive occasions (patient 23). 
Patients 10 and 15 did not receive treatment according to these guidelines because they 
received HSCT at the UAdM and UFdP respectively. Antiviral and immunosuppressive 
treatment received by these patients is shown in the follow-up graphs in the result 
chapters.
Immunosuppressive treatment usually consisted of methylprednisolone and was 
given at a dose and time period appropriate for the severity of GvHD symptoms. The 
type and time period of treatment received is shown in the result chapters.
Patients, who did not meet the criteria to be included in the follow-up cohort 
mentioned earlier, but from whom samples were used for clonotypic and other 
experiments that are shown throughout this thesis, are listed in Table 2-2.
Healthy donors from whom measurements are shown throughout this thesis are 
listed in Table 2-3.
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ID
HLA of 
interest
Diagnosis 
prior to HSCT
Sex
(r/d)
Age
(r/d)
CMV
serol.
(r/d)
HSC source**** Conditioning TCD of 
graft
GvHD
prophylaxis
CMV
disease*
Sample
no.**
Period
1 A2, B35 AML (tr2) m/f 43/41 +/+ m alio PBSC M sib Bu, Cam, Flu n CSA n 14 d31-dl45
2 A2, B35 MDS (pr) f/m 32/36 +/+ m alio PBSC M UR Flu, Mel n CSA, MMF n 35 , d88-d902
3 A 1,B35 EP m/m 63/32 +/- m alio PBSC M UR Cam, Flu, Mel n TA n 30 d33-d512
4 B35 AML-M4 m/m 44/38 +/+ alio PBSC M sib Cy,TBI n CSA, MTX n 37 d46-d734
5 A 1,B35 ALL-CR3 m/m 26/unknown +/+ alio BM M sib Eto, TBI n CSA, MTX n 9 d53-dl56
6 A2, B35 B-CLL m/m 44/47 +/+ m alio PBSC M sib Cam, Flu, Mel n CSA n 14 d23-dl98
7 A24, B35 AML-M4, CRl m 36/39 +/- alio BM M sib Cy, TBI n CSA, MTX n 20 d46-d818
8 B35 AML (trl) m 55/43 +/+ m alio PBSC M sib Cam, Flu, Mel n CSA n 4 d40-d60
9 B35 MM IgAK f 42 -1- auto PBSC Mel n - n 12 d33-d808
10 A24 T-ALL m/f 27/0 +/+ CB M UR + TPD MM sib ATG, Cyt, Flu, TBI n CSA n 11 d50-d360
11 A24 CML Ph+ 57/28 +/+ m alio PBSC M UR Cam, Flu, Mel n CSA n 35 d99-d791
12 A24 AA m/f 36/30 +/+ alio BM M sib ATG, Cy n CSA n 5 d54-d94
13 A2, A24 MM IgGK m 46 -t- auto PBSC Mel n - n 9 d21-d774
14 A 1,A 24 MMX f 51 4- auto PBSC Mel n - n 6 d27-dl94
15 A2, A24 CLL m 51/43 +/- m alio BM M sib Cy, Flu n CSA, MTX n 8 d ll-d l5 6
16 A24 HD (IVB) m 20 + auto PBSC Eto, Mel n - n 7 d36-d95
17 A24 MDS m/m 41/30 +/+ alio BM M UR Cy, Flu, TBI y CSA n 7 d 39-d ll8
18 A24 AML-CR2 (tr2) m 58/43 +/+ m alio PBSC M UR Cam, Flu, Mel n CSA, D ef n 22 d64-d830
19 A24 T-ALL-CRl m/f 25/25 +/+ alio PBSC M sib Cy, Flu y unknown n 14 d56-dl40
20 A24 CML Ph+ m/f 54/50 -/+ alio PBSC M UR Cy, TBI n CSA, MMF, MTX n 6 d32-d70
21 A1 FasL m/f 32/28 +/- m alio PBSC M sib Cam, Flu, Mel n CSA n 33 d55-d682
22 A1 AML-CRl f/m 44/41 +/+ alio PBSC M sib Cy, TBI CAM CSA n 18 d20-d384
23 A 1,A 2 MMk-CRI f/f 49/42 +/+ m alio PBSC M sib Flu, TBI n CSA, TA y 9 d38-dl85
24 A 1,A 2 myelofibrosis m/f 66/60 +/+ m alio PBSC M sib Cam, Flu, Mel n CSA y 5 d32-dl55
25 A1 ALL Ph+ m/m 19/33 +/- alio PBSC MM UR Cy, Flu, TBI y CSA n 5 d90-dl36
26 A 1,A 2 XLP m/m 18/unknown +/+ m alio PBSC M sib Cam, Flu, Mel n CSA n 12 d33-d296
27 A1 AML-CRl (tr3) Em 43/38 -/+ m alio PBSC M sib Cam, Flu, Mel n CSA n 9 d83-d209
28 A1 HD (IVA) m/m 21/32 -/+ m alio PBSC, MM UR Cam, Flu, Mel n CSA n 8 d64-dl55
29 A2 B-CLL m/f 53/42 +/+ m alio PBSC M sib Cam, Flu, Mel n CSA n 8 d52-dl97
30 A2 NK-NHL m/m 56/unknown +/- m alio PBSC MM UR Cam, Flu, Mel n CSA y 39 d33-d669
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Patient
ID
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
GvHD/systemic treatment Outcome
unknown
a GvHD, severe skin and lung c GvHD / Prednisolone and MMF 
mild skin GvHD/ no treatment
a GvHD untreated, severe chronic skin and lung GvHD / Prednisolone and MMF
none
none
skin a and c GvHD grade 1 -2 / Prednisolone and MMF
severe gut a GvHD grade 3 / MMF
none
none
skin a and c GvHD / Prednisolone and MMF
none
none
none
none
none
a GvHD, limited c GvHD (grade 2) / no systemic treatment
none
unknown
steroid refractory grade IV gut a GvHD / Prednisolone
c GvHD o f skin, eye, throat since day 328 post Tx,/ Prednisolone
skin a GvHD, grade 2 / Prednisolone
skin c GvHD / MMF, Prednisolone and Tacrolimus
none
mild skin c GvHD / no systemic treatment 
none
skin a GvHD grade 1 / Prednisolone and MMF 
none
skin c GvHD / Prednisolone
skin a and c GvHD grade 2 / Prednisolone
unknown
3 years post Tx; in remission, on Cyclosporine for cGvHD
2 years post Tx: cured, on steroids, numerous atypical infections as a result o f  
immunosuppression
3 years post Tx; several recurrent chest infections, on systemic steroids due to cGvHD
4 1/2 months post Tx; 3rd relapse, extremely poor prognosis
1 1/2 years post Tx; mixed chimaerism treated with DLI
2 years post Tx; recovered from GvHD, well
Died at day 82 post Tx after severe steroid-refractory gut GvHD and sepsis (pneumonia)
3 1/2 years post Tx; relapse, considered for alio Tx
1 % years post Tx; well, in remission
3 1/2 years post Tx; in molecular remission, well
2 years post Tx; well, 85% donor chimaerism
2 1/2 years post Tx; recurrence o f disease, no UR donor available for alio Tx 
1 year post Tx; relapse
1 1/2 years post Tx; well, in remission 
Day 95 post Tx; well
4 months post Tx; in remission
3 1/4 years post Tx; well, in remission
1 1/2 years post Tx; in remission
Died at day 83 post Tx after severe steroid-refractory gut GvHD and hepatic 
encephalopathy
3 years post Tx; full chimaerism, normal platelet count, no auto Ab, recovered from 
GvHD, well
2 years post Tx; in remission
2 years post Tx; in complete remission
Died at day 158 post Tx after recurrence o f  severe gut CMV disease
5 months post Tx; well
1 1/2 years post Tx; chimaerism 50;50, treatment with DLI 
Day 193 post Tx; well 
1 year post Tx; relapse 
1 year post Tx; in remission
3 years post Tx; well, in remission
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Table 2-1 Characteristics of patients of the follow-up cohort
This table lists all patients included in the fo llo w -u p  cohort and their characteristics. 
A bbreviations: Ab: antibody; AA: aplastic anaem ia; ALL: acute lym ph oblastic  leukaem ia; 
alio: a llogen e ic  transplant; AM L: acute m yelo id  leukaem ia (M 4: stage o f  d isease); A TG : anti­
thym ocyte globulin; auto: au to logou s transplant, B-: d isease  is associated  w ith  B  ce lls; BM : 
bone marrow; Bus: B usulfan; Cam: Cam path rece ived  in vivo ;  CAM : Cam path in the bag; 
CLL: chronic lym p h ocytic  leukaem ia; CM L: chronic m yelo id  leukaem ia (P h +  refers to  
Philadelphia ch rom osom e p ositiv ity ); C M V  d isease: cy tom egalov iru s d isease  w ith  proven  
organ in volvem ent (C M V  PCR p o sitiv e  tissu e b iopsy); C R l-3 :  in first to third com p lete  
rem ission; C SA : C yclosporine; Cy: C yclophospham ide; Cyt: Cytarabine; D ef: D efibrotide; 
DLI: donor lym ph ocyte infusion; EP: Erythropoietic protoporphyria; Eto: E toposide; f; fem ale; 
FasL: Fas Ligand d eficien cy; Flu: Fludarabine; (a, c) G vH D : (acute, ch ron ic) graft ve rsu s  host 
disease (listed  are sy stem ic treatm ents on ly); HD: H od gk in ’s d isease  (IV  A  and IV  B: stages o f  
disease); HLA: human leuk ocyte antigen; HSC: h aem atop oietic stem  cell; H SC T  
haem atopoietic stem  ce ll transplantation; IgA  k: im m u n oglobu lin  A  kappa light chain; IgG  k 
im m unoglobulin  G kappa light chain; 1: lam bda light chain; M: H L A  identical (m atched); m: 
m ini-transplant in vo lv in g  reduced-intensity con d ition ing (H SC  source) or m ale (sex ); M D S  
m yelod ysp lastic  syndrom e; M el: M elphalan; M M : m ultip le m yelom a (d isea se )  or 
m ism atched/H L A  non-identical (H SC  source); M M F: m ycop h en olate m ofetil; M TX: 
M ethotrexate; n: no; N H L: N on -H od gk in ’s Lym phom a; N K -: d isease  related to  natural k iller  
cells; PBSC : peripheral b lood  stem  cell; pr: progressive; serol.: sero logy; sib: related (s ib lin g )  
donor; T-: d isease  is associated  w ith  T cells; TA: Tacrolim us; TBI: total b ody irradiation; 
TCD: T ce ll depletion; trl: related to therapy o f  breast cancer; tr2: transform ed from  M D S; tr3: 
related to  therapy for previous HD; Tx: transplantation; UR: unrelated (donor); X LP: x -lin k ed  
lym phoproliferative d isease; y: yes
* disease: (C M V ) d isease  is indicated by a tissu e b iop sy  testin g  p o sitiv e  for C M V  PCR
** no: the num ber o f  sam ples included in the fo llow -u p  an alysis
*** period: indicates the period o f  fo llo w  up sh ow n  in days post transplantation (d)
**** Patient 10 received  a dual transplant w ith donor inform ation sh ow n  assoc ia ted  w ith  the 
cord b lood  (C B ) stem  ce lls  received , w hich  w ere H LA  m atched at the H L A -A 24  locu s. Third  
party donor (T P D ) stem  ce lls  w ere unm atched at the H L A -A 24  locus.
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Patient
ID
HLA of 
interest
Diagnosis 
prior to HSCT
Sex
(r/d)
Age
(r/d)
CMV
sero!.(r/d)
HSC
source Conditioning
TCD 
of graft
30b A2, B35 NK-NHL m 55 + auto BM Cyt, Eto, Mel none
31 A 1,B 35 MM m 52 + auto PBSC Mel none
32 A2, B35 NHL f 43 + auto PBSC BEAM none
33 A1 CML m /f 32/22 +/- alio BM Cy, TBI none
34 A l, A24 AML M4 f/m 30/39 +/+ alio PBSC Cy, Flu, TBI CAM
35 A2, B35 BThal m/m 31/16 +/+ alio PBSC Bus, Cam, Flu none
36 A24 NHL m 49 + auto BM CCNU, Cy, 
Cyt, Eto, 
Rituximab
none
37 A2 MM m 60 + auto PBSC Mel none
38 A2 MM f 60 + auto PBSC Mel none
Table 2-2 Characteristics of patients other than of the follow-up cohort
This table lists all patients and their characteristics for w hom  m easurem ents are sh ow n  w ithin  
this thesis but w ho w ere not e lig ib le  to  be included in the fo llo w -u p  cohort.
A bbreviations: alio: a llogen e ic  transplant; AM L: acute m yelo id  leukaem ia (M 4: stage o f  
disease); auto: au to logou s transplant, BE A M : con d ition in g  com p risin g  E top osid e, B iC N u  
(carm ustine) and M elphalan; BThal: B Thalassaem ia; BM : bone m arrow; Bus: B usulfan; Cam: 
Campath received  in vivo; CAM : T C D  by Cam path in the bag; C C N U : lom u stin e, an 
alkylating agent related to B C N U  (carm ustine); Cy: C yclop h osph am ide; Cyt: Cytarabine; Eto: 
Etoposide; f: fem ale; Flu: Fludarabine; HLA: hum an leu k ocyte  antigen; HSC: h aem atop o ietic  
stem  cell; HSCT: h aem atopoietic stem  ce ll transplantation; ID: id en tification  num ber; m  
m ale; M el: M elphalan; MM: m ultip le m yelom a; NH L: N o n -H o d g k in ’s L ym phom a; N K - 
d isease related to natural k iller ce lls; PBSC: peripheral b lood  stem  cell; serol.: sero logy ; TBI 
total body irradiation; TCD: T ce ll dep letion .
Subject ID HLA of interest Sex Age CMV serology
1 A 1 ,A 2 ,  B35 m 53 +
2 B35 f 50 +
3 A l ,  B35 f 40 +
4 B35 f 31 +
5 A 2, B35 f unknown +
6 A2, B35 m 47 +
7 A 24 m 36 +
8 A 2, A 24 f 52 +
9 A 24 f 28 +
1 0 A 2, A 24 m 46 +
1 1 A24 f 58 +
1 2 A l f 28 +
13 A l m 43 +
14 A l m 61 +
15 A2 f 34 +
16 A2 f 38 +
17 - m 28 -
18 A2 f 27 -
19 - f 23 unknown
Table 2-3 Brief characteristics of healthy blood donors
This table lists all healthy volunteers w ho donated b lood  for this study, and their 
characteristics.
A bbreviation: f: fem ale; ID: id en tification  num ber; m: m ale.
100
Chapter 2
2-3 Processing of blood samples
50-100 |il of heparinised blood was used to obtain absolute T cell counts whereas the 
remainder of each sample was used for cell separation. Both methods are described 
below.
2-3.1 Absolute cell counts
Heparinised blood samples were used for determination of T cell counts per volume of 
blood. This analysis was performed at the day of sampling. Initially 2 tests each 
requiring 50 pi of heparinised blood were performed.
20 pi of TriTEST antibody mix (Becton Dickinson (BD) Biosciences) containing either 
fluorescein isothiocyanate (FITC) conjugated anti-CD3, phycoerythrin (PE) conjugated 
anti-CD4 and peridinin chlorophyll protein (PerCP) conjugated anti-CD45 or FITC 
conjugated anti-CD3, PE conjugated anti-CD8 and PerCP conjugated anti-CD45 were 
added to each of two TruCOUNT tubes, which contained a dry pellet of a known 
number of beads (BD Biosciences). The exact volume of 50 pi blood was then added to 
each of the TruCOUNT tubes and incubated for 15 minutes in the dark. After a further 
15 minutes incubation with exactly 500 pi fluorescent-activated cell sorting (FACS) 
Lysing Solution (BD Biosciences), stained samples were immediately acquired on a 
FACSCalibur flow cytometer with four-colour fluorescence capability (BD 
Biosciences) using Multiset software (BD Biosciences) and calibration with CaliBRITE 
beads (BD Biosciences). Collaborators followed the exact same procedure after visiting 
the ANRI laboratories. A representative example of automatic cell gating by this 
software is shown in Figure 2-1.
CD45-PerCP CD3-PITC
i l
Figure 2-1 Gating of cell populations by Multiset software.
Flow  cytom etry plots represent autom atic detection o f  beads (purple), CD45^ CD3^ CD4^ and 
CD45^ CD3^ C D 8  ^ T ce lls  by M ultiset softw are for calcu lation  o f  absolute T cell counts per 
volum e o f  b lood.
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The use of 0.6x diluted antibody mix and usage of the MultiTEST antibody mix 
containing anti-CD45 PerCP, anti-CD3 FITC, anti-CD8 PE and anti-CD4 conjugated to 
Allophycocyanin (APC) were later verified in control experiments on ten test samples. 
This is demonstrated in Figure 2-2.
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8 1500 -
1000  -
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1000 1500 2000 2500 3000500
TriTEST count
Figure 2-2 Correlation of TruCOUNT results obtained by staining with TriTEST 
or MultiTEST antibody mix
This figure dem onstrates correlation betw een the results obtained by TruC O U N T  analysis  
using staining with TriTEST and with M ultiTEST antibody m ix.
Subsequently absolute counts were obtained by staining 50 pi of heparinised blood with 
20 pi of 0.6X diluted MultiTEST antibody in a single TruCOUNT tube. The alteration 
of the procedure enabled efficient use of financial resources by reducing the number of 
required TruCOUNT tubes by half and the amount of antibody mix to 30 % of the 
original. The principle of this procedure in comparison to the TriTEST procedure that 
was performed initially is demonstrated in Figure 2-3.
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CD45 PeiCP CD45 PeiCP
CD3FITC CD3FITC
CDS PE CD4PE
CD4 APC +
6
CD45 PeiCP 
CD3 FITC 
CDS PE
MultiTEST (one tube) TriTEST (two tubes)
Figure 2-3 Principle of TriTEST versus MultiTEST procedures for determining 
absolute cell counts from whole blood
This figure illustrates the use o f  4 co lour antibody m ix  in a s in g le  (bead con ta in in g) tube 
during M ultiT E ST  in com parison to  the use o f  3 co lou r antibody m ix in tw o  d ifferent tubes  
during TriTEST.
Other cost saving methods such as C ALT AG Counting Beads (C ALT AG) using 
two different solutions of fluorescent beads instead of tubes with dried beads (for use in 
a similar lyse-no-wash technique as used for TruCOUNT analysis) were tested but not 
found to be reliable.
In a minority of cases where a reliable TruCOUNT analysis could not be 
obtained from blood samples at the day of sampling, T cell counts per volume of blood 
were calculated by referring to lymphocyte counts obtained from routine analysis at the 
RFH and the percentage of CD4^ and CD8^ T cells of these lymphocytes obtained by 
flow cytometry staining. The preservative Cyto-Chex BCT (Streck Laboratories) was 
verified for use of TruCOUNT analysis in blood for up to 5 days after sampling for 
future studies (not shown).
2-3.2 Cell separation and storage
Peripheral blood mononuclear cells (PBMC) were isolated by density-gradient 
centrifugation. This was performed by layering 10 ml blood over 10 ml Lymphoprep 
(Nycomed) and centrifugation at 2,200 rpm (no break) for 20 minutes. The Ficoll 
contained in Lymphoprep is a neutral high mass hydrophilic polysaccharide. 
Centrifugation of blood over this reagent results in separation of layers containing 
plasma and other constituents on the top, PBMC below, Ficoll below that and 
erythrocytes and granulocytes as a pellet on the bottom. PBMC were then harvested 
from the middle layer and washed twice in RPMI 1640 medium with L-Glutamine 
(BioWhittaker). Resuspension for subsequent use was performed in the same medium 
supplemented with 10 % heat inactivated (at 55 °C for 1 hour) fetal calf serum (FCS), 
1 U/ml penicillin and 1 pg/ml streptomycin (both Bio Whittaker). This supplemented 
medium will subsequently be referred to as complete medium.
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2-4 Cell culture
2-4.1 Cell enumeration and viability
Cell counts were performed by dye exclusion method. Therefore 10 pi of the 
homogeneous cell suspension were stained with an equal amount of sterile filtered 
phosphate buffered saline (PBS) solution containing 0.4 % (w/v) trypan blue (BDH). 
Viable (non-stained) cells were counted in a haemocytometer (Neubaur Chamber, 
Weber) under a phase contrast Leica DM LB microscope (Meyer Instruments).
2-4.2 Cryopreservation of cells
Cells that needed to be stored for use at later time points were cryopreserved in pre­
cooled freezing mix containing heat inactivated FCS and 10% dimethyl sulfoxide 
(DMSO) (BDH). Therefore 1 ml aliquots containing a maximum of 1x10^ cells each 
were transferred to 1.5 ml cryotube vials (Nunc) and immediately placed in freezing 
containers (Sigma Aldrich) at -80 °C for 24 hours for an uniform cooling rate of 1 °C 
per minute from ambient temperature (by indirect immersion in an isopropyl alcohol 
bath) before storage in liquid nitrogen.
PBMC isolated from density gradient centrifugation layers with red blood cell 
trapping (that occurred in a minority of samples) were preferentially cryopreserved 
before further use because freezing resulted in reduction of contaminating red blood 
cells.
Cryopreserved samples were put back in culture by rapid warming at 37 °C, 
followed by at least two washing steps in 50 ml RPMI 1640 (Bio Whittaker) using 
centrifugation at 1,600 rpm for 10 minutes and incubation in complete medium for a 
few hours prior to further use to allow for recovery of cell surface molecules and 
cellular function.
2-4.3 General culture of cells
PBMC were usually incubated in complete medium (described in section 2-3.2). 
Hybridoma and EBV-transformed cell lines were cultured in the same medium in T-75 
flasks (FALCON) at 37 °C/5 % CO2 in a humidified incubator (IG 150, Jouan). All cell 
cultures were handled under semi-sterile conditions in a fume hood and tested for 
mycoplasma contamination using the VenorGeM Mycoplasma Detection Kit (Cambio 
Ltd) on a regular basis. This does not include cell culture of Escherichia coli strains, 
which is described in section 2-11.3. Half of the culture medium was typically
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replenished every 2 to 3 days or when change in pH (and therefore colour of the cell 
culture medium) indicated medium exhaustion.
Mycoplasma pneumoniae lack a cell wall and are therefore resistant to the 
effects of penicillin (which acts by disrupting the bacterial cell wall) that was used in 
complete medium to prevent infection of cell cultures with bacteria. To screen cell 
cultures for contamination with Mycoplasma or Acholeplasma, 100 pi of supernatant 
from the test culture were boiled at 95 °C for 5 minutes. After brief centrifugation to 
pellet cellular debris, the supernatant was used for PCR detection with Taq (Bioline) 
according to the manufacturer’s protocols.
The epithelial-like adherent choriocarcinoma cell line JAR (ATCC HTB-144) 
was grown under the conditions described above with half of the medium replenished 
with fresh medium every two to three days. Cells were passaged if they were greater 
than 80 % confluent by washing with sterile PBS followed by incubation with a 
premixed solution (GIBCO) containing trypsin and ethylene diamine tetraacetic acid 
(EDTA) at 37 °C for two minutes. Trypsin was removed by centrifugation and 
subsequent resuspension of cells in fresh complete medium.
The hTERT-BJl cell line (Clontech) was grown by Ay can Walker (Virology 
Department, Royal Free Hospital, London) in a 4:1 ratio of Dulbecco’s Modified 
Eagle’s Medium (DMEM, Sigma): Medium 199 (Sigma) with 10% heat inactivated 
FCS (BioWhittaker), 1 mM sodium pyruvate (Invitrogen) and 4 mM L-glutamine 
(GIBCO). This cell line expressed exogenous human telomerase reverse transcriptase 
(hTERT) resulting in an indefinite life span. It was passaged in the same way as 
described for JAR above.
2-4.4 Production of antibodies by culture of hybridomas
Hybridomas producing W6/32 (murine IgG 2a monoclonal antibody reactive to fully 
assembled anti-HLA class I) (Barnstable et a l,  1978) or BB7.2 (IgG 2b monoclonal 
antibody reactive to HLA-A2) (Parham and Brodsky, 1981) were a kind gift from Dr. 
Walter Bodmer (Imperial Cancer Research Fund, ICRF, now called CRUK). They were 
cultured as described in section 2-4.3 and were used to harvest antibodies from their 
supernatant.
After centrifugation at 3,000 rpm for 10 minutes to pellet cellular debris, 
supernatant was stored at 4 °C before purification of secreted antibody by Affi-Gel 
Protein A Agarose kit (BIO-RAD), which uses the property of Staphylococcus aureus" s
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Protein A that binds with high affinity to the Fc region of IgG (Kronvall and Williams, 
1969). In brief, sample supernatant that had been passed through a microporous filter 
having a pore size of 0.4 p, was passed through columns containing agarose beads 
coupled to protein A using a Peristaltic Pump PI (Amersham Biosciences). Columns 
were washed and specifically bound antibody eluted at low pH with buffers supplied 
with the Affi-Gel Protein A Agarose kit (BIO-RAD).
2-4.5 CMV infection of cells
H-TERT-BJl, JAR or other cells were plated at 8x10^ cells/dish in 5 different 35 mm 
Petri dishes. Infection experiments were performed in collaboration with Dr. Aycan 
Walker at the Virology Department at the RFH. Incubation at 37 °C/5 % CO2 for half a 
day ensured that cells were allowed to attach. One dish was used as a negative control 
and left untreated. The medium from the remainder was aspirated and 2 ml enhanced 
green fluorescent protein (EGFP) recombinant viral supernatant of either TOLEDO-F (a 
fibroblast adapted TOLEDO strain) or AD 169 supernatant added in duplicates. Both 
viral strains were a kind gift from Gavin Wilkinson, University of Wales College of 
Medicine. They had been grown in the hTERT BJl cell line and used at an MOl of 
approximately 1.
After incubation at 37 °C/5 % CO2 for 90 minutes, the supernatant was aspirated 
and replenished with 2 ml of the medium originally used for culturing the cells. Cells 
were grown for 48 to 72 hours before GFP expression was assessed using a fluorescent 
microscope (Olympus B x60). Pictures were taken using an attached camera (Olympus 
D Pll).
2-5 Fluorescent cell surface staining and analysis
2-5.1 Tetramer staining
The staining specificity of tetramers is temperature dependent with an optimum 
specificity obtained at 37 °C (Whelan et a l,  1999). Whelan and colleagues 
demonstrated that peptides that are unable to elicit functional CD8^ T cell responses, 
can stain these cells at 4 °C but not 37 °C when incorporated into tetramers. They 
therefore suggest that staining at 4 °C can detect cross reactive CD8^ T cells with low 
avidity for the tetramer more readily than staining at 37 °C. Therefore all tetramer- 
staining procedures were performed at this temperature.
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PBMC were stained in phosphate buffered saline (PBS) diluted from a lOx stock 
solution (Sigma-Aldrich) supplemented with 0.5 % FCS and 0.1 % (w/v) sodium azide 
(NaNa) (BDH) with the appropriate volume of tetramer solution at 37 °C for 30 minutes. 
Tetramer solutions were titrated to establish the volume required for optimum staining 
results. Amounts added were typically 1 pg of fluorescent tetramer solution in a staining 
volume of 50 pi. Control staining was performed using PBMC from individuals 
expressing irrelevant HLA alleles and CMV seronegative individuals.
After centrifugation of tetramer stained cells at 1,600 rpm for 3 minutes and one 
washing step in staining buffer, cells were resuspended in 50 pi PBS/FCS/NaNg and 
stained with 3 pi of FITC labelled anti-CD3 and PerCP labelled anti-CD8 antibodies 
(Becton Dickinson) at 4 °C for 20 minutes.
In some cases the second staining step included anti-CD3 or anti-CD8 antibody 
staining with fluorochrome combinations other than those mentioned above to allow for 
staining with a fourth reagent using a combination of labels including FITC, PE, PerCP 
and APC.
Washing thereafter was performed twice with PBS/0.1 % (w/v) NaNg. Cells 
were then fixed in PBS/1 % (w/v) paraformaldehyde (PFA) (BDH) to ensure that bound 
antibodies and tetramer did not dissociate from their ligand molecule on the cell surface, 
and were stored at 4 °C in the dark. Acquisition on a FACSCalibur flow cytometer 
(Becton Dickinson) was performed within 24 hours using CellQuest version 3.3 
software (Becton Dickinson) and analysed using FlowJo software Version 6.0 (Tristar).
2-5.2 Staining with other reagents
Cell surface staining not involving tetramers was performed in PBS supplemented with 
0.5 % FCS at 4 °C for 20 minutes followed twice by centrifugation at 1,600 rpm for 
3 minutes and washing in staining buffer. Cells were then fixed in PBS/1 % (w/v) PFA 
and stored at 4 °C in the dark until acquisition within 24 hours.
Many immunologically important cells can be defined based on what molecules 
are present on their surface. Numbered human clusters of differentiation (CD) are used 
to classify many epitopes on the cell surface of leukocytes. A combination of several 
surface markers is often used to associate cells with certain immune functions or 
properties.
Antibodies directed against different CDs were purchased from BD Pharmingen. 
These had fluorochromes FITC, PE, PerCP or APC directly conjugated and were used
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as described above. Antibodies used had the following epitope specificities (clones in 
brackets) and fluorochromes: CD3 (HIT3a) FITC, CD3 (SK7) PerCP, CD3 (SK7) APC, 
CD4 (RPA-T4) FITC, CD4 (SK3) PE, CD4 (SK3) PerCP, CDS (SKI) PE, CDS (SKI) 
PerCP, CDI6 (NKP15) FITC, CDI9 (4G7) FITC, CD25 (2A3) PE, CD27 (M-T27I) 
FITC, CD28 (L293) PE, CD45RO (UCHL-1) PE, CD56 (BI59) PE, CD57 (HNK-1) 
FITC, CD69 (L78) FITC.
Other antibodies used included anti-VG 7 antibody (clone ZOE, Immunotech) 
and anti-VG 20 antibody (clone ELL 1.4, Immunotech). These antibodies were not 
directly conjugated to fluorochromes. Therefore detection required staining with a 
secondary antibody. Primary antibodies were composed of mouse IgG heavy chain. 
Therefore FITC conjugated sheep anti-mouse IgG (whole molecule) antibody (Sigma 
Aldrich) was used as the secondary detection antibody. Briefly, cells were stained with 
2 pi anti-VG7 or 4 pi anti-VG20 antibody (volumes based on titration results) in 
PBS/FCS/NaNa in a total staining volume of 100 pi at 4 °C for 20 minutes followed 
twice by centrifugation at 1,600 rpm for 3 minutes and washing with staining buffer. 
Cells were then stained with 4 pi of FITC conjugated sheep anti- mouse IgG antibody in 
a total volume of 100 pi staining buffer at 4 °C for 30 minutes followed twice by 
centrifugation at 1600 rpm for 3 minutes and washing in staining buffer. Cells were then 
fixed in PBS/1 % (w/v) PFA and stored at 4 °C in the dark until acquisition within the 
next 24 hours.
HLA specific staining during preliminary experiments (not shown) was 
performed with the HLA-A24 specific murine IgG antibody 030041 HA (One Lambda), 
the HLA-B35 specific human IgG antibody HDG8D and the HLA-A1/24 specific 
human IgG antibody GV5D1. The latter two were obtained from Dr. Arend Mulder 
(Leiden University Medical Centre) and were used with FITC conjugated rabbit F(ab)2 
anti-human IgG secondary antibody (DakoCytomation).
Staining with non-fluorescent antibodies such as biotinylated antibodies or those 
conjugated to peroxidase is described in the sections describing the relevant assays (for 
example dot blot, western blot, ELI Spot and cell selection). Staining with 5,6- 
carboxyfluorescein diacetate succinimidyl ester (CFDASE) or intracellular cytokine 
(ICC) staining is described in sections 2-7.3 and 2-7.2 respectively.
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2-5.3 Flow Cytometry
Cells stained with fluorochrome-conjugated antibodies were visualised using flow 
cytometry. This technique is based on the principle that a beam of a single wavelength 
light is directed onto a stream of fluid. Detectors are aimed at the point where the stream 
passes through the light beam. In this study a FACSCalibur flow cytometer (Becton 
Dickinson) was used. This machine has one detector positioned in line with the light 
beam, called forward scatter (FSC), and five detectors positioned perpendicular to it. 
The last mentioned are the side scatter (SSC) and four fluorescent detectors. These 
detect green FITC emission (maximum 530 nm), orange PE emission (maximum 
585 nm) or red PerCP emission (maximum 650 nm), all excited by a blue argon laser 
(488 nm); or long red-blue APC emission (maximum 670 nm) excited by a red diode 
laser (635 nm). Each cell within the acquired liquid that passes through the beam 
scatters light. Light scattered in forward direction is directly proportional to the size of 
the cell (FSC) whereas light scatter at larger angles to the side (SSC) is caused by 
granularity and structural complexity of the cell. In addition fluorochromes on that cell 
are excited into emitting light. Light scattered to the sides is focused through a lens 
system and is collected by the SSC detector located at around 90 degrees from the 
laser’s path. Fluorescent light travels along the same path as the side scatter signal and 
is detected through a series of filters and mirrors so that particular wavelength 
information is delivered to the appropriate detector. The combination of scattered and 
fluorescent light that is picked up by the detectors is eventually converted to electronic 
signals.
Filters are used in order to separate fluorescence emission from the excitation 
light source and to resolve different colours. Detection channels (FL) therefore pass 
light in a specified range of wavelength (band-pass). Fluorochromes, however, emit 
light over a range of wavelengths and a signal from one fluorochrome may therefore 
overlap in a detector used for another fluorochrome. This is demonstrated in Figure 2-4.
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Figure 2-4 Spectral overlap
This figure represents the em ission  spectrum  o f  FITC (F L l ) in b lue and the em ission  spectrum  
o f  PE (FL 2) in dark red. Som e FITC fluorescence detected w ithin  the band-pass (grey shaded) 
o f  the FLl detector also appears w ithin in the FL2 detector (A ) and vice  ve rsa  (B ). This 
spectral overlap is represented in bright red.
Spectral overlap was manually compensated using control samples, each stained 
with a single colour in CellQuest software Version 3.3 (Becton Dickinson). Thereby a 
portion of one detector’s signal was subtracted from another, leaving only the desired 
signal.
For analysis of patient samples, 20,000 CD3^ CD8^ live lymphocyte events were 
collected whenever possible. The number of CMV specific CD8^ T cells per microlitre 
of blood was determined by multiplying the absolute number of CD8^ T cells 
determined by TruCOUNT analysis (compare section 2-3.1) by the percentage of CD8^ 
T cells, which bound to tetramer and fell within the live CD3^ lymphocyte gate as 
determined using flow cytometry (Figure 2-6, page 112). The results were considered 
positive if a distinctive population was seen for CD8^ T cells but not CD8' T cells.
Specificity of tetrameric complexes was confirmed by the absence of staining of 
cells from CMV seronegative donors expressing the appropriate HLA tissue type and 
the absence of staining of cells from CMV seropositive donors not expressing the 
appropriate HLA molecule. Only tetramers staining positive controls (PBMC from 
CMV seropositive individuals expressing the relevant HLA allele who had shown a 
response to the relevant peptide in ELI Spot assays) without staining of negative controls 
were used after the volume required for optimum staining results had been establish in 
titration experiments.
Further experiments confirming the staining specificity revealed no cross­
reactivity of HLA-A*0201/NLV tetramer in HLA-A*0205 and HLA-A*0217
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expressing individuals. Equally the HLA-B*3501/IPS tetramer did not cross-react with 
PBMC from individuals expressing HLA-B*3503, HLA-B*3508 or HLA-B*3502. 
These experiments were not performed for tetramers comprising HLA-A*0101 or 
(ms) HLA-A*2402 as the respective subtypes were so predominant that typing of 
recruited individuals expressing these alleles revealed an exclusive expression of HLA- 
A*0101 or HLA-A*2402 subtype.
Binding specificity of tetramers was additionally confirmed by measurement of 
CD3 fluorescence intensity as demonstrated in Figure 2-5. Specific binding of 
tetrameric complexes to a  and 6 chains of the T cell receptor molecule influences the 
CD3 molecule due to its proximity. This has been shown to result in decreased staining 
with anti-CD3 antibody (Hoffmann et al., 2000), whereas non-specific staining would 
not influence the binding of anti-CD3 antibody.
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Figure 2-5 CD3 down regulation after tetramer staining
Part B o f  this figure dem onstrates decreased stain ing o f  tetramer b inding ce lls  (red curve) with  
anti-CD3 antibody in com parison to ce lls  that did not bind tetramer (blue curve). The gating o f  
cell populations is shown in part A. The latter sh ow s liv e  CD3^ T ce lls  obtained from  patient 
12 at 54 days post HSCT, that were stained with H L A -A 2 4 /p p 6 5 (3 4 1-349) tetramer and anti- 
C D 8  antibody as a representative exam ple. A dditionally  to the graphical dem onstration the  
geom etrical mean o f  C D3-FITC fluorescen ce intensity is show n in the legend o f  part B.
Gating of tetramer stained PBMC was performed as illustrated in Figure 2-6 using 
FlowJo software Version 6 (Tristar).
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Figure 2-6 Boolean gating strategy used for tetramer FACS analysis
This figure dem onstrates stepw ise gating o f  PBM C from patient 12 stained with anti-C D3  
antibody, anti-CDS antibody and tetramer as a representative exam ple. Part A illustrates total 
PBM C, o f  w hich live lym phocytes w ere gated according to their characteristic forw ard/side  
scatter (F S C /SSC ) characteristics. C ells that fall w ithin this first gate are show n in a new dot 
blot in part B. This was used to gate on the CD3^ T cell population. Part C sh ow s ce lls  that fall 
within both o f  the first tw o gates. A third gate was drawn around the CDS^ T cell population  
and ce lls  falling w ithin all three gates are show n in part D on the left. T hose ce lls  were  
analysed for binding with tetramer (here 0 .87  %). C ells fa lling w ithin the first tw o gates (CD3^ 
T ce lls )  are show n in part D on the right. This w indow  dem onstrates sp ec ific  tetramer staining  
within the CDB^ but not CDS* T cell population.
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2-6 Tetramer guided cell sorting
2-6.1 Cell sorting using magnetic beads
PBMC stained with PE or APC labelled tetramer were separated on ice using anti-PE or 
anti-APC MACS micro beads and MS^ positive selection columns (Miltenyi Biotech) 
according to the manufacturers instruction.
When starting with low frequencies of tetramer binding cells, selection was 
preceded by a CD8^ selection step using the CD8^ T cell isolation kit II (Miltenyi 
Biotech). This step involved an indirect magnetic labelling system for the isolation of 
untouched CD8^ T cells from human PBMC. Non-CD8^ T cells, such as CD4^ T cells, 
y/0 T cells, B cells, NK cells, dendritic cells, monocytes, granulocytes, and erythroid 
cells, were labelled by using a cocktail of biotin-conjugated antibodies against CD4, 
CD 14, CD 16, CD19, CD36, CD56, CD123, TCRy/ô, and CD235a (glycophorin A). 
These cells were subsequently magnetically labelled with anti-biotin microbeads 
(Miltenyi Biotech) for depletion.
In brief, up to 10  ^PBMC were resuspended in 40 pi of pre-cooled and degassed 
buffer containing PBS, 0.5 % (w/v) bovine serum albumin (BSA) (Sigma) and 2 mM 
EDTA at pH 7.2 and incubated with 10 pi of biotin labelled antibody cocktail for 
10 minutes on ice. Subsequently an additional 30 pi of buffer and 20 pi of anti-biotin 
microbeads were added and the mix incubated for an additional 15 minutes on ice. 2 ml 
buffer were added and cells were spun at 1,500 rpm for 5 minutes and the supernatant 
discarded. The cell pellet was resuspended in 500 pi buffer and applied to a column that 
had been rinsed with 500 pi buffer and placed in the magnetic field of a MACS 
separator. The effluent was left to pass through the column completely before adding 
500 pi of buffer, which was repeated twice thereafter. It was collected as unlabelled 
CD8^ T cell fraction and used for the second purification step.
PBMC were stained with PE or APC labelled tetramer as described in section 2- 
5.1 but using PBS supplemented with 0.5 % (w/v) BSA (Sigma) and 2 mM EDTA as 
staining buffer. 2 ml buffer were added and cells spun at 1,300 rpm for 5 minutes. The 
supernatant was removed and cells washed again before resuspension in 80 pi buffer 
and incubation with 20 pi anti-PE microbeads for 15 minutes on ice. Cells were then 
washed as before and added to a column prepared as described. After passing of 500 pi 
buffer through the column for three times, it was removed from the magnet, placed on a
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collection tube and flushed with 1 ml buffer using the provided plunger to collect 
tetramer-PE labelled cells, which were passed over a second column to increase purity.
Sorting of PBMC was optimised by FACS sorting (refer to section 4-2.1.1), 
which is described in section 2 -6 .2 .
2-6.2 Cell sorting by flow cytometry
Flow cytometry based sorting of tetramer binding cells for TCR VB spectratyping 
(section 2-12) based on staining and gating of cells as described in section 2-5 was 
performed by Niga Nawroly at the flow cytometry laboratory. Department of 
Respiratory Medicine, Imperial College, London, UK using a FACS Aria instrument 
(Becton Dickinson).
2-7 Functional assays
2-7.1 Enzyme-linked immunospot (ELISpot)
Interferon gamma (INFy) release by PBMC was detected with antibodies from the 
enzyme-linked immunospot (ELISpot) for human IFNy kit (Mabtech) according to the 
manufacturer’s protocol.
Briefly, 96 well MultiScreen 0.45 pm Immobilon-P (PVDF) filter plates 
(MAIPS4510, Millipore) were coated with the monoclonal anti-human IFNy capture 
antibody (1-Dlk) at 15 pg/ml and incubated at 4 °C overnight. Unbound antibody was 
washed off with 0.45 pm sterile filtered PBS (AccuGene). 10^  PBMC in 200 pi 
complete medium were added to each well. All samples were tested in triplicates (a 
positive control was included in a single well). They were either incubated in the 
presence of the peptide of interest (10 pg/ml), PFIA (2 pg/ml) as positive control or 
medium alone to test for spontaneous cytokine release. Cell-free medium was used as a 
negative control.
Plates were incubated at 37 °C/5 % CO2 for 14 hours. Cells were then washed 
off with PBS for 6 times and plates incubated with 1 pg/ml biotinylated anti- human 
IFNy detection antibody (7-B6-1-biotin) in PBS containing 0.5 % FCS for 2.5 hours at 
room temperature. Plates were washed 6 times with PBS again and incubated with a 
1:1,000  dilution of streptavidin-alkaline phosphatase (provided with the kit) for
1.5 hours. Washed plates (6x with PBS) were finally incubated with 100 pi per well of 
alkaline phosphate substrate (0.1 M NaCl, 0.05 M MgCL and 0.1 M Tris-H C l
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(whereby Tris is used as abbreviation for trisbydroxymetbylaminometbane) at pH 9.5 
containing 32 pi 5-bromo-4-cbloro-3-indoIylpbospbate p-toluidine (BCIP, Gibco BRL) 
and 44 pi nitroblue tétrazolium chloride (NBT, Gibco BRL) per 10 ml buffer).
Colour development was usually observed after 2 minutes and stopped by 
washing plates with tap water. Plates were air dried and read on an automated counter. 
This was initially performed on an ELISpot AID System at the Immunology 
Department at the Hammersmith Hospital. When an ELISpot reader became available at 
Immunology Department of the RFH, all plates (including those initially read on the 
AID reader) were read using the same detection conditions using an Axiocam MR 
camera (Carl Zeiss) and SCHOTT KL 1500 LCD Cold Light source attached to a Stemi 
2000-C Stereo Microscope (Carl Zeiss) with TANGO microscope controller 
(Marzbauser) for analysis with KS ELISpot software Version 4.5.21 (Carl Zeiss). A 
representative example of results obtained from ELISpot assays is shown in Figure 2-7.
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Figure 2-7 IFNy ELISpot read out
This figure sh ow s a typical result obtained from  anti-hum an-IFN y antibody coated  w ells  in 
w hich 100 ,000  PBM C  had been incubated in com p lete m edium  w ithout stim ulation  (lane 1-3), 
with peptide (lane 4 -5 ) or with PHA (lane 7) fo llo w ed  by rem oval o f  ce lls  and d etection  o f  
released IFNy cytok ine with biotinylated secondary antibody and streptavid in-alkaline  
phosphatase, w hich w as visualised  by addition o f  en zym e substrate resu lting in coloured  spots 
for each responding cell.
Samples showing no response to the positive control PHA were excluded from analysis. 
The median values of spots per 100,000 PBMC were calculated and deviations from 
triplicate measurements represented as 25 and 75 percentiles.
2-7.2 Intracellular cytokine (ICC) staining
For this procedure triplicates of 1x10^ PBMC each were incubated with or without 
peptide to establish IFNy production. Staining with an isotype control was performed in 
addition to that. Due to the large number of cells required for this staining procedure 
(9x10^ PBMC in total), functional assays were preferentially performed using ELISpot 
(compare section 2-7.1). In some cases confirmatory experiments were performed using 
intracellular staining (ICS).
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Like ELISpot, ICS is a method for analysing cytokine production by single cells. 
The sensitivity of the method is lower (Tassignon et a l,  2005) but its advantage is the 
possibility to distinguish between subpopulations of cytokine producing cells by 
fluorescence-activated cell sorting (FACS) analysis without the need for prior isolation 
of the subpopulations.
Cells were resuspended in 500 pi RPMI (BioWhittaker) supplemented with 
10 % heat inactivated human AB serum (CAMBREX), 1 U/ml penicillin and 1 pg/ml 
streptomycin (both Bio Whittaker), 10 ng/ml Brefeldin A (BE A) (Sigma), 1 pg/ml anti- 
CD28 antibody (BD), with or without 10 ng/ml CMV peptide (Table 2-5, page 129) for 
incubation at 37 °C/5 % CO2 for 12 hours. BFA is a lactone antibiotic produced by 
fungi such as Eupenicillium brefeldianum. During the stimulation process it acts to 
inhibit transport to the Golgi complex thereby preventing the secretion of produced 
cytokines and resulting in their accumulation within the ER of cells instead.
Following incubation, cells were stained for surface marker expression. 
Therefore cells were spun at 1,600 rpm for 3 minutes, washed twice by resuspension in 
100 pi PBS/1 % FCS followed by centrifugation at 1,600 rpm for 3 minutes and 
discarding of the supernatant. The viability of cells was then briefly checked by dye 
exclusion method (compare section 2-3.2). Cells were stained with 3 pi PE conjugated 
anti-CD3 antibody and 3 pi PerCP conjugated anti-CD8 antibody (BD) in 50 pi 
PBS/FCS at 4 °C for 30 minutes.
Following surface staining and two further washes, cells were fixed and 
permeabilised to allow entry of anti-cytokine antibodies into the cells which can then be 
determined by FACS analysis. Permeabilisation was achieved by incubation in 100 pi 
Cytofix/Cytosperm buffer (BD) at 4 °C for 20 minutes. Samples were subsequently 
washed in 100 pi Perm/Wash solution (BD) before staining with 2 pi of either FITC 
conjugated anti-human IFNy antibody or FITC conjugated anti-mouse IFNy antibody as 
isotype control in 50 pi Perm/Wash buffer at 4 °C for 30 minutes. Following two 
further washing steps in Perm/Wash, the samples were resuspended in PBS/1 % (w/v) 
PFA and stored at 4 °C in the dark for up to 24 hours before acquisition on a 
FACSCalibur flow cytometer (Becton Dickinson) (section 2-5.3).
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2-7.3 Staining with 5,6-carboxyfluorescein diacetate succinimidyl 
ester (CFDASE)
PBMC were stained at 10  ^cells/ml in complete medium with 10 pM CFDASE from a 
5 mM stock solution prepared in dimethylsulfoxide (DMSO) (Molecular Probes) at 
37 °C in the dark for 10 minutes.
During the initial staining CFDASE passively diffuses into the cells, where two 
acetate groups are cleaved by intracellular esterases to yield highly fluorescent 
carboxyfluorescein succinimidyl ester (CFSE). The succinimidyl ester group reacts with 
intracellular amines to form fluorescent conjugates. A proportion of CFSE becomes 
coupled to long-lived intracellular molecules to form conjugates that cannot escape 
from the cells whereby stable fluorescent labelling is achieved (Parish, 1999).
CFSE stained samples were washed three times by resuspension in ice-cold 
complete medium followed by centrifugation at 1,600 rpm for 3 minutes and discarding 
of the supernatant. Cells were then incubated at 2x10^ cells/ml in complete medium at 
37 °C in the dark for subsequent stimulation. Each stimulation was performed in 
triplicate. Therefore cells were either left unstimulated or stimulated with CMV peptide 
(10 pg/ml) or phytohaemagglutinin (PHA) (2 pg/ml) for a defined period of time. All 
samples were left in culture for the same length of time after staining with CFSE.
After culture cells were spun at 1,600 rpm for 3 minutes and washed twice in 
PBS/0.5 % FCS. They were resuspended in 50 pi PBS/FCS and stained with 3 pi of 
APC labelled anti-CD3 and PerCP labelled anti-CD8 antibodies (BD) at 4 °C for 
20 minutes. Washing thereafter was performed twice with PBS. Cells were then 
immediately acquired on a FACSCalibur flow cytometer (BD) (section 2-5.3).
The dye-protein adducts that form in labelled cells are retained by cells 
throughout development and meiosis. The fluorescence intensity is progressively halved 
with each cell division and the amount of CFSE detected can thereby determine the 
degree of proliferation of cells since the time of staining.
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2-8 General Molecular Biology applications
2-8.1 Plasmid DNA midiprep
This method was modified from the original alkaline lysis described by Bimboim and 
Doly in 1979 (Bimboim and Doly, 1979). Therefore 50 ml overnight cultures were spun 
at 3,000 rpm for 20 minutes and cell pellets resuspended in 1 ml of a solution containing 
25 mM Tris and 10 mM EDTA at pH 8 . Then 2 ml of freshly prepared solution 
containing 200 mM sodium hydroxide (NaOH) and 1 % (v/v) sodium dodecyl sulphate 
(SDS) was added and incubated on ice for 5 minutes. The lysis of bacteria under 
alkaline conditions results in precipitation of DNA and proteins. 3 M sodium acetate 
(acetic acid) at pH 4.8 was added and incubated on ice for 45 minutes. The acetate- 
containing buffer neutralizes NaOH in the previous lysis step. It results in large and less 
supercoiled chromosomal DNA (and proteins) forming an insoluble white, rubbery 
precipitate with SDS while small bacterial DNA plasmids can renature and stay in 
solution. After centrifugation at 4,000 rpm for 20 minutes, supernatant was added to 
tubes containing 8 ml of absolute ethanol, gently mixed by inversion and spun at 4,000 
rpm at 4 °C for 10 minutes. 400 pi of solution containing 10 mM Tris and 1 mM EDTA 
at pH 8 was added to DNA pellets for incubation at 65 °C for 10 minutes. After addition 
of 500 pi lithium chloride (LiCl) the resulting solution was cooled to -20 °C for at least 
10 minutes. It was then spun at 10,000 rpm at 4 °C for 10 minutes and 1 ml of absolute 
ethanol was subsequently added to supernatant resulting in precipitation of DNA. 
Further centrifugation at 10,000 rpm at 4 °C for 10 minutes was performed to enable 
aspiration of supernatant. The resulting DNA pellet was dried in a 37 °C incubator for 
10 to 20 minutes before resuspension in 50 pi water and incubation in a water bath at 
65 °C for 10 minutes.
2-8.2 Plasmid DNA miniprep
The midiprep method described above was the preferred method of plasmid DNA 
isolation because of high DNA yields with good purity. Occasionally a miniprep 
method was used when a short processing time was prioritised to high DNA yields.
DNA was extracted by StrataPrep plasmid miniprep kit (Stratagene) according 
to the manufacturer. This method employs a modification of the alkaline method of cell 
lysis (Bimboim and Doly, 1979) and binding of DNA on a silica-based fiber matrix.
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Briefly 1.5 ml of a 10 ml overnight culture were spun at 13,000 rpm for 1 minute and 
the supernatant discarded. The pellet was resuspended in 100 pi of a ribonuclease- 
containing solution (50 mM Tris HCl (pH 7.5), 10 mM EDTA, 50 pg/ml RNase A) and 
gently mixed with 100 pi of a cell lysis solution (0.2 M NaOH, 1 % (w/v) SDS), and 
125 pi of a DNA-binding salt solution (containing an undisclosed chaotropic salt). As 
described above, the lysis of bacteria under alkaline conditions results in precipitation of 
DNA and proteins. A salt neutralising buffer results in large and less supercoiled 
chromosomal DNA forming an insoluble white, rubbery precipitate with SDS while 
small bacterial DNA plasmids can renature and stay in solution. The sample was then 
spun at 13,000 rpm for 5 minutes. The DNA containing supernatant was then 
transferred to a cup with fibre matrix, to which the DNA binds. The cup was seated 
inside a receptacle tube and contaminants were subsequently washed from the cup with 
wash buffer. Therefore the tube was spun at 13,000 rpm for 30 seconds. After removal 
of liquid from the tube, 750 pi of wash buffer (5 mM Tris HCl (pH 7.5), 50 mM NaCl, 
1.25 mM EDTA and 50 % (v/v) ethanol) were added to the cup and spun inside the tube 
at 13,000 rpm for a further 30 seconds. After removal of filtered liquid, the tube was 
spun for an additional 30 seconds and the cup was then transferred to a new tube. 50 pi 
sterile deionised water was placed on top of the fiber matrix and incubated at room 
temperature for 5 minutes for elution of the purified plasmid DNA, which was captured 
in the tube by centrifugation at 13,000 rpm for 30 seconds.
2-8.3 Absorbance measurement of DNA and RNA
DNA and RNA absorb ultraviolet light with an absorption peak at 260 nm wavelength. 
The amount of light absorbed can be related to the concentration of the absorbing 
molecule. At a wavelength of 260 nm, the extinction coefficient for double-stranded 
DNA is 20 (mg/ml)'^ cm'*; for single-stranded DNA and RNA it is 25 (mg/ml)'* cm '\ 
Thus, an optical density (OD) of 1 corresponds to 50 pg/ml for double-stranded DNA, 
and to 40 pg/ml for single-stranded DNA and RNA.
Nucleic acid concentration was measured at 260 nm and protein contamination 
was assessed by the ratio of absorbance at 260 nm: 280 nm (which corresponds to 2 .0  in 
pure nucleic acid solutions) using a spectrophotometer (Nanodrop).
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2-8.4 DNA endonuclease restriction digest
Restriction endonucleases are enzymes that recognise specific sequences of nucleotides 
and produce a double stranded cut in the DNA. Two incisions, one through each of the 
sugar-phosphate backbones of the double helix are made without damaging nitrogenous 
bases. These enzymes have been named after discovery in E. coli strains that appeared 
to be restricting the infection by certain bacteriophages and are therefore believed to be 
a mechanism evolved by bacteria to resist viral attack. Recognition sites of restriction 
enzymes mentioned throughout this thesis are summarised in Table 2-4.
Enzyme Source of Bacteria Recognition site Cleavage site
BamH I Bacillus GGATCC G/GATCC
amyloliquefaciens CCTAGG CCTAG/G
EcoRI Escherichia coli GAATTC G/AATTC
CTTAAG CTTAA/G
Hind III Haemophilus AAGCTT A/AGCTT
influenzae TTCGAA TTCGA/A
Nco 1 Gordonia CCATGG C/CATGG
rubripertincta GGTACC GGTAC/C
PstI Providencia stuartii CTGCAG CTGCA/G
GACGTC G/ACGTC
S a il Streptomyces albue GTCGAC GATCGAC
CAGCTG CAGCT/G
Table 2-4 Target sequences of restriction endonucleases
This table lists endonu cleases that w ere used, their source, recogn ition  sites and c lea v a g e  sites.
2-8.5 Gel electrophoresis
Gel electrophoresis is used for the separation of deoxyribonucleic acid or ribonucleic 
acid using an electric current applied to a gel matrix. Nucleic acids migrate from 
negative to positive electrodes due to the naturally occurring negative charge carried by 
their sugar-phosphate backbone. Gel electrophoresis can also be applied for proteins as 
is described in section 2 -11.8 and 2-11.13.
Gels were prepared by heating 100 ml of 0.5x Tris-Borate-EDTA (TBE) 
(Cambrex Bio Sciences) buffer containing 1 g (unless stated otherwise) of 
electrophoresis grade agarose (Gibco BRL) in a microwave oven for approximately 
2 minutes (until the agarose solution began to boil). The mix was cooled down to 
approximately 50 °C before adding 10 pi of 10 mg/ml ethidium bromide solution. The 
agarose solution was immediately poured into a sealed tray (Bio-RAD) with a comb 
placed to form wells and allowed to set at room temperature. The comb was then 
removed. 3 to 5 pi DNA solution of interest were mixed with 3 pi Bromphenol Blue
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loading dye (containing 0.25 % (w/v) xylene cyanol, 0.25 % (w/v) bromophenol blue 
and 50 % (v/v) glycerol) before loading into gel wells and run with 0.5x TBE buffer at 
100 Volts direct current in a SUB DNA cell (Bio-RAD). Bromophenol blue (3',3",5',5"- 
tetrabromopbenolsulfonpbtbalein) carries a slight negative charge at moderate pH, 
therefore migrating in the same direction as DNA in the gel (at 1 % agarose at the same 
rate as approximately 500 bp DNA fragments). Xylene cyanol is similarly used to 
indicate the progress of DNA separation during gel electrophoresis (at 1 % agarose 
migrating at the same rate as approximately 4,000 bp DNA fragments).
DNA separation was visualised and documented using a Gel Doc 1000 single 
wavelength (312 nm UV-B) mini-transluminator (Bio-RAD Laboratories Ltd.) and a 
Charged Coupled Device (CCD) camera using a Wratten 2a filter and 2x magnification 
lens.
2-8.6 Purification of DNA from gel bands
DNA was purified from agarose gel using the GFX purification kit (GE Healthcare). 
Therefore a narrow gel slice containing ethidium bromide stained DNA of the size of 
interest was cut with a sterile scalpel under UV light. The gel slice was transferred to a 
pre-weighted 1.5 ml microcentrifuge tube, which was then weighted again to determine 
the net weight of the gel slice. The slice was subsequently cut into several smaller 
pieces and 10 pi capture buffer per 10 mg of gel was added to the tube. After vigorous 
vortexing the sample was incubated at 60 °C for 15 minutes during which the agarose 
melted completely. The resulting solution was spun briefly for collection at the bottom 
of the tube and then transferred to a GFX column seated in a new collection tube. 
Following incubation at room temperature for 1 minute to allow DNA to bind to the 
glass fibre matrix the sample was spun at 13,000 rpm for 30 seconds and the flow­
through discarded. 500 pi wash buffer were then applied to the column, which was 
subsequently spun again and the flow-through discarded. The column was then placed 
into a new 1.5 ml microcentrifuge tube and the purified DNA was eluted by addition of 
10 to 50 pi of double distilled water (depending on the size of DNA band) directly on 
top of the matrix. Incubation at room temperature for 1 minute was followed by 
centrifugation at 13,000 rpm for 1 minute.
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2-8.7 Blue/white colony selection
PCR2.1 vector (Invitrogen) enabled screening of successful cloning reactions (section 
2-11.1) through the colour of the bacterial colonies. The molecular mechanism for 
blue/white screening is based on the Lac operon and briefly explained here. PCR2.1 
contains the 6 -galactosidase gene (Lac Z) within the multiple cloning site (MGS). 
Cloning in pCR2.1 was performed with isopropyl b-D-1 -thiogalactopyranoside (IPTG) 
present in the medium, which functions as the inducer of the Lac operon in the absence 
of lactose. If no cloned insert was present in the pCR2.1 vector (which would interrupt 
the Lac Z gene) IPTG triggered the expression of B-galactosidase by induction from the 
T7 promoter. The enzyme then processed 5-bromo-4-chloro-3-indolyl-B-D-galactoside 
(X-gal) within the medium (a colourless modified galactose sugar that is metabolized by 
p-galactosidase). The hydrolysis of colourless X-gal by the p-galactosidase caused the 
characteristic blue colour indicating that the colonies contained unmodified vector. 
White colonies indicated insertion of HLA sequence and thus loss of the cells' ability to 
hydrolyse the marker. An example of colonies grown under conditions for blue/white 
screening is shown in Figure 2-8.
Figure 2-8 Blue/white colony screening
This picture sh ow s part o f  a Petri dish with agar, on w hich  bacteria w ere grow n under 
conditions suitable for b lue/w hite screening. Several co lo n ie s  o f  blue or w hite appearance can 
be observed.
Growth of untransformed cells was suppressed by the presence of Kanamycin in the 
growth medium. A Kanamycin resistance gene on pCR2.1 allowed successfully 
transformed bacteria to survive despite the presence of the antibiotic.
122
___________________________________________________________________Chapter 2
2-8.8 Glycerol stock
Glycerol stocks were prepared from bacterial hosts carrying engineered DNA vectors. 
Therefore single colonies were picked from plates, on which they had been grown on 
selective medium overnight and were subsequently grovm with the appropriate selective 
liquid medium overnight. 0.5 ml of the overnight culture was then mixed with the same 
volume of glycerol in a screw cap microcentrifuge tube for storage at -80 °C.
2-8.9 Polymerase chain reaction (PCR)
Conventional PCR was performed on a FTC-200 Peltier Thermal Cycler (MJ Research 
INC.) using the conditions described in the relevant sections of this chapter. Therefore 
agarose gels or capillary electrophoresis were used for detection of PCR product sizes at 
the final phase of the PCR reaction.
Quantitative PCR was used for measuring the kinetics of PCR amplification 
during the early exponential phase of the reaction when (assuming 1 0 0 % reaction 
efficiency) doubling PCR products accumulate at every reaction cycle. It was performed 
in 96 well optical reaction plates (ABI Prism) using the spectrofluorometric thermal 
cycler ABI 7500 Real Time PCR instrument (Applied Biosystems) as described below 
for calculation of the quantitatively related amount of starting material and sensitive 
detection of variability between samples.
Therefore either an intercalating dye (SYBR Green I) or fluorescent Taqman 
probes were used. SYBR Green dye bound to the minor groove of double stranded 
DNA (increasing its fluorescence over a hundred fold upon binding) and as more 
amplicons were produced during the PCR reaction, the fluorescent signal increased.
Whereas SYBR Green bound to any double stranded DNA molecule, the use of 
fluorescent probes allowed specific detection of amplification of pre-determined targets. 
Taqman probes were designed to anneal to a specific sequence of the template between 
the forward and reverse primers used for amplification of the target. They contained a 
high-energy dye (reporter) at the 5’ end and a low-energy molecule (quencher) at the 3’ 
end. Excitation of the intact probe resulted in the reporter dye’s emission being 
suppressed by the quencher dye in close proximity due to fluorescence resonance 
energy transfer (FRET). During PCR, the 5’-exonuclease activity of the Tag DNA 
polymerase cleaved the probe that sits in the path of the enzyme. This stopped the 
transfer of energy from the reporter to the quencher that were no longer in proximity 
thereby decreasing the quencher signal and increasing the reporter signal with the latter
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captured by the sequence detection instrument. Using fluorescent probes, an increase in 
the product targeted by the reporter probe at each PCR cycle causes a proportional 
increase in fluorescence due to the breakdown of the probe and release of the reporter. 
Quantitative PCR is often performed on cDNA generated from the same quantities of 
RNA or with internal controls that allow for variations in the amount of RNA. For 
purposes for this project, however, absolute quantification of transcripts was not 
necessary and therefore cDNA generated from the total amount of RNA extracted with 
carrier was used to enable use of small cell numbers for quantitative PCR.
Analysis was performed using the ABI 7500 SDS software Version 1.2 (Applied 
Biosystems). The detection system plotted the level of fluorescence detected in the 
different wells as a function of the PCR cycle number, which allowed verification of 
successful PCR amplification. In addition a minimum threshold of detection was set, 
depending on the fluorescence detected in positive and negative control samples. An 
illustration is shown in Figure 2-9.
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Figure 2-9 Quantitative PCR amplification plot
This figure illustrates the level o f  fluorescen ce (D elta  Rn) detected in a representative 
duplicate sam ple that was plotted as a function o f  PCR cy c le  number. The threshold o f  
detection that was set for this assay is sh ow n  at 0 .0645  D elta Rn (green line).
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For assays using SYBR Green I, a dissociation curve was plotted for each sample. A 
representative example is shown in Figure 2-10. As temperature increases, PCR 
amplification products eventually dissociate into single strands. Dissociation to single­
stranded nucleic acids is known to occur rapidly at a certain temperature, which is 
called melting temperature (Tm). Using dissociation curves, specific PCR amplification 
can be detected as a curve with a single peak whereas nonspecific amplifications, 
including those of primer dimers, can be detected as a curve with multiple peaks 
resulting from different melting temperatures of the PCR products.
DissodrtionCwye
75
T s m p a r a t m  (C )
Figure 2-10 Quantitative PCR dissociation curve
This figure illustrates a representative exam ple o f  the derivate o f  fluorescen ce detected  in a 
duplicate sam ple, w hich is plotted against temperature. D issoc ia tion  curve analysis is perform ed  
after a com pleted PCR. Data is obtained by s low ly  increasing the tem perature o f  reaction  
solu tions from 58 °C (for TCR, section  2 -8 .9 .1 )  or 60 °C (for album in, section  2 -8 .9 .2 )  to  95 °C 
w hile continuously co llecting  fluorescence data. The increase in temperature cau ses PCR  
products to undergo dénaturation, a process accom panied  by release o f  S Y B R  Green 1 d ye and 
therefore decrease in fluorescence.
The detection system determined the threshold cycle value (Ct), which is the threshold 
cycle at which significant fluorescence is first detected above background. The Ct value 
was then translated into a quantitative result by the construction of a standard curve 
(refer to Figure 4-6 on page 273 for an example).
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2-8.9.1 T cell receptor (TCR) OR mRNA quantification
Several primers were designed and tested for amplification of TCR CB mRNA. The 
primer pair chosen for final amplification of a 195 bp product was CB forward 5’ TGA 
CTC CAG ATA CTG CCT GA 3’ (Alta Biosciences) and CB reverse 5’ CGT CTG 
ACA CCG AAR TGG AG 3’ (Alta Biosciences). The latter spans the boundary 
between exons 1 and 2 (marked in bold) thereby avoiding amplification from genomic 
DNA. The “R” at position 15 indicates that the primer was used at a 50:50 ratio of 
primers containing either A or G at this position, which accounts for differences 
between the TRBCl (IMGT accession number M l2887) and TRBC2 (IMGT accession 
number M l2888) genes containing a T or C at the corresponding positions respectively 
(refer to http://imgt.cines.fr for details).
Amplification was performed with 5 pi cDNA, 0.4 pM of each of the primers 
described above and 12.5 pi Power SYBR Green PCR Master Mix (Applied 
Biosystems) in a total volume of 25 pi using dénaturation at 95 °C for 5 minutes 
followed by 40 cycles of 95 ®C for 15 seconds and 58 °C for 1 minute and a dissociation 
stage of 95 °C for 15 seconds, 58 °C for 1 minute and 95 °C for 15 seconds on an ABI 
7500 Real Time PCR instrument (Applied Biosystems) using triplicate samples, non 
template controls and plasmid standards containing 10 to 10* molecules of TCR CB.
Control TCR CB plasmid was generated by PCR amplification using 1 pi of 
cDNA generated from healthy volunteers, 2 mM MgCli (Invitrogen), 0.4 mM 
deoxynucleotide-triphosphates (dNTPs), 0.4 pM of CB forward and reverse primers 
each and 0.53 units platinum tag (Invitrogen) with Ix platinum tag buffer (Invitrogen) 
in a final volume of 25 pi. PCR conditions were 95 °C for 1 minute followed by 
dénaturation at 95 °C for 30 seconds, annealing at 58 °C for 30 seconds and primer 
extension at 72 °C for 5 minutes for 30 cycles followed by a final polymerisation step of 
10 minutes at 72 °C. Resulting PCR products were used for ligation into pCR2.1 TOPO- 
TA cloning kit (Invitrogen), transformation of TOPI OF’ cells (Invitrogen) and plasmid 
DNA extraction as described in section 2-11.1.
The weight of a TCR CB DNA plasmid was calculated by multiplying the 
molecular weight of 2 nucleotides (660 glmol) with the total amount of base pairs 
contained in each plasmid (3,931 bp vector lengths plus 195 bp PCR product add up to 
4,126 bp of plasmid) resulting 2,723,160 g/wo/. As 1 mol has 6x10^^ molecules, the 
weight of DNA plasmid was divided by 6x10^^ to establish that 1 molecule of DNA
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plasmid weights 4.5386x10’** g. The plasmid DNA was linearised by digestion with 
8 pi Pstl (Roche) and 8 pi SuRE/Cut buffer H (Roche) at 37 °C overnight and used for 
absorbance measurement at 260 nm to establish the concentration of original plasmid 
DNA solution as 310 ng/pl, therefore 310x10’^  g/pl. This number was divided by the 
established weight of one molecule of plasmid DNA to determine a weight of 
6.8303x10*** molecules/pl as the molecular concentration of original plasmid DNA 
solution, which was subsequently diluted to obtain standards containing 10 to 10* 
molecules of TCR CB.
Control amplification of 105 bp amplicons was performed from the transferrin 
receptor gene (TfR, CD71, P90), which is constitutively low expressed in resting T 
cells. Therefore 5 pi cDNA sample was amplified with 0.5 pi ROX (5-carboxy-X- 
rhodamine) dye, 0.5 units platinum taq (Invitrogen), 3.5 mM MgCb, 0.2 mM dNTPs 
and 2.5 pi of pre-designed and validated primer/probe mix (with VIC dye label, minor 
groove binder (MGB) and non-fluorescent quencher (NFQ) located in exon 14) 
(Applied Biosystems) in a total volume of 25 pi with Ix platinum taq buffer 
(Invitrogen) in triplicates along with non-template controls and plasmid standards 
containing 10 to 10* molecules of transferrin receptor.
Standards were prepared as described for TCR CB using an initial PCR 
amplification with 2.5 pi of CD71 primer/probe mix (Applied Biosystems) instead of 
CB primers and an annealing temperature of 65 °C.
Thermal cycling was performed using dénaturation at 95 °C for 5 minutes 
followed by 40 cycles of 95 °C for 30 seconds and 60 °C for 1 minute on an ABI 7500 
Real Time PCR instrument (Applied Biosystems).
The TfR gene was chosen as the preferred template for control amplifications 
after comparison with a variety of different other constitutive genes. These other genes 
were considered not appropriate for quantitative PCR for various reasons. PCR 
amplification of a 285 bp template of the B Actin gene using the primers 5’ TCA TGA 
AGT GTG ACG TTG ACA TCC GT 3’ and 5’ CTT AG A AGC ATT TGC GGT GCA 
CGA TG 3’ resulted in consistent problems with non specific amplifications detected in 
non-template controls. PCR amplification from other genes resulted in dissociation 
curves with multiple peaks suggestive of unspecific amplification. Examples include the 
amplification from the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene 
using the primers 5’ GTC AGC CGC ATG TTC TTT T 3’ and 5’ ATC GCC CCA CTT
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GAT TTT 3’, which resulted in a dissociation curve with two different peaks 
originating from amplification of a 319 bp product in addition to amplification of a 
265 bp product from two different mRNA splice patterns. Multiple dissociation curves 
were also obtained during PCR amplification from a 345 bp template of hypoxanthine- 
guanine phosphoribosyltransferase (HPRT) using the primers 5’ CAG TCA ACA GGG 
GAC ATA AAA 3’ and 5’ TGA ACT CTC ATC TTA GGC TTT G 3’.
2~8.9.2 T ceil receptor excision circie p~REC) quantification
TREC analysis was performed on 4 samples from patient 28 that were obtained at day 
64, day 113, day 120 and day 127 post transplantation. Therefore triplicate samples of 
5x10^ PBMC were spun at 13,000 rpm for 1 minute and the supernatant removed. 50 pi 
of a 100 pg/ml proteinase K solution (Sigma) were added to the cell pellet and vortexed 
before incubation at 56 °C for 2 hours. This resulted in digestion of proteins and 
inactivation of nucleases for preservation of highly native, undamaged DNA. The 
solution was then vortexed again and incubated at 95 °C for 15 minutes to inactivate 
proteinase K. The sample was subsequently spun at 13,000 rpm for 1 minute to collect 
the resulting DNA lysate at the bottom of the tube and stored at -70 °C until use for 
TREC analysis.
For TREC analysis, 5 pi cell lysate was amplified with 0.5 units Platinum Taq 
(Invitrogen), 3.5 mM MgCE (Invitrogen), 0.2 mM dNTPs (Bioline), 0.4 pM TREC 
forward and TREC reverse primers (Sigma Genosys) each, 0.4 pM TREC probe (Sigma 
Genosys) and 0.5 pi of the 25 pM ROX reference dye (USB Corporation) in Platinum 
Taq buffer (Invitrogen) in a final volume of 25 pi.
Primers did amplify signal joint TREC (section 1-8.3) and were of sequences 
published by Douek and colleagues (Douek et a l, 2000). The TREC forward primer 
was 5’ CAC ATC CCT TTC AAC CAT GCT 3’, the TREC reverse primer was 5’ GCC 
AGC TGC AGG GTT TAG G 3’ and the TREC probe was 5’ F AM (6 - 
carboxyfluorescein) ACA CCT CTG GTT TTT GTA AAG GTG CCC ACT TAMRA 
(N,N,N’,N’-tetramethyl-5-carboxyrhodamine) 3’.
Thermal cycling was initiated with 2 minutes of incubation at 50 °C, followed 
by a first dénaturation step at 95 °C for 10 minutes and then 40 cycles of 95 °C for 
30 seconds and 60 °C for 40 seconds on an ABI 7500 Real Time PCR instrument 
(Applied Biosystems) along with triplicate plasmid standards (provided by A. Knight,
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ANRI) containing 10 to 10* molecules of TREC (standard curve slope -3.85, intercept 
46.10, coefficient of determination R^= 0.998769).
PBMC from the samples mentioned above \vere simultaneously used for surface 
staining with CD3 and CD4 (the patient had not recovered CD8  ^T cells) as described in 
section 2-5 for calculation of TREC numbers per CD4^ T cells.
Lysates were also tested by quantitative PCR for albumin, which confirmed the 
presence of similar quantities of the constitutive gene albumin in all cell lysates tested. 
This was performed by amplification of 5 pi lysate with 0.5 pM primer 1 (GCT GTC 
ATC TCT TGT GGG CTG T) and primer 2 (ACT CAT GGG AGC TGC TGG TTC) 
each and 12.5 pi Power SYBR Green PCR Master Mix (Applied Biosystems) in a total 
volume of 25 pi using dénaturation at 95 °C for 5 minutes followed by 40 cycles of 
95 °C for 30 seconds and 60 °C for 1 minute and a dissociation stage of 95 °C for 
15 seconds, 60 °C for 1 minute and 95 °C for 15 seconds on an ABI 7500 Real Time 
PCR instrument (Applied Biosystems).
2-9 Synthetic peptides
All peptides were purchased from Alta Biosciences, UK, and were at least 80 % pure. 
They were dissolved in dimethylsulfoxide (DMSO), their concentration determined by 
bicinchoninic acid (BCA) Protein Assay (PIERCE) (section 2-10) and stored at -20 °C. 
Proteins were diluted to the required quantity in <50 % DMSO and stored at 4 °C for up 
to 2 weeks before use for tetramer generation or stimulation experiments.
CMV derived peptides used during the main experiments described throughout 
this thesis are listed in Table 2-5.
Peptide position Length HLA restriction Sequence
pp65 (123-131) 9 HLA-B*3501 IPSINVHHY
ppSO (245-253) 9 HLA-A*0101 VTEHDTLLY
pp65 (363-373) 11 HLA-A*0101 YSEHPTFTSQY
pp65 (341-349) 9 HLA-A*0101 ' 
HLA-A*2402
QYDPVAALF
pp65 (113-121) 9 HLA-A*2402 VYALPLKML
pp65 (495-503) 9 HLA-A*0201 NLVPMVATV
Table 2-5 Peptides used in this study
This table lists peptides and the resp ective H L A  restriction in w hich  they have been studied  
w ithin  this thesis. 'R estriction o f  th is peptide by H L A -A *0101 w as reported previously  but not 
confirm ed in this study.
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Details of the peptides’ description in the literature are shown in the relevant result 
chapters.
2-10 Estimation of peptide and protein concentrations
The BCA Protein Assay (PIERCE) is based on the reduction of Cu^^ to Cu'^ in an 
alkaline medium, which is detected by bicinchoninic acid (BCA). Chelation of copper 
with protein in an alkaline environment results in formation of Cu^\ Chelation of two 
molecules BCA with one Cu'^ result in formation of a purple coloured reaction product, 
which absorbs at 562 nm depending on the protein concentration. The rate of BCA 
colour formation is dependent on the incubation temperature and protein concentration. 
The latter can be estimated by means of a standard curve.
Briefly, albumin standards containing bovine serum albumin (BSA) at a 
concentration of 2 mg/ml in 0.9 % (v/v) saline and 0.05 % (w/v) sodium azide 
(PIERCE) were diluted in water to 0.5 pg, 1 pg, 2 pg, 4 pg and 8 pg in a total volume 
of 500 pi each. Standards along with a negative control containing water only and 
samples at three different dilutions in water, each in a total volume of 500 pi, were 
incubated with 500 pi of freshly prepared BCA working reagent (mix of 50 parts of 
reagent A containing sodium carbonate, sodium bicarbonate and sodium tartrate in 
0.2 N NaOH, 48 parts of reagent B containing 4 % bicinchoninic acid in water and 
2 parts of reagent C containing 4 % cupric sulphate pentahydrate in water). After 
incubation in a heating block preheated to 60 °C for 60 minutes, samples were read in 
1 ml plastic cuvettes (Jencons PLS) on a spectrophotometer (Jenway) at 562 nm against 
water. The optical density of water was subtracted from all samples and protein 
concentration was determined using a standard curve generated from optical density of 
albumin standards.
2-11 Synthesis oftetramers
2-11.1 Cloning of HLA-A24 heavy chain cDNA
Cloning of HLA-A24 heavy chain required optimisation of different variables during 
molecular experiments with the final settings used described below.
Escherichia coli (E. coli) JM109 K12 derivate host cells (Stratagene) were 
grown on plates with selective M9 Medium (90 mM Na2HP0 4 xlH 2 0 , 22 mM KH2PO4,
8.5 mM NaCl, 18 mM NH4CI with addition of 0.4 % (w/v) glucose, 1 mM thiamine, 
0.1 mM CaCb, 1 mM MgS0 4  and 1.5 % (w/v) agar) by overlaying 50 to 200 pi cell
130
__________________________________________________________________ Chapter 2
culture on different Petri dishes (BD) containing the selective culture medium with
1.6 % (w/v) bacterial agar (Gibco BRL). Single colonies were picked and incubated in 
2XYT medium (16 g tryptone (Gibco BRL), 10 g yeast extract (Oxoid) and 5 g NaCl 
(BDH) per litre) shaking at 37 °C until they reached an ODeoonm of 0.9. Then 25 pi of 
JM109 culture were grown with 5 pi M l3 bacteriophage containing the HLA- 
A*24020101 sequence (provided by Dr. Ann-Margaret Little, Tissue Typing 
Laboratories, ANRI) in 5 ml 2XYT medium overnight. Cells were spun at 3,300 rpm 
and pellets used for DNA extraction using a Miniprep Kit (Stratagene).
DNA was used for polymerase chain reaction (PCR) to amplify the extracellular 
region of the HLA-A*2402 nucleotide sequence. Regions encoding the trans-membrane 
and intracellular portion of the HLA-A24 protein were excluded because these 
hydrophobic regions can complicate solubilisation and refolding of the expressed 
protein in later steps during the generation of tetramers and they are not needed for the 
molecule to bind to the T cell receptor. Primers were designed to amplify HLA- 
A*24020101 (IMGT/HLA accession number HLA0050) region 65 to 909 whereby 
positions 65-78 and 897 to 909 were modified leaving the regions spanning exon 2 
(starting at 74) to exon 4 (ending at 895) largely intact. PCR is illustrated in Figure 
2-11. The primers used were designed to add an Nco I (including the start codon) or 
BamH 1 restriction site to either site of the PCR product (primer “ 131” containing a Nco 
I restriction site (blue) and a codon encoding methionine marking the start of 
transcription (underlined): 5’ GCA CCA TGG GCT CTC ACT CCA TG 3’; primer 
“140” containing a BamH I restriction site (orange): 5’ CTG GGA AG A CGG ATC 
CCA TCT CAG GGT 3’). Primers were purchased from Amersham Pharmacia Biotech.
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C M13DNA65 909 J^^^^^equeno^ncodin^h^iL^A *2402010^x^^celluIa^iegioi^^^^^^^^
primer with primer with
Ncol site BaniHl site
Primer 131 : 5' GCJCCATGQGCTCTCACTCCATG 3 ’
I I I I I I I I I I I I I I I
HLA-A24 (65-87) : 5* CCTGGGCAGGCTCCCACTCCATG 3
-------------- 79
------------- 896
HLA-A24(883-909) : 5' ACCCTGAGATGGGAGCCATCTTCCCAG '3
I I I I I I I I I I I I I I II I I I I I I I I I 
Primer 140 (RC) : 3' ACCCTGAGATGEGATCCGTCTTCCCAG 5'
Figure 2-11 Illustration of HLA-A24 PCR amplification primers that add Nco I 
and BamH I restriction sites
This figure illustrates the sites o f  am plification o f  the extracellular region o f  H L A -A 24  (from  
residue 65 to 909 ) from M l3 D N A  containing the H L A -A 24 sequence. The sites w here  
primers m odify the original sequence with N co  I (b lu e) and Bam H  1 (orange) restriction sites  
are illustrated in the upper part o f  the graph w hereas alignm ent o f  th ese prim ers (prim er 140  
shown in reverse com plem ent) with the H L A -A 24 n ucleotid e sequence is sh ow n  in the low er  
part o f  the graph.
Amplification was performed in 50 pi reactions using 2.5 U High Fidelity Platinum Taq 
(Invitrogen) to circumvent the occurrence of mutations in the extracellular region of 
HLA-A24. Other reagents included 0.2 mM deoxyribonucleotide triphosphates (dNTPs) 
(Bioline), 2 mM MgS04  (Invitrogen) and 0.2 pM of both primers in Ix High Fidelity 
buffer (Invitrogen). The PCR amplification programme involved 94 °C for 2 minutes 
followed by 35 cycles of 30 seconds at 94 °C, 30 seconds at 55 °C and 90 seconds at 
68 °C and a final cycle of 30 seconds at 94 °C, 30 seconds at 55 °C and 10 minutes at 
68 °C.
The melting temperatures (Tm) of each primer were calculated as 64 °C for 
primer “131” and 67 °C for primer “ 141” using the formula 
Tm = 61.2 + 0.41(%GC)-500/L (whereby % GC is the percentage of deoxyguanosine 
and deoxycytidine bases contained in the primer and L is the length of the primer). An 
annealing temperature of 55°C was used to account for the mismatch in primers.
PCR products were subjected to gel electrophoresis on a 0.8 % TAE (0.04 M 
Tris acetate, 1 mM EDTA) gel, which is demonstrated in Figure 2-12.
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Figure 2-12 PCR amplification of HLA-A24 from JM109 plasmid DNA
This figure sh ow s gel electrophoresis (0 .8  % agarose, 100 V olt) o f  PCR products obtained  
after am plification o f  M l3 D N A  (contain ing the H L A -A *24020101  seq u en ce) w ith  primers 
131 and 140, w hich w as v isu alised  by use o f  ethidium  brom ide and exp osu re to  u ltraviolet 
light. Lane 1: 1 k ilo  base (kb) D N A  Ladder (Invitrogen), lane 2: PCR product from  water 
template; lane 3 and 4: PCR product from D N A  isolated  from  tw o  d ifferent JM 109 host cell 
clones; lane 5: blank; lane 6: 1 kb Plus D N A  Ladder (Invitrogen). The m olecular w eig h t o f  the 
marker’s relevant standards (in  bp) is show n b esid e the gel picture.
Bands corresponding to a size of 845 bp were recovered from the gel using GFX gel 
band purification kit (GE Healthcare) and ligated into pCR2.1 vector using the pCR2.1 
TOPO-TA cloning kit (Invitrogen) as illustrate in Figure 2-13.
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Ncol BamHl
\
G G A
I I I
5 '  G C A C C A T G Q G C T C T . ^ X ^ X ' V ' V ^ ^ ’V ’V ’V ' ^ T C C G T C T T C C C A G ( A )  3 '
m o d i f i e d  H L A - A 2 4 ( 6 5 - 9 0 9 )
a  ATG S a d  BamH
I I
G CCA AGC TTG GTA CCG AGC TCG/GAT CCA CTA 
GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT
tC oR I
<^4^3 Reverse Primer 
ICAGGAA ACA GCT ATG ACC ATG ATT
GTC CTT TGT CGA TAC TCG TAC TAA
Bs/XI (^ R j )
GTA ACG GCC GCC AGT GTG CTG GAA TTC GCC CTT
CAT TCC CGG CGG TCA CAC GAC CTT AAG CGG G
G GGC GAA TTC TCC 
TTC CCG CTT AAG ACG
EcoR V BstK I Not\ Xho\ Nsi \ Xb a \  Apa\
I I I I
AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC TAT 
TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC GGG ATA
T7 Promoter Forward (-20) Primw%Z)
AGT GAG TCG TAT TA|C AAT TCA CTC SCC G’l ’C U T T ^ Â Q A A  CGT CGT GAC TGG GAA AAC 
TCA CTC AGC ATA ATIG TTA AGT GAC CGG CAG CAA AAT G^T GCA GCA CTC ACC CTT TTG
a pCR®2.1-T0P0
3.9 kb
/
Figure 2-13 Illustration of ligation of Nco 1/BamH I modified HLA-A24 insert into 
pCR2.1 vector
This figure illustrates the site o f  ligation o f  the N co  I/Bam H  I m odified  H L A -A 24  PCR  
product into pCR2.1 vector (m od ified  from  a pCR2.1 TO PO map provided at 
http://w w w .invitrogen.com ). EcoRI restriction sites and sites for sequ en cin g with M l 3 primers 
that w ere used in further experim ents are h ighlighted  in circles.
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The pCR2.1 TOPO-TA vector contains single 3’-deoxythymidine (T) overhangs for TA 
cloning and the enzyme Topoisomerase I covalently bound to its DNA via 3’ phosphate 
as illustrated in Figure 2-14.
Figure 2-14 Illustration of the TOPO TA version of the pCR2.1 vector
This figure illustrates the sp ec ific ities o f  pCR2.1 T O PO  T A  that are d escrib ed  in the text 
(m odified  from pCR2.1 TO PO T A  m anual, h ttp ://w w w .in v itrogen .com )
Taq polymerase has a nontemplate-dependent terminal transferase activity that adds 
single deoxy adenosine (A) to the 3’ ends of PCR products. The overhanging T residues 
of the vector allow for efficient ligation of PCR inserts into the vector. High Fidelity 
Platinum Taq (Invitrogen) likely resulted in less efficient cloning due to partial removal 
of the A’ overhang but was used as its advantages of proofreading may outweigh this 
disadvantage.
The enzyme topoisomerase I from Vaccinia virus specifically recognises the 
pentameric sequence (C/T)CCTT and cleaves the phosphodiester backbone of duplex 
DNA after that sequence in one strand (Shuman, 1991) enabling the DNA to unwind. 
The energy resulting from this cleavage is conserved by formation of a covalent bond 
between the 3’ phosphate of the cleaved strand and a tyrosyl residue (Tyr-275) of the 
enzyme. This bond can subsequently be attacked by the 5’ hydroxyl of the original 
cleaved strand, thus reversing the reaction and releasing the enzyme (Shuman, 1994). 
Therefore topoisomerase I functions both as a restriction enzyme and ligase. It can 
cleave and rejoin DNA during replication and enables faster ligation of PCR products 
than is possible with conventional methods. A salt solution prevents free topoisomerase 
from re-binding and nicking the plasmid.
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Briefly, 1 pi or 4 pi of PCR product diluted in sterile water were incubated with 1 pi 
vector solution and 1 pi salt solution in a total volume of 5 pi at room temperature each 
for either 5 or 25 minutes before storage at -20 °C. No difference was observed between 
the four experimental variations.
Chemically competent TOP IGF’ cells (Invitrogen) were transformed with 
pCR2.1 containing HLA-A24. Therefore cells were chilled at 4 °C for 30 minutes in the 
presence of plasmid DNA and were then briefly heat shocked (at 42 °C for 3 minutes) 
causing the DNA to enter the cells. Transformed cells were grown overnight on LB 
plates (10 g tryptone, 5 g yeast and 10 g NaCl per L, pH 7) containing IPTG (Alexis 
Biochemicals), X-gal (Sigma) and 80 pg/ml Kanamycin (Sigma). Single white colonies 
(compare section 2-8.7) were picked and grown overnight in LB medium containing 
50 pg/ml Kanamycin.
Plasmid DNA was extracted by midiprep (compare section 2-8.1) and tested for 
the existence of an insert by digestion with EcoRI followed by gel electrophoresis. 
Therefore 2 pi DNA (<1 pg) was incubated with 1 pi EcoRI (Gibco BRL) and 1 pi 
SuRE/Cut Buffer H (Roche) in a total volume of 10 pi at 37 °C for 4 hours. EcoRI cuts 
the vector at position 284 and 302. The insert should be ligated into the vector at 
position 291. Therefore digest of clones with successful ligation would result in the cut 
of an 862 bp insert (original 845 bp product plus 17 bp flanking vector region) from the 
remaining vector as shown in Figure 2-15.
L lU ID 2U 2D 3U 3D 4U 4D 5U 5D 6U 6D 7U 7D 8U 8D 9U 9DI OU lODl lU 1 ID L
T o
Figure 2-15 EcoRI digestion of plasmids from TOPlOF’ clones that had been 
transformed with pCR2.1-HLA-A24
This figure sh ow s gel electrophoresis (0 .8  %  agarose, 100 V olt) o f  p lasm id D N A  extracted  
from T O PlO F’ clon es transform ed with p C R 2 .1-H L A -A 2 4  and d igested  w ith EcoRI flanking  
the clon in g  site o f  pCR2.1 (com pare Figure 2 -1 3 ) Lanes L: 1 kb Plus D N A  Ladder 
(Invitrogen); other lanes; D N A  from  clon es 1 to  10 (11:  a plasm id previously  m odified  to  
contain H L A, used as p ositive  control) that w ere either not d igested  (U ) or d igested  with  
EcoRI (D ). The m olecular w eigh t o f  relevant s ize  standards (in  bp) is show n b esid es the gel 
picture.
Bands visible from undigested plasmids from TOPlOF’ clones separated by gel 
electrophoresis (Figure 2-15) demonstrated different conformations of plasmid DNA. In
136
___________________________________________________________________ Chapter 2
general, five conformations exist. The one running the slowest during gel 
electrophoresis is nicked open-circular DNA, in which one strand is cut. Linear DNA 
may be visible below. That confirmation has free ends, either because both strands were 
cut or because the DNA was linear in vivo. Bands running at the highest positions for 
cut and uncut plasmids shown in Figure 2-15 appear to be of linear conformation. 
Below that three more conformations may theoretically be visible. Relaxed circular 
DNA is fully intact with both strands uncut but has been enzymatically relaxed. 
Supercoiled DNA is covalently closed-circular. In this conformation DNA is fully intact 
(both strands uncut) with a twist built in resulting in a compact form. DNA can also be 
present as supercoiled denatured DNA, which has unpaired regions that make it slightly 
less compact, which can result from excessive alkalinity during plasmid preparation. 
Lower bands in Figure 2-15 lanes lU - l lU  likely represent plasmids in supercoiled 
conformation. In lanes ID-l lD digestion with EcoRI resulted in all plasmids being 
linearised. An additional small band is visible in plasmids that contained the HLA-A24 
insert (clones 3, 5, and 7-11).
DNA from clones that demonstrated presence of HLA-A24 inserts was also used 
for confirmatory sequencing (Advanced Biotechnology Centre, Imperial College, 
London, UK) using M l3 forward and M l3 reverse primers (Figure 2-13) provided with 
the TOPO-TA cloning kit (Invitrogen). The sequence of the M l3 forward primer was 
5 -GTA AAA CGA CGG CCA G-3' and that of the M l3 reverse primer was 5 -CAG 
GAA ACA GCT ATG AC-3'. The molarity of these primers (required to provide the 
optimum primer concentration for sequencing) was calculated using the formula 
[(number of A nucleotides x 312.2) + (number of G nucleotide x 328.2) + (number of C 
nucleotide X 288.2) + (number of T nucleotide x 303.2)] - 61. Nucleotide sequencing 
was performed using BigDye V3.1 chemistry on an Applied Biosystems 3100 capillary 
sequencer using 96 °C for 10 seconds, 46 °C for 5 seconds and 60 °C for 4 minutes for 
35 cycles. This showed that clone 3 (compare Figure 2-15) contained the HLA-A24 
sequence without mutations.
The pCR2.1 TOPO TA vector was chosen for initial cloning of HLA-A24. This 
is because TOPO TA features (efficient Topoisomerase I dependent TA cloning, 
presence of a cloning cassette comprising a large range of restriction sites and the 
presence of a gene encoding 6-Galactosidase) offered excellent conditions for efficient 
ligation and for different sub-cloning options if needed for later projects. The plasmid
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DNA from clone 3 containing an insert of the right size and sequence was kept as stock 
in this vector.
DNA was subsequently digested with Nco I and BamH I for transfer into a 
different vector that is better suited for expression of the HLA-A24 protein for tetramer 
generation. Therefore 2 pi DNA (<1 pg) was incubated with 1 pi Nco I (Gibco BRL) 
and 1 pi BamH 1 (Gibco BRL) and 1 pi Buffer 3 (Gibco BRL) in a total volume of 
10 pi at 37 °C overnight. The HLA-A24 insert was recovered from an 826 bp band 
using GFX purification (GE Healthcare) for subcloning into the protein expression 
vector pET3d-bsp2 described below.
The vector pETS was a gift from Dr. Studier (now commercially available from 
Novagen, Cambridge Bioscience, UK under the name pET3d) with a vector map shown 
in Figure 6-1 in the appendix. It was modified by Christina Zamoyska at the ANRI to 
contain a sequence coding for a biotinylation target for the enzyme biotin protein ligase 
(BirA) that was originally described by Schatz and colleagues (Schatz, 1993). This 
sequence was constructed from four complementary oligo nucleotide linkers (colours 
shown in accordance with Figure 2-16):
• CATGGATCGGATCCCGGCTCCGGCTCCCTGCATCATATTTTTGAAG
• CTAGCCTAGGGCCGAGGCCGAGGGACGTAGT
• CACAGAAAATTGAATGGCGCCATCGTTAAA
• ATAAAAACTTCGTGTCTTTTAACTTACCGCGGTAGCAATTTCTAG
These were made to anneal and were then ligated into an Nco I/BamH I digested pET3d 
vector. This resulted in complementary binding of the fragment’s Bgl II overhang and 
the vector’s BamH I digested site, thereby cancelling the BamH 1 restriction site at this 
position of the vector. The presence of the sequence for BirA substrate peptide (bsp2) in 
the vector resulted in a new BamH I restriction site near the Nco I restriction site that 
was present in the vector originally. This enabled subcloning of the modified HLA-A24 
sequence into Nco 1/BamH I digested pET3d- bsp2 vector, which is illustrated in Figure 
2-16.
138
Chiyter2
-------  modified HIA-A24(65-909)
Nco\ BamH\
S'GCACCATOGGCTCT 
5
GGATCCGTCTTCCCaS 3' 
CcrAü3CAO*AGGGTC 3'
biotxnyletion target
overhang 
Ncol
CATOGATCG
lAOCC TA .3GOOCOaOOOCO»OOQ*COTJmTATAAAAACTTCGTOTCTTTTAACTTACCGCGGTAQCAATTTCTAG 3 '
cancels
Ncol site in original 5' ccatgg BamHl site in original
pET3d (4637 bp) at 510 Vtaog 3 ' ^t 546
Bgl II 
overhang
—b»o«mvUtion »lt« 
—bsp2 tag 
—T7 terminator 
—BimH!
HLA-A24btp2- 
T7 promoter- 
T7 transcription start- 
Xb*h
■Hindlll
-EcoRI
pET3dHLA-A24bsp2 
5493 bp
Figure 2-16 Illustration of HLA-A24 ligation into pET3d-bsp2
This figure illustrates the clon in g  o f  the 80 bp sequ en ce en cod in g  the b iotinylation  target into 
the N co  I/BamH I digested pET3d vector (at its original p ositions 5 4 6 -5 1 0 ) via Bgl II (red) and 
N co I (blue) overhangs. The am ino acid sequence o f  the b iotinylation  substrate w ith the lysin e  
residue (K ) biotinylation target underlined is show n ab ove the en cod in g  bsp2 nucleotide  
sequence. Ligation o f  the H L A -A 24 sequence m odified  to be flanked by N co  I/B am H  I using  
the original N co  I (blue) and the new ly form ed Bam H  I (orange) restriction sites o f  the 
m odified pET3d-bsp2 vector is illustrated on the top o f  the figure. This resulted in insertion o f  
m odified H L A -A 24 (826  bp) at the positions 1 to 9 o f  the original bsp2 sequence w ith the 
resulting expression vector being 5,493 bp. An ATG  start codon is provided w ithin the N co  I 
recognition site and a TA A  stop codon is provided w ithin  the bsp2 sequence (resulting in a 
891 bp sequence available for translation). The vector is show n in op posite  d irection to  the 
map o f  the original pET3d (Figure 6-1 in the appendix) so  that the cloned  region can be 
view ed clock w ise  (see  Figure 6-2  in the appendix for com plete nucleotide sequ en ce, for 
alignm ent o f  sequencing primers and for the sequence o f  the translated H L A -A 24bsp 2 protein  
with its calculated m olecular w eight). Abbreviations: Ap: A m picillin  resistance gen e, ori: 
origin o f  replication. This figure w as generated using CLC D N A  W orkbench softw are.
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Subcloning of HLA-A24 into pET3d-bsp2 was performed by incubation of 2 pi 
(approximately 25 ng) of cut pET3d-bsp2 vector with 1 pi T4 ligase (Gibco), 1 pi of 5X 
T4 ligase buffer (Gibco), 2 pi (approximately 10 ng) of the modified HLA-A24 
sequence and water in a total volume of 10 pi in a water bath at 14 °C overnight.
PET-3d-bsp2 vectors containing HLA-A*2402 were used to transform E. coli 
XL 1-Blue cells (Novagen). This strain was used for production of large quantities of 
plasmid DNA. DNA extracted from these cells was used for sequencing (Advanced 
Biotechnology Centre) and DNA with the confirmed sequence of the HLA insert and C 
terminal bsp2 was transformed into different host cells for protein expression as 
described later (sections 2-11.3 and 2-11.4).
Sequencing primers binding the external section of the vector cloning cassette 
were 5’ GGA GAC CAC AAC GGT TTC CC 3’ (forward primer “161”) and 5’ TGC 
TAG TTA TTG CTC AGC GG 3’ (reverse primer “162”, similar to the T7 terminator 
primer, Novagen) initially.
Later the forward sequencing primer was changed to T7 promoter sequencing 
primer 5’ TAA TAC GAC TCA CTA TAG GG 3’ (Invitrogen) and additional 
sequencing with internal primers was performed. Internal primers were designed for 
sequencing of HLA-B*3501 inserts. The sequences of these were 5’ TAC GAC GGC 
AAG GAT TAC ATC GCC 3’ (aligning to positions 424 - 447 within exon 3 of HLA- 
B350101 in forward direction) and 5’ CTC AGG TCC TCG TTC AGG GCG ATG 3’ 
(aligning to positions 441 - 464 within exon 3 of HLA-B35*0101 in reverse direction). 
They were also used for sequencing of HLA-A*2402 inserts, for which the reverse 
primer was mismatched at two positions (marked in bold). Designed primers were 
purchased from Alta Biosciences. The alignment of sequencing primers to the 
nucleotide sequence of HLA-A24-pET3d-bsp2 is illustrated in Figure 6-2 in the 
appendix.
2-11.2 Cloning of other HLA heavy chains and &2-niicroglobulin
The HLA-A*0201 and HLA-B*350101 constructs had been made in-house previously 
by Geraldine Aubert and Armando van der Horst (ANRI). They were propagated in 
XL 1-Blue and their sequences were confirmed before use in this study. In the case of 
HLA-B35 the sequencing results from one colony demonstrated a single amino acid 
substitution (Alanine -* Valine) at position 245 of the HLA chain, which was probably 
introduced during the initial PCR. This specific mutation in the a3 domain (exon 4) was
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reported to result in expression of heavy chain with diminished CD8 interaction (Salter 
et a l, 1990, Salter et a l, 1989). Tetramers made from V245 heavy chain can interact 
with T cells with increased specificity (Bodinier et a l , 2000). Therefore DNA from this 
clone was chosen for HLA-B35 protein expression to generate HLA-B35/CMV peptide 
tetramer.
The HLA-A*0101 construct was a gift to the ANRI laboratory from 
Dr. Falkenburg (Department of Immunohaematology and Blood Transfusion, Leiden 
University Medical Centre, Netherlands). Wild-type HLA-A*2402 was cloned as 
described above and mutated HLA-A*2402 (msHLA-A*2402) was a kind gift from 
Prof. Sato (Sapporo Medical University School of Medicine, Japan) (described in (Sato 
et a l, 20 0 2 )).
Cloning of HLA-B*4402 and HLA-B*4403 was performed by cDNA generation 
of RNA extracted from EBV-transformed B cell lines WT47 (HLA-B*4402 
homozygous) and PF97387 (HLA-B*4403 homozygous) cell lines provided by 
Dr. Steve Marsh (ANRI). Both cell lines are from the International Histocompatibility 
Workshop Cell Panel (accession numbers IHW9063 and IHW9027). HLA-B44 
amplification was performed with primers of the sequences 5’- GGG CGT CGA CGG 
ACT CAG AAT CTC CCC AGA CGC CGA G -3’ and 5’- CCG CAA GCT TCT GGG 
GAG GAA ACA CAG GTC AGC ATG GGA AC -3’. It was performed in 50 pi 
reactions using 2.5 U High Fidelity Platinum Taq (Invitrogen), 0.2 mM 
deoxyribonucleotide triphosphates (dNTPs) (Bioline), 2 mM MgS0 4  (Invitrogen) and 
0.4 pM of both primers in Ix High Fidelity buffer (Invitrogen). The PCR amplification 
programme involved 94 °C for 2 minutes followed by 35 cycles of 30 seconds at 94 °C, 
30 seconds at 55 °C and 90 seconds at 68  °C and a final cycle of 30 seconds at 94 °C, 
30 seconds at 55 °C and 10 minutes at 68  °C. PCR products were subsequently ligated 
into pCR2.1 as described for HLA-A24. However, folding of HLA-B44 protein requires 
an in vitro system very different from what is described for other HLA proteins in 
subsequent sections. Experiments for the generation of HLA-B44/CMV tetramer 
subsequently had to be discontinued (when unforeseen problems with a vector that was 
planned to be used for expression meant that a new project would be needed to continue 
this work) and are therefore not described further.
The 62-microglobulin (62m) was cloned into the pHNl ampicillin resistant 
vector and transformed into E.coli strain XA90 (MacFerrin et a l, 1990). It was kindly
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donated to the ANRI laboratories by the late Professor Don Wiley (refer to (Garboczi et 
a l, 1992) for details of the construct).
2-11.3 Expression of HLA heavy chain and light chain proteins 
using induction with IPTG
PET-3d-bsp2 vectors containing HLA-B*3501, HLA-A*0201 or wild type HLA- 
A*2402 nucleotide sequences, PET-3a-bsp vectors containing HLA-A*0101 nucleotide 
sequences or pET-21d-bsp vectors containing mutated (ms) HLA-A*2402 nucleotide 
sequences were used to transform the E. coli strain BL21(DE3) pLysS (Novagen). The 
wild-type HLA-A*2402 construct was additionally used to transform BLR(DE3)pLysS 
and HMS174(DE3)pLysS E. coli cells (Novagen) as will be explained later during this 
section. All E. coli strains used for transformation experiments were chemically 
competent.
The above-mentioned E. coli strains (compare Table 2-6) were used for tightly 
controlled protein expression in the T7 RNA polymerase-based system. In this system 
the target gene is cloned under the control of the T7 promoter, which is not recognised 
by E. coli RNA polymerase. Therefore virtually no expression occurs until a source of 
T7 polymerase is provided, avoiding production of proteins potentially toxic to the host 
cell that may otherwise cause plasmid instability. The strains mentioned above are 
lysogens of the bacteriophage DE3. Therefore they contain a chromosomal copy of the 
T7 RNA polymerase gene under the control of lacUV5 promoter inducible by IPTG. In 
pET21d (but not pET3d or pET3a), the DE3 lysogen also encodes for a Lac repressor 
gene that additionally represses the transcription of T7 RNA polymerase and thereby 
transcription from the target gene. The bacteria with pLysS designation carry a low- 
level expression plasmid that encodes T7 lysozyme, which binds to T7 RNA 
polymerase thus inhibiting transcription by this enzyme. Therefore transcription of pET 
encoded proteins was very minimal during the initial period of bacterial culture. T7 
lysozyme is a bifunctional protein. It also cuts specific bonds in the peptidoglycan layer 
of the E.coli cell wall (Inouye et a l, 1973). High levels of T7 lysozyme are tolerated 
when produced from a cloned gene because the protein is not passed through the inner 
membrane to reach the peptidoglycan layer (Studier et a l, 1990). Presence of this 
protein confers an additional advantage during purification of target protein because it 
aids cell lysis during membrane disruption by detergents or freeze/thaw of cells. Upon 
IPTG induction, overproduction of the T7 RNA polymerase effectively shuts down any 
low level inhibition by T7 lysozyme or Lac repressor.
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Expression of Bim from the pHNl plasmid in E.coli strain XA90 can be induced 
with IPTG (Ezaz-Nikpay et a l, 1994) similar to E. coli strains using the T7 RNA 
polymerase-based system. Like the pET vectors used, pHNl conferred resistance to 
ampicillin by carriage of the B-lactamase gene.
E.coli clones transformed with sequences encoding HLA heavy chain or B2IÎI 
were grown in 1 litre 2XYT medium supplemented with 50 pg/ml ampicillin (Sigma) 
and strain specific antibiotic selection shown in Table 2-6. Therefore bacteria were 
scraped off the top of frozen glycerol stock (compare section 2 -8 .8) and inoculated into 
10 ml of selective medium at 37 °C shaking at 180 rpm overnight. The overnight culture 
was then inoculated into 1 litre of selective medium at 37 °C shaking at 180 rpm until 
the mid-log of the exponential growth phase (ODôoonm = 04. - 0.6). At that time protein 
expression was induced by addition of IPTG to a final concentration of 2 mM. 1 ml pre- 
and post-induction cell culture samples were taken for assessment of protein expression 
by SDS-PAGE (section 2-11.8). After growth for 4 hours, cells were harvested by 
centrifugation at 4,000 g for 20 minutes at 4 °C (Beckman JB-6 ) and purified as 
described in sections 2-11.6 and 2-11.7.
E. coli strain Antibiotic selection
BL21 (DE3)pLysS 34 pg/ml Chloramphenicol
BLR(DE3)pLysS 34 pg/ml Chloramphenicol 
5 pg/ml Tetracyclin hypochloride
HMS174(DE3)pLysS 34 pg/ml Chloramphenicol 
200 pg/ml Rifampicin
BLR 5 pg/ml Tetracyclin hypochloride
HMS174 200 pg/ml Rifampicin
XA90 none
Table 2-6 E. coli strain specific antibiotic resistance used for cell culture
This table lists E. c o li strains used  for exp ression  o f  heavy chain and B2m proteins and the 
antibiotic selection  used for culture o f  each strain in addition  to 50 p g/m l A m p ic illin  (all from  
Sigm a Aldrich).
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Protein expression was uncomplicated for HLA-A*0101, HLA-A*0201, HLA-B*3501 
and 132m resulting in large amount of protein in form of inclusion bodies (compare 
Figure 2-19, page 151). HLA-A*2402 encoded protein, however, was not produced 
efficiently. Target proteins may interfere with gene expression or integrity of the host 
cell that prevents substantial amounts of target proteins to be produced. Plasmids 
containing toxic genes may be destabilised in the host cells. This was shown to occur by 
cyclic adenosine monophosphate (cAMP) mediated derepression of lacUV5 promoter 
(Grossman et a l, 1998), which can be prevented by addition of glucose (inhibiting 
cAMP production through inhibition of the cAMP-producing enzyme, adenylate 
cyclase, as a side effect of glucose transport into the cell) to culture medium. Addition 
of 1 % glucose in the culture medium, however, was not found to improve HLA-A24 
protein expression in hosts. Alternatively bacteria were grown in medium supplemented 
with carbenicillin instead of ampicillin. Ampicillin resistance can be lost in cultures as 
the antibiotic is degraded by the 6-lactamase enzyme secreted by bacteria and the drop 
of pH that usually accompanies bacterial fermentation. This may be avoided by use of 
the related antibiotic carbenicillin, which is less sensitive to low pH. However, this 
approach was not found to influence the amount of HLA-A24 protein expressed either.
BL21 is the most widely used host for target gene expression. It is deficient in 
Ion and ompT proteases that can degrade proteins during purification. BLR and 
HMS174 were used as alternative hosts for induction of HLA-A24 protein. They are 
recA' (encoding a DNA repair protein with co-protease function) derivatives that may 
help stabilise target plasmids containing repetitive sequences or whose products may 
cause the loss of the DE3 prophage. However, these hosts produced only small amounts 
of the protein as illustrated in Figure 2-17.
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Figure 2-17 HLA-A24 expression in HMS174 (DE3) pLysS
This figure illustrates S D S -P A G E  (com pare section  2 -1 1 .8 )  separation o f  proteins expressed  
by induction  o f  p E T 3d -b sp 2-H L A -A 24 transformed E. c o l i  w ith IPTG. Lane 1: ce ll culture pre 
induction , lane 2: ce ll culture 4 hours post induction, lane 3: purified inclusion  body, lane 4: 
em pty, lane 5: BenchM ark^w Pre-stained Protein Ladder (Invitrogen). The m olecular w eigh t 
(in  k D a) o f  m arkers is show n beside the gel w ith the heavy chain expected  b elow  the sixth  
standard from  the top o f  approxim ately 34 kDa.
Most HLA-A24 transformed cultures did not result in formation of inclusion bodies 
with a predominant protein band of the expected size (approximately 34 kDa). The best 
expression obtained from host strains is shown in Figure 2-17. Even in that example, 
however, the abundance of expression is low. Therefore alternative expression of HLA- 
A24 by induction with bacteriophage was tested.
2-11.4 HLA-A24 protein expression using RNA polymerase delivery 
by infection of hosts with bacteriophage XCES
Introduction of T7 RNA polymerase by infection of host cells with bacteriophage ACE6 
is a less convenient method than induction of DE3 lysogens by IPTG but may be a good 
alternative for expression of toxic genes. The method is based on the principle that 
X.CE6 infection of hosts leads to the newly made T7 RNA polymerase to transcribe 
target DNA so actively that normal phage development cannot proceed.
A stock of bacteriophage XCE6 (Novagen) was prepared in ED8739 and LE392 
E.coli hosts (Novagen) according to the manufacturer’s protocol. Host cells mixed with 
different phage stock dilutions in top agar were grown on duplicate plates prepared with
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NZY medium (10 g NZY amine, 5 g yeast extract, 5 g NaCl per litre) supplemented 
with 0.2 % (w/v) maltose and 10 mM MgSO#. The resulting lysis plaque-forming units 
(pfu) were counted to determine the titer of the phage stock. Controls used were plates 
with top agar containing host cells without phage, plain top agar or plates without top 
agar.
Non-lysogenic E. coli clones BLR and HMS174 (Novagen) transformed with 
pET-3d-bsp2 containing the sequence encoding HLA-A*2402 were grown in 1 litre 
2XYT medium (containing 16 g tryptone, 10 g yeast extract and 5 g NaCl per litre) 
supplemented with 0.2 % (w/v) maltose, 50 pg/ml ampicillin (Sigma) and strain specific 
antibiotic selection (Table 2-6) at 37 °C shaking at 180 rpm. After reaching 
OD6oonm=0.3, glucosc was added to a final concentration of 4 mg/ml and cultures 
grown further to an ODôoonm = 0 . 6 - 1 .  Protein expression was induced by addition of 
MgS0 4  to a final concentration of 10 mM and XCE6  stock to a final concentration of 2,
3 or 4x10^ pfti/ml. Pellets from pre- and post-induction samples prepared from 1 ml cell 
culture were stored at -20 °C for analysis by SDS-PAGE (section 2-11.8). After growth 
for 4 hours, cells were harvested by centrifugation (4,000 g for 20 minutes at 4 °C).
This method also resulted in small amount of HLA-A24 protein being produced. 
In comparison, best production of wild type HLA-A24 was achieved in IPTG induced 
HMS174 (DE3) pLysS hosts as illustrated in Figure 2-17. Therefore yet another 
alternative way of expressing this protein was exploited.
2-11.5 Protein expression from mutant HLA-A*2402 seq u en ce
It is important to obtain large amount of soluble HLA protein for the construction of 
tetramers. However, conventional methods of expression and the use of variations of 
these to circumvent potential toxicity of HLA-A24 protein were not efficient.
Therefore low expression of the protein in E. coli strains may have been due to 
reasons other than toxicity. Sato and colleagues (Sato et a i, 2002) developed a mutant 
HLA-A24 heavy chain (msHLA-A24), in which mammalian codon usage was 
exchanged for silent mutated nucleotide sequences that were described to be 
preferentially used by E. coli previously (Wada et a i,  1992, Zhang et a i, 1991).
Professor Sato kindly donated the HLA-A24 expression vector for use in this 
project. This vector contained the HLA-A*2402 sequence region 73 - 900, which was 
modified to contain a start codon, restriction sites and E. coli preferred codons followed 
by a C-terminal BirA substrate (Sato et a i,  2002) in pET21d. After transformation into
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BL21(DE3)pLysS (Novagen), expression was performed as described in section 2-11.3 
and resulted in production of large amounts of HLA-A24 protein in form of inclusion 
bodies (compare Figure 2-18, page 149).
2-11.6 Protein purification from inclusion body preparations
Cell pellets obtained after expression of wild type heavy chains and 62m were 
resuspended in 10 ml Bug Lysis Buffer (25 % (w/v) sucrose (BDH), 50 mM Tris-HCl,
1 mM EDTA, pH 8 ) and centrifugated at 4,000 g for 10 minutes at 4 °C. Pellets were 
resuspended in 10 ml B-Per Buffer (Pierce) supplemented with 25 mg lysozyme 
(Sigma) on ice. Membrane disruption was facilitated by freezing and subsequent 
thawing of cells. Samples were then sonicated (Jencons Ltd.) in 15-second bursts on ice. 
The inclusion bodies were pelleted at 10,000 g for 20 minutes at 4 °C. Washing steps 
were performed once in detergent buffer (20 mM Tris-HCl, 0.2 M NaCl, 1 % (v/v) 
sodium deoxycholate, 1 % (v/v) Nonidet P40, 2 mM EDTA pH 7.5) and subsequently in 
triton buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 0.5 % (v/v) TritonXlOO, 
pH 8 ) for at least three times using centrifugation at 10,000 g for 10 minutes at 4 °C in 
between. Purified proteins were stored in resuspension buffer (50 mM Tris-HCl, 1 mM 
EDTA, 1 mM phenylmethylsulphoxide (PMSF) and 2 mM dithiotreitol (DTT) pH 8 ) at 
-20 °C for analysis using SDS-PAGE (section 2-11.9). All proteins except mutated 
HLA-A24 were solubilised by rolling at 4 °C overnight in freshly prepared urea buffer 
(8  M urea, 0.1 mM EDTA, 0.1 mM DTT, 0.01 M Tris-HCl, 0.1 M NaH2P0 4 ) that had 
been deionised with Amberlite (Merck). Undissolved material was removed by 
centrifugation at 10,000 g before use for refolding (section 2-11.9).
In contrast, cell pellets from msHLA-A24 6 xHis tagged protein were not washed 
with detergents but solubilised by resuspension in buffer A (8  M urea, 20 mM HEPES 
pH 8 and 50 mM NaCl) and sonication. Samples were spun at 4,000 rpm for 10 minutes 
at 4 °C and the supernatant collected for purification using nickel- nitrilotriacetic acid 
(Ni-NTA) described in section 2-11.7.
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2-11.7 Mutant HLA-A24 protein purification by nickel- nitrilotriacetic 
acid (Ni-NTA)
The msHLA-A24 expression vector contained the HLA-A*2402 sequence and a C- 
terminal BirA substrate sequence followed by a thrombin recognition site in pET21d. 
This enabled the use of the amino acid motif hexa histidine (6 xHis tag), which is 
encoded downstream of the HLA-A24 in the pET21d vector (Sato et al., 2002). The tag 
can be used for specific purification of the target protein. Nitrilotriacetic acid (NTA), a 
chelating agent that forms coordination compounds with metal ions such as Nickel 
(Ni^^) is used for this purpose. Proteins tagged with 6 xHis tag can be separated from 
other proteins present in cell lysates by affmity-purification over columns containing 
Ni-NTA agarose beads. The affinity medium contains metal ions to which the 
polyhistidine-tag binds. After contaminating proteins are washed off, the purified 
protein can then be eluted from the column. The thrombin cleavage site (Leu-Val-Pro- 
Arg/Gly-Ser) at the C-terminal end of the HLA-A24-bsp construct can be used for 
removal of the polyhistidine tag. Following purification of HLA-A24-bsp-6xHis 
protein, thrombin can be used to selectively cleave and remove the purification tag from 
the HLA-A24-bsp protein with a high degree of specificity. This, however, did not seem 
necessary as the tag did not interfere with subsequent generation of functional tetramer.
Briefly, protein expressed from the msHLA-A24 construct was loaded onto 2 ml 
Ni-NTA-agarose resin (Qiagen, Hilden, Germany) in a glass column and equilibrated 
with 10 ml buffer A (8 M urea, 20 mM HEPES pH 8 and 50 mM NaCl) containing 
20 mM Imidazole (BDH Laboratory supplies, UK). The sample was washed with 30 ml 
o f the same buffer. 5 ml buffer A containing 250 mM Imidazole were then added and 
the purified sample collected. At this concentration of Imidazole, the 6 xHis-tagged 
proteins dissociated because they could no longer compete for binding sites on the Ni- 
NTA resin resulting in elution of the HLA-A24 protein. The buffer was exchanged with 
10 mM Tris-HCl pH 8 using two PD-10 columns (Amersham Pharmacia Biotech, 
Uppsala, Sweden).
The purity of the resulting protein solutions (wild type HLA heavy chain or Bzm 
in urea buffer or msHLA-A24 in 10 mM Tris-HCl) were tested by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) as will be described in 
section 2-11.8. A representative gel is shown in Figure 2-18. The concentration of 
protein was assessed by BCA assay (Pierce, UK) as described in section 2-9 and 
aliquots were stored at -70 °C.
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Figure 2-18 msHLA-A24 protein expression
This figure illustrates SD S -P A G E  separation o f  proteins expressed  by induction o f  pET21d- 
b sp -m sH L A -A 24  transform ed E. c o li  w ith IPTG. Lane 1: Bench M a r k P r e - s t a in e d  Protein  
Ladder (Invitrogen ), lane 2: 10 pi culture sam ple pre induction , lane 3 and 4 :10  pi culture 
sam ples at 2 and 4 hours post induction, lane 5-7: 2 , 5, 10 and 15 pi inclusion  body post N i-  
N T A  p urification , lane 9: 10 pi non-purified in clu sion  body. The m olecular w eigh t (in  kD a) o f  
markers is sh ow n  b esid e the gel.
2-11.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE)
Before separation on a gel, proteins are usually exposed to a detergent such as SDS that 
denatures secondary and non-disulfide linked tertiary structures and applies a negative 
charge to proteins, which is in proportion to their mass. Without SDS, proteins would 
migrate in the gel depending not only on their molecular weight but also their 
mass/charge ratio (compare native gel, section 2-11.13). Brief heating of protein 
samples in the presence of a reducing agent (such as DTT) can further denature them by 
reducing disulfide linkages, thus overcoming some forms of tertiary protein folding and 
breaking quaternary protein structures (oligomeric subunits). Subsequently proteins 
migrate relative only to their size and not their shape or charge in a reducing SDS- 
PAGE.
The pore size of the gel used in polyacrylamide gel electrophoresis (PAGE) is 
determined by the concentrations of acrylamide and bis-acrylamide used. Gels consisted 
of a 15 % resolving lower gel (375 mM Tris-HCl pH 8 .8 , 50%  ProtoGel (containing 
30 % (w/v) Acrylamide and 0.8 % (w/v) Bis-Acrylamide; National Diagnostics), 0.1 % 
(w/v) SDS (Sigma), 0.03 % (w/v) ammonium persulphate (APS) (Pharmacia Biotech)
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and 0.03 % (v/v) Tetramethylethylenediamine (TEMED) (Amersham Biosciences)) 
overlaid with a stacking upper gel (125 mM Tris-HCl pH 6 .8 , 17 % ProtoGel, 0.1 % 
(w/v) SDS, 0.1 % (w/v) APS and 0.1 % (v/v) TEMED). These were prepared in a 
Mighty Small multi-gel caster (Hoefer Scientific Instruments) by pouring of the lower 
gel overlaid with butan-2 -ol until it set (to create an even surface) followed by the upper 
stacking gel poured above it and insertion of a gel comp to create loading wells.
Lysis of culture supernatant samples was performed in PBS containing 1 % SDS 
at room temperature for 30 minutes followed by removal of undissolved material by 
centrifugation at 13,000 rpm prior to running on the gel.
An equal volume of protein solution or lysis samples was added to loading 
buffer (50 mM Tris-HCl pH 6 .8 , 2 % (w/v) SDS, 0.1 % (w/v) bromphenol blue, 10 % 
(v/v) glycerol and 100 mM DTT (Sigma)) and denatured at 98 °C for 3 minutes. 
Samples were then loaded onto the gel and run with electrophoresis buffer (25 mM Tris 
Base, 250 mM Glycin, 0.1 % (w/v) SDS, pH 8.3) at 150 volts in a Mighty Small II gel 
tank (Hoefer Scientific Instruments).
Gels were stained with coomassie staining solution (10% (v/v) glacial acetic 
(BDH) acid and 0.25 % (w/v) coomassie brilliant blue (Sigma) in 1:1 
methanol (BDH)/water) under gentle shaking for 20 minutes and excess colour was 
washed off with de-staining solution (16.5 % (v/v) methanol and 5 % (v/v) glacial acetic 
acid) that was frequently changed over a time period of at least 12 hours. Pictures were 
taken under white light as described in section 2-8.5. Thereafter original gels were 
transferred to Whatman paper that was pre-wet with detaining solution and covered 
with saran wrap film before drying at 80 °C for 3 hours using a horizontal vacuum gel 
drier (model 583, Bio-RAD) for preservation.
SDS-PAGE was used to confirm the presence of proteins produced by E. coli. 
Abundance of contaminating proteins served as a qualitative assessment of the purity of 
the protein preparations. A representative gel demonstrating high abundance and purity 
of bands corresponding to the expected HLA heavy chain and Gim protein sizes of 
34 kDa and 11.4 kDa respectively is shown in Figure 2-19.
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Figure 2-19 SDS-PAGE of HLA-Al, HLA-A2, HLA-B35 and Bzm proteins
T his figure illustrates S D S -P A G E  separation o f  H L A  heavy chain  and Û2m proteins exp ressed  
by in du ction  o f  pE T 3d-bsp2 H LA transform ed E. c o l i  w ith  IPTG. The left gel dem onstrates  
exp ression  o f  H L A -A *0101  protein, the m iddle gel d em onstrates exp ression  o f  H L A -A *0201  
and H L A -B *3501  protein and the right gel d em onstrates exp ression  o f  H L A -A *0201 and 6 2 m 
proteins. Lane 1, 8  and 9: BenchMark^M Pre-stained Protein Ladder (Invitrogen ), lane 2: 10 pi 
culture sam p le pre induction, lane 3 and 4: 10 pi culture sam ples at 3 and 5 hours post 
in du ction , lane 5: 1 pi H L A -A l in clu sion  body. Lane 6 : 3 p i H L A -B 35  in clu sion  b od y, lane 7: 
2 pi H L A -A 2  in clu sion  body, lane 10: 5 pi H L A -A 2 in clu sion  body, lane 11: 5 pi 6 2 m 
in c lu sion  b od y . The m olecular w eigh t (in  k D a) o f  markers is sh ow n  b esid e the gel.
2-11.9 HLA/peptide complex dilution refolding
Solution containing B2m of an amount equal to 4.8 mg was added dropwise and slowly 
to 200 ml pre-cooled refolding buffer (400 mM L-Arginine HCl, 100 mM Tris-HCl 
pH 8 , 5 mM reduced glutathione, 0.5 mM oxidised glutathione, 0.5 mM PMSF, 2 mM 
EDTA) stirring at 4 ”C. Peptide originally diluted in DMSO was diluted in water and 
added to an amount equalling 2 mg. Solubilised HLA heavy chain was then added in an 
amount equal to 6.2 mg. Heavy chain was added dropwise and stepwise over a period of 
at least 3.5 hours to avoid formation of aggregates.
HLA-B35 protein was observed to form aggregates easily. Therefore for 
refolding of HLA-B35/peptide complexes, the heavy chain was diluted to <1 mg/ml in 
fresh urea buffer prior to addition to IL refolding buffer to decrease the formation of 
aggregates.
Refolding was allowed to proceed at 4 “C stirring slowly over 72 hours. The 
refolding mixture was spun for 20 minutes at 10,000 g at 4 “C to remove aggregates and 
filtered through a 45 pm filter if necessary before concentrating to 20 ml using a stir cell
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with a 10,000 molecular weight cut off (MWCO) membrane (Amicon, UK) with 
applied pressure. The concentrate was further concentrated to 2 ml in a vivaspin 
concentrator (Sautorius). Aggregate was removed by centrifugation for 10 minutes at
14,000 rpm at 4 °C and filtration through a 0.2 pm HT Tufffyn Membrane low protein 
binding filter (PALL) before the refolded complex was purified using Fast Protein 
Liquid Chromatography (FPLC).
2-11.10 Fast Protein Liquid Chromatography (FPLC)
Protein complexes were purified after initial refolding and again after biotinylation 
(section 2-11.11 ) to remove excess biotin. This was performed by separation of proteins 
depending on their weight on a FPLC gel filtration XK 16/70 column packed with 
120 ml superdex 75 matrix (Pharmacia Biotech) connected to an ÀKTA low-pressure 
automated chromatography system using Unicom 3.10 software (Amersham-Pharmacia, 
UK). The purification system was set to demonstrate absorbance at 280 nm online and 
to collect 3 ml fractions of eluted proteins.
Initial purification was performed in Low Salt Buffer (10 mM Tris-HCl pH 8 ,
5 mM NaCl) as illustrated in part A of Figure 2-20 and the fractions of interest (marked 
refold) were concentrated to a volume of approximately 100  to 2 0 0  pi using a vivaspin 
concentrator (Sautorius) at 4 °C. Post biotinylation purification was performed as 
illustrated in part B of Figure 2-20. Therefore High Salt Buffer (10 mM Tris-HCl pH 8 , 
150 mM NaCl) was used. This buffer aids stabilisation of the protein complex but was 
not used initially because its high salt concentration can inhibit the biotinylation 
process. Purified post biotinylation fractions (marked refold) were concentrated to 
approximately 100 pi.
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Figure 2-20 Purification of protein complexes by FPLC
T his figure illustrates purification o f  refolded protein com p lex  from aggregate, ex c e ss  6 2 m and 
ex c ess  peptide (and arginine originating from buffer) in part A. A further purification step  
from aggregate and ex cess  biotin after b iotinylation  o f  protein com p lex  is illustrated in part B. 
A bsorbance at 280  nm w as recorded in m illi absorbance units (m A U , blue lin e) and co llected  
in fractions num bered b elow  the graph (red).
The refolded protein complex (consisting of 34 kDa HLA/bsp protein, 11.5 kDa 6201 
protein and 1 kDa peptide) runs in the fractions corresponding to a size range of 35- 
40 kDa because charge and shape in addition to size of the complex influence its 
migration. The presence of refolded protein complex was confirmed by comparison 
with size standards, which were run after each cleaning procedure as illustrated in 
Figure 2-21 and additionally by testing of the refold fractions using dot blot assay 
(compare section 2- 11. 12).
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Figure 2-21 FPLC trace of size standards
This figure illustrates FPLC o f  s ize  standards u sing b ov in e  serum  album in (B S A ) o f  6 6  kD a, 
ovalbum in (O V A ) o f  47  kDa and carbonic anhydrase (C A ) o f  2 9  kDa. U nits are identical to  
those described for F igure 2 -20 .
The column was cleaned regularly after 20 runs or before storage in 20 % ethanol. 
Therefore filtered and degassed solutions prepared from double distilled water were run 
through the column in sequential steps. 2 column volumes (240 ml) of 1 mg/ml pepsin 
in 0.1 M glacial acetic acid and 0.5 M natrium chloride were run in reverse flow 
direction at 0.5 ml/minute and incubated at room temperature over night. 2 column 
volumes of water were then run at 1 ml/minute followed by 60 ml of 30 % isopropanol 
at 0.5 ml/minute, 2 column volumes of water at 1 ml/minute reverse flow direction, 
60 ml of 0.5 M NaOH at 0.5 ml/minute and 2 column volumes of water at 1 ml/minute.
If decreased performance was observed by the occurrence of less well separated 
peaks in FPLC traces, the column was repacked and tested for efficiency by injection of 
1 ml 0.5 % (v/v) high-performance liquid chromatography (HPLC) grade acetone 
solution (Sigma Aldrich) in double distilled water using High Salt Buffer and 
calculations according to the manufacturer (typically 6,300 plates/meter).
2-11.11 Biotinylation of refolded monomers
The E. coli biotin holoenzyme synthetase, BirA, catalyzes transfer of biotin to the 
epsilon amino group of a specific lysine residue of the biotin carboxyl carrier protein 
(BCCP) subunit of acetyl-CoA carboxylase. For exploitation of this process, vectors 
engineered to encode HLA heavy chain proteins, also incorporated a minimal substrate
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peptide LHHIFEAQKIEWR required for BirA-catalyzed biotinylation (Schatz, 1993) at 
the C terminal (compare Figure 2-16, page 139). Thereby purified refolded 
HLA heavy chain/G2m/peptide complexes could be tetramerised with fluorescently 
labelled streptavidin. This was necessary to increase avidity of complexes for their 
cognate T cell receptors to enable stable fluorescent binding of specific T cells that 
could thereby be visualised and quantified.
Purified refolded complexes were incubated with 1 pi (corresponding to 1 pg or
5,000 units) BirA enzyme (Avidity), 25 pi of Biomix A (0.5 M bicine pH 8.3) and 
Biomix B (100 mM adenosine-5’-triphosphate (ATP), 100 mM magnesium acetate, 
400 M biotin, pH 7.0) (Avidity, Denver), each in a total volume of 250 pi buffer 
(10 mM Tris-HCl pH 8.0 and 5 mM NaCl) containing Ix complete protease inhibitor 
(Roche) (1.5 pg/ml Chymotrypsin, 0.8 pg/ml Thermolysin, 1 mg/ml Papain, 1.5 pg/ml 
Pronase, 1.5 pg/ml Pancreatic Extract and 0.002 pg/ml Trypsin) at 25 °C overnight.
Thereafter monomers were immediately purified from excess biotin by FPLC as 
described above and protein concentration was assessed by BCA assay (section 2-10).
2-11.12 Confirmation of refolding and biotinylation using protein dot- 
blot and western blot
Correct folding of protein complex was confirmed by testing the refold fractions with 
mouse anti-conformational HLA monoclonal antibody (mAb) W6/32. This antibody 
was produced from hybridomas as described in section 2-4.4. It recognises a 
determinant present on the class I heavy chain but only when the heavy chain is in 
complex with 62m (Barnstable et a l,  1978, Ways and Parham, 1983). Additionally 
biotinylation of protein complex was confirmed by testing with peroxidase conjugated 
ExtrAvidin antibody (Sigma).
For confirmation of correct folding, Hybond enhanced chemiluminescence 
(ECL) nitrocellulose membrane (Amersham Life Science) that had been incubated in 
transfer buffer (48 mM Tris base, 39 mM glycin, 0.037 % (w/v) SDS and 20 % (v/v) 
methanol) at room temperature for 15 minutes was used to deposit 10 pg (or a dilution 
thereof) of test samples onto it with a vacuum dot blotter (Hybridot Manifold, Bethesda 
Research Laboratories). Each dot was washed twice with 200 pi PBS. The membrane 
was subsequently transferred to a 50 ml Falcon tube (BD) filled with blocking buffer 
(PBS, 10 % (w/v) powdered milk (Marvel)) for incubation on a rolling cylinder at 4 °C 
overnight. After three washes for 15 minutes in PBS/0.05 % (v/v) Tween 20 (BDH
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Biochemicals), the membrane was cut and samples were incubated either with 5 pg/ml 
W6/32 primary antibody in blocking buffer or blocking buffer only as a negative control 
for one hour. Membranes were then washed for a further three times with 
PBS/Tween 20 before incubation with 1:2,500 dilution of secondary peroxidase 
conjugated goat anti-mouse antibody (Sigma) for one hour. After three washes 
peroxidase was detected by incubation of membrane with ECL reagent (ECL reagent 
kit, Amersham Pharmacia Biotech) for 1 minute and immediate detection by exposure 
of wrapped membrane to an x-ray photographic film (MXB film, GRl autoradiography 
blue sensitive, Kodak) in a dark room using exposure times ranging from 45 seconds,
2 minutes, 5 minutes, 15 minutes, 1 hour to overnight to ensure detection at maximal 
signal to noise ratio. A representative dot blot is shown in Figure 2-22 part A.
Biotinylation was confirmed in a similar way using a single incubation with a 
1:1,000 final dilution of peroxidase conjugated ExtrAvidin antibody (Sigma) instead of 
primary W6/32 and secondary peroxidase conjugated goat anti-mouse antibody. A 
representative dot blot is shown in Figure 2-22 part B.
B
W6/32 Buffer 10|jg
HCIB
IB
FPLC aggregate 
FPLC (12^
FPLC refold 
Positive control
FPLC refold 1 
pre bio
FPLC refold 1 
post bio
FPLC refold 2 
post bio
FPLC refold 2 
pre bio
Figure 2-22 Protein dot blot of refolded complex
Part A o f  this dot blot illustrates probing o f  sam ples with W 6/32 on the left and buffer alone on  
the right that were subsequently detected  with (horseradish) peroxidase conjugated goat anti­
m ou se antibody (Prom ega). Sam p les tested w ere HLA heavy chain in clu sion  body (HC IB ), 
6 2 m in clu sion  body (6 2 m IB), pre b iotinylation  FPLC fractions eluting at a trace position  
(com pare Figure 2 -20 ) correlating w ith aggregate (FPLC aggregate) or 132m (FPLC 132m ), post 
b iotinylation  FPLC fractions e lu tin g  at a trace position  correlating with refold (FPL C  refold) 
and refolded com plex that had been su ccessfu lly  used for generation o f  tetram er previously  
(p o sitiv e  control). Part B illustrates tw o different refolded com p lexes (FPLC refold 1 and 2) 
b efore (pre b io) and after b iotinylation  (post b io) that w ere detected with p eroxidase  
conjugated  ExtrAvidin antibody (S igm a).
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For Western blot, a SDS-PAGE gel was prepared and 2 pg of pre biotinylation samples, 
post biotinylation samples and unbiotinylated or biotinylated myelin basic protein 
(MB?) controls (Avidity) were run along with a protein ladder as described in section 2- 
11.8. A membrane was incubated shortly using blocking buffer containing 0.13 M 
NaCl, 2.68 mM KCl, 24.77 mM Tris Base, 0.05 % (v/v) Tween 20 and 5 % (w/v) 
powdered milk, and the SDS-PAGE gel was immediately blotted onto that membrane 
using transfer buffer containing 25 mM Tris Base, 200 mM glycin and 20 % (v/v) 
methanol at 200 mA at 4 °C for 2 hours using a vertical Western blot apparatus (model 
Criterion, Bio-RAD) that was assembled in a cold room.
The membrane was then washed with Tris buffered saline (TBS)/0.05 % (v/v) 
Tween 20 and subsequently incubated in blocking buffer containing a final 1:8,000 
dilution of peroxidase conjugated ExtrAvidin antibody (Sigma) for one hour. After 
extensive washing in TBS/Tween 20, peroxidase was detected by incubation of 
membrane with ECL reagent (ECL reagent kit, Amersham Pharmacia Biotech) for 
1 minute and immediate detection by exposure of membrane to an x-ray photographic 
film (MXB film, GRI autoradiography blue sensitive, Kodak) in a dark room using an 
exposure time of 1 minute. A representative gel is shown in Figure 2-23.
1 2  3 4
Figure 2-23 Western blot of refolded complex
T his w estern blot show s the separated HLA heavy chain o f  a refolded H L A /peptide com p lex  
b efore b iotinylation  in lane I, unbiotinylated  M B P control in lane 2, the separated heavy chain  
o f  a refolded H LA/peptide com p lex  post b iotinylation  in lane 3 and the sam e co m p lex  m ixed  
w ith b iotinylated  M BP control in lane 4.
Figure 2-23 illustrates a faint signal from HLA heavy chain that was separated from the 
unbiotinylated HLA/peptide complex, which is likely to be due to minimal biotinylation 
occurring at the time of bacterial expression, as the BirA enzyme is constitutive of 
E. coli bacteria. In contrast, no signal was observed for the unbiotinylated MBP control, 
whereas both the biotinylated MBP control and the HLA heavy chain separated from 
the biotinylated HLA/peptide complex were detected as an upper (representing a 
molecular weight of MBP with Avitag of 44,846 kDa plus 244 Da of biotin) and a lower
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band (representing a molecular weight of 34 kDa of the HLA heavy chain protein) 
respectively.
2-11.13 Estimation of biotinylation efficiency by native gel
Biotinylation efficiency was estimated using 2 pg biotinylated or unbiotinylated 
monomers, each with or without incubation with 3 pg or 6 pg ExtrAvidin (Sigma) for 
one hour at room temperature. All samples were run on an 8 % native gel consisting of 
a resolving lower gel (375 mM Tris pH 8.8, 27 % ProtoGel, 0.3 % (w/v) APS and 
0.03 % (v/v) TEMED) overlaid with a stacking upper gel (125 mM Tris-HCl pH 6.8, 
17% ProtoGel (containing 30%  (w/v) Acrylamide and 0.8 % (w/v) Bis-Acrylamide; 
National Diagnostics), 1 % APS (w/v) and 0.1 % (v/v) TEMED) that had been pre-run 
at 150 volts for 30 minutes in 24.8 mM Tris/192 mM Glycin to remove any excess salts.
Unlike SDS-PAGE type electrophoreses (compare section 2-11.8), native gel 
electrophoresis does not use a charged denaturing agent. The proteins being separated 
are not denatured but remain in their native state, therefore differ in molecular mass and 
intrinsic charge and experience different electrophoretic forces dependent on their 
charge-to-mass ratio.
Samples were loaded with an equal volume of loading buffer (50 mM Tris-HCl 
pH 8.8, 0.1 % (w/v) bromphenol blue and 10% (v/v) glycerol) and run at 150 volts. 
Gels were stained, photographed and dried as described in section 2-11.8 with a 
representative gel shown in Figure 2-24.
1 2 3 4 5 6 7  8 9  10
*
Figure 2-24 Shift of biotinylated proteins in native gel
T h is native gel dem onstrates 3 p g  and 6  p g  o f  E xtrA vidin  in lanes 1 and 2 resp ective ly . 
L anes 3-5  contain 2 p g  unbiotinylated  protein com p lex  either a lone (lan e 3 ) or after incubation  
w ith 3 p g  (lane 4 )  or 6  p g  (lane 5) E xtrA vid in . Lanes 6 - 8  contain  2 p g  b iotinylated  protein  
co m p lex  either alone (lane 6 ) or after incubation w ith 3 p g  (lan e 7 ) or 6  p g  (lane 8 ) 
E xtrA vid in . Lanes 9 -10  contain  Ip g  com m ercia lly  b iotinylated  product B S l 3 0 0  (A v id ity )  
eith er alone (lane 9 ) or after incubation  w ith  3 p g  ExtrA vidin  (lane 10) as a p o sitiv e  control.
Native gels were used to estimate the efficiency of biotinylation of generated protein 
complexes. Successful biotinylation resulted in a shift of product when incubated with
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biotin binding ExtrAvidin in contrast to product on its own (lanes 7 and 8 in comparison 
to lane 6) in native gels. This was due to biotinylated products forming a complex with 
ExtrAvidin and therefore running slower in the gel. The abundance of unshifted and 
shifted protein bands was used to estimate the percentage of monomer that was 
biotinylated efficiently. This estimate was taken into account for calculation of the 
amount of fluorescently labelled streptavidin to be added during tetramerisation of 
HLA/peptide complexes.
2-11.14 Tetramerisation of biotinylated monom ers
Biotin binds very tightly to the tetrameric protein avidin. As an alternative 2- 
iminobiotin may be used, which is a cyclic guanidino analogue of biotin whose 
interaction with avidin is pH dependent and thus reversible (Orr, 1981).
Streptavidin is a homologue of avidin found in Streptomyces avidinii. It is one of 
the strongest noncovalent biological interaction known with a dissociation constant in 
the order of 4x10''^ M and can only be broken above 70 °C (Holmberg et a l,  2005). 
The same interaction occurs with ExtrAvidin that was used in reactions described 
earlier (sections 2-11.12 and 2-11.13), which lacks the “RGD” (Arginine-Glycine- 
Aspartic acid, an attachment site for adhesive extracellular matrix proteins such as 
integrins that can influence immunological functions (Ruoslahti, 1996)) sequence 
present in streptavidin.
PE or AFC conjugated streptavidin (Biogenesis) was added to biotinylated 
purified monomers at a molar ratio of 1:4. This process was performed stepwise and 
very slowly within 3.5 hours shaking on ice. The resulting tetramers (in 10 mM Tris- 
HCl pH 8, 150 mM NaCl) were supplemented with 0.1 % (w/v) sodium azide and 10 % 
(v/v) glycerol and kept at -20 °C for storage or 4 °C for short-term use. The composition 
of tetrameric HLA/peptide molecules is illustrated in Figure 2-25. In comparison, a 
crystallographic model of an HLA/peptide tetramer complex can bee seen in Figure
1-12 on page 80.
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a2|fluorescent label
streptavidin
Figure 2-25 Composition of HLA/peptide tetramer
T his figure illustrates the binding o f  four b iotinylated H L A (# )/B 2m (# ) /p e p tid e (^ )  m onom ers  
to streptavidin ( ♦ )  conjugated  to a fluorescent label (y e llo w ).
2-12 S p ec tra ty p in g
2-12.1 RNA extraction
Several RNA extraction methods were tested initially (described in section 4-2.1). The 
final method used for extraction of RNA from small numbers of tetramer sorted cells 
(<5,000) is described below. Alterations made during m-RNA extraction from larger 
cell numbers are described thereafter. To eliminate RNase and DNA contamination, 
experiments were performed in a fume hood dedicated to RNA work. Disposable filter 
tips were used and all labware such as the hood surface and pipettes were cleaned with 
“RNase AWAY” reagent (Invitrogen) before use.
PBMC were spun at 13,000 rpm for 1 minute and the supernatant aspirated. Cell 
pellets were used immediately or stored at -70 °C for RNA extraction at a later time. 
Therefore fresh or thawn pellets were kept on ice and total RNA was extracted using the 
RNeasy Micro Kit (Qiagen) according to the manufacturer’s instructions.
Samples were lysed and homogenised using guanidine-isothiocyanate lysis. 
75 pi of buffer RLT (guanidine thiocyanate containing buffer provided with the kit) 
containing 1 % (v/v) B-mercaptoethanol (BDH Biochemicals) was added to the cell 
pellet, and the sample was mixed by vortexing for 1 minute. After addition of 5 pi of a 
4 ng/pl poly-A RNA carrier solution to the lysate, homogenisation was performed by 
resuspension using a fine pipette tip. This resulted in disruption of plasma membranes, 
release of RNA, shearing of high molecular weight genomic DNA and reduction of 
viscosity of the cell lysate. 75 pi of 70 % sterile, American Chemical Society (ACS) 
grade ethanol (Sigma Aldrich) was added to provide ideal binding conditions. The well- 
mixed lysate was then loaded onto a column sitting in a collection tube resulting in
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binding of RNA to the silica-gel-membrane in the column. This procedure isolates RNA 
molecules longer than 200 nucleotides thereby enriching for mRNA. Tubes were spun 
at 13,000 rpm for 15 seconds and the flow-through discarded. Samples were washed by 
addition of 350pl buffer RWl (supplied with the kit), spun at 13,000 rpm for 
15 seconds and the flow-through discarded. Traces of DNA that may co-purify were 
removed by deoxyribonuclease (DNase) treatment on the column using digestion with 
RNase-free DNase. Therefore DNase I (2.72 Kunitz units/pl) was diluted 1:8 in buffer 
RDD (supplied with the kit) and 80 pi were pipetted directly onto the membrane for 
incubation at room temperature for 15 minutes. DNase and contaminants were then 
washed off by addition of 350 pi buffer RLT and centrifugation at 13,000 rpm for 
15 seconds. The flow through was discarded and the column transferred to a new 
collection tube for a further wash with 500 pi buffer RPE (supplied with the kit). After 
centrifugation and discarding of the collection tube, 500 pi of 80 % sterile, ACS grade 
ethanol (Sigma Aldrich) were added and the membrane dried by centrifugation at
13.000 rpm for 2 minutes. The centrifugation was repeated in a new collection tube at
13.000 rpm for a further 5 minutes. Purified RNA was captured in a new collection tube 
by elution with 12 pi RNase-free water and centrifugation at 13,000 rpm for 1 minute 
resulting in a final volume of approximately 10 pi RNA. It was either used for RT-PCR 
immediately or stored at -70 °C.
When using cell numbers above 5,000, the same method was used. However, no 
poly-A RNA carrier was used and the volume of buffer RLT added to cell pellets and 
that of 70 % ethanol added to the lysate was 350 pi instead of 75 pi. If cell pellets were 
large enough to be visible, homogenisation was performed by passing of the lysate 
through a 20-gauge needle (0.9 mm diameter) fitted to an RNase-free syringe instead of 
vortexing and resuspension.
2-12.2 Reverse transcription PCR
Most reverse transcriptases are intended for use with approximately 1 pg RNA. For 
reverse transcription (RT) PCR of RNA obtained from small cell numbers, optical 
absorbance measurement to establish the concentration of RNA solution obtained by 
RNA extraction was omitted. This was to avoid loss of material and because carrier 
RNA was used during the extraction of RNA. The total of extracted RNA was used for 
RT PCR with sensiscript reverse transcriptase (Qiagen), an enzyme designed for 
RT PCR of small amounts of RNA. Therefore the total volume of RNA (10 pi) was 
denatured in the presence of 1 pi of 500 pg/pl random primers (Promega) and 2 pi of
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5 mM dNTP (provided with the sensiscript reverse transcriptase) at 65 °C for 5 minutes 
and subsequently chilled on ice immediately before the reaction. 7 pi of master mix 
(containing 2 pi of lOX reaction buffer (provided with the sensiscript reverse 
transcriptase), 1 pi of recombinant RNasin ribonuclease inhibitor (Promega), 1 pi of 
sensiscript reverse transcriptase (Qiagen) and 3 pi of RNase free water (provided with 
the sensiscript reverse transcriptase) per sample) was then added to the sample for 
incubation at 37 °C for 1 hour. During this reaction sensiscript reverse transcriptase 
transcribes complementary DNA from the RNA template (RNA-dependent DNA- 
polymerase activity) and degrades RNA in RNA:DNA hybrids (RNase H activity). This 
resulted in a total volume of 20 pi cDNA for immediate use in PCR reactions or storage 
at -20 °C.
RT-PCR from high numbers of cells (not post FACS sort) was initially 
performed using 1 pg RNA solution in a volume of 10 pi with 1 pi of 500 ng/pl random 
primers (Promega) and 1 pi of 10 mM dNTPs (Bioline) for 5 minutes at 65 °C and 
subsequent chilling on ice. The resulting 12 pi template was reverse transcribed in a 
20 pi total reaction volume with 400 units Moloney Murine Leukaemia Virus (M-MLV) 
reverse transcriptase (Promega), 10 mM DTT (Sigma) and 80 units RNasin RNase 
inhibitor (Promega) in M-MLV RT buffer (Promega) by incubation at room temperature 
for 10 minutes followed by 50 minutes at 37 °C. The reaction was terminated by 
incubation at 70 °C for 15 minutes and the resulting cDNA was stored at -20 °C. During 
optimisation procedures, RNA extracted with RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s protocol resulted in an elution volume of 20 pi and was 
subsequently used for M-MLV reverse transcription using double the volumes 
mentioned above.
2-12.3 Confirmation of c-DNA quality by B-Actin PCR amplification
0.5 pi c-DNA was amplified in a 25 pi reaction volume using 0.5 units Taq (Bioline),
2 mM MgCl] (Bioline), 0.4 mM dNTPs (Bioline), 0.4 mM 5’6-actin primer with the 
sequence 5’ TCA TGA ACT GTG ACG TTG AC A TCC GT 3’ (Promega) and 0.4 mM 
3'B-actin primer with the sequence 5’ CTT AG A AGC ATT TGC GGT GCA CGA 3’ 
(Promega) in PCR buffer (Bioline).
PCR conditions were 94 °C for 2 minutes followed by 94 °C for 30 seconds, 
65 °C for 1 minute and 68 °C for 2 minutes for 40 cycles and final polymerisation at 
68 °C for 7 minutes.
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5 fil of PCR products were subjected to gel electrophoresis as described in section 2-8.5 
to test amplification of the constitutive gene 6-actin. 
1 2 3 4 5 6 7 8 9
Figure 2-26 B-Actin PCR
T his figure sh o w s separation o f  15 pi o f  B-Actin PCR products (285  bp) on a 1.5 % agarose  
(0 .5 x )  T B E  g e l that w as run at 100 vo lts. S how n are PCR products obtained from  cD N A  from  
188 (lane 2 , not v is ib le ), 375 (lane 3), 7 5 0  (lan e 4 ), 1 ,500  (lane 5), 3 ,0 0 0  (lan e 6 ) 
(1 7 4 x C E M )T 2  c e lls  a lon g  with a p o sitiv e  control o f  c D N A  obtained from 3 0 0 ,0 0 0  PBM C  
(lane 7) and a n ega tive  control o f  non-tem plate RT PCR product (lane 8 ) and H yperladder IV  
(B io lin e )  in lane 1 and 9. The m olecular w eigh t o f  the m arker’s standards (in  bp) is show n  
b esid e the gel picture.
2-12.4 Fluorescent ICR VB multiplex PCR
1 pi c-DNA was amplified in a 12.5 pi reaction volume using 0.265 units Platinum Taq 
(Invitrogen), 2 mM MgCb (Invitrogen), 0.4 mM dNTPs (Bioline), 0.4 pM unlabelled 
constant region C6 primer and a mixture of labelled VB primers at optimised 
concentration ratios (Table 2-7) in PCR buffer (Invitrogen). PCR conditions were 95 °C 
for 1 minute followed by dénaturation at 95 °C for 30 seconds, annealing at 58 °C for 
30 seconds and primer extension at 72 "C for 5 minutes for 30 cycles followed by a final 
polymerisation step at 72 T  for 10 minutes.
Platinum Taq DNA polymerase was chosen for this application because it is 
complexed with a proprietary antibody that inhibits polymerase activity until it is 
denatures at 94 T .  This results in a number of advantageous properties including 
reduced primer dimer formation.
Initial optimisation experiments demonstrated superior amplification results with 
an extended period of the primer extension step at 72 “C for 5 minutes. The experiments 
were initially performed to test whether long PCR extension periods may result a more 
uniform detection of PCR product lengths during spectratyping. Taq DNA polymerase 
has a nontemplate-dependent terminal transferase activity that adds a single
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deoxyadenosine (A) to the 3’ ends of some of the PCR products. Therefore 
spectratyping may demonstrate 2 peaks with a size difference of one nucleotide in PCR 
products amplified from the same TCR cDNA template. Long extension cycles did not 
influence this phenomenon but continued to be used because they gave better 
amplification results.
7 multiplex PCR reactions (A-G) were performed per sample. These included 
optimised ratios of primer concentrations, which were multiplexed according to 
compatibility and amplicon size as listed in Table 2-7. Ratios of primers were optimised 
to achieve similar fluorescence intensities of PCR products from all VB families within 
each PCR reaction from c-DNA obtained from total PBMC from CMV seronegative 
young healthy volunteers.
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Mix Molarity Specificity 5’ label Prim er sequence Amplicon size
A
2.36 pM 
1.59 pM 
3.19 pM 
13.29 pM
VBl
VB2
V05S2
V135S1
primer
primer
primer
primer
PAM
JOE
TAMRA
JOE
5-CAA GAG TTC CCT GAG TTG GAG-3 
5-TGA AGG ATG GAA GGG TGA GGT-3 
5-GGT AAG TAT AGG TGT GAG GTG-3 
5-ATA GTT GAG TGA GAG AGA GAG AAA G-3
185-214 bp 
182-220 bp 
176-214 bp 
242-271 bp
B
2.66 pM
2.66 pM 
3.99 pM 
13.29 pM 
31.88 pM
VB6
VB7
VB8
VB9
VB16
primer
primer
primer
primer
primer
PAM
JOE
PAM
TAMRA
JOE
5-AGG GGT GAG GGA TGG GTG TG-3 
5-GTG AAT GGG GGA AGA GGT GTG-3 
5-TAG TTT AAG AAG AAG GTT GGG-3 
5-AAA TGT GGA GAG AAA GGT GAG-3 
5-GAG TGT AAA GAG GAT GAG TGG-3
182-211 bp 
188-220 bp 
248-277 bp 
185-217 bp 
229-261 bp
C
3.99 pM 
2.66 pM
1.99 pM
VB12
VB13S2
VB13S1
primer
primer
primer
PAM
TAMRA
JOE
5-GAG AAA GGA GAA GTG TGA GAT-3 
5-GTT GGT GAG GGT AGA ACT GGG-3 
5-GAG GAA GGA GAA GTG GGG AAT-3
219-248 bp 
236-271 bp 
218-247 bp
D
2.39 pM 
2.92 pM 
26.57 pM
VBll 
VB20 
VBl 5
primer
primer
primer
PAM
TAMRA
JOE
5-AGA GTG TGG AGA ATA AGG AGG-3 
5-TGT GAG GTG GGG GAG AAT GTG-3 
5-GTG TGT GGA GAG GGA GAG GGT-3
186-218 bp 
212-244 bp 
188-214 bp
E
1.33 pM 
10.63 pM 
5.31 pM
VB3
VB24
VB17
primer
primer
primer
PAM
TAMRA
JOE
5-TGT AGA GAG AAG AAG GAG GGG-3 
5-AAA GAT TTT AAG AAT GAA GGA GAG-3 
5-GAG AGA TAG TAA ATG ACT TTG AG-3
185-214 bp 
232-261 bp 
235-270 bp
F
2.66 pM 
15.94 pM 
16.63 pM 
6.64 pM
VB18
VB23
VB14
VB21
primer
primer
primer
primer
PAM
TAMRA
PAM
PAM
5-GAG TGA GGA ATG GGA AAG GAA-3 
5-TGA TTT GGT TTT ATG AAA AGA TGG-3 
5-TGT GGA AAA GAG AAG AGG AAT-3 
5-GAT ATG AGA ATG AGG AAG GAG-3
220-246 bp 
248-277 bp 
185-211 bp 
242-280 bp
G 2.6 pM 7.97 pM
VB4
VB22
primer
primer
PAM
TAMRA
5-GAT ATG AGA GTG GAT TTG TGA TT-3 
5-GAG AGA AGT GTG AAA TAT TGG A-3
222-251 bp 
221-250 bp
Table 2-7 VO prim er multiplexing
OsLA
This table dem onstrates the seq u en ces and lab els o f  VB fam ily  sp ec ific  prim ers and the m olarity at w hich  they w ere u sed  
in m ultip lex  PCR reactions w ith  C 6 prim er 5 ’ C T T  C TG  A T G  G C T  C A A  AC A  C 3 ’ to obtain  am p licon s o f  the range o f  s ize  listed .
9
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All VB primers were labelled at the 5’ end and were purchased from Sigma Genosys 
except V621, which was purchased from ABI. The CB primer was unlabelled and was 
of the sequence 5’ CTT CTG ATG GCT CAA ACA C 3’ (Alta Biosciences). JOE (6- 
carboxy-4', 5'-dichloro-2', 7-dimethoxyfluorescein) labelled primers were of HPLC 
grade. Due to limited resources F AM and TAMRA labelled primers were not HPLC 
purified. Lack of HPLC purification posed no challenge for F AM labelled primers. 
Singleplex PCR using unlabelled VB primers and F AM labelled CB primer were 
performed to confirm results for amplifications from VB families VB13S2, 22 and 24 
because initial test experiments demonstrated that free TAMRA dye runs within the size 
area of interest for these amplifications.
Primer sequences used were in accordance with Fernandes and colleagues 
(Fernandes et a i,  2005) except for VB5S1. Labels used and multiplexing of primers 
were modified from this report. The sequence of the VB5S1 primer (Choi et a l, 1989) 
was chosen due to superior amplification obtained with this primer than with VB5S1 
primer used by Fernandes and colleagues, which lacks the first 4 nucleotides at its 
5’ end.
To ensure uniformity, VB multiplex PCR was performed by preparation of a 
primer master mix for each of the 7 reactions and a master mix containing the other 
PCR reagents. The latter was divided into smaller master mixes that contained cDNA 
from one sample each and which in turn were combined with the appropriate amount of 
one of the seven primer master mixes before PCR amplification.
Initial primer sequences used during optimisation of the VB PCR are shown in 
Table 2-8.
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Label Specificity Primer sequence (5’-3’)
none VBl GCACAACAGTTCCCTGACTTGCAC
none VB2 TCATCAACCATGCAAGCCTGACCT
none VB3 GTCTCTAGAGAGAAGAAGGAGCGC
none VB4 ACATATGAGAGTGGATTTGTCATT
none VB5.1 ATACTTCAGTGAGACACAGAGAAAC
none VB5.2-3 TTCCCTAACTATAGCTCTGAGCTG
none VB6 AGGCCTGAGGGATCCGTCTC
none VB7 CCTGAATGCCCCAACAGCTCTC
none VB8 CCATCATGCGGGGACTGGAGTTGC
none VB9 CCTAAATCTCCAGACAAAGCT
none VBIO CTCCAAAAACTCATCCTGTACCTT
none VBll TCAACAGTCTCCAGAATAAGGACG
none VB12 AAAGGAGAAGTCTCAGAT
none VB13.1 CAAGGAGAAGTCCCCAAT
none VB13.2 GGTGAGGGTACAACTGCC
none VB14 GTCTCTCGAAAAGAGAAGAGGAAT
none VB15 AGTGTCTCTCGACAGGCACAG
none VB16 AAAGAGTCTAAACAGGATGAGT
none VB17 CAGATAGTAAATGACTTTCAG
none VB18 GATGAGTCAGGAATGCCAAAGGAA
none VB19 CAATGCCCCAAGAACGCACCCTG
none VB20 ACGTCTGAGGTGCCCCAGAAT
none VB21 ATTCACAGTTCGGTAAGGATCGA
none VB22 GGGCAGAAACTCGAGTTTCTGGTT
none VB23 TTTATGAAAAGATGCAGAGCGAT
none VB24 AAGTCAAGTCAGGCCCCAAAGCT
FAM CB CACCCACGAGCTAGCTCCACGTGGTC
Table 2-8 VB primers used for singleplex PCR
T h is tab le d em onstrates the seq u en ces and lab els o f  VB fam ily  and CB sp e c ific  prim ers (A lta  
B io sc ie n c e s )  that w ere used at 0 .4  m M  in in itial s in g le  PCR reactions.
Initial singleplex VB PCR amplifications were performed using 1 pi c-DNA in a 25 pi
reaction volume with 0.5 units Platinum Taq (Invitrogen), 2 mM MgCb (Invitrogen), 
0.4 mM dNTPs (Bioline), 0.4 mM F AM labelled constant region primer and 0.4 mM 
unlabelled VB primer (Table 2-8) in PCR buffer (Invitrogen). PCR conditions were 
95 °C for 1 minute followed by dénaturation at 95 °C for 30 seconds, annealing at 58 °C 
for 30 seconds and primer extension at 72 °C for 1 minutes for 29 cycles followed by a 
final polymerisation step at 72 'C  for 10 minutes.
2-12.5 Fragment analysis by capillary gel electrophoresis
2 pi of 1:10 dilutions of PCR products were mixed with 7.75 pi 0.1 % (v/v) Tween 20
(BDH Biochemicals) and 0.25 pi energy transfer (ET)-ROX (5-carboxy-X-rhodamine) 
labelled size standard (ET-ROX 550, Amersham Biosciences) containing 22 bands at
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25 base pair periodicity ranging from 75 to 550 bp and two feature bands at 60 and 
310 bp.
Determination of size and fluorescence intensity of PCR products was then 
performed with the linear polyacrylamide (LPA) separation polymer MegaBACE Long 
Read Matrix (Amersham Biosciences) on a MegaBACE 1000 (Amersham Biosciences), 
a fluorescence-based DNA analyser using an array of 96 capillaries for capillary gel 
electrophoresis. Therefore samples were pipetted into 96-well plates (Robbins 
Scientific) and denatured at 95 °C for 5 minutes followed by chilling on ice. The sample 
plate, two control plates containing LPA buffer (Amersham Biosciences) and 6 vials 
containing MegaBACE Long Read Matrix (Amersham Biosciences) were spun at
10,000 rpm for 2 minutes before loading into the MegaBACE instrument. The settings 
used were 3 kV injection voltage, 10 kV run voltage, 60 seconds injection time and 
80 minutes run time at 44 °C.
Traditional gel electrophoresis can separate DNA fragments by using an electric 
current applied to a gel matrix. DNA migrates from negative (cathode) to positive 
(anode) electrodes due to the naturally occurring negative charge carried by their sugar- 
phosphate backbone (compare section 2-8.5).
During capillary electrophoresis in the MegaBACE, an electric field is used to 
cause the DNA fragments to migrate into (electrokinetic injection) and through 
(electrophoresis) the capillaries. As in gel electrophoresis, the DNA fragments are 
separated by size, with the shorter fragments moving faster (early peaks in the 
electropherogram) than the longer fragments (late peaks in the electropherogram). The 
large surface-to-volume ratio of the capillary efficiently removes the heat generated 
during electrophoresis. With less heat, capillary electrophoresis can be performed at a 
higher voltage, which produces more rapid fragment migration and shorter separation 
times. The DNA fragments are detected near the outlet end of the capillary. The output 
of the detector is sent to a computer. The data is then displayed as an electropherogram, 
which reports detector response as a function of time. Separated products appear as 
peaks with different retention times in an electropherogram.
To record four dyes separately, the MegaBACE 1000 instrument uses an 
emission optical pathway consisting of beamsplitters, filters, and photomultiplier tubes 
(PMTs) that detect laser induced fluorescence. Light from two lasers is used to scan the 
capillaries containing the fluorescently labelled samples. It excites the fluorescent dyes, 
which then emit fluorescent light. Two beamsplitters are used to split the emitted
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fluorescent light. Each of four filters permits only a specific range of light to pass 
through, which corresponds to the emissions of one of the dyes. PMTs are then used to 
detect the filtered light and convert the light into electrical current, producing an 
electropherogram for each capillary. A blue laser (488 nm) is used during a forward 
scan of samples whereas a green laser (532 nm) is used during the return scan.
Figure 2-27 illustrates detection of size standards from the ET-ROX ladder in 
channel 1 from emitted light through beamfilter A and filter 1 and detection of PCR 
products amplified with unlabelled CB and FAM labelled VB primers in channel 2 from 
emitted light through beamfilter A and filter 2. Fluorescence from the ladder and the 
described PCR products is induced by the 488 nm laser during the forward scan of 
capillaries. The beamsplitter has a wavelength cut off of 540 nm, thereby allowing light 
emitted by ET-ROX (maximum 607 nm) to pass whereas light emitted by FAM 
(maximum 517 nm) is reflected. The figure further illustrates detection of PCR products 
amplified with unlabelled CB and TAMRA (N,N,N’,N’-tetramethyl-5- 
carboxyrhodamine) labelled VB primers in channel 3 from emitted light through 
beamfilter B and filter 3, and detection of PCR products amplified with unlabelled CB 
and JOE labelled VB primers in channel 4 from emitted light through beamfilter B and 
filter 4. Fluorescence from both types of PCR products is induced by the 532 nm laser 
during the return scan of capillaries. The beamsplitter has a wavelength cut off of 
570 nm, thereby allowing light emitted by TAMRA (maximum 574 nm) to pass 
whereas light emitted by JOE (maximum 548 nm) is reflected.
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Figure 2-27 The MegaBACE’s emission optical pathway for the detection of laser 
induced fluorescence
This figure is m odified  from an illustration from the M egaB A C E  1000 m anual (A m ersham  
B iosc ien ces). It dem onstrates the set o f  filters and beam splitters used during capillary gel 
electrophoresis for the d etection  o f  em ission  o f  dyes (that were used for TCR VB PCR) in four 
different channels in the M egaB A C E  instrument.
The ET-ROX size standard uses energy transfer. Two fluorescent dyes are attached to 
the same molecule. FAM acts as a donor dye and ROX as an acceptor dye. The blue 
laser emits light at 488 nm, which is near the absorption maximum of FAM. FAM 
absorbs the blue laser light and then transfers the energy to excite ROX, which then 
emits its characteristic fluorescent light spectrum. Energy transfer results in the 
effectively emitted signal of dual labelled molecules to be greatly increased compared 
to the signal from molecules labelled with single dyes (Ju et a l, 1996).
During fluorescence detection on the MegaBACE, spectral overlap can occur as 
described in section 2-5.3 (compare Figure 2-4, page 110). The PMT converts light 
energy into an electrical current. Increasing the voltage applied to a PMT increases the 
signal amplification. The PMT voltages used for optimal recording of the dyes were 
selected after a spectral overlay matrix was generated. Therefore 2 pi of each of the FL, 
JOE and TMR standards from the matrix standard reagent “Matrix FL-JOE-TMR- 
CXR” (Promega) and 0.25 pi ET-ROX standard were each loaded in duplicate with 8 pi 
0.1 % (v/v) Tween 20, denatured and run as described above. The resulting file was 
then used to create a spectral overlap matrix according to the manufacturer’s 
instructions. Data was then analysed with Genetic Profiler software Version 1.1 
(Amersham Biosciences).
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2-13 Cloning and sequencing of TCR VB transcripts
Complementary DNA generated from tetramer sorted PBMC was used for PCR 
amplification of TCR VB products. Samples used were HLA-B35/CMV pp65 (123-131) 
sorted cells from patients 4, 8 and 9 at days 122, 53 and 713 post transplantation, 
respectively, and HLA-A24/CMV pp65 (341-349) sorted cells from patient 11 at day 
588 post transplantation (compare section 4-2.5).
Therefore 1 pi cDNA was amplified in a 25 pi final volume of Ix platinum taq 
buffer (Invitrogen) with 0.4 pM of relevant VB primer, 0.4 pM CB primer, 2 mM MgCb 
(Invitrogen), 0.4 mM dNTPs (Bioline) and 0.265 units platinum taq (Invitrogen) at 
95 °C for 1 minute followed by dénaturation at 95 °C for 30 seconds, annealing at 58 °C 
for 30 seconds and primer extension at 72 °C for 5 minutes for 30 cycles followed by a 
final polymerisation step of 10 minutes at 72 °C.
cDNA from HLA-B35/CMV pp65 (123-131) sorted cells was amplified with VB 
primers 6 and 12 whereas cDNA from HLA-A24/CMV pp65 (341-349) sorted cells was 
amplified with VB primers 7 and 20. The sequences of primers were as listed in Table
2-7 but without fluorescent labels.
PCR products were run on a 1.5% agarose TBE gel and products of the 
expected size range between 182 and 248 bp (compare Table 2-7) were purified using a 
GFX purification kit as described in section 2-8.6. 4 pi of purified DNA solution was 
ligated into pCR2.1 for transformation of TOPI OF’ cells and plasmid DNA extraction 
from resulting bacterial clones as described in section 2-11.1. GFX cleaned DNA from 
clones that demonstrated presence of inserts by EcoRI digest testing was used for 
sequencing (Advanced Biotechnology Centre, Imperial College, London, UK) using 
M l3 forward (5 -GTA AAA CGA CGG CCA G-3 ) and M l3 reverse (5 -CAG GAA 
ACA GCT ATG AC-3') primers provided with the TOPO-TA cloning kit (Invitrogen). 
Sequencing was performed using BigDye V3.1 chemistry on an Applied Biosystems 
3100 capillary sequencer using 96 °C 10 seconds, 46 °C 5 seconds, 60 °C 4 minutes, 
35 cycles and results were analysed using IMGT/V-QUEST.
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2-14 Data collection and analysis
Collected data was analysed using Microsoft Office 2004 for Macintosh, Kaleidagraph 
Version 4.03 (Synergy), Edit View Version 1.0.1, CLC DNA Workbench Version 3 or 
instrument specific software such as Genetic Profiler Version 1.1 (Amersham 
Biosciences) for analysis of files generated on the MegaBACE 1000 DNA sequencer 
and ABI 7500 SDS software Version 1.2 (Applied Biosystems) for analysis of data 
generated by quantitative PCR. For analysis of TCR sequences the IMGT/V-QUEST 
web tool (http://imgt.cines.fr) was utilized and for analysis of flow cytometry data 
FlowJo Version 6.0 software (Tristar) was used. Chemical formula drawing was 
performed with ChemDraw Ultra Version 11.0.1 (CambridgeSoft).
Statistical tests were carried out using the Prism 3 software (GraphPad) package 
using a two-tailed Mann-Whitney U test.
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CHAPTER 3 ESTABLISHING PROTECTIVE LEVELS 
OF CDS* T CELLS WITH DIFFERENT HLA/CMV 
PEPTIDE TARGETS IN HSCT PATIENTS
3-1 Introduction
Following primary infection CMV causes mild or subclinical illness in 
immunocompetent hosts and enters a latent phase that usually persists for the life of the 
host. The first chapter introduced the importance of CMV reactivation in profoundly 
immunosuppressed HSCT patients. CMV infection occurs in 69 % of CMV seropositive 
patients (Meyers et a l ,  1986) and remains a significant cause of morbidity and 
mortality. CMV specific CDS^ T cells are thought to be required to maintain the virus in 
a latent state and investigations during this project aim to further the knowledge of the 
role of these cells in patients.
Due to the limitations of current antiviral therapies, alternative approaches, such 
as an adoptive transfer of donor-derived CMV specific CDS^ T cell clones, are of great 
interest in the field. It was demonstrated that CMV specific CDS^ T cells inversely 
correlate with viral replication and clinical status in patients (Aubert et a l ,  2001, 
Cwynarski et a l ,  2001). Adoptive cell transfer has been shown to reduce the rate of 
viral reactivation and may therefore combat potentially fatal CMV related 
complications in HSCT patients (Einsele et a l,  2002, Walter et a l,  1995). To make this 
therapy available to a wide range of patients expressing different HLA alleles, it is 
important to address the question of which number of CMV specific CDS^ T cells 
restricted by a variety of HLA alleles may inversely correlate with the ability to detect 
CMV reactivation in patients.
Previous studies mainly focused on enumeration of CMV specific CDS^ T cell 
responses restricted by HLA-A2 and HLA-B7 (Aubert et a l,  2001, Cwynarski et a l,  
2001, Engstrand et a l,  2000, Gillespie et a l,  2000, Gratama et a l,  2001, Komatsu et 
a l,  2003, Mohty et a l,  2004, Ozdemir et a l,  2002, Singhal et a l,  2000). It was found 
that recovery of 1x10^ (Cwynarski et a l,  2001) to 2x10^ (Aubert et a l ,  2001) HLA- 
A2/pp65 specific CD8^ T cells/L of blood is associated with protection from CMV 
disease in patients.
Currently, however, it is unknown at what level CMV specific CD8^ T cells 
targeting other common HLA/peptide combinations may be correlating with protection
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against CMV. This study investigates CD8^ T cells towards multiple CMV peptides that 
were previously shown to be presented by common HLA alleles (compare Chapter 1). 
Their “protective levels” may be regarded as surrogate markers for the total CMV 
specific response that correlates with protection against CMV in HSCT patients, which 
will be discussed in section 3-3.2.
This chapter describes the pattern of recovery of CMV specific CD8^ T cells 
targeting different HLA/peptide combinations and the correlation of these cells with 
protection from CMV in HSCT patients. Section 3-2 describes the longitudinal 
monitoring of individual patients followed by statistical calculations of cell numbers 
that inversely correlated with the ability to detect CMV reactivation in four subsections 
depending on the different HLA/peptide combinations studied. It demonstrates a 
detailed qualitative and quantitative analysis of individual patient responses 
highlighting interesting observations and grouping patient responses according to 
occurrence of CMV reactivation and detection of CMV specific CD8^ T cells.
Section 3-3 demonstrates the main findings from the quantitative analysis of 
CMV specific CD8^ T cells targeting different HLA/peptide combinations and serves to 
integrate and compare all major findings from section 3-2. It also contains a comparison 
with recent literature, conclusions and implications of results.
Immune responses were investigated using sensitive HLA/peptide tetramers. 
The generation of several different reagents for this purpose was a main part of this 
project. The results obtained during optimisation of the production of the tetramers is 
described in Chapter 2, section 2-11 rather than in this chapter to draw the reader’s 
attention to the outcome of T cell measurements in this chapter. These measurements 
were correlated to CMV DNAemia, measured by quantitative PCR during routine viral 
monitoring by the Virology department. Royal Free Hospital for all patients except 
patients 10 and 15. In patient 10 CMV load was measured at the Universidad Autonoma 
de Madrid in Spain. In patient 15 CMV was detected by antigenaemia rather than 
DNAemia using perinuclear staining of leukocytes indicating the number of CMV 
infected cells per 200,000 PBMC (van der Bij et a l ,  1988) stained during routine viral 
monitoring by the Virology department of the Universidade de Federal do Parana in 
Brazil. Measurements of tetramer binding cells and CMV load were performed on 
peripheral blood of patients taken at frequent time points post transplantation.
The functionality of T cells was assessed by ELISpot assays testing the release 
of INFy from cells upon stimulation with their target peptide. Besides CMV viral load
174
____________________________________________________________________ Chapter 3
and CMV-specific CD8^ T cell immunodeficiency, CD4^ lymphopenia was also 
reported to be a predictor of late CMV disease and death after allogeneic stem cell 
transplantation (Boeckh et a l ,  2003). Therefore total numbers of CD4^ T helper cell 
counts, known to influence the functionality of CD8^ T cells, were also measured and 
are correlated with the analysis of CMV specific CD8^ T cell responses in this study.
HLA-A*0201 restricted CD8^ T cell responses to CMV pp65 (495-503) are the 
most studied and best known cytotoxic T cell responses to CMV. Initial studies on 
CMV specific CD8^ T cells focused on frequency measurements of CD8^ T cells 
restricted by HLA-A*0201 because this allele is amongst the most common HLA type 
in Caucasoids and many other ethnic groups. Frequency measurements of CMV specific 
CD8^ T cells restricted by HLA-A*0201 were therefore used as an archetype for 
comparison with responses targeting other HLA/peptide combinations in this study.
Prolonged antiviral treatment and the development of chronic graft versus host 
(GvH) disease are risk factors for the development of late-onset CMV disease in HSCT 
patients (Einsele et a l ,  2000). A placebo-controlled study of ganciclovir treatment 
demonstrated that the suppression of viraemia by prolonged antiviral treatment results 
in a decrease in priming of CMV specific CD8^ T cells (Li et a l ,  1994). GvH disease 
(GvHD) necessitates immunosuppressive treatment, which impairs the development and 
function of CMV specific CD8^ T cell responses. Most of the patients that received 
allogeneic HSCT in the study described here received aciclovir as antiviral prophylaxis 
and cyclosporine A alone or with methotrexate as GvHD prophylaxis (compare Table
2-1 on page 99). Illustrations demonstrating the pattern of recovery of CMV specific 
CD8^ T cell responses in HSCT patients in this chapter indicate periods of active 
immunosuppression and antiviral treatment (usually intravenous ganciclovir at 5 mg/kg 
of body weight twice a day, intravenous foscamet at 90 mg/kg of body weight twice a 
day or oral valganciclovir at 900 mg/kg of body weight twice a day, compare section 2- 
2.5) that was received by patients in addition to these prophylactic measurements.
It is appreciated that CMV specific CD8^ T cell levels and CMV disease are also 
influenced by different transplant related factors (Peggs, 2004b). These include CMV 
serostatus and donor relationship to recipient (Cwynarski et a l ,  2001, Ljungman et a l,  
2003), conditioning regimens (Junghanss et a l ,  2002), use of TCD (Chalandon et a l,  
2006), type of transplant (Trenschel et a l ,  2000), GvHD (Meyers et a l ,  1986) and age 
of recipient (Enright et a l ,  1993) or donor (Baron et a l ,  2006). These parameters are 
therefore listed in Table 2-1 on page 99 specifying patient characteristics in Chapter 2.
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3-2 Results
The outcome of the investigation of CMV specific CD8^ T cell responses in HSCT 
patients is described below. Responses targeting different CMV peptides presented by 
different HLA alleles have been studied. As described in the introductory chapter 
(section 1-11), the HLA alleles chosen for analysis are HLA-Al, HLA-A2, HLA-A24 
and HLA-B35. The pattern of HLA-B35 restricted responses is simpler to explain than 
the pattern of responses restricted by the other HLA types. This is because responses 
restricted by HLA-B35 were found to be more consistent amongst patients whereas 
individual circumstances resulted in responses restricted by other HLA types to be less 
consistent amongst patients. Therefore not all of the responses restricted by HLA types 
other than HLA-B35 could be considered for statistical analysis in the same way as 
responses restricted by HLA-B35. Responses restricted by HLA-B35 are therefore 
described first.
3-2.1 CMV specific CD8* T cell responses restricted by HLA-B35
This section will describe the observation that low numbers of CMV specific CD8^ T 
cell responses restricted by HLA-B35 inversely correlated with the ability to detect 
CMV reactivation in HSCT patients. The CMV peptide target that was studied will be 
described first. Then the results of the longitudinal monitoring of patients will be 
shown. One sub section will be dedicated to responses observed in patient 7, which 
were suspected to be crossreactive and were investigated in more detail. A statistical 
comparison of CD8^ T cells assigned to different groups depending on viral load 
measurements at the time of sampling will then be shown and response levels in healthy 
volunteers will be listed. A comparison to HLA-A*0201 restricted CMV pp65 (495- 
503) specific responses will be shown in a later section (section 3-3, from page 238).
3-2.1.1 CMV targets of CDS* T cell responses restricted by 
HLA-B35
As outlined in Chapter 1 (section 1-11.2), the CMV tegument phosphoprotein, pp65, is 
considered one of the most important antigens for cellular immunity in CMV infection.
Common subtypes of HLA-B35 demonstrate amino acid substitutions within the 
peptide binding cleft region. This micropolymorphism was reported to influence the 
relative binding stability and thereby immunodominance of viral peptides including 
pp65 between individuals expressing different HLA-B35 subtypes (Burrows et al., 
2007, Green et a l ,  2004, Tynan et a l,  2005).
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Responses restricted by the most common subtype, HLA-B*3501, are analysed in this 
section. These CD8^ T cell responses target the 9mer located at the region pp65 123- 
131 with the sequence IPSINVHHY, which was described by Gavin and colleagues 
(Gavin et a l ,  1993). Only one other CMV antigen (Kern et a l ,  2002) of HLA-B*3501 
restricted CD8^ T cells had been reported at the time of initiation of this project. This 
epitope (pp65(173-183)) was reported in only one individual. In contrast pp65 (123- 
131) is thought to be the strongest known epitope in the context of HLA-B*3501 
(Burrows et a l ,  2007). Other CD8^ T cell antigens derived from pp65, lie within the 
regions 181-195 and 187-201 overlapping at 187 to 195 (Wills et a l,  1996), of which 
peptide 187-195 was later reported to be restricted by HLA-B*3503 (Wills et a l,  
2002b) whereas pp65 188-195 was reported to be restricted by HLA-B*3502 (Villacres 
et a l ,  2003) and most recently HLA-B*3508 (Burrows et a l ,  2007).
HLA-B*3501 restricted CMV pp65 (123-131) specific CD8^ T cell responses 
investigated in this study will subsequently be abbreviated as HLA-B35/pp65 specific 
CD8^ T cell responses.
3-2.1.2 Monitoring of CMV specific CDS* T ceils in patients 
expressing HLA-B35
15 HSCT patients were originally recruited for the study of HLA-B35/pp65 specific 
CD8^ T cell responses. They and their donors express HLA-B*3501; patient, donor, or 
both are CMV seropositive. Patients from whom samples were collected from earlier 
than 100 days post transplantation onwards with at least 4 collections post 
transplantation were included in the follow-up cohort (n = 9) to establish a threshold of 
protective levels of responses to this HLA/peptide target. Detailed patient characteristics 
are given in Table 2-1 on page 99. HLA-B35/pp65 specific CD8^ T cells detected in the 
9 patients are shown in this chapter. The average start of follow- up was day 44 (range 
day 23 - 88) and the average end of follow-up was day 481 (range day 60 - 902) post 
transplantation with an average of 19 samples taken per patient (range 4 -3 7 ).
The pattern of recovery of CMV specific CD8^ T cells observed in patients post 
HSCT is illustrated in line graphs. To best illustrate the pattern of responses seen in 
patients over time, samples were collected as frequently as once a week whenever 
possible. It must be noted, however, that the larger the gap between two samples taken 
(depending on patient’s availability) the more likely it was that an intermittent peak or 
transient decrease of the response may have been missed and lines shown between data
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points on the graph are used for easier viewing rather than assuming that they reflect the 
actual pattern of the response between data points measured. Tetramer binding cell 
numbers were correlated with viral load and functionality of cells was tested by IFNy 
assays for samples with sufficient cell numbers. The results are summarised in Figure 
3-1. Due to low cell numbers obtained from patient samples, ELISpot measurements in 
patient 3 and patient 8 were performed at a single time point only.
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The time course of a patient who failed to demonstrate a protective CMV specific 
response and who therefore remained at high risk of CMV reactivation is shown by 
patient 3 in Figure 3-1. The patient had received intense conditioning with Campath-IH 
in vivo and received his transplant from a CMV seronegative donor. A temporarily low
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level of CMV specific CD8^ T cells in this patient at 491 days post transplantation was 
not sustained. The lack of a protective response correlated with very low numbers of 
total CD8^ T cells (^28 cells/pl apart from transient increase at around day 491). Total 
CD4^ T cells were low, fluctuating between 126 and 294 cells/pl of blood from day 272 
post transplantation onwards. The lymphocytes reconstituted by the patients did consist 
of NK cells mainly (only 17.7% of lymphocytes were T cells whereas 64%  of 
lymphocytes were NK cells at day 299 post transplantation). The few T cells present 
were mainly CD4^ T cells (75 % of T cells at day 299 post transplantation) and of 
memory phenotype (89.6 % of CD3^ CD4^ T cells were CD45RO^ CD27 and 81.4 % 
of CD3^ CD8^ T cells were CD45RO^ CD27*). In addition to the lack of HLA- 
B35/pp65 specific CD8^ T cells the patient had no CMV specific responses restricted by 
HLA-Al either (compare Figure 3-16 in section 3-2.3.2 on page 217). This was 
reflected by the occurrence of multiple episodes of CMV replication, which were only 
temporarily resolved by antiviral treatment.
Part A in Figure 3-1 demonstrates that the remaining patients reconstituted and 
sustained significant numbers of pp65 (123-131) specific CD8^ T cells. In accordance 
with this, some of these patients did not reactivate CMV (patients 5 and 7). Others 
eventually resolved CMV replication without any viral copies detected at the end of the 
follow-up period (patients 1, 2, 4, 6, 8 and 9). These patients therefore appear to have 
reconstituted levels of CMV pp65 (123-131) specific CD8^ T cells that were protective. 
Although the level of CMV specific CD8^ T cells detected in patient 1 was very low, 
the genuineness of the response was confirmed by the functional assay, which 
demonstrated IFNy release by PBMC upon stimulation with CMV pp65 (123-131) 
peptide, shown in Figure 3-1.
Some patients expressed several of the HLA types for which CMV specific 
CD8^ T cells were investigated in this chapter (compare Table 2-1, page 99). These 
patients, whose HLA-B35/pp65 specific CD8^ T cells responses are shown in this 
section, were also monitored for the presence of CMV specific CD8^ T cells restricted 
by other HLA alleles. The latter will be shown in later sections. Of these, patient 6 also 
reconstituted HLA-A*0201 restricted CMV specific CD8^ T cells (Figure 3-21, page 
229) whereas such cells were not observed in patient 1 or patient 2 (Figure 3-23, page 
231). Patient 1 and 2 expressed HLA-A*0201 but not HLA-B*0702. Therefore the lack 
of HLA-A*0201 restricted CMV specific CD8^ T cells cannot be explained by the 
dominance of CMV specific CD8^ T cell responses restricted by HLA-B*0702 over
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those restricted by HLA-A*0201 that was reported previously (Lacey et a l,  2003). 
Furthermore patient 5 reconstituted HLA-A*0101 restricted CMV specific CD8^ T cells 
(Figure 3-14, page 214) but patient 7 did not reconstitute CMV specific CD8^ T cells 
restricted by HLA-A*2402 (Figure 3-9, page 201). Possible dominance of CMV 
specific CD8^ T cells restricted by one HLA allele over those restricted by another HLA 
allele will be discussed in section 3-3 from page 238.
The protective capacity of HLA-B35/pp65 specific CD8^ T cells was best 
demonstrated by observations in patient 9. This patient reactivated CMV at 42 days post 
autologous transplantation. CMV specific T cells were present and their level was rising 
rapidly until day 53. In accordance with this the viral load had already dropped at day 
49 before Ganciclovir was given from day 54 to 62 post transplantation. CMV 
replication was subsequently not detectable from day 59 post transplantation onwards. 
HLA-B35/pp65 specific CD8^ T cells therefore most likely caused the initial drop in 
viral load and protected the patient fi-om subsequent reactivation.
Tetramer staining was used as a direct approach to visualise and quantify CMV 
peptide pp65 (123-131) specific CD8^ T cells in absolute terms and as a percentage of 
total CD8^ T cell response in patients. Additionally the functionality of these responses 
was confirmed by ELISpot assays measuring the IFNy release after stimulation with 
pp65 (123-131) as spot-forming units (SFU) per 100,000 PBMC. Some variations 
between the two assays are expected. If CD8^ T cells represent a different proportion of 
PBMC in different patients, these patients will have different numbers of SFU observed 
in the ELISpot assay even if they demonstrate a similar number of CMV specific CD8^
T cells observed by tetramer staining. Nevertheless Figure 3-1 on page 180 
demonstrates cytokine release of PBMC from patient blood samples at the time points 
when pp65 (123-131) specific CD8^ T cell staining of PBMC was positive in these 
patients. This confirms functionality of responses quantified by tetramer staining.
3-2.1.3 HLA-B35 restricted CDS* T cell response with potential 
crossreactivity in patient 7
Of all the patients in whom HLA-B35/pp65 specific CD8^ T cell responses were 
measured, one was of particular interest. Patient 7 was CMV seropositive. In contrast to 
other patients of this HLA type specific follow-up cohort this patient received a 
myeloablative, non-TCD transplant from a CMV seronegative donor (Table 2-1, page 
99) and was therefore at greater risk of CMV reactivation (Cwynarski et a l ,  2001,
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Gandhi et a l ,  2003a) because the contribution of newly generated CMV specific T cells 
from the naïve T cell pool of donor origin during the first 6 months after transplantation 
may be negligible (Roux et a l ,  2000) and recipient T cells typically survive only when 
the graft is thoroughly depleted of donor T cells (Roux et a l,  1992). Nevertheless a high 
frequency of total CD8^ T cells bound HLA-B35/pp65 tetramer since the first time of 
measurement at day 46 post transplantation in patient 7. At that time 11 percent of total 
CD8^ T cells were HLA-B35/pp65 specific. CMV specific T cells of donor origin have 
recently been demonstrated in a HSCT patient early after receiving a non T cell 
depleted graft from a CMV seronegative donor and reactivation of CMV (Chalandon et 
al., 2006). Reactivation of CMV, however, was not evident at any time post 
transplantation in patient 7. The development of a primary CMV specific response of 
high frequency was surprising. Two observations in particular indicated that this CMV 
response might be unusual. First, the pattern of CMV response closely resembled the 
rising of total T cell numbers during a period of acute GvHD and second the HLA- 
B35/pp65 specific CD8^ T cells demonstrated an unusual staining profile.
Soon after engraftment at day 17 post transplantation, acute GvHD of grade 1 - 2 
was diagnosed from day 21 post transplantation onwards. The patient subsequently 
received increased levels of Cyclosporine from day 42 post transplantation and 
additional Prednisolone treatment from day 62 to 94 post transplantation. CMV specific 
and total T cell numbers were initially high and dropped in parallel with the 
immunosuppressive treatment given after day 62 post transplantation. Cell numbers 
recovered after day 117 post transplantation. Prophylactic Cyclosporine treatment had 
been reduced from day 222 and stopped at day 249. Mycophenolate Mofetil treatment 
was given for chronic GvHD from day 136 to 301. Subsequently CMV specific CD8^ T 
cells increased after day 335 post transplantation. An unusually dim tetramer staining 
profile of HLA-B35/pp65 specific CD8^ T cells was observed during the first period of 
follow-up until day 363 post transplantation and is shown in Figure 3-2.
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Figure 3-2 Dim and bright tetramer staining of HLA-B35/pp65 specific CD8  ^ T 
cells in patient 7
R epresentative exam p les o f  tetram er stained PBM C  from patient 7 are sh ow n  in A  in 
com parison to typical sta in ing profiles from all other patients o f  this fo llow -u p  cohort w ho  
dem onstrated sign ifican t num bers o f  tetramer binding ce lls  in B. F low  cytom etry p lots sh ow  
CD3^ live  lym ph ocytes sorted according to their surface expression  o f  CDS on the x -ax is and 
H L A -B 35/pp 65 tetram er sta in ing on the y -ax is. The geom etrical m ean o f  H L A -B 35/p p 65  
tetramer stain ing intensity is g iven  above each plot. For sam ples from patient 7 at day 475  and 
day 818 post transplantation, the geom etrical m ean o f  dim  and bright sta in ing populations as 
marked by pink circles is show n.
After day 363 post transplantation CMV specific CD8^ T cells were present in higher 
numbers per volume of blood than before (Figure 3-1, page 180) and demonstrated two 
populations of an unusually dim and a normal bright tetramer staining profile 
respectively (Figure 3-2). The latter staining profile resembled the staining levels of 
CMV specific CD8^ T cells observed in other patients. These observations in patient 7 
led to the hypothesis that alloreactive T cells present at the time of GvHD symptoms in 
the patient, may have cross-reacted with the HLA-B35/pp65 tetramer. The possibility of 
CMV specific CD8^ T cells cross-reacting with alloantigen was reported previously
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(Gamadia et a i ,  2004, Nahill and Welsh, 1993). These CMV crossreactive CD8^ T cells 
may demonstrate a dim tetramer staining profile due to low affinity of the TCR for the 
HLA/peptide complex (Crawford et a i,  1998, Yee et a i ,  1999). In contrast, cells 
observed at later time points in patient 7 may represent true CMV specific CD8^ T cells 
with high affinity for the HLA/peptide complex that demonstrate a bright staining 
profile comparable in staining levels to those seen in other patients.
T cell avidity is a complex parameter that is influenced by peptide affinity, TCR 
expression levels and requirement for accessory molecules (reviewed in (Huppa and 
Davis, 2003, McKee et al., 2005)). However, findings from Yee and colleagues suggest 
that low versus high avidity of T cells can be visualised by dim versus bright staining 
with peptide-MHC tetramer and that the underlying mechanism is not related to the 
level of CD8 accessory molecule expression or the density of TCR expression (Yee et 
a i,  1999).
Tetramers bind to CD8^ T cells and label them according to their antigenic 
(TCR) specificity. However, TCR also exhibit a degree of promiscuity for HLA/peptide 
ligands and this crossreactivity is an essential requirement for a comprehensive T cell 
response to foreign antigens (Davis et a i,  1998, Mason, 1998). It has been argued that 
the enhanced avidity afforded by tetramerisation of HLA/peptide monomers (refer to 
section 1-10) may allow tetramer binding to TCR with low affinities that would not 
generate physiological responses (Howard et a i ,  1999). The crossreactivity of tetramers 
was correlated to the temperature used during tetramer staining procedures (Whelan et 
a i,  1999). Strongly recognised (high affinity) HLA/peptide complexes are thought to 
interact long enough to trigger the TCR but rapidly enough to be available for several 
cycles of binding (Lanzavecchia et a i ,  1999) that may be needed for full T cell 
activation (Valitutti et a i,  1995). Just as the ability of HLA/peptide complexes to 
activate T cells depends on their off-rate (Lanzavecchia et a i ,  1999), the ability of 
tetramers to stain T cells depends upon a sufficiently slow off-rate (Whelan et a i,  
1999). Staining at high temperature likely increases the off-rate beyond the threshold at 
which tetramers incorporating weakly recognised HLA/peptide can form stable 
complexes with a TCR. Staining at low temperature may allow for sufficient interaction 
of tetramers incorporating weakly recognised HLA/peptide to result in stable binding to 
a TCR despite an inability of these HLA/peptide complexes to activate T cells (Whelan 
et a i ,  1999). Therefore tetramer staining during this study was performed at a 
temperature of 37 °C that was reported to result in reduced staining by tetramers
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incorporating weakly recognised HLA/peptide without reducing the staining by 
tetramers incorporating strongly recognised HLA/peptide (refer to section 2-5.1). 
Staining at that temperature shows a very good correlation with peptide activity in 
cytotoxicity assays, which suggests that it can accurately reflect the specificity of T 
cells for HLA/peptide presented on the cell surface at physiological levels (Burrows et 
a l,  2000). This, however, cannot preclude crossreactivity similar to that, which would 
generate physiological crossreactive responses. Therefore CD8^ T cells may bind 
tetramer because they possess TCR with concise specificity to the HLA/peptide that is 
incorporated in the tetramer or because they possess TCR with specificity to a foreign 
HLA/peptide complex but sufficient avidity to crossreact with the tetramer.
T cell avidity can be tested in vitro by evaluating the peptide amounts required 
for induction of a T cell response (reviewed in (Snyder et a l,  2003)). Cytokine secretion 
in response to CMV pp65 (123-131) by PBMC from patient 7 had been observed during 
the entire period of follow-up (Figure 3-1, page 180). Therefore affinity of PBMC was 
tested by ELISpot assay using titration of pp65 (123-131). PBMC from patient 7 early 
post transplantation (day 77, when CMV specific T cells demonstrated a dim tetramer 
staining profile) and samples from the same patient late post transplantation (day 818, 
when CMV specific T cells demonstrated a dim and bright tetramer staining profile) 
were compared to samples from other patients with evident HLA-B35/pp65 specific 
CD8^ T cells. Response curves are shown as percentage of responses to undiluted 
peptide in Figure 3-3.
A variation of this graph (Figure 6-3, page 335) illustrating original median 
values and errors calculated from triplicate measurements is shown in the appendix.
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Figure 3-3 IFNy release of PBMC in response to serial dilutions of CMV peptide 
pp65 (123-131)
IFNy release in responses to  1:2 d ilutions o f  C M V  pp65 (1 2 3 -1 3 1 ) w as m easured in triplicate  
for tw o PBM C sam ples from  patient 7 (so lid  lines, A: sam ple taken at day 77 , B: sam ple taken 
at day 818  post transplantation) and five  sam ples from other patients (dashed lin es, C: patient 
30b at 763 days post transplantation, D: patient 31 at 700  days post transplantation, E: patient 
6  at 8 6  days post transplantation, F: patient 9 at 367  days post transplantation and G: patient 32  
at 483 days post transplantation). A  w eighted  curve fit (75  % sm ooth ing in the program  
Kaleidagraph) from  the m edian SFU  above unstim ulated controls from  triplicate  
m easurem ents w as calcu lated  for each patient sam ple. For clarity o f  the graphical d isplay  
individual data points are not show n but can be seen  in a variation o f  this graph (Figure 6 -3 )  in 
the appendix. R esp onse curves are represented as percent o f  response to the h ighest 
concentration o f  peptide ( 1 0  p g /m l).
Not all response curves in this figure demonstrate 100 % of response towards undiluted 
peptide. Cells from some of the samples demonstrated higher responses to middle range 
dilutions of peptide than to undiluted peptide. This may be the result of general 
fluctuation of data points around the titration trend line reflecting the limits of the 
ELISpot sensitivity. Alternatively it may be the result of a prozone effect that may have 
been caused for example by a mild toxic effect of high peptide concentrations.
Figure 3-3 suggests that cells from patients 7 and 31 titre out slightly faster than 
other responses (Figure 3-3: A, B, and C). This, however, cannot be observed when 
original data points (instead of percentages of the neat response) are plotted (Figure 6-3 
in the appendix, page 335). That figure shows higher initial responses in curve D and F, 
which derive from samples with 2.6 % and 3.8 % of their CD8^ T cells being specific 
for pp65( 123-131), than in other curves, which derive from samples with 1.5 % (A and
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B), 1.9 % (C), 1.3 % (E) and 1.0 % (G) of their CD8^ T cells being specific for pp65 
(123-131).) All of the curves titer out rapidly from the 5^  ^ dilution (1:32, corresponding 
to 312.5 ng/pl) onwards in Figure 6-3.
Overall, no significant difference in affinity between the sample from patient 7 
taken early post transplantation (day 77, dim tetramer staining, curve A) and at a later 
time (demonstrating 67 % dim and 33 % bright tetramer staining, curve B) or those 
from other patients with HLA-B35/pp65 specific CD8^ T cell responses (curves C, D, 
E, F and G) were observed in Figure 3-3 or Figure 6-3.
The experiment was designed in a way that relied on the presentation of peptide 
by antigen presenting cells (APC) present within PBMC. ELISpot assays using APC 
pulsed with different peptide concentration could be used in future experiments to 
confirm results. The variation in staining intensity originally observed during tetramer 
staining may reflect a rapid dissociation rate for TCR-peptide/MHC interaction. This 
may result in a lower proportion of tetramer bound TCRs from low affinity T cells at a 
given time reflected in a lower fluorescent intensity than from high affinity T cells. This 
could be investigated by receptor-ligand binding assays in future studies.
A further observation suggests that binding of tetramer stained cells may be 
different for the cells that appear as a dim tetramer stained population in comparison 
with those that appear as a bright tetramer stained population in Figure 3-2 on page 184. 
As described in section 2-5.3, binding specificity of tetramers was confirmed by 
decreased CD3 fluorescence intensity in the tetramer staining populations in 
comparison to the total CD8^ T cell populations during flow cytometry (Figure 2-5, 
page 111). Interestingly, cells from patient 7 at day 818, demonstrated less CD3 
fluorescence in the bright tetramer populations (107 fluorescence units) than in the dim 
tetramer populations (112 fluorescence units). Both populations had less CD3 
fluorescence than the total CD8^ T cell population (114 fluorescence units).
Low cell numbers were available from this patient. Further experiments such as 
using an in vitro skin explant model (Sviland and Dickinson, 1999) would have been 
possibilities to further explore whether the dim staining cells observed in patient 7 may 
be true CMV specific CD8^ T cells or crossreactive. Due to the limited material 
available, however, the staining results from this patient can serve as an observation 
only. The hypothesis on dim tetramer binding cells being allo-crossreactive could not be 
proven and the significance of the unusual staining profiles observed in patient 7 
remains unknown. Responses from this patient are therefore considered similar to
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responses of other patients within the follow-up cohort for subsequent statistical 
analysis to establish protective response levels in the context of HLA-B35.
3-2.1.4 Statistical anaiysis of the protective ievei of HLA-B35 
restricted CMV specific CDS* T cells and summary
The numbers of CMV specific CD8^ T cells measured per volume of peripheral blood 
(compare Figure 3-1 on page 180, upper graph in each box) were analysed statistically. 
CMV specific CD8^ T cell numbers measured in all patients were sorted into three 
groups. One group contained responses from patients that did not experience CMV 
reactivations. Responses from other patients were separated according to the occurrence 
of CMV reactivations during the time of measurement. Responses measured from the 
last peak of CMV reactivation onwards were placed into a second group, whereas those 
measured prior to the last CMV reactivation peak were considered in a third group. The 
assignment of responses to these three groups can be explained as follows. A lack of 
responses in patients not experiencing CMV reactivations may occur but in general the 
level of CMV specific CD8^ T cells in patients who never reactivate is considered 
protective in this analysis. The level of CMV specific CD8^ T cells in patients during 
periods of CMV reactivation is likely to be not protective although these responses may 
include peak levels of protective responses that are subsequently not sustained. In 
contrast, the level of responses measured since the last CMV reactivation may be 
considered to be protective. The three groups of responses were statistically analysed 
using a two-tailed Mann-Whitney U test. The results are shown in Figure 3-4 with the 
medians indicated as lines.
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Figure 3-4 Statistical analysis of HLA-B35/pp65 specific CD8  ^T cell responses
The figure sh ow s absolute num bers o f  tetramer binding ce lls /p l o f  peripheral b lood. Com pared  
are values in patients 1, 2 , 3, 4 , 6 , 8  and 9 m easured post transplantation until the last observed  
C M V  reactivation (A B 3 5 /p p 6 5  during C M V ) versu s  values m easured from  the peak o f  the last 
C M V  reactivation onwards in these patients (A B 3 5 /p p 6 5  post C M V ) and values in patients 5 
and 7 w ho did not reactivate C M V  (▼ B 35/p p 65 w /o  C M V ). Data groups w ere statistically  
analysed using a tw o-tailed  M ann-W hitney U test w ith  the m edians and p va lu es (p < 0 .02  
regarded sign ifican t) indicated in the graph.
The nine patients of the follow-up cohort can be grouped into the 7 patients who 
reactivated CMV during the monitoring period (patients 1, 2, 3, 4, 6, 8 and 9) and the 
two patients who did not (patients 5 and 7). The median of CMV specific CD8^ T cell 
numbers measured in patients who did not reactivate the virus was 3.6 cells/pl. CMV 
specific CD8^ T cell numbers measured during the period of CMV reactivation (median 
0.3 cells/pl) were significantly lower than cell numbers measured after CMV 
reactivation in the reactivating group of patients (median 4.9 cells/pl) and cell numbers 
measured in patients who did not reactivate the virus. The latter two response groups 
were not significantly different from each other. This demonstrates a broad inverse 
correlation between the HLA-B35/pp65 specific CD8^ T cell numbers and the viral load 
in HSCT patients. Significantly higher CMV specific CD8^ T cell numbers were 
detected in patients that had resolved CMV reactivations than during the period of CMV 
reactivation. The magnitude of responses in patients after resolution of CMV was 
similar to the magnitude of responses in patients that did not reactivate CMV.
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Inter-individual variation from the protective level of CMV specific CD8^ T cells 
described above is demonstrated in Table 3-1.
Patient Median protective level 
(2S'\ 75* percentile)
Number of samples
1 1.46 (1.30, 1.86)) 9
2 4.10 (2.80, 5.00) 3
4 4.20 (2.70, 5.45) 35
5 5.30 (2.20, 5.60) 9
6 10.17 (8.21, 15.05) 12
7 3.29 (2.13, 12.43) 20
8 14.97 2
9 13.79 (10.77,37.00) 11
Table 3-1 Protective levels of HLA-B35/pp65 specific CDS T cell responses in 
individual patients
The m edian  o f  the ab so lu te  num ber o f  tetram er b ind ing c e lls /p l o f  peripheral b lood  in patients 
1, 2 , 4 , 6 , 8  and 9 m easured  from  the peak o f  the last C M V  reactivation  onw ards and o f  
ab so lu te  num bers o f  tetram er b in d in g  ce lls  in patients 5 and 7 w ho did not reactivate C M V  are 
listed  as m edian  p ro tective  le v e ls  (in  italics: ca lcu lated  from  <3 sam p les). T he n um ber o f  
sam ples used  to  ca lcu la te  the m edian  is sh ow n  on the right.
Patient 3 is not included in Table 3-1 because multiple CMV reactivations spanning the 
entire time of follow-up indicated that protective levels of HLA-B35/pp65 specific 
CD8^ T cell numbers were not reached in this patient. Apart from a temporary peak of 
2.14 cells/pl, this patient demonstrated <0.14 CMV specific CD8^ T cells/pl blood 
(Figure 3-1, page 180).
Table 3-1 demonstrates higher responses in patients 6, 8 and 9 than in other 
patients. In patient 6 this results from peak levels. He recovered 4.1 HLA-B35/pp65 
specific CD8^ T cells/pl blood post CMV reactivation with intermittent spikes in his 
response. In patient 8 HLA-B35/pp65 specific CD8^ T cells were measured from 2 
samples post CMV reactivation only before the patient died. This response most likely 
represented the peak levels of CD8^ T cells, which numbers may have decreased 
thereafter. High levels of HLA-B35/pp65 specific CD8^ T cells were also observed in 
patient 9. After an initial spike of the response, subsequent levels decreased to 
4.44 cells/pl blood, which did plateau at around 12 cells/pl blood thereafter. Patient 9 
was the only autologous patient in this cohort (compare Table 2-1 on page 99). This 
may explain the high level of CMV specific CD8^ T cell numbers observed in this 
patient because it was reported previously that CMV specific CD8^ T cells expand to 
much greater number in autologous than allogeneic HSCT patients early post
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transplantation. This was suggested to be due to activation of allo-transferred cells, 
which are more prone to apoptosis than auto-transferred cells (Ferrari et a l ,  2006).
Calculating the median from the levels shown in Table 3-1 results in a value of 
4.75 cells/pl of blood, which lies between the level of responses measured in all patients 
since the last peak of CMV reactivation (median 4.9, Figure 3-4. page 190) and the 
level of responses measured in all patients who did not reactivate CMV (median 3.6, 
Figure 3-4). It thus confirms that the calculation of the protective level of responses is 
similar for both approaches, the calculation using measurements from all patient 
samples (with varying samples numbers from different patient) and the calculation 
using a single calculated value per patient.
It can be concluded that HLA-B35/pp65 specific CD8^ T cells are protective at a 
level of approximately 4.4x10^ cells/L of blood (Figure 3-26, page 241). This final 
value has been established by calculating the median of responses measured in patients 
1, 2, 4, 6, 8 and 9 since the last peak of CMV reactivation and all responses measured in 
patients 5 and 7. This value would only slightly change (5x10^ cells/L of blood) if 
responses from patient 7 were omitted (compare section 3-2.1.3 from page 182 
onwards). Section 3-3 from page 238 onwards will show that the protective level of 
HLA-B35/pp65 specific CD8^ T cells established here is considerably lower than for 
CMV specific CD8^ T cells targeting other HLA/peptide combinations such as HLA- 
A*0201 restricted CMV pp65 (495-503) specific responses.
Low levels of HLA-B35/pp65 specific CD8^ T cell responses can also be 
observed in healthy CMV seropositive volunteers. Six CMV seropositive healthy 
individuals expressing HLA-B*3501 (compare Table 2-3 on page 100) were recruited 
and their blood tested for HLA-B35/pp65 specific CD8^ T cells. The frequency of CMV 
specific cells amongst CD8^ T cells was found to be 0.27 % in one individual and 
<0.07 % in another two of the six individuals tested. Discrete populations can be 
observed in flow cytometry plots in the two patients demonstrating very low 
percentages of CMV specific CD8^ T cells (Figure 3-5). The remaining three 
individuals had no detectable HLA-B35/pp65 specific CD8^ T cells.
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Figure 3-5 Staining profiles of HLA-B35/pp65 specific CD8 T cells of low 
frequency in healthy volunteers 1 and 3
The figure sh o w s tetram er stained peripheral b lood  ce lls  from tw o healthy volunteers. F low  
cytom etry p lots sh ow  ce lls  sorted depending on their surface expression  o f  C D 8  and H L A - 
B 35/pp65 tetramer staining. P lots on the left represent CD3^ live lym ph ocytes. P lots on the 
right represent the C D 8  ^ fraction o f  these ce lls . N um bers in the upper right com er o f  p lots  
represent the c e lls  show n in pink circular gates as a percentage o f  total c e lls  in that plot.
A summary of all levels of HLA-B35/pp65 specific CD8^ T cells observed in healthy 
volunteers is demonstrated in Table 3-2.
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Healthy
volunteer
HLA-B35/pp65 specific cells as a 
percentage of CD8  ^T cells
HLA-B35/pp65 specific cells 
per microlitre of blood
1 0.05 0.15
2 undetectable undetectable
3 0.07 0.38
4 undetectable undetectable
5 undetectable undetectable
6 0.27 0.87
Table 3-2 HLA-B35/pp65 specific CD8  ^T cell levels in healthy volunteers
T his table sh o w s id en tifica tion  num bers o f  healthy vo lu n teers in the left co lu m n  and the H L A -  
B 35 /p p 65  sp ec ific  C D 8  ^ T  ce ll cou n ts detected  in peripheral b lood  o f  th ese  vo lu n teers by use  
o f  tetram er sta in in g  in the m id d le  and right co lum n. C oun ts are represented as a p ercen tage o f  
the total C D 8  ^ T  ce ll p opu lation  in the m idd le colum n and as a num ber per v o lu m e o f  b lood  in 
the right colum n.
The level of HLA-B35/pp65 specific CD8^ T cell responses observed in CMV 
seropositive healthy volunteers is much lower than that observed in HSCT patients 
(p<0.0001, compare also Figure 3-26 and Figure 3-27 on page 241 and 245 
respectively). This was also observed for other HLA/peptide combinations and will be 
discussed further in section 3-3 from page 238 onwards.
The level of HLA-B35/pp65 specific CD8^ T cell responses observed in CMV 
seropositive healthy volunteers is also lower than the level of CMV pp65 (495-503) 
specific CD8^ T cells that can be observed in CMV seropositive healthy volunteers 
expressing HLA-A*0201 (compare Table 3-11, page 237).
A range of other CMV specific CD8^ T cell responses targeting different 
HLA/peptide combinations will be compared to HLA-A*0201 restricted CMV pp65 
(495-503) specific responses in the following sections.
3-2.2 CMV specific CD8* T cell resp onses restricted by HLA-A24
In many ethnic groups, HLA-A24 is one of the most common HLA types with HLA- 
A*2402 being the most frequent allele (compare section 1-11.1). HLA-A*2402 
restricted CMV specific CD8^ T cells have been studied mainly by Japanese groups 
(Akiyama et a l ,  2002, Kuzushima et a l ,  2001, Masuoka et a l ,  2001, Morita et a l ,  
2005, Sakagawa et a l ,  2006) because the HLA-A*2402 allele has a much higher gene 
frequency (32.7 %) than HLA-A*0201 (10.6 %) in Japan (Tokunaga et al., 1997) and is 
represented in 58 % of Japanese (Sette and Sidney, 1999).
This section will demonstrate that low levels of CMV specific CD8^ T cells 
restricted by HLA-A*2402 protect HSCT patients from CMV reactivation. Two CMV
194
____________________________________________________________________ Chapter 3
peptide targets studied in the context of this allele will be described first. This will be 
followed by results indicating that one of these targets does not induce CD8^ T cell 
responses of significant frequency in HSCT patients. Longitudinal monitoring of CD8^ 
T cells specific for the second target will be shown for individual patients. Subsequently 
assignment of responses to different groups according to viral load in patients will be 
performed. The protective level of CD8^ T cells to the second target will then be 
established by statistical comparison of these groups. Finally levels in patients and 
healthy volunteers will be summarised and a comparison to HLA-A*0201 restricted 
CMV pp65 (495-503) specific responses will be shown in section 3-3 from page 238 
onwards.
3-2.2.1 CMV targets of CDS* T ceil responses restricted by 
HLA-A24
This section describes HLA-A*2402 restricted CD8^ T cell responses directed towards 
CMV pp65. CMV pp65 peptides targeted by CD8^ T cells restricted by HLA-A*2402 
had been identified immediately prior to the start of this project. The peptide 
FTSQYRIQGKL at position pp65 369-379 is an llm er originally described by 
Longmate and colleagues (Longmate et al., 2001). A study by Kuzushima and 
colleagues aiming at identifying pp65 peptides restricted by HLA-A*2402, however, 
did not confirm responses to this peptide (Kuzushima et a l ,  2001). They used 
computer-assisted algorithms, MHC stabilization and enzyme linked immunospot 
assays to identify peptides and demonstrated a highly focused response towards the 
peptide QYDPVAALF located at the pp65 341-349 region. Endogenous processing and 
presentation of pp65 (341-349) was confirmed using cytotoxic assays in addition to 
flow cytometry based techniques. Interestingly, this peptide was shown to bind to HLA- 
Cw*0401 as well as HLA-A*2402 (Kondo et a l,  2003). Yet another study suggested 
that CD8^ T cell responses to this peptide do occur also in the context of HLA-A*0101 
(Ghei et a l ,  2005), which will be discussed in the next section (3-2.3 from page 206). 
The peptide VYALPLKML, which is located at the pp65 113-121 region, was also 
recognised by CMV specific CD8^ T cell lines in the study by Kuzushima and 
colleagues but only at concentrations higher than pp65 (341-349). The peptide pp65 
(113-121) was also found to bind HLA-A24 and induce CD8^ T cell responses 
independently by another group of scientists (Masuoka et a l,  2001). It was therefore 
decided to investigate CD8^ T cell responses to both, pp65 (341-349) and pp65 (113- 
121), in this study.
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3-2.2.2 Monitoring of CMV specific CDS* T ceiis in patients 
expressing HLA-A24
16 HLA-A*2402 positive HSCT patients, who each received transplants from HLA- 
A*2402 positive donors were recruited for the study of HLA-A*2402 restricted CMV 
pp65 (341-349) and pp65 (113-121) specific CD8^ T cell responses. Patient, donor, or 
both were CMV seropositive. Detailed patient characteristics are given in Table 2-1 on 
page 99. Patients from whom at least 4 samples were collected starting at less than 100 
days post transplantation were included in the follow-up cohort (n = 12) in order to 
establish the threshold for a protective level of responses to this HLA/peptide target. 
The average start of follow- up was day 45 (range day 11 - 99) and the average end of 
follow-up was day 370 (range day 70 - 830) post transplantation with an average of 13 
samples taken per patient (range 5 -35). Numbers of tetramer binding CD8^ T cells 
were correlated with viral load and functionality of cells was tested by IFNy assays for 
some of the samples with sufficient cell numbers.
CD8^ T cell responses targeted to CMV pp65 (113-121) were absent or very low 
in most patients. Antigen specific T cell numbers lie below a level of 1.12 cells/pl of 
peripheral blood in all patients of the HLA-A24 follow-up cohort. This is demonstrated 
in Figure 3-6.
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Figure 3-6 Background levels of HLA-A*2402 restricted CMV pp65 (113-121) 
specific CD8  ^T cell responses
The figure sh ow s ab solu te num bers o f  H L A -A *2402/p p 65  (1 1 3 -1 2 1 ) tetramer b ind ing ce lls /p l 
o f  peripheral b lood  in patients o f  the H L A -A 24 fo llow -u p  cohort. The scale o f  the y -a x is  is 
over 60  tim es low er than that o f  Figure 3 -4  on page 190. G roups represent responses m easured  
post transplantation until the last observed C M V  reactivation (♦ A 2 4 /p p 6 5  during C M V ) 
versu s  absolute num bers o f  tetramer binding ce lls  m easured from the peak o f  the last C M V  
reactivation onwards in patients 10 to 12 and 17 to 19 (A A 2 4 /p p 6 5  post C M V ) and absolute  
numbers o f  tetram er b inding ce lls  in patients 7 and 13 to 16, w ho did not reactivate C M V  
(▼ A 24/pp 65 w /o  C M V ). Data groups w ere statistically  analysed using a tw o-tailed  M ann- 
W hitney U test w ith the m edians and p values (p < 0 .02  regarded sign ifican t) indicated in the 
graph.
This graph does not include patient 20, who was CMV seronegative and had no 
detectable CMV replication after receiving a transplant from a CMV seropositive donor 
suggesting that primary infection did not occur. According to experiences from 
comparing these staining results with results obtained from staining of control samples, 
the HLA-A*2402/CMV pp65 (113-121) tetramer has a lower sensitivity (resulting in 
higher background staining) than that observed with other tetramers including the HLA- 
B35/pp65 specific tetramer mentioned in the previous section. Most of the HLA- 
A*2402/CMV pp65 (113-121) specific CD8^ T cell responses measured are at the limit 
of staining specificity. No significant absolute numbers can be observed in Figure 3-6.
Responses to CMV pp65 (113-121) and pp65 (341-349) were correlated to viral 
load in patients and the functionality of cells was tested using an IFNy assay for samples
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with sufficient cell numbers. As no significant responses to pp65 (113-121) were found, 
they may be considered as a non-specific background staining of tetramer and therefore 
as a negative control in the following figures. Analysis focuses on HLA-A*2402 
restricted CMV pp65 (341-349) specific CD8^ T cell responses from here on, which 
will subsequently be abbreviated as HLA-A24/pp65 specific CD8^ T cell responses.
Figure 3-7 demonstrates responses in patients that initially reactivated CMV but 
subsequently reconstituted a sustained HLA-A24/pp65 specific CD8^ T cell response 
with no further viral copies detected in their blood. The CMV specific CD8^ T cell 
levels measured at those late time points appear to be protective in patients 10 to 12.
days post transplantation
D CMV viral load IFNy secretion of PBMCs in response to 
♦CMVpp65 (341-349) or ACMVp65 (113-121)
 numt)er of tetramer* CMV specific CDS* T cells stained with
♦HLA-A24/pp65 (341-349) or a  HLA-A24/pp65 (113-121)
 \  A:
 ) b:
absolute count 
percentage
Figure 3-7 Monitoring of HLA-A24/pp65 specific CD8 T cell responses in patients 
10 to 12
♦  H L A -A 2 4 /p p 6 5 (3 4 1-349) and A H L A -A 2 4 /p p 6 5 (l 13-121) tetramer b inding C D 8  ^ T  ce lls  
in different patients are show n in separate boxes. Viral load m easurem ents are sh ow n  a lon g  
with the absolute count o f  C M V  sp ec ific  CDS" T cell responses in A. Part B indicates the IFNy 
response to C M V  peptide (triplicate m easurem ents w ith the error representing the range from  
the 25^  ^ to the 75^* percentiles) a lon g  with C M V  sp ec ific  C D 8  ^ T  cell response as a percentage  
o f  the total C D 8  ^ T  cell response (respon ses are only show n for tim e points w hen ELI Spot 
analysis had been perform ed). The sca le o f  the right y -ax is is larger for patient 10 in A to  
adjust for higher responses. Horizontal bars in yellow /red  or blue indicate im m unosuppressive  
( ■  MMF: m ycophenolate m ofetil, |  P rednisolone) and antiviral ( H  G an ciclovir, B  
Foscam et) treatm ent respectively .
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Patient 10 had received antithymocyte globulin (ATG) as one of the conditioning 
regimens prior to transplantation (Table 2-1, page 99). This reagent has a potent 
capacity to deplete T cells but has been shown to decline to sub-therapeutic levels by 1 
month after allogeneic HSCT (Waller et a l,  2003). Initial CMV reactivations during the 
first months post transplantation in patient 10 were treated with antiviral drugs. After 
cessation of the latter, HLA-A24/pp65 specific CD8^ T cell numbers increased and 
were sustained at high level until the end of the follow-up period at approximately 
1 year post transplantation. No further CMV replication was detected in this patient.
Patient 11 received aciclovir as CMV prophylaxis during nearly the entire time 
of follow-up. Aciclovir induced encephalopathy, however, necessitated temporary 
administration of ganciclovir from day 141 to 169 post transplantation and subsequently 
prophylactic aciclovir was administered at lower doses than usual. This may have 
contributed to continued episodes of CMV replication. In addition to prophylaxis with 
cyclosporine A until day 602 post transplantation, the patient received prolonged 
treatment with prednisolone and MMF (indicated in Figure 3-7) due to acute and 
chronic GvHD. This may explain the delayed rise in HLA-A24/pp65 specific T cells 
responses from day 532 post transplantation onwards. Subsequently HLA-A24/pp65 
specific CD8^ T cell responses decreased but remained at a plateau level, which 
appeared to be protective because there was no CMV reactivation observed since then. 
IFNy release of PBMC (day 630 post transplantation) in response to CMV pp65 (113- 
121) and CMV pp65 (341-349) was additionally measured by intracellular cytokine 
staining in patient 11 confirming responses to the latter peptide only. This is illustrated 
in Figure 3-8.
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Figure 3-8 Intracellular staining confirming the presence of PBMC responses to 
pp65 (341-349) but not pp65 (113-121) in patient 11
This figure sh ow s flow  cytom etry plots illustrating stain ing for intracellular IFNy in PBM C  
(gated on live  CD3^ lym p h ocytes) from patient 11 (630  days post transplantation) that were 
stim ulated with pp65 (341 -3 4 9 ), pp65 (1 1 3 -1 2 1 ) or left unstim ulated.
Patient 12 reconstituted high levels of HLA-A24/pp65 specific CD8  ^ T cell responses 
after his first CMV reactivation, which was treated with Ganciclovir. The CMV specific 
T cell level reconstituted most likely cleared the subsequent low-level reactivation, for 
which no antiviral treatment was received. HLA-A24/pp65 specific CDS^ T cells appear 
to be protective as no further viral load was detected in the patient thereafter.
Except patients 10 to 12 (Figure 3-7) no other patients of the follow-up cohort 
(n = 12) reconstituted significant sustained numbers of HLA-A24/pp65 specific CD8  ^T 
cells. 4 of these other 9 patients demonstrated reconstitution of high levels of CD8  ^ T 
cell responses specific for other HLA/CMV peptide targets. This is illustrated in Figure
3-9. These patients were protected by responses other than HLA-A24/pp65 specific 
CD8  ^T cells and no CMV replication was observed.
The other 5 (patients 16 - 20) of the 9 patients that did not reconstitute 
significant numbers of sustained HLA-A24/pp65 specific CD8  ^ T cells but were 
protected from repeated CMV replications are shown in Figure 3-10.
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Figure 3-9 Monitoring of HLA-A24/pp65 specific CD8  ^T cell responses in patients 
7 and 13 to 15
♦  H L A -A 2 4 /p p 6 5 (3 4 1-349) and A  H L A -A 2 4 /p p 6 5 (l 13 -121) responses in A and B are show n  
in the sam e way as described for Figure 3-7  on page 198. An excep tion  is patient 15, for whom  
the C M V  viral load has been m easured using antigenaem ia w ith units expressed  as infected  
ce lls  per 2 0 0 ,0 0 0  PBM C. There have not been su ffic ien t ce ll num bers to perform functional 
assays in this patient. Part C sh ow s responses to other H L A /peptide targets (▼ H L A -A 2/p p 65 , 
X H L A -A l/p p 6 5 , + H L A -A l/p p 5 0 , A H L A -B 3 5 /p p 6 5 ). Horizontal bars indicate 
im m unosuppressive ( ■  MM F: m ycophenolate m ofetil, ■  Prednisolone) treatment.
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Figure 3-10 Monitoring of HLA-A24/pp65 specific CD8  ^ T cell responses in 
patients 16 to 20
♦  H L A -A 2 4 /p p 6 5 (3 4 1-349) and ▲ H L A -A 2 4 /p p 6 5 (1 1 3 -1 2 1 ) responses are sh ow n  in the 
sam e w ay as described for Figure 3 -7  on page 198. D ue to lim ited cell num ber availab le from  
patient 20 , functional assays cou ld  not be perform ed. Horizontal bars in yellow /red  or blue  
indicate im m unosuppressive ( ■  P rednisolone) and antiviral ( ■  G an ciclovir) treatm ent 
respectively .
202
____________________________________________________________________ Chapter 3
No responses were measured in patients 18 to 20 whereas a response of less than 
1.9 cells/pl (Figure 3-7 A, page 198) and low levels of IFNy release (peak responses of 
29 and 20 SFU shown in Figure 3-7 B) were observed in patient 16 and 17. These are 
considered insignificant and, for patients 16 and 17, may be due to background in both 
assays. Patients 16 to 20 did not reconstitute CD8^ T cell responses to any of the other 
CMV targets investigated using the limited repertoire of tetramer reagents available. In 
patient 20 this finding was not surprising (recipient CMV-/donor CMV+, no detection 
of primary CMV infection). Patient 19 had low numbers of total T cells during the time 
of follow-up and might have been otherwise protected. The remaining patients (patient 
16, 17 and 18) however did reconstitute high numbers of total T cells and therefore 
CD8^ T cell responses to CMV targets other than the ones measured during this project 
likely protected them against CMV.
In conclusion, only 3 of the 12 patients monitored in this section demonstrated 
HLA-A24/pp65 specific CD8^ T cells (Figure 3-7). The presence of cells stained with 
tetramer broadly correlated with the presence of IFNy released in response to HLA- 
A24/pp65 peptides (Figure 3-7 on page 198, Figure 3-9 on page 201 and Figure 3-10 on 
page 202) indicating functionality of CMV specific CD8^ T cells measured.
3-2.2.3 Statistical analysis of the protective level of HLA-A24/pp65 
specific CDS* T cells and summary
No significant response to CMV pp65 (113-121) was observed in any of the patients. 
Therefore a statistical analysis of responses was performed for HLA-A*2402 restricted 
CMV pp65 (341-349) specific CD8^ T cells only. However, only 3 (patients 10 - 12) of 
the 12 patients monitored in this section demonstrated responses of the latter specificity 
(subsequently abbreviated as HLA-A24/pp65). Therefore inclusion of all 12 patients for 
analysis in the same way as that shown for responses in the context of HLA-B35, would 
demonstrate a median approaching zero for all response groups (compare Figure 6-4 in 
the appendix). This comparison is unlikely to be biologically meaningful.
Aiming to establish the level of HLA-A24/pp65 specific CD8^ T cells at which 
patients were protected from CMV replication, measurements in patients that did not 
reconstitute these cells were omitted from the analysis. Responses in patients 10 to 12 
(compare Figure 3-7 on page 198) were grouped depending on the occurrence of CMV 
replication at the time of sampling and a statistical comparison was performed in the 
same way as that shown for responses in the context of HLA-B35 (compare section 3-
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2.1.4 from page 189 onwards). Among patients 10 to 12 there was none without CMV 
replication and therefore responses were assigned to two groups only, with results 
shown in Figure 3-11.
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Figure 3-11 Statistical analysis of HLA-A24/pp65 (341-349) specific CDS T cell 
responses
This figure illustrates the absolute num bers o f  tetramer b ind ing cells/jul o f  peripheral b lood  in 
patients 10 (n=  11), 11 (n=  31 ) and 12 (n=  5) post transplantation until the last observed  C M V  
reactivation (♦ A 2 4 /p p 6 5  during C M V ) versus  absolute num bers o f  tetramer b inding ce lls  
m easured from the peak o f  the last C M V  reactivation onw ards in these patients (A A 2 4 /p p 6 5  
post C M V ). Data groups were statistically  analysed  using a tw o-tailed  M ann-W hitney U test 
with the m edians and p values (p < 0 .02  regarded sign ifican t) indicated in the graph.
Significantly higher responses were detected in patients following resolution of CMV 
reactivation (median 7.6 cells/pl) than during the period of CMV reactivation (median 
0.3 cells/pl). The protective level of HL A-A24/pp65 specific CD8^ T cells (7,6 cells/pl) 
will be compared to levels observed for CMV specific CD8^ T cells targeting other 
HLA/peptide combinations in section 3-3 from page 238 onwards.
A possible limitation of this analysis would be that the “post CMV” group 
contained only those patients in whom HLA-A24/pp65 specific T cell levels were 
measurable; other patients were likely protected by other responses (responses from 
patient 20 were not included because the CMV seropositive patient received HSCT 
from a seronegative donor and primary infection was not detected) and therefore not 
informative. In the case of the “reactivating” group, if some patients never achieved
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measurable levels of HLA-A24/pp65 specific T cells; these patients would be included 
since they clearly have no protective responses. However, there were none such patients 
in this group. For an objective comparison, a variation of this analysis including all 
patients (except patient 20) of this group (Figure 6-4) is shown in the appendix.
It has to be noted, however, that the level of protective responses varied between 
individuals, which is demonstrated in Table 3-3.
Patient Median protective level 
(25'\ 75* percentile)
Number of samples
10 21.67 (15.15,53.60) 6
11 3.80 (2.06,8.47) 15
12 6.77 (6.45,7.09) 3
Table 3-3 Protective levels of HLA-A24/pp65 specific CD8  ^ T cell responses in 
individual patients
T he m edians o f  the ab so lu te  num ber o f  tetram er b ind in g  c e lls /p l o f  peripheral b lood  in patients 
10 to  12 m easured from  the peak o f  the last C M V  reactivation  onw ards are listed  a lon g  w ith  
the num ber o f  sam p les used  to  ca lcu late th ese  m edians.
The calculation of HLA-A24/pp65 specific CD8^ T cells correlating with protection 
from CMV reactivation resulted in a higher value obtained for patient 10 than for 
patients 11 and 12. However, following the initial peak of responses after the last CMV 
reactivation, cells declined to a level of 10.24 cells/pl at day 98 in patient 10, which is 
similar to an initial plateau level of 7.63 cells/pl at day 630 in patient 11 and 
7.41 cells/pl at day 94 in patient 12 (Figure 3-7, page 198). HLA-A24/pp65 specific 
CD8^ T cell levels in patient 10 only rose to higher levels after day 98. CMV 
reactivation was not observed after a level of 10.24 cells/pl was present at day 98 in 
patient 10. Subsequent high levels in that patient may therefore reflect temporary 
differences in homeostatic drive of T cells (refer to section 1-11.2, page 86 and section 
3-3.3, page 244) between that patient and patients 11 and 12, which may be explained 
by their different transplant types (Table 2-1, page 99).
Low levels of HLA-A24/pp65 specific CD8^ T cell responses were observed in 
healthy volunteers. Five CMV seropositive healthy volunteers expressing HLA-A*2402 
were recruited and their blood tested for CMV pp65 (341-349) specific CD8^ T cell 
responses. The frequencies of CMV specific CD8^ T cells observed are shown in Table 
3-4.
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Healthy
volunteer
HLA-A24/pp65 specific cells as a 
percentage of CD8  ^T cells
HLA-A24/pp65 specific cells per 
microlitre of blood
7 undetectable undetectable
8 0.09 0.63
9 0.10 0.59
10 0.02 0.12
11 0.02 0.08
Table 3-4 HLA-A24/pp65 specific CD8  ^T cell levels in healthy volunteers
T his table sh o w s id en tification  num bers o f  healthy vo lu nteers a lon g  w ith the C M V  pp65 (3 4 1 -  
3 4 9 ) sp ec ific  CD8^ T ce ll cou n ts d etected  in peripheral b lood  o f  th ese  volunteers. C ounts are 
represented as a percentage o f  the total CD8^ T ce ll p opulation  and as a num ber per v o lu m e o f  
blood.
They range from undetectable to 0.12 % of total CD8^ T cells. This converts into a 
range of undetectable to 0.63 cells/pl of peripheral blood, which is lower than the level 
observed in HSCT patients (p = 0.0022) and might be considered as background.
3-2.3 CMV specific CD8* T celi responses restricted by HLA-A1
This section will demonstrate that the number of CMV specific CD8^ T cells restricted 
by HLA-Al that inversely correlated with the ability to detect CMV reactivation in 
HSCT patients are higher than those numbers of CMV specific CD8^ T cells restricted 
by HLA-B35 or HLA-A24 that were shown in the previous sections.
Three CMV peptide targets studied in the context of HLA-Al will be described 
first. This will be followed by results indicating that one of these targets does not induce 
CD8^ T cell responses of significant frequency in HSCT patients. Longitudinal 
monitoring of CD8^ T cells specific for the other two targets in individual patients will 
then show dominance of responses targeting the CMV pp50 epitope. Assignment of 
CMV pp50 specific CD8^ T cells to different groups according to viral load in patients 
will be performed to establish the protective level of CD8^ T cells to this target. Finally 
levels in patients and healthy volunteers will be summarised. A comparison to CMV 
specific CD8^ T cell responses targeting other HLA/peptide combinations will be 
shown in section 3-3 from page 238 onwards.
3-2.3.1 CMV targets of CDS* T cell responses restricted by HLA-Al
Section 3-2.2 demonstrated CD8^ T cell responses to the CMV pp65 (341-349) 9mer in 
the context of HLA-A*2402. During the time of this project it was reported that CD8^ T 
cell responses to the similar CMV pp65 (341-350) lOmer occur in the context of HLA- 
A*2402 and HLA-A*0101 (Provenzano et al., 2003). In that paper, CDS^ T cell
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responses to the lOmer in individuals expressing HLA-A*0101 or HLA-A*2402 were 
demonstrated by measurement of IFNy mRNA expression of unmanipulated, peptide 
stimulated PBMC and by IFNy protein production of PBMC in response to 
restimulation with the 1 Omer after 2 weeks in vitro sensitisation. The same group also 
described IFNy mRNA and protein production of PBMC in response to restimulation 
with the 9mer pp65 (341-349) after 2 weeks in vitro sensitisation (Ghei et a l,  2005). It 
may therefore be possible to use CD8^ T cell responses reactive to the (9mer or 1 Omer) 
peptide for adoptive therapy in patients, who express either the HLA-A*0101 or HLA- 
A*2402 alleles.
Therefore the 9mer QYDPVAALF and the lOmer QYDPVAALFF were tested 
against binding motifs and epitope prediction algorithms for HLA-A24 and HLA-Al 
each within this study before attempting the generation of HLA-Al/pp65 (341-349) 
tetramer (for testing for the presence of HLA-Al restricted pp65 (341-349) specific 
CD8^ T cells within ex vivo PBMC in HSCT patients).
The amino acid sequence of QYDPVAALF(F) was compared to HLA motifs in 
the Syfpeithi (Rammensee et a l ,  1999) and the HLA Ligand/Motif (Sathiamurthy et a l, 
2003) databases. These are available at http://www.syfpeithi.de/ and 
http://hlaligand.ouhsc.edu respectively, comprising peptide sequences eluted from class 
1 and class II MHC molecules together with entries compiled from published reports. 
Motifs defined for HLA-A*01 and HLA-A*2402 are shown in Table 3-5 and Table 3-6 
below.
Peptide position 1 2 3 4 5 6 7 8 9
I D L Y
S E
L G G G
I N V
P Y I
T D P L Y
S E M
M
I
Table 3-5 HLA-A*01 peptide motifs
T his table lists  peptide m otifs for H L A -A * 0 1 . M otifs sh ow n  in the upper part (K u b o e t  a l ,  
1994, D iB rin o  et  a l ,  1993 , Falk e t  a l ,  1994) w ere found in the S yfpeith i database and indicate  
anchor residues at the indicated  p osition . M otifs sh ow n  in ita lics b e lo w  the dashed  lin e  
(D iB rin o  et  a l ,  1994 , K ubo et  a l ,  1994 ) w ere found in the H L A  lig a n d /m o tif  database o f  the 
N ational Institutes o f  H ealth.
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Peptide position 1 2 3 4 5 6 7 8 9
Y L 
F F
I
Y F  
F W
I
L
Table 3-6 HLA-A*2402 peptide motifs
This table lists peptide m otifs  for H L A -A * 2 4 0 2 . M otifs sh ow n  in the upper part (M aier et  a i ,  
1994, K ubo et  a l ,  1994) in d icate anchor resid ues at the indicated  p osition  that w ere found in 
the S yfpeith i database w hereas m otifs  sh ow n  b elo w  the dashed  lin e (Ibe et  a i ,  1 9 96 ) w ere  
found in the H LA  lig a n d /m o tif  database o f  the N ational Institutes o f  Health.
Peptide QYDPVAALF(F) was found to fît the amino acid residue motifs for peptides 
binding to HLA-A*2402 (Table 3-6, Y at position 2 and F at position 9) and HLA-A*01 
(Table 3-5, anchor D at position 3 and preferred residue P at position 4).
In addition to the comparison of peptide sequences with HLA binding motifs in 
the two databases described earlier, the peptide sequences were tested against epitope 
prediction algorithms built upon the Syfpeithi HLA ligand datasets (epitope prediction 
algorithms are not available from the HLA Ligand/Motif database). The score obtained 
during this test indicates the probability of the peptide of being processed and presented 
by the respective HLA allele. The scoring system evaluates every amino acid within a 
given peptide. Individual amino acids may be given the arbitrary value 1 for amino 
acids that are only slightly preferred in the respective position, optimal anchor residues 
are given the value 15; any value between these two is possible. Negative values are 
also possible for amino acids, which are disadvantageous for the peptide's binding 
capacity at a certain sequence position. The allocation of values is based on the 
frequency of the respective amino acid in natural ligands, T cell epitopes, or binding 
peptides (Rammensee et a l, 1999). For example, the maximal score for HLA-A*0201 
peptides is 36. The well-known epitope GILGFVFTL derived from the influenza A 
matrix protein scores 30.
Testing of the QYDPVAALF(F) peptide sequence on Syfpeithi algorithms is 
shown in Table 3-7.
208
Chapter 3
9mer lOmer
HLA-A*2402 24 21
HLA-A*01 12 14
Table 3-7 Predicted score of ligation strength of QYDPVAALF(F) to HLA-Al and 
HLA-A24
T his table sh o w s the ligation  scores o f  the nonam er (9m er) Q Y D P V A A L F  and the decam er  
(lO m er) Q Y D P V A A L F F  to  H L A -A * 2 4 0 2  and H L A -A *01 accord in g to  the S yfp eith i 
algorithm  (R am m en see e t  a l ,  1999).
Section 3-2.2 (from page 194 onwards) showed investigations of the peptide 
QYDPVAALF in the context of HLA-A*2402. In contrast Figure 3-12 (page 210) in 
this section shows that this peptide could not be refolded with HLA-A*0101. Therefore 
50 PBMC samples from CMV seropositive individuals bearing HLA-A*0101 but not 
HLA-A*2401 were tested for ex vivo IFNy release of PBMC from HSCT patients in 
response to QYDPVAALF (Figure 3-13, page 212).
Along with responses targeting CMV pp65 (341-349), CD8^ T cell responses 
targeting the well described llm er located at the region pp65 363-373 with the 
sequence YSEHPTFTSQY (Longmate et a l,  2001, Retiere et a l,  2000) were 
investigated within this study. MHC class I molecules generally present peptides of 8 to 
10 amino acids in size but longer peptides such as CMV pp65 (363-373) can also bind. 
Crystal structures demonstrated that longer peptides can maintain the conserved 
bonding networks around the N and C peptide termini, thereby displacing the centre of 
the peptide away from the groove to an elevated position above the a  helices of the 
MHC (Probst-Kepper et a l, 2004, Speir et a l, 2001). Due to the likely bulge of CMV 
pp65 (363-373) it may fit not only the amino acid residues 2 and 3 (S and E at position 
2 and 3) but also residue 9 (Y at position 11) of the motifs for peptides binding to HLA- 
A*01 (Table 3-5).
During the time of this project a new CMV peptide was reported to induce 
HLA-A*0101 restricted CD8^ T cell responses (Elkington et a l,  2003). This peptide is 
a 9mer located at the region pp50 245-253 with the sequence VTEHDTLLY, which fits 
the amino acid residue motifs for peptides binding HLA-A*01 (Table 3-5, T at position 
2, E at position 3, L at position 7 and Y at position 9). Publications before that reported 
that CD8^ T cell responses to CMV are dominated by CMV pp65 (compare section 3- 
2.1.1, page 176). The study by Elkington and colleagues, however, described a 
significant response to the protein CMV pp50. In view of these new findings at the 
time, HLA-A*0101 restricted CD8^ T cell responses to CMV pp50 (245-253) were
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investigated along with responses to the two targets described above (CMV pp65 (341- 
349) and pp65(363-373)) and results are shown in this section.
3-2.3.2 Monitoring of CMV specific CDS* T cells in patients 
expressing HLA-A1
CD8^ T cell responses to the peptide CMV pp65 (341-349) were assessed using the 
IFNy ELI Spot assay. Refolding of the peptide with HLA-A*0101 was not sufficient for 
generation of tetramer although the peptide could be refolded with HLA-A*2402. This 
is demonstrated in Figure 3-12. Therefore tetramer staining of CMV pp65 (341-349) 
specific CD8^ T cell responses was not possible.
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Figure 3-12 Refolding of HLA-A*0101/CMV pp65 (341-349)
T his figure illustrates purification o f  refolded protein com p lex  from aggregate, e x c e ss  B2m and 
excess  peptide (com pare Figure 2 -2 0 , page 153). FPLC traces on the left hand side  
dem onstrate successfu l refolding o f  H L A -A *2402  with C M V  pp65 (3 4 1 -3 4 9 ) and su ccessfu l 
refolding o f  H L A -A *0I01  with another C M V  peptide (marked in blue) w hereas the FPLC  
trace on the right dem onstrates very low  effic ien cy  o f  refolding o f  H L A -A *2402  with C M V  
pp65 (3 4 1 -3 4 9 ).
210
____________________________________________________________________ Chapter 3
50 samples were randomly selected from 10 patients and 1 healthy volunteer, who were 
CMV seropositive and expressed the HLA-A*0101 allele. They were used to test 
cytokine release from PBMC in response to stimulation with CMV pp65 (341-349) in 
comparison to pp50 (245-253) and pp65 (363-373) peptides that are known to be 
restricted by HLA-A*0101. Results can be seen in Figure 3-13.
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Figure 3-13 No significant IFNy responses to CMV pp65 (341-349) but to CMV 
pp65 (363-373) and CMV pp50 (245-253) in individuals expressing HLA-A*0101
This diagram sh ow s IFNy resp onses to different peptides in 50 sam ples from C M V  
serop ositive patients and one healthy volunteer exp ressin g  H L A -A *0101 but not H LA- 
A * 2402 . R esponses to ■  pp65 (3 4 1 -3 4 9 )  are show n on the top along with responses to ■  pp65  
(3 6 3 -3 7 3 ) in the m iddle and to ■  pp50 (2 4 5 -2 5 3 ) on the bottom .
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Figure 3-13 demonstrates very low IFNy release of PBMC in response to CMV pp65 
(341-349) from individuals expressing HLA-A*0101 but not HLA-A*2402. Patient 
PBMC samples with responses of up to 201 spot forming units to HLA-A*0101 
restricted pp50 (245-253) and pp65 (363-373) peptides did not show responses above 
22 spot forming units to CMV pp65 (341-349). PBMC that showed low responses to 
CMV pp65 (341-349) were from samples demonstrating high levels of spontaneous 
IFNy release and may be an experimental artefact reflecting the limits of this assay. 
These results are in accordance with the failure to refold CMV pp65 (341-349) with 
HLA-A*0101 despite refolding of the same peptide with HLA-A*2402 described 
earlier. Both observations suggest that CMV pp65 (341-349) is not immunologically 
relevant in the background of HLA-A*0101. Thus only responses measured to the two 
peptides conventionally defined in the context of HLA-A*0101 that successfully 
refolded with HLA-A*0101 are shown from here onwards and are subsequently 
abbreviated as HLA-Al/pp65 and HLA-Al/pp50 CD8^ T cell responses.
15 HLA-A*0101 positive patients receiving haematopoietic stem cell transplants 
from HLA-A*0101 positive donors were recruited for the study of HLA-A*0101 
restricted CD8^ T cell responses to CMV pp65 (363-373) and CMV pp50 (245-253). 
Patient, donor, or both were CMV seropositive. Detailed patient characteristics are 
given in Table 2-1 on page 99. Patients from whom at least 4 samples were collected 
starting at less than 100 days post transplantation were included in the follow-up cohort 
(n=l l )  in order to establish the threshold for a protective level of responses to these 
HLA/peptide targets. The average start of follow- up was day 48 (range day 20 - 90) 
and the average end of follow-up was day 279 (range day 136- 682) post 
transplantation with an average of 13 samples taken per patient (range 5-33) .  Numbers 
of tetramer binding CD8^ T cells were correlated with viral load and functionality of 
cells was tested by IFNy assays for some of the samples with sufficient cell numbers.
5 of the 11 patients within this follow-up cohort reconstituted HLA-A*0101 
restricted CMV specific CD8^ T cells that inversely correlated with the ability to detect 
CMV reactivation. Responses to CMV pp50 (245-253) were predominant and seemed 
protective in these patients whereas responses to CMV pp65 (363-373) were of lower 
frequency or absent. Figure 3-14 shows responses in 2 of these patients (patients 5 and 
14) who did not reactivate CMV. Both patients appeared to be protected by HLA- 
Al/pp50 specific CD8^ T cell responses. It should be noted that patient 5 additionally 
reconstituted HLA-B35/pp65 specific CD8^ T cell responses (compare Figure 3-1, page
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180). Patient 14 did not demonstrate protective responses in the context of other HLA 
types (compare Figure 3-9, page 201).
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Figure 3-14 Monitoring of HLA-A*0101 restricted CMV specific CD8 T cell 
responses in patients 5 and 14
♦  H L A -A l/p p 5 0 (2 4 5 -2 5 3 ) and A  H L A -A l/p p 6 5 (3 6 3 -3 7 3 ) responses in tw o patients are 
show n in separate boxes. Viral load m easurem ents are illustrated along with the absolute count 
o f  C M V  sp ecific  CD8^ T ce ll responses in A. Part B illustrates the IFNy response to C M V  
peptide (triplicate m easurem ents w ith the error representing the range from the 2 5 *  to the 75*  
percentiles) along w ith C M V  sp ec ific  C D 8 T cell response as a percentage o f  the total CD8" 
T ce ll response (responses are on ly  show n for tim e p oints when ELISpot an alysis had been  
perform ed). Apart from standard prophylaxis described in section  2 -2 .5 , patients did not 
receive any further im m unosuppressive or antiviral treatm ent.
The other 3 of the 5 patients who reconstituted HLA-Al/pp50 specific CD8^ T cell 
responses, initially reactivated CMV post HSCT and patient 23 additionally had CMV 
detected in his tissue samples. These patients received steroid treatment for GvHD and 
therefore had periods of suppressed T cell function. However, their CMV specific CD8^ 
T cell numbers then increased, and subsequently these patients resolved their CMV 
reactivations with no further viral copies detected in their blood at the end of the follow- 
up period. These results are shown in Figure 3-15. Patient 21 received antiviral 
treatment only for his first CMV reactivation. Subsequent viral reactivations in this 
patient and reactivations observed in patient 22 were resolved without antiviral 
treatment. Patient 23 reconstituted high frequencies of HLA-A*0201 restricted CMV
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specific CD8^ T cell responses (Figure 3-21, page 229) in parallel with HLA-A*0101 
restricted responses from day 185 post transplantation. He recovered from CMV related 
symptoms and was well and in remission with no further CMV replication in his blood 
at 2 years post transplantation.
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Figure 3-15 Monitoring of HLA-A*0101 restricted CMV specific CD8  ^ T cell 
responses in patients 21 to 23
♦  H L A -A l/p p 5 0 (2 4 5 -2 5 3 ) and ▲ H L A -A l/p p 6 5 (3 6 3 -3 7 3 ) responses are show n in the sam e  
way as described for Figure 3 -14  on page 214 . Stars (* ) indicate treatment using donor  
lym phocyte infusion  (D L l). Horizontal yellow -red  and blue bars indicate im m unosuppressive  
( ■  M M F, ■  Prednisolone, ■  T acrolim us) and antiviral ( ■  G anciclovir, ■  F oscam et)  
treatment respectively .
Following the withdrawal of Cyclosporine on day 186 post transplantation patient 21 
had become severely thrombocytopenic consistent with the recurrence of autoimmune 
antibodies associated with the recipient’s FAS ligand deficiency. To establish full donor 
chimaerism that may eradicate the recipient B cell clones that are contributing to the 
immune phenomena, the patient received escalating doses of DLL During this time 
HLA-Al/pp50 specific CD8^ T cell numbers declined. GvHD since day 328 post 
transplantation was treated systemically with Prednisolone since day 419 post 
transplantation. This most likely caused HLA-Al/pp50 specific CD8^ T cells to remain 
at low levels enabling further CMV replication. As the Prednisolone dose was reduced 
at day 437, HLA-Al/pp50 specific T cells were finally reconstituted and sustained 
without further reactivation. 3 years post transplantation the patient was in full 
chimaerism. It is assumed that a graft versus recipient B cell clone response occurred in
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parallel with the GvH response. The patient demonstrated normal platelet counts, 
remained well and a case study has been published recently (Dimopoulou et a l, 2007) 
to report the first adult patient with ALPS (autoimmune lymphoproliferative syndrome) 
successfully being treated with HSCT and DLL
HLA-Al/pp50 specific CD8^ T cells in the 5 patients (patient 5, 14, 21, 22 and 
23) shown in Figure 3-14 and Figure 3-15 likely controlled CMV replication in these 
patients. PBMC from them released IFNy in response to CMV peptide, which 
confirmed functionality of cells. Patients 21 to 23 (Figure 3-15) reconstituted higher 
levels of CMV specific CD8^ T cell levels than patients 5 and 14 (Figure 3-14). This 
may be due to increased proliferation of cells upon antigenic stimulation since patients 
21 to 23, in contrast to patients 5 and 14, experienced episodes of CMV replication.
2 patients (patients 3 and 25) of the follow-up cohort did not reconstitute 
sustained levels of HLA-Al/pp50 specific CD8^ T cell responses and demonstrated 
multiple episodes of CMV replication. Longitudinal monitoring of responses in these 
patients is shown in Figure 3-16. Reconstitution of a low frequency of HLA-Al/pp50 
specific CD8^ T cell responses in patient 3 was transient. The pattern of HLA-B*3501 
restricted (Figure 3-1, page 180) and HLA-B*0702 restricted (not shown) CMV specific 
CD8^ T cell responses in this patient closely resembled the pattern of responses shown 
here. All of these responses are of low frequency and correlate with very low numbers 
of total CD8^ T cells (^28 cells/pl except at days 470 and 491 post transplantation when 
112 and 202 cells/pl were present respectively, cell numbers decreased again thereafter) 
in patient 3. Patient 25 also demonstrated low numbers of total CD8^ T cells 
(^61 cells/pl). Both patients were at risk for CMV reactivation and demonstrated 
multiple viral replication episodes accordingly.
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Figure 3-16 Monitoring of HLA-A*0I01 restricted CMV specific CD8  ^ T cell 
responses in patients 3 and 25
♦  H L A -A l/p p 5 0 (2 4 5 -2 5 3 ) and A  H L A -A l/p p 6 5 (3 6 3 -3 7 3 ) responses are sh ow n  in a sim ilar  
way as described for Figure 3-14 . Horizontal orange and blue bars indicate  
im m unosuppressive ( ■  D exam ethasone) and antiviral ( ■  G anciclovir, ■  F oscam et) treatm ent 
respectively .
Responses from all of the 7 patients described above will be analysed statistically to 
establish the protective level of HLA-Al/pp50 specific CD8^ T cells in section 3-2.3.3.
Similar to observations for HLA-A*2402 restricted CMV responses, there were 
also 3 patients (patients 26 - 28) in the cohort described here who did not have 
measurable CMV copies in their blood and did not reconstitute significant numbers of 
HLA-A*0101 CMV specific CD8^ T cell responses. These data are shown in Figure 
3-17 and Figure 3-18.
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Figure 3-17 Monitoring of HLA-A*0101 restricted CMV specific CD8 T cell 
responses in patients 26 to 28
♦  H L A -A l/p p 5 0 (2 4 5 -2 5 3 ) and ▲ H L A -A l/p p 6 5 (3 6 3 -3 7 3 ) responses are show n in a sim ilar 
way as described for Figure 3 -14  on page 214 . Horizontal yellow -red  bars indicate  
im m unosuppressive ( ■  M M F, ■  P rednisolone) treatment.
2 of these, patients 27 and 28, were CMV seronegative, received a transplant from a 
CMV seropositive donor and demonstrated no CMV reactivation. Previous studies 
suggest that expansion of CMV specific CDS^ T cells post HSCT are likely antigen 
driven (Peggs et al., 2003d) and therefore it is not expected that significant numbers of 
those cells would be detected in these patients. Interestingly, patient 28 did not 
reconstitute significant numbers of total CD8^ T cells during the entire 5 months of the 
follow-up period post transplantation. DNA from PBMC collected at day 64, 113, 120 
and 127 from this patient was therefore used in TREC analysis and results suggested 
that new CD8^ T cell production had not occurred during that time period. Phenotypic 
analysis confirmed that the vast majority of T cells were CD4^ and mainly of effector- 
memory phenotype (88.3 % and 87.1 % of CD4^ T cells were CD27‘ and CD45R0^ at 
day 113 and 127 post transplantation respectively). This is consistent with a failure of 
immune reconstitution.
The 3^  ^ patient without significant numbers of HLA-Al/pp50 specific CD8^ T 
cell responses and no CMV reactivation was patient 26, who was CMV seropositive and 
had a seropositive donor. No HLA-Al/pp50 specific CD8^ T cell responses (Figure
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3-17) nor responses to any of the other CMV targets investigated (compare Figure 3-23 
page 231) were present. However, it appears likely that this patient was protected by a 
different response not measured because he recovered reasonable numbers of up to 477 
total CD8^ T cells/pl blood and the repertoire of tetramer reagents used to measure 
other potential CMV targets was limited. Therefore including undetectable HLA- 
A*0101 restricted CMV specific CD8^ T cell levels from patients 26 - 28 in the analysis 
to establish the number of CMV specific CD8^ T cells that inversely correlate with the 
ability to detect CMV reactivation may not be biologically meaningful and responses 
from these patients were not included in the statistical comparison shown in section 3-
2.3.3, page 221 (an analysis including all patients is shown in the appendix).
Patient 24 was also omitted from this analysis. He did not reconstitute and 
sustain CD4^ T helper cell counts above the critical value (Figure 3-18, C on page 220). 
This lack of sufficient CD4^ T helper cells likely influences his protection against CMV 
as is discussed in more detail in section 3-3, page 238. It is likely that this underlies the 
observation that patient 24 undergoes CMV reactivation even while maintaining high 
levels of CMV specific CD8^ T cells. This is demonstrated for HLA-A*0101 restricted 
CD8^ T cells in Figure 3-18 below and for HLA-A*0201 restricted CD8^ T cells in 
Figure 3-24 in section 3-2.4 on page 225.
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Figure 3-18 HLA-A*0101 restricted CMV specific CD8 T cell responses and lack 
of CD4  ^T cell help in patient 24
♦  H L A -A l/p p 5 0 (2 4 5 -2 5 3 ) and ▲ H L A -A l/p p 6 5 (3 6 3 -3 7 3 ) responses are sh ow n  in a sim ilar  
way as described for Figure 3 -1 4  (page 2 1 4 ) in A and B. CD4^ T cell s /p  1 o f  b lood  ( • )  are 
illustrated in graph C. The dotted line represents the critical value o f  CD4^ T ce lls  show n to 
correlate with infection and overall survival in HSCT patients (K im  et a i ,  20 0 6 ). Horizontal 
blue bars indicate antiviral treatm ent w ith G anciclovir.
CD4^ T helper cell counts >200 cells/pl were only temporarily reached at day 77 post 
transplantation in this patient. Before and after that time point CD4^ T helper cell counts 
measured were below 123 cells/pl and CMV reactivations occurred. Finally the patient 
suffered from CMV disease and died. This is despite him having reconstituted high 
numbers of CMV pp50 (245-253) and some pp65 (363-373) specific CDS^ T cells, 
which release IFNy in response to the relevant peptide (Figure 3-18, page 220). All
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other patients within the HLA-Al follow-up cohort recovered CD4^ T helper cell 
counts above the critical threshold of 200 cells/pl. Therefore it is assumed that the lack 
of protection from CMV in patient 24 was due to low CD4^ T helper cell counts. 
Numbers of HLA-Al/pp50 specific CD8^ T cells from this patient were therefore not 
analysed to establish the protective level of HLA-Al/pp50 specific CD8^ T cells in 
section 3-2.3.3.
3-2.3.3 Statistical analysis of the protective level of HLA-A1 
restricted CMV specific CDS* T ceils and summary
Responses to three different CMV peptides were analysed in the context of HLA- 
A*0101. Results suggest that one of these peptides, CMV pp65 (341-349), may not be 
of major immunological relevance in the context of HLA-A*0101. Analysis of 
responses targeting the other two peptides demonstrated that responses to CMV pp50 
(245-253) were predominant and protective in HSCT patients whereas responses to 
CMV pp65 (363-373) were of lower frequency or absent. Significant numbers of CMV 
pp65 (363-373) specific CD8^ T cells that may have conferred protection against CMV 
were only observed in patients 14 and 23. It was not possible to perform a meaningful 
statistical analysis of these responses from these two patients along with patients 3 and 
25 who were not protected because the response group “Al/pp65 post CMV” would 
consist of a single value from patient 23 only. Therefore a statistical analysis of 
responses was only performed for HLA-Al/pp50 specific CD8^ T cells.
Inclusion of all 11 patients for analysis (compare Figure 6-5, which includes 
CMV pp65 (363-373) specific CD8^ T cells, in appendix) in the same way as shown for 
responses in the context of HLA-B35 may not be biologically meaningful. 4 patients of 
this follow-up cohort were omitted from this analysis for reasons described in the 
previous section (3-2.3.2 from page 210).
Figure 3-19 shows a statistical analysis of the number of HLA-Al/pp50 tetramer 
binding CD8^ T cells in correlation with viral load in patients 3, 5, 14, 21, 22, 23 and 25 
(compare Figure 3-14 on page 214, Figure 3-15 on page 215 and Figure 3-16 on page 
217).
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Figure 3-19 Statistical analysis of HLA-Al/pp50 specific CD8  ^T cell responses
This graph sh ow s the absolute numbers o f  H L A -A l/p p 5 0  tetramer b inding ce lls /p l o f  
peripheral b lood in patients 3 , 21 , 2 2 , 23 and 25 m easured post transplantation until the last 
observed C M V  reactivation ( ♦  during C M V ) versus  absolute numbers o f  tetramer binding  
ce lls  m easured from the peak o f  the last C M V  reactivation onwards in those patients that 
resolved their C M V  reactivations (patients 2 1 -2 3 ) ( A  post C M V ) and absolute num bers o f  
H L A -A l/p p 5 0  tetramer b inding ce lls  in patients 5 and 14 w ho did not reactivate C M V  (▼  w /o  
C M V ). Data groups were statistically  analysed using a tw o-tailed  M ann-W hitney U test w ith  
the m edians and p values (p < 0 .02  regarded sign ifican t) indicated in the graph.
The HLA-Al/pp50 specific CD8^ T cell responses analysed in Figure 3-19 were 
detected at high levels during the CMV reactivation period in some of the samples from 
the CMV reactivating group of patients. One reason for this could be the initial 
reconstitution of protective levels of CMV specific T cells, which subsequently 
decreased and enabled further CMV reactivation. This can be observed in the pattern of 
T cell responses seen in patient 3 (Figure 3-16, page 217) and patient 21 (Figure 3-15, 
page 215). A temporary decrease in T cell levels was not observed for patients 22 and 
23. Although blood samples were taken weekly in patient 22 at that time, it is possible 
that a decrease in T cell levels was missed in between samples taken from patient 22 
and especially patient 23 as the clinical status of the latter prohibited frequent sampling 
at the time before his last CMV reactivation period (Figure 3-15, page 215).
222
____________________________________________________________________Chapter 3
In summary, an inverse correlation between HLA-Al/pp50 specific CD8^ T cells and 
viral load was observed in HSCT patients. Significantly higher cell numbers (p<0.0001) 
were detected in patients that had resolved CMV reactivations (median 20.2 cells/pl) 
than during the period of CMV reactivation (median 0.5 cells/pl). The magnitude of 
CD8  ^T cell numbers in patients after resolution of CMV was similar to the magnitude 
of responses in patients that did not reactivate the virus (median 15.6 cells/pl). 
Responses to CMV pp50 (245-253) are likely to have protective capacity in patients and 
IFNy release to the peptide has been observed (Figure 3-14, page 214 and Figure 3-15, 
page 215).
One limitation of this analysis is that the “post CMV” and “w/o CMV” groups 
contain only those patients in whom HLA-Al/pp50 specific T cell levels were 
measurable; other patients were considered to be protected by other responses (patient 
26, who reconstituted reasonable numbers of total CD4^ and CD8^ T cells) or to be not 
informative due to other reasons (patients 27 and 28 were CMV-/+ without primary 
infection, patient 24 did not recover necessary T helper cell levels, compare section 3- 
2.3.2 for details). In the case of the “reactivating” group, two patients (patients 3 and 
25) never achieved measurable levels of HLA-Al/pp50 specific T cells; these patients 
are included since they clearly have no protective responses. Their total CD8^ T cell 
numbers are very low and it is impossible to determine what protective responses they 
may achieve in the future, if any.
For an objective comparison, variations of this analysis that either include all 
patients (except patients 27 and 28 who were CMV seronegative and received HSCT 
from a seropositive donor, after which primary infection was not detected) of this group 
(Figure 6-5) or exclude patients 3 and 25 (Figure 6-6) are shown in the appendix. The 
latter demonstrates significant differences between response groups comparable to 
Figure 3-19.
The number of HLA-Al/pp50 specific CD8^ T cells that inversely correlated 
with the ability to detect CMV reactivation in HSCT patients and levels observed in 
healthy volunteers (as described below) will be compared to levels observed for CMV 
specific CD8^ T cells targeting other HLA/peptide combinations in section 3-3 from 
page 238 onwards. The level of protective responses varied between individual patients, 
which is demonstrated in Table 3-8.
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Patient Median protective level 
(25^ percentile, 75**' percentile)
Number of samples
5 9.47 (2.93, 15.71) 8
14 16.67 (16.22, 24.29) 6
21 14.20 (11.46, 17.51) 8
22 24.46 (20.16, 33.38) 11
23 - 1
Table 3-8 Protective levels of HLA-Al/pp50 specific CD8  ^ T cell responses in 
individual patients
The m edian valu es o f  all ab so lu te num bers o f  tetram er b ind in g  ce lls /p l o f  peripheral b lood  
m easured in patients 5 and 14 (w h o  did not reactivate C M V ) and o f  v a lu es m easured from the 
peak o f  the last C M V  reactivation  onw ards in patients 21 , 22  and 23 (in  italics: ca lcu lated  from  
<3 sam p les) are illustrated a lon g  w ith  the num ber o f  sam ples used to  calcu late each  m edian  
value.
The calculation of HLA-Al/pp50 specific CD8^ T cells correlating with protection from 
CMV reactivation resulted in a higher level obtained for patient 23 than for other 
patients. However, the level for patient 23 was calculated from a single value only 
(Figure 3-15 on page 215), which may reflect the peak of the response.
CMV specific T cell levels measured in 5 CMV seropositive volunteers 
expressing HLA-A*0101 are shown in (Table 3-9).
Healthy
volunteer
HLA-Al restricted cells as a 
percentage of CD8  ^T cells
HLA-Al restricted cells per 
microlitre of blood
CMV pp50 CMV pp65 CMV pp50 CMV pp65
1 0.28 0.04 1.00 0.16
3 0.43 0.07 2.49 0.41
12 0.92 0.93 3.00 3.03
13 3.58 0.05 14.32 0.20
14 0.79 0.58 3.16 2.32
Table 3-9 HLA-A*0101 restricted CMV pp65 (363-373) and CMV pp50 (245-253) 
specific CD8  ^T cell levels in healthy volunteers
T his table sh ow s C M V  sp ec ific  CD8^ T ce ll counts detected  in peripheral b lood  o f  C M V  
serop ositive  healthy volu nteers exp ressin g  H L A -A * 0 1 0 1 . C ounts are represented as a 
percentage o f  the total CD8^ T ce ll population  and as a num ber per v o lu m e o f  b lood .
The results observed in healthy volunteers show that - similar to observations in HSCT 
patients - the level of responses to CMV pp50 (245-253) were equal to (volunteer 12 
and 14) or greater than (volunteer 1, 3 and 13) responses to CMV pp65 (363-373) in the 
same HLA-A*0101 expressing CMV seropositive individuals.
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HLA-Al/pp50 specific CD8^ T cell numbers range from 0.28 to 3.58 % of total CD8^ T 
cells. This converts into a range of 1.00 to 14.32 cells/pl of peripheral blood, which is 
lower than the level observed in HSCT patients (p = 0.0046), compare Figure 3-26 on 
page 241.
A comparison of the levels described here with the levels of CMV specific CD8^ 
T cells targeting other HL A/peptide combinations will be shown in section 3-3 from 
page 238 onwards.
3-2.4 CMV specific CD8* I  cell responses restricted by HLA-A2
In the sections above measurements of protective levels of responses towards different 
HLA/CMV peptide combinations were established for comparison with measurements 
of HLA-A*0201 restricted CMV pp65 (495-503) specific CD8^ T cells. Most of the 
knowledge about CMV specific CD8^ T cells has been derived from studying cells 
targeting the latter HLA/peptide combination. Due to the high prevalence of the HLA- 
A*0201 allele in the Caucasoid population, HLA-A*0201 restricted CMV pp65 (495- 
503) specific CD8^ T cells are one of the most studied CMV specific CD8^ T cells and 
as such might be considered as a archetype for comparison of CMV specific CD8  ^ T 
cell responses targeting other HLA/peptide combinations. To make the best possible 
direct comparison between responses to new targets studied in this project and 
responses to the archetype target, HLA-A*0201 restricted CMV pp65 (495-503) 
specific CD8^ T cell responses were studied and are shown in this section.
This allowed for not only comparing responses towards new HLA/CMV peptide 
targets with HLA-A*0201 restricted CMV specific responses that were established in 
previous studies but also comparing those responses with the level of HLA-A*0201 
restricted CMV specific responses measured in this study. This comparison will be 
shown in section 3-3 from page 238 onwards.
Patients and volunteers recruited for analysis in this section expressed HLA- 
A*0201 but not HLA-B*0702 because it is known that CMV specific CD8^ T cell 
responses restricted by HLA-B*0702 dominate those restricted by HLA-A*0201 (Lacey 
et a i, 2003). This observation is also discussed further in section 3-3.
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3-2.4.1 CMV targets of CD8* T cell responses restricted by HLA-A2
CD8^ T cells that were investigated in this section targeted the CMV pp65 (495-503) 
peptide with the sequence NLVPMVATV, which was originally described by Wills and 
colleagues (Wills et a l, 1996). HL A-A*0201 restricted CMV pp65 (495-503) specific 
CD8^ T cell responses are subsequently abbreviated as HLA-A2/pp65 specific CD8^ T 
cell responses.
3-2.4.2 Monitoring of CMV specific CDS* T ceils in patients 
expressing HLA-A2
15 HSCT patients bearing the HLA-A*0201 allele who received a transplant from 
HLA-A*0201 positive donors were recruited for the study of HLA-A2/pp65 specific 
CD8^ T cell responses. Patient, donor, or both were CMV seropositive with detailed 
patient characteristics shown in Table 2-1 on page 99. Patients from whom at least 4 
samples were collected starting at less than 100 days post transplantation were included 
in the follow-up cohort (n = 10) in order to establish the threshold for a protective level 
of responses to this HLA/peptide target. The average start of follow- up was day 36 
(range day 11 - 88) and the average end of follow-up was day 368 (range day 145 - 902) 
post transplantation with an average of 15 samples taken per patient (range 5 - 39). 
Numbers of tetramer binding CD8^ T cells were correlated with viral load and the 
functionality of cells was tested by IFNy assays for some of the samples with sufficient 
cell numbers.
4 of the 10 patients within this follow-up cohort reconstituted significant 
numbers of HLA-A2/pp65 specific CD8^ T cells that inversely correlated with the 
ability to detect CMV reactivation (Figure 3-20 and Figure 3-21) and will be discussed 
first. Data on the remaining 6 patients will be described thereafter.
Figure 3-20 shows the responses in 2 patients (patients 13 and 15) who 
reconstituted and sustained HLA-A2/pp65 specific CD8^ T cells at a similar plateau 
level and were protected from CMV replication. Due to a history of CMV pneumonitis, 
patient 13 received high doses of prophylactic antiviral treatment until day 97 post 
transplantation, which may have helped to prevent CMV reactivation in the early phase 
post transplantation. Both patients also expressed HLA-A*2402 but did not reconstitute 
CMV specific CD8^ T cells restricted by that HLA type (Figure 3-9, page 201). HLA- 
A2/pp65 specific CD8^ T cell responses were assumed to be protective in both 
individuals.
226
Chapter 3
patient 151 10* 1 10*70 70
60 608000 8000
50
6000 6000
40 40
30 304000 4000
20
2000 200010
350 20 40 60 80 100 120 140 160
300
250
200
150
100
days post transplantation
•3 CMV viral load .... ▲ IFNy secretion of PBMGs in response to CMV pp65 (495-503) peptide
♦  number of HLA-A2/pp65(495-503) 1 A: absolute count
tetramer* CMV specific CDS* T cells B: percentage
Figure 3-20 Monitoring of HLA-A2/pp65 specific CDS T ceil responses in patients 
13 and 15
H L A -A 2/pp65 sp ecific  CD8^ T ce lls  are show n. Part A  represents viral load m easurem ents 
along w ith the absolute count o f  C M V  sp ec ific  CD8^ T ce lls . In patient 15 C M V  viral load has 
been m easured using antigenaem ia instead o f  PCR with units expressed as in fected  ce lls  per 
2 0 0 ,0 0 0  PBM C. Part B represents the IFNy response to C M V  peptide (triplicate m easurem ents 
with the error representing the range from  the 2 5 “’ to  the 75*  percentiles) a lon g w ith C M V  
sp ecific  CD8" T ce lls  as % o f  total C D 8 T ce lls  (respon ses are on ly  show n for tim e points 
when ELISpot analysis had been perform ed). ELISpot assays were not perform ed on sam ples  
from patient 15 due to in sufficien t ce ll num bers available. Apart from standard prophylaxis 
(described in section  2 -2 .5 ) patients did not receive any further im m unosuppressive or antiviral 
treatment.
At first sight, the development of an early CMV specific response in patient 15 was 
surprising. Like patient 7 described in section 3-2.1.3 (page 182), this patient was CMV 
seropositive and had received a non-TCD transplant from a CMV seronegative donor. 
During conventional transplantation, recipient T cells typically survive only when the 
graft is thoroughly depleted of donor T cells (Roux et a l , 1992). However, (in contrast 
to patient 7) patient 15 had received reduced-intensity conditioning (RIC) before HSCT 
(Table 2-1, page 99). Thereby mixed chimaerism with 45 - 55 % donor cells was 
established in the patient during the time of follow-up. This might explain the 
persistence of recipient T cells in this patient. In comparison, earlier throughout this 
chapter (section 3-2.1.3, page 182) it was hypothesised that cells from patient 7 
(receiving myeloablative conditioning) may be crossreactive to alloantigen. It appears, 
however, that this is not applicable for patient 15, who did not experience GvHD. Also,
227
____________________________________________________________________Chapter 3
tetramer staining cells from patient 15 did not demonstrate extremely low fluorescence 
intensity similar to cells observed in patient 7 (Figure 3-2, page 184). The presence of 
CMV genomes in tissue samples but not blood was reported previously (Dimitroulia et 
a l, 2006). Accordingly CMV replication in tissues, that may have gone unnoticed, 
might have sparked the expansion of residual recipient T cells (with CMV reactivity, 
not crossreactivity as suspected in patient 7) in patient 15.
Results observed in another 2 (patients 6 and 23) of the 4 patients who 
reconstituted significant numbers of HL A-A2/pp65 specific CDS^ T cells that inversely 
correlated with the ability to detect CMV reactivation are illustrated in Figure 3-21. 
These patients initially reactivated CMV post HSCT and patient 23 additionally had 
CMV detected in his tissue samples. However, both reconstituted HLA-A2/pp65 
specific CDS^ T cells and subsequently resolved their CMV reactivations. Patient 6 
received antiviral treatment for his first CMV reactivation but a subsequent viral 
reactivation in this patient was resolved without antiviral treatment. Patient 23 
reconstituted high frequencies of HLA-A2/pp65 specific CDS^ T cells from day 185 
post transplantation. He recovered from CMV related symptoms and was well and in 
remission with no further CMV copies in his blood at 2 years post HSCT. Viral copies 
remained undetected after the end of the follow-up period in both patients suggesting 
that the measured T cell responses were protective. Patient 6 also reconstituted HLA- 
B35/pp65 specific CD8^ T cells (Figure 3-1, page 180) and patient 23 also reconstituted 
HLA-Al/pp50 specific CD8^ T cells (Figure 3-15, page 215).
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Figure 3-21 Monitoring of HLA-A2/pp65 specific CD8  ^T cell responses in patients 
6 and 23
H L A -A 2/pp65 sp ecific  CDS T cell responses o f  tw o patients are show n in the sam e w ay as 
described for Figure 3 -20  on page 227 . Horizontal yellow -red  and b lue bars indicate 
im m unosuppressive ( ■  M M F, ■  Prednisolone, ■  T acrolim us) and antiviral ( ■  G anciclovir) 
treatment respectively .
HLA-A2/pp65 specific CDS^ T cells in the 4 patients shown in Figure 3-20 
(page 227) and Figure 3-21 likely controlled CMV replication in these patients. PBMC 
from these patients released IFNy in response to CMV peptide, which confirmed the 
fimctionality of these cells.
One patient (patient 30) of this follow-up cohort did not reconstitute sustained 
levels of HLA-A*0201 restricted CD8^ T cell responses to CMV pp65 (495-503) and 
experienced multiple episodes of CMV replication despite antiviral treatment. 
Longitudinal monitoring of CMV specific CD8^ T cell numbers in this patient is shown 
in Figure 3-22.
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Figure 3-22 Monitoring of HLA-A2/pp65 specific CDS T cell responses in patient 
30
H L A -A 2/pp65 sp ecific  CD8^ T ce ll responses are show n in the sam e w ay as described for 
Figure 3 -20  on page 227 . Horizontal yellow -red  and blue bars indicate im m unosuppressive ( ■  
Prednisolone,) and antiviral ( ■  G anciclovir or V algan ciclov ir , ■  F oscam et) treatm ent 
respectively.
The donor of patient 30 was CMV seronegative. Conditioning with Campath-IH as well 
as prolonged immunosuppressive treatment that was received by patient 30 post 
transplantation due to acute and chronic GvHD may have hindered the development of 
CMV specific T cell responses of a level adequate for protection. This patient received 
prophylactic cyclosporine A during the entire period of the follow-up. HLA-A2/pp65 
specific CD8^ T cell responses were absent post allogeneic transplantation and the 
patient developed CMV disease involving the gastrointestinal tract and also leading to 
blindness in one eye. Total numbers of CD4^ and CD8  ^ T cells were first recovered at 
day 350 post HSCT and remained at high levels from day 564 onwards. Interestingly, 
this patient previously had an autologous transplant, after which high levels of nearly 
1x10* HLA-A2/pp65 specific CD8^ T cells/L of blood could be observed (data not 
shown, samples from this time period are referred to as from patient 30b throughout this 
thesis).
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Responses from all of the 5 patients described above will be analysed statistically to 
establish the protective level of HLA-A2/pp65 specific CD8^ T cells in section 3-2.4.3, 
page 234.
Similar to observations for HLA-A*2402 and HLA-A*0101 restricted CMV 
specific CD8^ T cells, there were also 3 patients (patients 1, 2 and 26) in the cohort 
described here who did not reconstitute significant numbers of HLA-A2/pp65 specific 
CD8^ T cells and were likely to be protected by other CD8^ T cell responses. This data 
is shown in Figure 3-23 and conclusions on the immunodominance of HLA-A2/pp65 
specific CD8^ T cell responses drawn from these results will be discussed in section 3-
2.4.3.
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Figure 3-23 Monitoring of HLA-A2/pp65 specific CD8  ^T cell responses in patients 
1, 2 and 26
H L A -A 2/pp65 sp ecific  CD8^ T cell responses are show n in a sim ilar w ay as described for 
Figure 3-20  on page 227 . Horizontal yellow -red  and blue bars indicate im m unosuppressive ( ■  
Prednisolone,) and antiviral ( ■  G anciclovir) treatment respectively .
No HLA-A2/pp65 specific CD8^ T cells were detected in patient 1. Nevertheless two 
reactivations of CMV were quickly resolved. One contributing factor may be the 
antiviral treatment, which is indicated in the graph. However, the patient did 
reconstitute HLA-B35/pp65 specific CD8^ T cells (Figure 3-1 on page 180). Therefore 
those cells may have been protective in this patient.
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Patient 2 also reconstituted HLA-B35/pp65 specific CD8^ T cells (Figure 3-1, page 
180) in parallel to HLA-A2/pp65 specific CD8^ T cells (Figure 3-23). The levels of both 
responses were similar initially but after the last CMV reactivation at day 549 post 
transplantation responses restricted by HLA-A2 were lower than those restricted by 
HLA-B35. This situation is not easy to interpret. It seems most likely that CMV specific 
CD8^ T cell responses restricted by HLA-B35 were protective in the patient whereas 
responses restricted by HLA-A2 were a bystander effect because the frequency of the 
latter was near the background level observed for the relevant tetramer.
Despite a lack of detectable HLA-A2/pp65 specific CD8^ T cells in patient 26, 
this patient did not reactivate CMV (Figure 3-17, page 218). Given that he had 
reconstituted reasonable numbers of CD8^ T cells it seems likely that he may be 
protected by yet another response not measured here.
None of the three patients whose responses are shown in Figure 3-23 expressed 
HLA-B*0702 and therefore the low or absent responses restricted by HLA-A*0201 
cannot be explained by the dominance of HLA-B*0702 restricted responses in 
individuals expressing HLA-A*0201 and HLA-B*0702 that was reported previously 
(Lacey et a l,  2003). However, as outlined above, all three patients are likely to be 
protected by yet another response than that targeting HLA-A2/pp65. Conclusions on a 
possible hierarchy of immunodominance between the different CMV specific CD8^ T 
cells that can be drawn from these results will be discussed in section 3-3.
HLA-A2/pp65 specific CD8^ T cell responses in two patients who did not 
recover critical levels of total CD4^ T helper cell counts are shown in Figure 3-24. The 
importance of CD4^ T helper cell counts for the functionality of antiviral CD8^ T cells 
is explained in detail in section 3-3, from page 238. Low numbers of CD4^ T helper 
cells are likely to influence protection from CMV irrespective of CMV specific CD8^ T 
cell levels in these patients.
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Figure 3-24 Monitoring of HLA-A2/pp65 specific CDS T cell responses and lack 
of CD4  ^T cell help in patients 24 and 29
H L A -A 2/pp65 sp ecific  CDS" T cell responses are sh ow n  in a sim ilar w ay as described for 
Figure 3 -20  on page 227 . •  CD4" T cell counts are sh ow n  in graph C. The dotted line  
represents the critical value o f  CD4" T ce lls  show n to correlate with infection  and overall 
survival in H SC T patients (K im  et a i ,  2 0 0 6 ). H orizontal yellow -red  and b lue bars indicate 
im m unosuppressive ( ■  Prednisolone) and antiviral ( ■  G anciclovir, ■  F oscam et) treatment 
respectively.
Patient 29 had very high levels of HLA-A2/pp65 specific CDS^ T cells (note higher 
scale in Figure 3-24 than in previous figures) despite continuous CMV replication. 
HLA-A2/pp65 specific CD8^ T cells made up an unusually high frequency of 69.4 % of 
the total CD8^ T cell population at day 64 post transplantation. This translates into 44.4 
cells/pl of peripheral blood at that time. The frequency of those cells subsequently 
decreased to 25.5 % of total CD8^ T cells, which translates into 56.1 cells/pl due to an 
increased number of total CD8^ T cells in the patient at day 197 post transplantation.
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One patient sample at day 114 post transplantation was used for functional testing of 
these cells confirming that PBMC released IFNy in response to CMV peptide. However, 
the patient had extremely low numbers of CD4^ T cells, which reached only a quarter of 
the critical level reported to correlate with infection and overall survival in HSCT 
patients (Kim et al., 2006) during the follow-up period. In patient 24 CD4^ T helper cell 
counts above this critical level were only temporarily reached at day 77 post 
transplantation. Before and after that time point (when CD4^ T helper cell counts were 
low) CMV reactivations occurred despite the patient reconstituting high numbers of 
HL A-A2/pp65 specific CD8^ T cells, which were capable of IFNy release in response to 
CMV peptide. A similar pattern was observed for responses restricted by HLA-Al in 
patient 24 (Figure 3-18, page 220). This patient was not able to control multiple periods 
of CMV replication. He died at day 158 post transplantation after experiencing severe 
gut CMV disease. All patients described in this thesis, except the two described above, 
reconstituted CD4^ T helper cell counts >160 cells/pl. High levels of CMV specific 
CD8^ T cells of all HLA restrictions investigated in this chapter prevented or resolved 
CMV replication in all patients except these two who had low CD4^ T helper cell 
counts. HLA-A2/pp65 CD8^ T cell numbers from patients 6, 13, 15, 23 and 30 but not 
from the 5 patients shown in Figure 3-23 and Figure 3-24 (patients 1, 2, 24, 26 and 29) 
were analysed to confirm the protective level of HLA-A2/pp65 CD8^ T cells 
established in previous studies and will serve for a comparison with levels established 
for CD8^ T cells targeting other HLA/CMV peptide combinations in section 3-2.4.3.
3’2.4.3 Statistical anaiysis of the protective ievel of HLA-A2 
restricted CMV specific CDS* T celis and summary
HLA-A2/pp65 specific CD8^ T cell responses were studied within this project to allow 
for a comparison of responses towards new targets described in the previous sections 
with this archetype. Cell numbers observed in patients 6, 13, 15, 23 and 30 (compare 
section 3-2.4.2: Figure 3-20 on page 227, Figure 3-21 on page 229 and Figure 3-22 on 
page 230) are statistically analysed for their correlation with CMV viral load in patients 
here with results shown in Figure 3-25.
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Figure 3-25 Statistical analysis of HLA-A2/pp65 specific CDS T cell responses
This figure illustrates the absolute numbers o f  tetramer binding ce lls /p l o f  peripheral b lood  in 
patients 6, 23 and 30 m easured post transplantation until the last observed C M V  reactivation  
( ♦  during C M V ) versus  absolute num bers o f  tetramer binding ce lls  m easured from the peak o f  
the last C M V  reactivation onwards in those patients that resolved  their C M V  reactivations  
(patients 6 and 23 ) ( A  post C M V ) in com parison to absolute num bers o f  tetramer b inding ce lls  
in patients 13 and 15 w ho did not reactivate C M V  (▼  w /o  C M V ). Data groups w ere 
statistically  analysed using a tw o-tailed  M ann-W hitney U test w ith the m edians and p valu es  
(p<0.02  regarded sign ificant) indicated in the graph.
Figure 3-25 demonstrates that HLA-A2/pp65 specific CD8^ T ceil numbers broadly 
correlated inversely with the viral load in HSCT patients. Most T cell responses during 
the period of CMV replication in patients 6, 23 and 30 were not detectable, compared to 
significantly higher levels (p<0.0001) measured after the period of CMV reactivation 
(median 14.4 cells/pl). These responses were similar to those measured in patients 13 
and 15, who did not reactivate the virus (median 13.0 cells/pl).
One limitation of this analysis is that the “post CMV” and “w/o CMV” groups 
contain only responses from those patients in whom HLA-A2/pp65 specific T cell 
levels were measurable; other patients were considered to be protected by other 
responses (patients 1 and 2 demonstrated HLA-B35/pp65 specific CD8^ T cells, and 
patient 26 reconstituted reasonable numbers of total CD4^ and CD8^ T cells) or to be 
not informative due to other reasons (patients 24 and 29 did not recover critical T helper
235
____________________________________________________________________Chapter 3
cell levels, compare previous section for details). In the case of the “reactivating” group, 
one patient (patient 30) never achieved measurable levels of HLA-A2/pp65 specific T 
cells; that patient is included since he clearly had no protective response. It is 
impossible to determine what protective response he may achieve in the future, if any.
For an objective comparison, variations of this analysis that either include all 
patients of this group (Figure 6-7) or exclude patient 30 (Figure 6-8) are shown in the 
appendix. Both graphs demonstrate statistically significant differences between the 
sample groups comparable to results shown in Figure 3-25.
Inter-individual variations from the levels established above are shown in Table
3-10.
Patient Median protective level 
(25*** percentile, 75*** percentile)
Number of samples
6 14.06 (9.55,16.61) 12
13 16.10 (11.85, 34.60) 10
15 11.53 (10.19, 12.96) 8
23 33.63 - 1
Table 3-10 Protective levels of HLA-A2/pp65 specific CD8  ^ T cell responses in 
individual patients
This table lists the m edian va lu es o f  ab solute num bers o f  tetram er b in d in g  c e lls /p l o f  
peripheral b lood  in patients 6 , 23 and 30  m easured from  the peak o f  the last C M V  reactivation  
onw ards and for ab solute num bers o f  tetram er b ind ing ce lls  in patient 13 and 15 w h o  did not 
reactivate C M V  (in italics: calcu lated  from  <3 sam p les) a lon g  w ith  the num ber o f  sam ples  
used to ca lcu late each m edian value.
Table 3-10 demonstrates a slightly higher level of cells correlating with protection 
against CMV for patient 23 than others. The level for patient 23 was calculated from a 
single sample value. That sample was the first sample to be obtained after a CMV 
replication peak and therefore likely represented the peak of the T cell response (Figure 
3-21) whereas calculations for other patients incorporated peak values and values 
obtained from samples taken after T cell responses had diminished to a lower sustained 
value.
It can be concluded that the level of HLA-A2/pp65 specific CD8^ T cells that 
inversely correlated with the ability to detect CMV reactivation in patients from this 
study (13xlO^/L, compare Figure 3-26 on page 241) is similar to protective levels of 
10x10^ (Cwynarski et a l,  2001) to 20x10^ (Aubert et a l,  2001) cells/L of blood
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established for HLA-A*0201 restricted CD8^ T cell responses to CMV pp65 (495-503) 
in HSCT patients previously.
The protective level of HLA-A2/pp65 specific CD8^ T cell responses in HSCT 
patients established above was compared to the protective levels of CMV specific CD8^
T cell responses restricted by HLA-B35, HLA-A24 and HLA-Al that were established 
in the previous sections and a statistical analysis is shown in Figure 3-26 in section 3-3 
on page 241.
Similar to the CMV specific CD8^ T cell responses restricted by other HLA 
types described in the previous sections, HLA-A2/pp65 specific CD8^ T cell response 
levels were also analysed in six healthy CMV seropositive volunteers (Table 3-11).
Healthy
volunteer
HLA-A2/pp65 specific cells as a 
percentage of CD8  ^T cells
HLA-A2/pp65 specific cells per 
microlitre of blood
1 0.81 2.59
5 0.61 2.96
6 0.42 1.35
8 3.26 22.14
10 1.28 7.42
15 0.23 1.18
Table 3-11 HLA-A2/pp65 specific CD8 T cell levels in healthy volunteers
This table lists id en tification  num bers o f  healthy volu nteers and the H L A -A 2/p p 65  sp ec ific  
CD8^ T ce ll counts detected  in peripheral b lood  o f  th ese  vo lu nteers by use o f  tetram er sta in ing. 
C ounts are represented as a p ercentage o f  the total CD8^ T ce ll population  and as a num ber per 
v o lu m e o f  b lood.
Table 3-11 demonstrates the frequency of HLA-A2/pp65 specific CD8^ T cells 
observed in healthy control samples. This translates to a mean frequency of 1.1 % of 
HLA-A2/pp65 specific CD8^ T cells (median 0.71 %, range 0.23 - 3.26 %) and mean 
absolute number of 6.27x10^ HLA-A2/pp65 specific CD8^ T cells/L (median 2.78x10^ 
T cells/L, range 1.18 - 22.14) was observed in healthy control samples (n = 6).
The level of HLA-A2/pp65 specific CD8^ T cell responses that was observed in 
healthy volunteers during this study is similar to findings published previously. Aubert 
and colleagues reported a mean frequency of 1.3 % of HLA-A2/pp65 specific CD8^ T 
cells (median 0.935 %, n = 13, range 0.29 - 5 %) and an absolute number estimated at a 
mean of 8.7x10^ HLA-A2/pp65 specific CD8^ T cells/L. This value was based on an 
average CD8^ T cell count of 0.67 (range 0.2 - 1.14) x 10^  T cells/L within that study 
(Aubert et al, 2001).
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HLA-A2/pp65 specific CD8^ T cell numbers measured in healthy individuals during 
this study are lower than the level observed in HSCT patients (p = 0.0066), compare 
Figure 3-26 on page 241.
3-3 Discussion
The main aim of this chapter was to evaluate and compare ex vivo CMV specific 
CD8^ T cells with different HLA/peptide targets in patients post HSCT.
3-3.1 Correlation of CMV specific CD8* T cells with protection from 
CMV in HSCT patients
Overall a broad inverse correlation was observed between the numbers of tetramer 
binding CD8^ T cells and the CMV viral load at the time of sampling in patients, who 
had reconstituted at least 160 CD4^ T helper cells/pl blood. This suggests functionality 
of CMV specific CD8^ T cells in vivo. Although limited cell numbers did not allow for 
assessment of cytotoxicity, IFNy ELISpot analysis demonstrated cytokine release of 
PBMC in response to the same CMV peptides that were used to generate tetramers. 
This is important for the protective capacity of these cells in patients since it has been 
suggested that a fraction of CMV specific CD8^ T cells may be non-functional 
(Engstrand et al., 2003, Ouyang et a l,  2003, Zhang et al,  2003).
Numbers of CD8^ T cells targeting a specific HLA/CMV peptide combination 
were analysed separately in different sections throughout this chapter. Each HLA 
specific section includes a statistical analysis of T cell responses grouped according to 
the viral load observed at the time of sampling in patients. Not all of the responses 
measured in HSCT patients could be used for a meaningful statistical analysis. Four 
exceptions were considered which are explained below.
Firstly, some responses were observed at very low frequency or in a very limited 
number of patients not allowing for quantitative statistical analysis. Under HLA- 
A*0101 restriction, frequencies of CD8^ T cells targeting CMV pp65 (341-349) were 
insignificant in all patients, and CD8^ T cells targeting CMV pp65 (363-373) were 
absent or of lower frequency than CD8^ T cells targeting CMV pp50 (245-253). Due to 
observation of significant numbers of CMV pp65 (363-373) specific CD8^ T cells that 
may have conferred protection against CMV in only two patients, a statistical analysis 
was only possible for HLA-Al/pp50 but not HLA-Al/pp65 specific CD8^ T cells
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(compare section 3-2.3.3, page 221). Under HLA-A*2402 restriction, frequencies of 
CD8^ T cells targeting CMV pp65 (113-121) were insignificant in all patients.
Secondly, responses in CMV seronegative patients who received a transplant 
from a CMV seropositive donor and did not experience a primary infection were 
omitted from statistical analysis.
Thirdly, patients in whom CMV was controlled despite a lack of detection of 
significant CMV specific CD8^ T cells with the relevant tetramer were observed in this 
and other (Aubert et a i ,  2001) studies. Findings from HLA-A2 expressing CMV 
seropositive populations reported HLA-A2/pp65 specific CD8^ T cells in 75 % 
(Gratama et a i,  2001) to 77 % (Komatsu et a i,  2003) of individuals tested previously. 
Provided that total CD8^ T cell counts were reconstituted, CD8^ T cells specific for 
other HLA/CMV targets were likely to protect such patients. This was shown for some 
patients in this chapter, in whom staining with one of the other reagents of the tetramer 
panel was positive. CMV specific immune cells not covered by the tetramers used in 
this study likely protected others. Responses measured in those patients were not 
informative (undetectable responses cannot be used to establish response levels that 
may be protective in patients) and were therefore omitted from subsequent statistical 
analysis to establish protective levels of CMV responses.
Fourthly, CMV specific CD8^ T cell responses were not statistically analysed in 
patients with extremely low CD4^ T cell levels. Although CD8^ T cells can resolve 
acute virus infections without CD4^ T cell help, long-term control of persistent infection 
requires CD4^ T cells (Matloubian et a i,  1994). There are a number of mechanisms by 
which CD4^ T cells can influence the CD8^ T cell responses:
• Findings from Janssen and colleagues suggested that the presence of CD4^ T 
cells during priming is dispensable for primary expansion and differentiation of 
CD8^ T cells but not for secondary CD8^ T cell expansion upon re-encounter 
with antigen (Janssen et a i,  2003).
• CMV specific CD8^ T cells are dependent on CD4^ T cells that provide essential 
IL2 (Salkowitz et a i ,  2004). This is especially pronounced for highly 
differentiated CD8^ T cells that have lost CD28 expression (Topp et a i ,  2003). 
CD28‘ CD8^ T cells are increased in the CMV specific CD8^ memory T cell 
pool (Gillespie et a i ,  2000). CD28 interacts with CD80 and CD86 on APC and 
co-engagement of CD28 and TCR results in increased sensitivity to TCR
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stimulation due to increased stability of the immunological synapse (Viola and 
Lanzavecchia, 1996) and survival of T cells after stimulation (due to increased 
expression of anti-apoptotic proteins and IL2) (Boise et a l ,  1995).
• It was reported that a lack of CD4^ T cells could result in silencing of persistent 
antiviral CD8^ T cells, which proliferate but are unable to kill the virus (Zajac et 
a l,  1998).
• Besides providing IL2 as a growth and survival factor (Vella et a l,  1998), CD4^ 
T cells are important for conditioning APC through CD40-CD40L interactions 
(Schoenberger et a l,  1998). Therefore it is likely that in the absence of sufficient 
helper activity (and contact of T helper cells with dendritic cells through CD40- 
CD40L interactions) dendritic cells may not provide sufficient costimulatory 
signals to CD8^ T cells, thus disrupting their normal function (Kalams and 
Walker, 1998).
• CD8^ T cells generally recognise endogenously processed antigen presented via 
MHC class I. However, exogenous antigen may also enter the otherwise 
endogenous class I presentation pathway, a process know as cross presentation 
(Bevan, 1976). CMV cross presentation has been demonstrated by cell entry of 
defective envelope particles called dense bodies (Pepperl et a l,  2000). In turn, 
induction of CD8^ T cells by cross-priming has also demonstrated to require 
CD4^ T cell help, a process which has been termed conditioning (Ridge et a l , 
1998) or licensing (Lanzavecchia, 1998) of DC.
Thus it is clear that memory CD8^ T cells may be compromised in disease states that 
result in deficits in CD4^ T cell numbers or function. CD8^ T cells have a more rapid 
recovery rate than CD4^ T cells leading to an inversion of the normal CD4/CD8 ratio 
(2:1) early post transplantation (Dumont-Girard et a l,  1998, Singer et a l,  1983). 
Patients lacking critical numbers of CD4^ T cells post HSCT may not be able to 
translate the number of CMV specific CD8^ T cells into protection against CMV. 
Absolute CD4^ and CD8^ T cell counts were measured by TruCOUNT analysis or were 
retrieved from routine hospital counts in a minority of patients. Patients 24 and 29 did 
not recover CD4^ T helper cell counts of ^160 cells/pl like other patients in this study. 
This cut-off level is similar to the threshold of 200 CD4^ T cells/pl blood that was 
reported to correlate with infection and overall survival in HSCT patients (Kim et a l,  
2006). CMV specific CD8^ T cell responses from patients 24 and 29 were therefore
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omitted from statistical analysis aiming at establishing CMV specific CD8^ T cells 
correlating with protection in patients.
3-3.2 CMV specific CDS* T cells correlate with protection from CMV in 
HSCT patients at different levels depending on the HLA/peptide 
combination but may not mediate protection
The protective levels established in the HLA specific analysis of this chapter 
vary for different HLA/peptide combinations. This is illustrated in Figure 3-26, which 
summarises data shown in the previous HLA specific sections.
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Figure 3-26 Comparison of protective levels of CMV specific CDS T cell responses 
with different HLA/peptide targets in HSCT patients
This represents an illustration o f  the absolute numbers o f  tetramer b inding cel I s/p  I o f  
peripheral b lood measured post transplantation since the last observed C M V  reactivation or 
during the entire fo llow -u p  period in patients w ho did or did not reactivate C M V  respectively . 
R esponses were grouped into colum ns according to their H L A/peptide target sp ec ific ity  with  
the m edian and num ber o f  responses analysed show n in the legend on the right. Data groups 
were statistically analysed u sing  a tw o-tailed  M ann-W hitney U test w ith the m edians and p 
values (p<0.02  regarded sign ifican t) indicated in the graph.
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Since HLA-specific analysis in this chapter demonstrated similar levels of responses in 
patients who had resolved CMV reactivation and patients who did not reactivate, these 
groups have been combined in Figure 3-26. Protective levels established previously 
(Cwynarski et a l ,  2001, Aubert et a l ,  2001) for HLA-A*0201 and/or HLA-B*0702 
restricted CMV pp65 specific CD8^ T cell responses are indicated as a dashed line in 
Figure 3-26. Samples were analysed from patients with various diseases and transplant 
modalities (compare Table 2-1 on page 99) during this project. Nevertheless the 
statistical analysis was powerful enough to detect significant differences between CD8^
T cell responses targeting different HLA/CMV peptide combinations. The medians of 
CMV specific CD8^ T cell numbers that inversely correlated with the ability to detect 
CMV in HSCT patients were in the range of 4x10^ to 17x10^ cells/L of blood. 
Protective responses to HLA-Al/pp50 and HLA-A2/pp65 lie within the range of 
previously established levels for HLA-A2/pp65 and HLA-B7/pp65 and are not 
significantly different from each other (p = 0.1985). However, protective responses to 
HLA-B35/pp65 and HLA-A24/pp65 are significantly lower than responses to the other 
two targets (see p values <0.008, Figure 3-26) and again, not significantly different 
from each other (p = 0.1641). It has to be noted that the protective level of HLA- 
A24/pp65 responses was established from a small dataset (n = 3) and therefore needs to 
be interpreted with care. A recent study, however, is in accordance with findings from 
this project. The authors of that study reported HLA-A24/pp65 specific CD8^ T cells to 
be present with a frequency of 0.4x10^ cells/L of blood, which was significantly lower 
than the frequency of 23x10^ HLA-A2/pp65 specific CD8^ T cells/L of blood that they 
observed in HSCT patients (Morita et a l,  2005).
The levels of CMV specific CD8^ T cells established in this chapter generally 
correlated with protection from subsequent CMV reactivation in patients and therefore 
are referred to as protective throughout this thesis. A few insignificant exceptions can 
be explained as follows. In patient 12 and patient 22, a low-level replication was still 
observed shortly after protective levels of CMV specific CD8^ T cells had been reached. 
However, these were resolved quickly and may simply reflect the time needed by CD8^ 
T cells to effectively impact on CMV replication. In patient 12 it is possible that a 
temporary drop of the response below the protective level has been missed between 
samples taken at day 59 and 80 post transplantation because CMV specific CD8^ T cell 
numbers decreased until day 59 and increased from day 80 (Figure 3-7, page 198). 
Alternatively the low-level PCR result of 931 and 236 CMV copies/ml blood at day 73
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and 77 post HSCT in patient 12 respectively can be considered insignificant (which is 
consistent with antiviral treatment guidelines described in section 2-2.5). In patient 22 
the functionality of responses that were measured may have been partially compromised 
due to Prednisolone treatment at the time of observed low-level CMV PCR results (202, 
406 and 828 copies/ml at day 56, 87 and 108 post HSCT, which again can be 
considered insignificant) because further CMV replication was prevented after cessation 
of this immunosuppressive treatment (Figure 3-15, page 215). This project did not aim 
to prove the protective capacity of CMV specific CD8^ T cells in HSCT patients per se. 
Rather this study was performed based on previous findings that reported evidence for 
CMV specific CD8^ T cells being protective (Reusser et a l ,  1991, Walter et a l ,  1995) 
and aimed to compare the numbers of different CMV specific CD8^ T cells (targeting 
different HLA/peptide combinations) that inversely correlate with the ability to detect 
CMV reactivation in patients. The results of investigations described in this chapter do 
not prove that CMV specific CD8^ T cells mediated protection. The magnitude of CD8^ 
T cells targeting a specific CMV epitope is inversely correlated with viral load and 
therefore correlates with protection in patients, but it may be possible that protection 
was mediated by other immune responses either individually or in combination with the 
cell populations detected. These could be cells with higher sensitivity, which may 
expand and/or function at a lower viral load than the CMV specific CD8^ T cells 
measured using the panel of tetramers available for this study. If so the CMV specific 
CD8^ T cells measured would be a surrogate marker. Due to their inverse correlation 
with viral load, however, cell levels measured are useful to indicate if the immune status 
in patients is sufficient for the protection from CMV reactivation. Therefore in patients 
with at least 160 CD4^ T helper cells/pl blood present, CMV specific CD8^ T cell levels 
measured are a marker of protection independently of their capacity to mediate 
protection.
A possibility to prove that CD8^ T cells targeting a specific CMV epitope are 
mediating protection from CMV in vivo is to adoptively transfer those cells to patients 
with uncontrolled CMV reactivations and establish whether the transfer may result in 
subsequent protection from any further CMV reactivations. Findings from patients 24 
and 29 in this study suggest that efficiency of CMV specific CD8^ T cells would require 
the presence of CD4^ T cells. Cobbold and colleagues demonstrated that CMV 
reactivation resolved completely after adoptive transfer of various CMV specific CD8^ 
T cells in eight patients and markedly reduced CMV viral load in a single patient after
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adoptive transfer of HLA-B35/pp65 specific CD8^ T cells (Cobbold et a l,  2005). This 
merits further adoptive transfer studies with each subset of CMV specific CD8^ T cells 
in a larger patient cohort to confirm the protective capacity of the different subsets of 
CMV specific CD8^ T cells.
3-3.3 Correlation of CMV specific CD8^ T cells with protection at 
different levels depending on the HLA/peptide combination can a lso  be 
observed in healthy virus carriers
As Riddell and Greenberg reviewed, healthy CMV seropositive individuals maintain 
high levels of CMV specific T cells which they suggest may be required to control 
intermittent episodes of virus reactivation (Riddell and Greenberg, 2000), the 
occurrence of which was subsequently confirmed (Ling et a l ,  2003). During this project 
CMV specific CD8^ T cells were measured in a small number of CMV seropositive 
healthy volunteers expressing the HLA tissue types under investigation. The results 
from this analysis demonstrate (similar to observations in HSCT patients) different cells 
levels depending on the antigen specificity of cells. Figure 3-27 demonstrates 
significant differences between CMV specific CD8  ^T cell responses targeting different 
HLA/CMV peptide combinations.
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Figure 3-27 Comparison of CMV specific CDS T cell counts targeting different 
HLA/peptide combinations in healthy individuals
This figure represents C M V  sp ec ific  responses observed  in healthy in dividuals. It illustrates 
the absolute numbers o f  tetram er binding ce lls /p l o f  peripheral b lood  m easured in C M V  
seropositive individuals exp ressin g  the relevant HLA tissu e types. R esp onses w ere grouped  
into colum ns according to their H L A /peptide target sp ec ificity  w ith the m edian and num ber o f  
responses analysed show n in the legend on the right. Data groups w ere statistically  analysed  
using a tw o-tailed  M ann-W hitney U  test w ith the m edians and p values (p < 0 .02  regarded 
sign ificant) indicated in the graph.
Similar to HSCT patients (Figure 3-26), frequencies of CMV specific CD8^ T cells 
targeting HLA-B35/pp65 or HLA-A24/pp65 are significantly lower (median 
0.08 cells/pl blood for both) than those targeting HLA-Al/pp50 or HLA-A2/pp65 
(median 3.00 and 2.78 cells/pl blood respectively) in healthy volunteers (Figure 3-27, 
p<0.02). Frequencies of two high-responders and three low-responders amongst the 
healthy virus carriers (compare Table 3-9, page 224) result in a median of 0.41 HLA- 
Al/pp65 specific CD8^ T cells/pl blood. These results are in accordance with findings 
in a recent publication describing lower frequencies of HLA-B35/pp65, HLA-A24/pp65 
or HLA-Al/pp65 specific CD8^ T cells (0.9 ± 0.6, 0.1 ± 0.1 and 1.3 ± 0.5 cells/pl) than
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HLA-A2/pp65 specific CD8^ T cells (6.4 ± 1.8 cells/pl) in healthy individuals (Lidehall 
et ai,  2005).
Figure 3-28 demonstrates that overall the frequencies of tetramer binding cells 
were significantly higher in HSCT patients than in healthy controls, a phenomenon that 
was also reported by others (Aubert et al,  2001, Gratama et al,  2001).
131
129
70-
f  50- 
o  4 0 - 
8  30 -
20 -  
10 -  
0 -
1
It
Y
p<0.0001
♦  median=8.65 n=190 
▲ median=0.94 n=22
20n
8 15H
QO
o
S5
Ü
lOJ
5 -
0-1 — — —
y y
Y
pcO.OOOl
♦  median=1.63 n=190 
A  median=0.18 n=22
Figure 3-28 Comparison of CMV specific CD8  ^ T cell counts in protected HSCT 
patients and healthy individuals
The numbers o f  tetramer b inding ce lls /p l (left graph) and the numbers o f  tetram er b inding  
ce lls  as a percentage o f  CDS^ T ce lls  (right graph) m easured in C M V  serop ositive individuals  
are illustrated. R esponses were separated into m easurem ents in those H SC T patients that w ere 
regarded as protected (“SCT patients”, pooled  data from Figure 3 -26 ) and m easurem ents in 
healthy virus carriers (“healthy subjects”, pooled  data from Figure 3 -27 ) w ith the m edian and 
number o f  responses analysed show n b elow  the graphs. A statistically  com parison was 
performed using a tw o-tailed  M ann-W hitney U test w ith the m edians and p values (p < 0 .02  
regarded sign ificant) indicated in the graph.
Chalandon and colleagues were using tetramers with HLA-A*0101/CMV pp65 (363- 
373), HLA-A*0201/CMV pp65 (405-503) and HLA-B*0702/CMV pp65 (265-275 and 
417-426) specificities and observed an average of 6.7 ±4.6%  tetramer binding cells 
amongst total CD8^ T cells in HSCT patients in contrast to an average of 1.3 ± 1.6 % in 
patients before transplantation and an average of 0.7 ± 0.7 % in CMV seropositive 
donors (Chalandon et a l,  2006). Data shown in Figure 3-28 translate into an average of 
2.4 ±2.8 % tetramer binding cells amongst total CD8^ T cells in HSCT patients in 
contrast to an average of 0.6 ± 1.0 % in healthy CMV carriers. The average of tetramer
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binding cells in HSCT patients observed in this study is lower than in the study by 
Chalandon and colleagues, which likely results from the use of tetramers with 
specificity for cells present at lower levels (HLA-B35/pp65 n = 101, total n = 190).
In this study supranormal frequencies of CMV specific CD8^ T cells were 
observed at the peak of responses after CMV reactivation in HSCT patients. Maximum 
frequencies observed amongst CD8^ T cells were 8.89 % for HLA-A24/pp65, 20.2 % 
for HLA-B35/pp65, 22.6 % for HLA-Al/pp50 and 69.4 % for HLA-A2/pp65 specific 
CD8^ T cells. High frequencies of up to 21 % (Cwynarski et a l,  2001) and 40%  
(Ozdemir et a l , 2002) of CMV specific cells amongst CD8^ T cells in HSCT patients 
were also observed in other studies. Although an exceptionally high frequency of 26 - 
50 % and 65 % of CMV specific cells amongst CD8^ T cells during undetectable and 
detectable CMV DNA respectively was observed in one healthy individual (Lang et al, 
2002) and frequencies of up to 23 % were reported in some old individuals (Khan et a l , 
2002b), such frequencies observed in healthy individuals were usually below 5 % of all 
CD8 T^ cells (Gillespie et a l , 2000).
This difference to frequencies observed in HSCT patients may be due to high in 
vivo viral antigen stimulation in HSCT patients given that Cwynarski and colleagues 
found CMV reactivation to be a significant predictor of CMV specific CD8^ T cell 
reconstitution in univariate analysis (Cwynarski et a l ,  2001). Findings described here, 
however, demonstrate similar levels of CMV specific CD8^ T cells in non-reactivating 
patients and patients post CMV reactivation, which are higher than levels observed in 
healthy virus carriers. The finding of similar levels of CMV specific CD8^ T cells in 
non-reactivating HSCT patients and patients post CMV reactivation is consistent with 
reports by others (Gallez-Hawkins et a l,  2005). This suggests a transplant related rather 
than stimulation related reason behind the higher level of viral CD8^ T cells in HSCT 
patients than in healthy controls. T cell homeostasis is regulated by the competition of 
different T cells for endogenous stimuli like cytokines and access to APC (Kedl et a l ,
2000). T cells may compete when the number of APC or antigen is limited and the T 
cells are present in numbers high enough to influence one another. This competition can 
occur between CD8^ T cells responding to the same HL A/antigen (direct competition) 
or, more rarely, between CD8^ T cells responding to different HLA/antigen (cross 
competition) (Kedl et a l,  2003). This is discussed in more detail in section 1-11.2. 
Upon transfer of cells to a lymphopénie environment such as conditioned HSCT 
recipients, T cells proliferate until the cellularity of the T cell compartment has been
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restored (Ernst et a l,  1999, Goldrath et a l,  2000). The homeostatic drive in addition to 
CMV antigen stimulus in HSCT patients may explain the high levels of CMV specific 
CD8^ T cells observed. After resolved CMV replication episodes, T cells may not 
contract to the same levels observed in healthy virus carriers but remain at higher levels 
in HSCT patients due to higher availability of space and endogenous stimuli. This leads 
to an inflation of CMV specific CD8^ T cells over time, which is discussed further in 
Chapter 4.
3-3.4 Potential origin and cross reactivity of CMV specific CD8* T ceiis 
in recipients of HSCT
Recipients of allogeneic stem cell transplantation can reconstitute CMV specific CD8^ 
T cells from different cell populations. Following receipt of unmanipulated stem cells 
most T cells are of donor origin (Roux et a l,  1996, Gandhi et a l,  2003a). They may 
stem from mature donor T cells transfused with the graft or from donor haematopoietic 
progenitors in the graft that underwent TCR gene rearrangement in the thymus of the 
recipient and gave rise to naive T cells. Alternatively CMV specific CD8^ T cells can 
originate from mature recipient T cells that survived the conditioning regimen (Butturini 
et a l,  1986) and escaped attack by donor T cells if the graft was thoroughly depleted of 
those cells (Roux et a l ,  1992). This may be more pronounced in HSCT using reduced- 
intensity conditioning.
Only 17 % of CMV seronegative recipients who received transplants from 
seropositive donors were reported to experience CMV infection (Goodrich et a l ,  1994). 
Consistent with that infection was not observed in all three patients fulfilling these 
criteria in this study.
Delayed reconstitution of CMV specific CD8^ T cells was reported post HSCT 
from CMV seronegative donors (Cwynarski et a l ,  2001, Gandhi et a l,  2003a). In 
accordance with that CMV specific CD8^ T cell reconstitution was absent or delayed in 
most CMV seropositive patients who received transplants from seronegative donors in 
this study. Two patients, patient 7 and 15, however, had 10 % and 3 % CMV specific 
cells detected within their CD8^ T cell populations as early as 46 and 22 days post 
transplantation from a CMV seronegative donor respectively. To my knowledge this is 
the first observation of early detection of such cells in CMV seropositive recipients who 
did not experience CMV replication after receiving transplants from seronegative 
donors. CD8^ thymic emigrants can be observed by 2 months after allogeneic HSCT
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(Weinberg et a l,  2001), but it has been suggested that the contribution of newly 
generated T cells from the naïve T cell pool may be negligible during the first 6 months 
for CD4^ T cells and during the first 9 months post transplantation for CD8^ T cells 
(Fallen et a l,  2003). Therefore it is likely that CMV specific CD8^ T cells in patient 7 
and 15 observed during this project derived from mature cells rather than from donor 
haematopoietic progenitors. The graft received by myeloablated patient 7 was not T cell 
depleted suggesting that cells may have been of donor rather than recipient mature T 
cell origin. In comparison, patient 15 received a non-myeloablative transplant involving 
reduced-intensity conditioning, which was reported to induce mixed T cell chimaerism 
by 4 weeks post HSCT in a majority of patients (Laport et a l,  2008). Exposure to 
antigen apparently was not required for maintenance of tetramer binding T cells because 
CMV DNAemia was not detected in peripheral blood in either patient. This may not 
preclude subclinical CMV reactivation at localised tissue sites. CMV specific CD8^ T 
cells demonstrating dim staining with tetramer coincided with the occurrence of acute 
GvHD in patient 7 (Figure 3-1, page 180 and Figure 3-2, page 184). It is therefore 
suspected that T cell receptors of those cells may have been crossreactive with another 
antigen in the recipient. The possibility of virus specific CD8^ T cells cross-reacting 
with alloantigen was reported previously (Gamadia et a l ,  2004, Nahill and Welsh, 
1993). Alloreactive cells may directly participate in GvHD or the cytokines released in 
response to GvHD may contribute to the maintenance of CMV specific T cells. Allo- 
crossreactivity has been suggested previously for CMV specific CD8^ T cells observed 
in CMV seronegative recipients who received transplants from seropositive donors and 
who had not experienced CMV replication (Cwynarski et a l ,  2001, Gandhi et a l,  
2003a). Due to insufficient material, however, crossreactivity of tetramer binding T 
cells could not be substantiated in patient 7. Crossreactivity is not likely for patient 15 
who did not show clinical signs of GvHD. CMV reactivation that was not detected at 
localised tissue sites may have induced proliferation of residual mature T cells of 
recipient origin in this patient. Reduced intensity conditioning in this patient resulted in 
45 - 55 % chimaerism at the time of follow-up, which is consistent with the hypothesis 
that tetramer binding cells originated from mature recipient T cells.
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3-3.5 Co-dominance of CMV specific CD8* T cells targeting different 
HLA/peptlde combinations
In view of previous findings of HLA-B*0702/pp65 (417-426) restricted CMV 
pp65 specific CD8^ T cell responses dominating HLA-A*0201/pp65 (495-503) 
restricted CMV pp65 specific CD8^ T cell responses (Lacey et a l,  2003), results from 
this project were observed closely to detect any possible recurring dominance of a 
particular response in patients. In other studies CMV seropositive individuals 
expressing HLA-A*0201 and HLA-B*0702 demonstrate dominant responses restricted 
by the HLA-B*0702 but not all of these individuals lack responses restricted by HLA- 
A*0201 (Hebart et a l ,  2002, Nastke et a l ,  2005) suggesting preferential peptide 
presentation (compare section 1-7 from page 58 onwards) or preferential clonal 
proliferation rather than clonal deletion as the underlying mechanism for the observed 
dominance. Analysis of CMV seropositive patients simultaneously expressing several 
different HLA tissue types, for which tetramer reagents were available during this 
project, revealed no obvious dominance of either of the CMV specific CD8^ T cells 
restricted by HLA-B35, HLA-Al and HLA-A2 over each other. CMV specific CD8^ T 
cells restricted by HLA-A24, however, seemed to be subdominant. All patients 
expressing HLA-A24 and one of the other HLA types simultaneously responded solely 
with CMV specific CD8^ T cells restricted by the other HLA type. Previous studies 
suggested that the CMV pp65 (341-349) CD8^ T cell epitope presented by HLA- 
A*2402 may not be immunodominant (Kondo et a l ,  2003) due to the very low 
percentages (-0.1 %) of CD8^ T cells targeting this epitope in healthy seropositive 
individuals (Kuzushima et a l ,  2001). Similarly, low frequencies were observed in 
healthy individuals during this project (Table 3-4, page 206). First published 
observations of HLA-A*2402 restricted CMV pp65 (341-349) specific CD8^ T cells in 
HSCT patients demonstrated frequencies of up to 2.85 % of CD8^ T cells (Gondo et a l,
2004). Three patients studied here reconstituted maximum frequencies of 1.41 %, 
5.00% and 8.89% HLA-A*2402 restricted CMV pp65 (341-349) specific cells 
amongst their CD8^ T cells. These are possibly the highest frequencies of those cells 
that have been observed ex vivo yet. However, HLA-A24/pp65 specific CD8^ T cells 
were present in only a fraction of patients expressing the HLA-A*2402 allele (3 of 12). 
The presence of HLA-A24/pp65 specific CD8^ T cells in only a fraction of patients 
expressing the HLA-A*2402 allele may be one possible explanation for the suggestion
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that this allele is one of the HLA alleles associated with an increased risk of CMV 
reactivation in the HSCT setting (Chen et al,  2001).
Co-dominance of CMV specific CD8^ T cells with targets other than HLA- 
A24/pp65 was observed amongst virus carriers. Figure 3-29 demonstrates similar 
frequencies of CMV specific CD8^ T cells restricted by HLA-B35 versus HLA-Al or 
HLA-A2 in patients expressing two of these HLA alleles simultaneously.
Patient 31. day 1560 
HLA-A*0101/pp50(245-253)
10^
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3 .
»
10"
Patient 32. day 717 
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10'
10"
lor-
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Patient 32. day 717 
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Figure 3-29 Co-dominance of CMV specific CD8  ^T cells restricted by HLA-B35, 
HLA-Al or HLA-A2 in two representative patients
This representative exam ple dem onstrates tetramer stained PBM C from tw o patients. Flow  
cytom etry plots show  CD3^ live  lym phocytes sorted according to their surface expression  o f  
C D 8 on the x-axis and stain ing with different H L A /C M V  tetramer on the y -ax is.
Figure 3-30 illustrates the relative frequencies of CMV specific CD8^ T cells with 
different target specificities in the same virus carriers.
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— ► Arrow points towards the one of a pair of tetramers that bound with significantly higher frequency to PBMCs from 
a CMV seropositive subject expressing both relevant HLA alleles
  Represents staining with a pair of tetramers that bound with similar frequency to PBMCs from a CMV seropositive
subject expressing both relevant HLA alleles
Figure 3-30 Co-dominance of CMV specific CD8  ^T cells in CMV carriers eligible 
for assessment with multiple tetramers
The upper right part o f  this figure represents each observation  o f  sim ilar (= ) or considerably  
different ( ^ )  frequencies o f  tetram er b inding PBM C that w ere observed  in C M V  carriers w ho  
expressed  the relevant H LA a lle les  enab ling stain ing w ith m ultip le tetram ers. The low er left 
part o f  the table sh ow s an interpretation o f  these data as dom inance or co -d om in an ce betw een  
C M V  sp ecific  CD8^ T ce lls  w ith  different H L A /peptide targets. T his graph w as drawn in a 
sim ilar way as a graph by Lidehall and co lleagu es (L idehall e t  a l ,  2 0 05 ).
Apart from the subdominance of HLA-A24/pp65 specific CD8^ T cell responses 
described earlier, findings demonstrate no exclusive (sub)dominance of CMV specific 
CD8^ T cells of one target specificity over others. In accordance with this co-dominance 
of CMV specific CD8^ T cell epitopes was also described in other studies (Nastke et a l,
2005). HLA-A2/pp65 and HLA-B7/pp65 specific CD8^ T cells may have been seen as 
dominant over other CMV specific CD8^ T cells by some researchers in the field
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previously. Results from Figure 3-30 challenge this view because frequencies of HLA- 
B35/pp65 specific cells substantially exceeded those of HLA-A2/pp65 specific cells in 
two patients (patients 1 and 2).
3-3.6 Revision of a single CMV epitope suggested  to be presented by 
HLA-A1 and HLA-A24 alleles
A previous study suggested that CD8^ T cell responses recognise the peptide CMV 
pp65 (341-349) presented not only by HLA-A*2402 (compare section 3-2.2) but also 
by HLA-A*0101 (Ghei et a l,  2005). That study measured IFNy mRNA transcript 
production by cells that were peptide induced (versus unstimulated) for 3 hours in vitro. 
This peptide induction was performed after a 2-week sensitisation (cell culture in the 
presence of a 16mer comprising the sequence RQYDPVAALFFFDIDL or pp65 (341- 
349), and IL2) and subsequent culture in peptide-free medium overnight. This 
measurement was performed using cDNA for quantitative real time PCR. Additionally 
IFNy protein release by cells (at 24, 48 and 72 hours after re-stimulation with pp65 
(341-349), that was performed after 2-week sensitisation with the same peptide or 
RQYDPVAALFFFDIDL) was assessed by ELISA.
Studying the pattern of CD8^ T cell responses to pp65 (341-349) presented by 
either HLA-A*2402 or HLA-A*0101 would be of interest because it has been 
suggested that significant differences (such as recruitment of distinct TCR repertoires 
and significant differences in the functional avidity of CD8^ T cells) exist between 
CD8^ T cells targeting identical epitopes but restricted by different HLA (Leslie et al,
2006). However, the restriction of pp65 (341-349) by HLA-A*0101 was not confirmed 
in this study. The peptide CMV pp65 (341-349) refolded with HLA-A*2402 but not 
HLA-A*0101 in vitro (Figure 3-12, page 210) and no considerable IFNy release of ex 
vivo PBMC from individuals expressing HLA-A*0101 (and not expressing HLA- 
A*2402) was observed using ELI Spot assays (Figure 3-13, page 212).
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3-3.7 Implications of findings and final conclusions
Cytomegalovirus disease has been recognised as a significant challenge in HSCT 
recipients. Patients are immunosuppressed profoundly in the early post-transplant 
period, and reactivation of CMV from latently infected cells remains a significant cause 
of morbidity and mortality.
Previous investigations demonstrated that CMV specific CD8^ T cell numbers 
(inversely) correlate with viral replication and clinical status in patients. These mainly 
focused on enumeration of CMV specific CD8^ T cell responses restricted by HLA-A2 
and HLA-B7 (Aubert et a/., 2001, Cwynarski et a l ,  2001, Engstrand et al, 2000, 
Gillespie et a l,  2000, Gratama et a l,  2001, Komatsu et a l,  2003, Mohty et a l,  2004, 
Ozdemir et a l,  2002, Singhal et a l,  2000). This may have been for several reasons. 
Firstly, these alleles are amongst the most common HLA alleles in many ethnic groups. 
Secondly, their high numbers are easily detectable in patients and they were 
subsequently regarded as predominant. Thirdly, the generation of staining reagents for 
other CMV specific CD8^ T cells responses such as those restricted by HLA-A24 and 
HLA-B35 can require some modification of the standard protocol (compare Chapter 2).
Tetramer based monitoring established that recovery of 1x10^ (Cwynarski et al,
2001) to 2x10^ (Aubert et a l,  2001) HLA-A2/pp65 specific CD8^ T cells/L of blood is 
associated with protection from CMV disease in patients.
The study described here aimed to compare the pattern of CMV specific CD8^ T 
cell frequencies targeting other common HLA/peptide combinations in HSCT patients 
over time and to investigate the correlation of these cell frequencies with protection 
from CMV in patients.
To my knowledge, at the time of initiating this project this was the first study to 
conduct a longitudinal study of HLA-B35/pp65 specific CD8^ T cell responses in the 
HSCT setting. CD8^ T cells targeting pp65 (123-131) restricted by HLA-B*3501 were 
measured. Other studies previously enumerated CD8^ T cells targeting pp65 (187-195) 
restricted by HLA-B*3503 (Wills et a l,  2002b) in healthy virus carriers or CD8^ T cells 
targeting pp65 (188-195) restricted by HLA-B*3502 in HIV infected patients (Villacres 
et a l,  2003). CD8^ T cells targeting pp65 (123-131) restricted by HLA-B*3501 have 
previously be monitored longitudinally in liver transplant patients (Hassan-Walker et 
al,  2001). The occurrence of HLA-Al/pp50 specific (Lacey et a l,  2005) and HLA- 
A24/pp65 specific CD8^ T cell responses (Gondo et a l,  2004, Morita et a l,  2005) were
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demonstrated in the HSCT setting by other groups during the time of investigations for 
this project. However this study aimed to further these findings by more frequent 
analysis for determination of the level of responses correlating with protection from 
CMV in HSCT patients.
Findings from this study demonstrated that CMV specific CD8^ T cells with 
different target specificities developed co-dominantly in HSCT patients. T cells were 
functional and, in contrast to previous reports (Ghei et a l ,  2005), recognised CMV 
peptides including pp65 (341-349) in a highly HLA specific manner. Surprisingly CMV 
specific CD8^ T cells were also detected in two recipients early post HSCT from CMV 
seronegative donors and it was suspected that these cells might be crossreactive in at 
least one of the two patients. It was found that CMV specific CD8^ T cell levels above 
which patients appeared to be protected from subsequent CMV replication if CD4^ T 
cells >160 cells/pl were present were significantly different depending on their target 
specificity.
Findings suggest an important role for HLA-B35/pp65 specific CD8^ T cell 
responses. These responses inversely correlated with the ability to detect CMV 
reactivation at significantly lower levels than HLA-Al/pp50 and HLA-A2/pp65 specific 
CD8^ T cell responses in HSCT patients. This suggests that HLA-B35/pp65 specific 
CD8^ T cells may be of higher efficiency with fewer cell numbers required to protect 
patients from CMV replication than is the case for HLA-Al/pp50 or HLA-A2/pp65 
specific CD8^ T cells. HLA-A24/pp65 specific CD8^ T cell responses also inversely 
correlated with the ability to detect CMV reactivation at lower levels than the latter two 
mentioned but were only observed in a minority of patients in this study and may be 
regarded as subdominant. Lower frequencies of HLA-B35/pp65 and HLA-A24/pp65 
specific than HLA-Al/pp50 and HLA-A2/pp65 specific CD8^ T cells were also 
observed in healthy volunteers.
These findings raise the question of how complex the total CMV specific CD8^
T cell response may be. Table 3-12 lists an estimate of these proportions by the use of 
data shown earlier within this chapter but this time demonstrated as the ratio of the 
increase of CMV specific CD8^ T cells and total CD8^ T cells after CMV reactivation.
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Patient HLA-B35/pp65 HLA-A24/pp65 HLA-Al/ppSO HLA-A2/pp65
1 10.2 %
2 0.9 % 0.8 %
4 0.5 %
6 1.3% 7.2%
8 13.4%
9 8.5 %
10 (e) 0.8 %
10 (1) 37.7 %
11 10.2%
12 1.0%
21 (e) 12.4%
21 (1) 2.1 %
22 3.3%
23 2.1 % 2.2%
Table 3-12 Estimated proportion of CMV specific CD8 T cells targeting different 
HLA/peptide combinations of the total CMV specific CD8  ^T cell response
Patients w ith  sign ifican t num bers o f  tetram er b ind ing ce lls  after at least on e C M V  reactivation  
period are listed  on the left (e: early reactivation period, 1: late reactivation  period). The 
increase o f  ce lls  bound by d ifferent tetram ers (listed  on the top o f  the co lu m n s) is sh ow n  as a 
percentage o f  the increase o f  all CD8^ T  ce lls  at the sam e tim e. T he increase in ce ll num bers 
w as m easured from  a tim e point im m ediately  prior to C M V  reactivation  until the first peak o f  
the resp onse observed  after that C M V  reactivation . D u e to  a gap b etw een  sam p lin g  before and 
after C M V  reactivation  in patient 12 (F igure 3 -7 , page 198) the increase o f  the response has 
been m easured from  the tim e point o f  the lo w est resp onse post C M V  reactivation  onw ards in 
th is patient.
It should be noted that these values would represent the actual values of the proportion 
of the total CMV specific CDS^ T cell response if the increase of total CDS^ T cells post 
CMV reactivation was purely CMV specific. Due to cytokine induced bystander 
activity of some CDS^ T cells, as an example, this may not be the case and therefore 
numbers may be an underestimate. However, findings shown in Table 3-12 suggest that 
CMV specific CD8 T cells measured within this project represent only a fraction of the 
total CMV specific CD8^ T cell response in these patients.
CD8^ T cells targeting different HLA/peptide combinations were seen to expand 
in parallel. Interestingly the pattern of these different responses was observed to vary 
slightly. For example in patient 6, HLA-A2/pp65 specific CD8^ T cells peaked at an 
earlier time point than HLA-B35/pp65 specific CDS^ T cells after CMV reactivation 
around day 56 post HSCT. In contrast in patient 2, HLA-B35/pp65 specific CDS^ T 
cells peaked at an earlier time point than HLA-A2/pp65 specific CD8^ T cells after 
CMV reactivation around day 549 post HSCT. In both patients the CMV specific CDS^
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T cells reaching their peak earlier are also of higher magnitude than CMV specific 
CD8^ T cells reaching their peak later.
The composition of the total CMV specific CD8  ^ T cell response appears to 
change over time. Table 3-12 shows an estimated 0.8 % of the total CMV specific CD8^
T cell response to be targeting HLA-A24/pp65 after an early CMV reactivation (day 65) 
in patient 10. This response had increased to an estimated proportion of 37.7 % of the 
total CMV specific CD8^ T cell response after a later CMV reactivation (day 89) in this 
patient. In contrast the HLA-Al/pp50 specific CD8^ T cell response observed in 
patient 21 was estimated to have decreased from 12.4% after an early CMV 
reactivation (day 153) to 2.1 % of the total CMV specific CD8^ T cell response after a 
later CMV reactivation (day 438).
These observations and findings shown in Figure 3-30 (page 252) suggest that 
the total CD8^ T cell response to CMV may be complex and multifaceted. The HLA- 
A2/pp65 specific CD8^ T cell response may not be as universally immunodominant as 
previously thought. Attempts were undertaken to study the proportion of antigen 
specific CD8^ T cells within the total CMV specific CD8^ T cells that are restricted by a 
single HLA allomorph. Therefore it was aimed to use CMV permissive - and HLA class 
I deficient cells lines. Transfection with a single HLA class I protein would then allow 
the study of T cells responses (restricted to that HLA protein) towards cell lines that 
were either infected with CMV, infected with a vector containing a specific CMV 
derived protein or pulsed with CMV epitope peptides. Since primary trophoblasts are 
known to be CMV permissive (Fisher et a l,  2000, Maidji et a l ,  2002) and the 
syncytiotrophoblast-like human choriocarcinoma cell line JAR, a first trimester 
trophoblast cell model, is deficient for classical major HLA class I molecules (King et 
a l , 1996), JAR was chosen as one of the cell line candidates for this experiment. This 
cell line was successfully transfected with HLA class I and infected with influenza A 
previously (Gobin et a l , 1997). Unfortunately, this and other cell lines tested could not 
be productively infected with two available CMV laboratory strains in this study. An 
example of the infection trials is shown in Figure 3-31. It may be that CMV infects only 
cytotrophoblasts but not syncytiotrohoblasts or that the cell line was non-productively 
infected as was demonstrated for trophoblast cell lines infected with other viruses 
previously (Liu et a l,  1995b, Zachar and Ebbesen, 1991). Alternatively the fibroblast 
adapted virus strains used, may not be suitable for the infection of the epithelial-like cell 
line used.
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Limited accessibility of other virus strains and of primary trophoblasts as well as the 
expertise required for handling of those, made it not feasible to use them in this study. 
Therefore experiments were not pursued further. However, future experiments could 
use a different combination of cell line and virus strain similar to that used in a recent 
report (LaMarca et al., 2006).
BJ1-uninfected BJI-ToledoF-GFP 
(48hrs pi)
BJ1-AD169-GFP 
(48hrs pi)
JAR-unlnfected J AR-ToledoF-G FP 
(48hrs pi)
JAR-AD169-GFP 
(48hrs pi)
Figure 3-31 CMV infection of cell lines
This figure sh ow s fluorescent m icrophotographs o f  the hT E R T -B Jl control fibroblast cell line 
on the top and o f  the JAR cell line on the bottom . C ells on the left were left uninfected; ce lls  in 
the m iddle are shown 48 hours post in fection  with the enhanced green fluorescent (EG FP) 
recom binant T oledo-F  C M V  strain; ce lls  on the right are show n 48 hours post in fection  with  
the EGFP recom binant A D I 69  C M V  strain. In both C M V  strains EG FP w as used as a reported 
gene under the transcriptional control o f  the 62 .7  prom oter (M cSharry e t a i ,  2 0 0 3 ). The 62 .7  is 
the m ost abundantly transcribed early gene from the C M V  gen om e with m axim al 
am plification betw een 8 and 14 hours post in fection  and rem aining actively  transcribed during 
the replication cyc le  (M cD on ough  e t  a l ,  1985). Expression o f  EGFP can be seen  under U V  
light, w here it em its green light. O bservations after 72 hours w ere sim ilar (not show n).
As the staining reagents for HLA-B35/pp65 and HLA-A24/pp65 specific CD8^ 
T cells are now readily available commercially and their measurement was reported to 
be feasible for routine monitoring (Buxbaum et a l,  2006), future investigations may 
hopefully include responses to these and new targets (such as new pp65 epitopes 
restricted by HLA-A*2402 and HLA-B*3501 described in 2007) that are constantly 
discovered (Burrows et a l,  2007, Khan et al, 2007). A study funded by Beckman 
Coulter, one of the companies offering tetramers commercially, recently investigated 
CMV specific CDS^ T cell responses to a variety the targets. Responses were monitored
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in HSCT patients and a brief, one-page long, report confirmed detectable portions of 
tetramer binding cells for all tetramers without going into much detail (Gratama et a l ,
2004). The authors of that study reported dim staining for HLA-A24/pp65, which was 
not observed with in-house made tetramer in this study. Furthermore they reported an 
inverse correlation between three clinical factors (the risks of recurrent viraemia, CMV 
disease and extensive GvHD) and CMV specific CD8^ T cell responses in patients. That 
report therefore confirms the importance of responses targeting a variety of CMV 
specific targets restricted by different HLA types in HSCT patients.
It remains to be shown in future cell transfer experiments whether CMV specific 
CD8^ T cells targeting different HLA/peptide combinations actually mediate protection 
or whether they are surrogate markers of the immune status and thus the ability of 
patients to combat CMV. The proportion of these cells within the total of CMV specific 
CD8^ T cells that are restricted by a single HLA allomorph could be studied using the 
extravillus cytotrophoblast cell line SGHPL-4 infected with the CMV strain RVdlMwt- 
GFP as described by LaMarca and colleagues (LaMarca et a l , 2006) in the future.
Certain subsets within CMV specific CD8^ T cells may be most effective at 
immediate clearance of the majority of virus infected cells whereas others may be 
necessary for long term control of CMV replication from latently infected cells. This 
may explain the phenotypic diversity that can be observed within CMV specific CD8^ T 
cells (Figure 3-32). This heterogeneity has also been observed within CMV specific 
CD8^ T cells of the same clonal origin ( Weekes et a l , 1999c, Wills et a l , 2002b).
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Figure 3-32 Heterogeneous phenotypes of CMV specific CDS T cells
Flow cytometry plots represent CD8^ T cells that were bound by tetramers listed on the right. Staining 
with CD27 and CD45RO on the left demonstrates various differentiation stages o f  CMV specific 
memory CD8^ T cells. Staining on the right demonstrates the proportions o f  CMV specific CD8^ T cells 
that are CD57^ CD28', a phenotype that was previously associated with terminally differentiated non­
proliferating effector T cells (Kern et a i ,  1996) but was since reported to represent a highly 
differentiated T cell subset with unique functionality (including the capability o f  proliferation) late after 
activation (Chong et a/., 2008).
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CD8^ T cells targeting a single CMV epitope may not be able to confer long-term 
protection from CMV in patients. Nevertheless, in the presence of CD4^ T helper cells, 
the transfer of such CD8^ T cells may be enough for the sum of all responses to be 
effectively preventing CMV from uncontrolled replication and thereby avoiding 
irreparable damage by the direct or indirect effect of CMV dissemination in patients.
The findings of this study are important because they can aid the development of 
adoptive transfer of donor-derived CMV-specific CD8^ T cells that can be obtained by 
tetramer guided cell sorting. In a previous study this has been shown to reduce the rate 
of viral reactivation and combat potentially fatal CMV related complications in patients 
reconstituting their immune system after conditioning for stem cell transplantation 
(Cobbold et a i, 2005, Keenan et a l, 2001). Due to the limitations of current antiviral 
pharmacotherapies, alternative approaches such as an adoptive therapy are needed. The 
presence of CD4^ T helper cells necessary for the functionality of CMV specific CD8^ 
T cells can be ensured by the use of an alternative cell selection methods for adoptive 
therapy such as cytokine capture assay. This involves a 20 hour incubation period of 
donor-derived PBMC with CMV protein and subsequent isolation of CD4^ and CD8^ T 
cells secreting IFNy by IFNy capture beads and has recently been demonstrated to be 
feasible and effective in a clinical environment (Mackinnon et a l, 2007).
It may not be necessary to transfer CMV specific CD8^ T cells at the levels 
established to inversely correlate with the ability to detect CMV reactivation in patients. 
In contrast, findings from adoptive cellular therapy trials demonstrated a high degree of 
in vivo expansion of transferred cells (Cobbold et a l,  2005, Mackinnon et a l, 2007). 
However, the knowledge of protective levels of CMV specific CD8^ T cells restricted 
by a variety of HLA alleles is important to be able to monitor the effectiveness of 
treatment modalities in a majority of patients, each expressing a variety of HLA alleles. 
Tetramer based monitoring can be of clinical use as a decision tool for patient 
management. Consistent with that a recent trial that based antiviral therapy on results 
from monitoring CMV specific immunity at 3-6 months post HSCT enabled 25 % of 
patients who had late CMV DNAemia to be spared additional antiviral therapy without 
development of CMV disease. It was suggested that this strategy may allow more 
targeted use of treatment to patients at highest risk of developing CMV disease 
(Avetisyan et a l, 2007).
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CHAPTER 4 CLONOTYPIC ANALYSIS OF EX VIVO 
CD8  ^ T CELLS WITH DIFFERENT HLA/CMV PEPTIDE 
TARGETS
4-1 Introduction
The previous chapter described the measurement of ex vivo CMV specific CD8^ T ceil 
responses with different HLA/CMV peptide target specificities and their functionality in 
HSCT patients. Findings demonstrated that the median number of CMV specific CD8^
T cells, which inversely correlated with the ability to detect CMV reactivation in 
patients was significantly different for different HLA/CMV peptide targets, which has 
important clinical implications.
This chapter describes the clonality of cells that were quantified in the previous 
chapter. Therefore the diversity of TCR used by the different CMV specific CD8^ T 
cells was analysed. Some viral infections are known to generate T cells with public 
TCR usage (refer to section 1-8.2). Focused TCR usage was also shown for HLA- 
A*0201/CMVpp65(495-503) and HLA-B*0702/CMVpp65(417-426) (subsequently 
abbreviated as HLA-A2/pp65 and HLA-B7/pp65 respectively) specific CD8^ T cells 
previously. Spectratyping and subsequent bacterial cloning of these cells demonstrated 
the use o f a restricted number of TCR V6 families without conservation of CDR3 
lengths or junctional motifs when donor PBMC were cultured with autologous DC and 
CMV antigen in vitro (Peggs et al., 2002). CMV specific CD8^ T cells derived from 
limiting dilution assay after stimulation with CMV infected fibroblasts also used a 
restricted number of VB families as demonstrated by flow cytometry with VB specific 
antibodies (Wills et al., 1996). It has been suggested recently that the underlying 
mechanism for this TCR repertoire focusing may be the selection of high affinity clones 
into the memory CD8^ T cell pool (Day et a l, 2007).
Although recent publications argue against it (as will be discussed in section 4- 
3), it is possible that TCR CDR3 diversity may be underrepresented during the analysis 
of sequences of T cell clones that were generated by cell expansion, because only clones 
able to proliferate in vitro may be detected. TCR analysis reported prior to initiation of 
this project was limited in that it was only performed for CMV specific T cells 
restricted by HLA-A2, HLA-B7 and HLA-B44 (Weekes et a l, 1999b, Peggs et a l, 
2002).
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This study aimed to compare the diversity of TCRs used by ex vivo CMV specific CD8^
T cells with different HLA/CMV peptide target specificities. Ex vivo TCR analysis may 
be difficult in healthy virus carriers due to low frequencies of CMV specific CD8^ T 
cells but it is possible in patients who expand these T cells after CMV reactivation post 
HSCT. TCR diversity of cells with a wide range of target specificities was assessed by 
spectratyping. The basics and examples of the application of this method were 
explained in section 1-8.2.
Spectratyping results can be illustrated in histograms representing peaks of 
fluorescent PCR products separated according to size. Each peak represents a set of T 
cell receptors bearing the same CDR3 length. The deletion and addition of nucleotides 
during rearrangement of T cell receptors is random. Therefore, for any VB family, an 
unperturbed polyclonal repertoire such as that of cord blood is represented by a set of 
peaks distributed in a Gaussian pattern, with the most frequent CDR3 length situated in 
the centre (Garderet et a i, 1998). Clonal expansion results in changes in the relative 
peak heights. Skewing of the Gaussian distribution can be observed with increasing age, 
due to antigenic stimulation. Contraction of the T cell repertoire after 
immunosuppression can also lead to iatrogenic gaps in the spectratype. In both cases, 
oligoclonality is indicated by predominance of only a few size classes in a spectratype 
(Gorski et al., 1994, Pannetier et a l , 1995).
Findings from analysing the clonality of CD8^ T cells with different HLA/CMV 
peptide target specificities may help to further the knowledge of which cells may be 
most effective in patients. The virus may easily escape a monoclonal T cell response by 
production of antagonist peptide. It is, however, unlikely that such peptides are 
produced for all TCRs of a polyclonal response.
Knowledge of the clonality of CMV specific CD8^ T cells may be useful for the 
development of treatment modalities using TCR gene transfer. The knowledge of TCRs 
used by CD8^ T cells targeting different CMV antigens may be of clinical use for 
enhancing the detection during the monitoring of CMV responses in high-risk 
immunodeficient patients by the use of clonotypic probes. Furthermore the clonality of 
responses has an impact on patients beyond their protection against CMV related 
disease development. This includes overall narrowing of the TCR repertoire resulting in 
accelerated immune ageing in patients.
Section 4-2.1 within this chapter first describes what challenges were 
experienced during the spectratyping of small numbers of cells and how these were
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overcome. Findings from analysing the TCR diversity of CMV specific CD8^ T cells 
are subsequently shown in separate smaller sub-sections within section 4-2.2, sorted by 
the HLA/peptide combinations targeted. Potential artefacts from this analysis and 
confirmatory experiments are described in sections 4-2.3 and 4-2.4. Section 4-2.5 then 
demonstrates bacterial cloning and sequencing of TCRs from 4 VB families, 2 of these 
each derived from HLA-A24/pp65 and HLA-B35/pp65 specific CD8^ T cells. These 
were performed to assess the level of heterogeneity within the dominant CDR3 size 
classes observed by spectratyping. The impact of findings from these experiments is 
then discussed in section 4-3.
4-2 Results
This section describes the experimental estimate of TCR diversity of ex vivo CMV 
specific T cell responses in HSCT patients. The analysis was focused on CD8^ a /p  T 
cells targeting the different HLA/CMV peptide combinations investigated in Chapter 3.
4-2.1 Preparation of ex vivo CMV specific CDS* T cells for TCR VS 
analysis
TCR CDR3 diversity may be underrepresented during the analysis of sequences of T 
cell clones that were generated by expansion in response to CMV antigen, because only 
clones able to proliferate in vitro may be detected with this method. It was therefore 
decided to analyse the TCR diversity of CMV specific CD8* T cells directly ex vivo 
using cDNA from sorted tetramer binding cells for PCR with TCR VB family specific 
primers. Some products were used further for bacterial cloning and sequencing with 
results shown in section 4-2.5 from page 298 onwards.
To estimate the TCR diversity of ex vivo CMV specific CD8* T cells, PBMC 
stained with HLA/CMV peptide tetramer were sorted into the cell fraction that bound to 
tetramer and the remaining fraction of cells that did not bind to tetramer. RNA was then 
extracted from sorted cells followed by reverse transcription PCR to obtain cDNA. PCR 
amplification of the TCR CDR3 region from cDNA was performed and PCR products 
of different lengths were separated by gel/capillary electrophoresis.
Without in vitro expansion, numbers of sorted tetramer binding cells were 
initially small (often <3,000). Therefore several experimental steps needed extensive 
optimisation to achieve successful TCR VB analysis of ex vivo CMV specific CD8* T 
cells, which is described below.
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4-2.1.1 Optimisation of sorting efficiency of CMV specific CD8* 
T cells
PBMC stained with PE (or APC) labelled tetramer were initially sorted with anti-PE (or 
anti-APC) magnetic beads over two consecutive MACS columns with a representative 
result illustrated in Figure 4-1.
Presort Postsort
: rt ' i
CDS
Figure 4-1 One-step sorting of tetramer stained cells using magnetic beads
This figure dem onstrates a representative exam ple o f  tetram er sorted PBM C  (patient 38). F low  
cytom etry plots represent CD3^ live  lym phocytes w ith ’stain ing profiles before bead sorting  
show n on the left and after bead sorting on the right. N um bers represent the ce lls  w ithin each  
quadrant as a percentage o f  total ce lls  in that plot.
This sorting approach resulted in very poor purity of sorted cells (70 % contamination 
of tetramer binding cells in the representative example shown). This was not adequate 
for further molecular analysing of these cells.
To achieve higher purity of sorted cells, a 2-step approach was then adopted. 
CDS^ T cells were enriched in a first step by depletion of non-CD8^ T cells with an 
antibody cocktail described in section 2-6.1, then stained with tetramer and sorted as 
described. However, the purity of sorted cells was highly dependent on their frequency 
within the original cell population, an observation also made by others (Bodinier et a l, 
2000). Two representative cell sorting examples are shown in Figure 4-2 demonstrating 
higher purity of sorted cells that were present at high frequency in the original 
population (panels A) than of cells that were present at low frequency in the original 
population (panels B). This may be due to less saturation of beads during the binding of 
magnetic beads to cells with low numbers of specific cells than during the binding to
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cells with high numbers of specific cells. This may, in turn, result in higher carry over 
of non-specific cells during the sorting of cells with low numbers of specific cells. 
Alternatively, the low purity of sorted cells may have resulted from a fixed background 
staining by tetramers leading to a lower signal to noise ratio during tetramer staining of 
low numbers of specific cells.
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Figure 4-2 Two-step sorting of tetramer stained cells using magnetic beads
Tetramer stained peripheral b lood  ce lls  from tw o individuals (A: patient 38; B: patient 4 ) are 
shown. F low  cytom etry plots represent CD3"  ^ live  lym ph ocytes w ith stain ing profiles before 
bead sorting shown on the left and after bead sorting on the right. N um bers in the upper right 
com er o f  the plots represent the ce lls  show n in gates as a percentage o f  total ce lls  in that plot.
Representative examples shown in Figure 4-2 are similar to findings reported by 
Bodinier and colleagues. In this study, specific cells with a frequency of 0.4 % in the 
original population were enriched to 10.0 % after sorting whereas specific cells with a 
frequency of 2.1 % in the original population were sorted to a purity of 72.3 % (Figure 
4-2). In comparison, specific cells with a frequency of 0.2 % in the original population 
were enriched to 8.6 % after sorting whereas specific cells with a frequency of 1.4 % in
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the original population were sorted to a purity of 75.9 % in the study by Bodinier and 
colleagues (Bodinier et a l, 2000).
Sorted cells of high purity were not obtained with either the 1-step or the 2-step 
approach using magnetic beads from either StemCell Technologies or Miltenyi Biotech. 
Magnetically sorted cells of purities as low as 10 % of CD3^ T cells (corresponding to 
98.8 % of CD8^ T cells) were used for adoptive therapy trials previously (Cobbold, 
2005, Cobbold et a l, 2005). However, I felt that it should be attempted to achieve high 
purity of sorted cells before proceeding to molecular analysis, which involves highly 
specific PCR methods that may pick up amplicons originating from contaminating cells.
To test whether purity can be increased with a different sorting method, cell 
sorting was subsequently performed by flow cytometry (section 2-6.2). With this 
technique, live cells that simultaneously stained positive for CD3, CD8 and tetramer 
were sorted with high purity (>90 %) and were additionally counted during the sorting 
process, whereas a cell count after magnetic bead sorting would result in loss of 
material. It may be that sorting by FACS with live gating enabled better capture of 
tetramer stained cells in comparison to sorting by magnetic beads because cells of low 
fluorescence intensity (resulting from TCR downregulation) may not be distinguished 
efficiently from unstained cells during sorting with magnetic beads. Two representative 
examples of cells sorted by flow cytometry are shown in Figure 4-3.
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Figure 4-3 Sorting of tetramer stained cells using flow cytometry
Plots illustrate tetramer stained PBM C from tw o individuals (A: patient 22 , H LA- 
A * 0 l0 l/p p 5 0  tetramer staining; B; patient 34, H L A -A *O IO I/pp65 tetram er staining). 
CD3^ CD8^ live ce lls  are dem onstrated with staining profiles before sorting show n on the left 
and staining profiles after bead sorting show n on the right. N um bers in the upper right com er  
o f  the plots represent the ce lls  show n in gates as a percentage o f  total CD8^ T ce lls .
4-2.1.2 Optimisation of mRNA yields by phytohaemagglutinin 
stimulation of T cells and choice of more efficient cDNA production 
methods
Sorting of ex vivo CMV specific CD8^ T cells resulted in low yields of cells. To be able 
to analyse the TCR repertoire of these cells, a short stimulation of cells was performed 
to boost TCR mRNA levels. The rational behind this approach is that TCR transcription 
is up-regulated during T cell activation, which can be achieved by phytohaemagglutinin 
(PHA) or phorbol esters (Wotton et al., 1993). To avoid artefacts introduced by 
differential proliferation of individual clones, it was intended to limit stimulation to a
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time period before cell division was initiated, while still inducing blasts and an increase 
in the TCR mRNA levels in the lymphocytes.
To establish the duration of stimulation necessary, blast transformation and 
proliferation were assessed by means of forward and side scatter characteristics and by 
CFSE staining of cells that had been stimulated with PHA for different time periods. 
First experiments demonstrated that blast transformation occurred after only one hour 
(Figure 4-4). Due to their larger surface area, lymphoblasts stain slightly brighter with 
CFSE than their resting counterparts. This was confirmed by back-gating analysis. 
Histograms illustrate that no dilution of CFSE occurred in cells after stimulation with 
PHA for 1 hour when compared to unstimulated cells indicating that proliferation did 
not occur within this short time period.
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Figure 4-4 PHA stimulation induces lymphocyte blasts within 1 hour
C FSE and CD3 stained peripheral b lood ce lls  from healthy volunteer 17 that w ere either 
unstim ulated (A ) or stim ulated with PHA for I hour (B ) are sh ow n . F low  cytom etry plots and 
histogram s on the right represent live  lym phocytes gated as show n on the left.
No proliferation after PHA stimulation for up to 20 hours was observed in initial 
experiments. Therefore the use of longer time periods was investigated. Results can be 
seen in Figure 4-5. These were obtained from duplicate samples, each stained with 
CFSE and stimulated with PHA for a fixed period of time before CD3 staining and 
assessment by flow cytometry.
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(Continued)
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Figure 4-5 PHA stimulation for up to 32 hours fails to induce proliferation of 
lymphocytes
CFSE and CD3 stained peripheral b lood  ce lls  from healthy volunteer 18 that were either 
unstim ulated or stim ulated with PHA for different periods o f  tim e (indicated in the graph) are 
shown. Flow  cytom etry plots and histogram s on the right represent live  lym phocytes gated as 
show n on the left.
All cells were left in culture for the same duration of time (7 days) during this 
experiment to adjust for gradual loss of CFSE over time (PHA stimulant was added at 
different times before harvest). This may explain why blasts shown in Figure 4-5 are 
less prominent than those shown in Figure 4-4, which were left in culture for less than 2 
days. Daughter cells demonstrating lower CFSE staining (<10^ fluorescence units) than 
parental cells are first visible after 48 hours of PHA stimulation (Figure 4-5). Results
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from this experiment demonstrate that PHA stimulation induced blast formation of cells 
after the shortest stimulation period (2 hours) in the absence of proliferation for up to 32 
hours.
To confirm up-regulation of the TCR by PHA stimulation and establish the 
shortest possible time to achieve optimal TCR mRNA up-regulation, TCR mRNA 
levels in cells were assessed after stimulation with PHA for different time periods. 
Therefore several primer pairs were designed and tested for amplification of TCR CB by 
quantitative PCR (qPCR) using SYBR Green. The chosen pair had one primer lying 
across an intron/exon boundary to avoid amplification from genomic DNA and was 
designed to amplify a 195 bp fragment from TCR CBl or CB2 cDNA. TCR CB PCR 
products obtained from cDNA from healthy volunteers were cloned into pCR2.1 
plasmid DNA vectors. These plasmids were then used to generate TCR dilutions 
containing known quantities of TCR molecules, for use as a standard in qPCR analysis. 
Control amplifications were performed using primers for a constitutive gene, which 
encodes the transferrin receptor (TfR). TfR standards for qPCR were prepared in the 
same way as for the TCR. 1x10^ PBMC from quadruplicate cultures stimulated with 
PHA for different time periods were harvested for RNA extraction and subsequent 
productions of cDNA, which was used to quantify TCR mRNA expression along with 
the control TfR mRNA. Standard curves for TCR and TfR copy numbers had very 
similar slopes as illustrated in Figure 4-6.
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Figure 4-6 Standard curves obtained during qPCR of TCR and TfR dilutions
This graph sh ow s Ct values (threshold cycles: PGR cy c le  at w hich  a statistically  sign ificant 
increase o f  the fluorescent signal w as first detected) m easured by qPCR o f  standards 
containing lO' to 10* m olecu les o f  target cD N A .
From these standard curves the efficiency of primer pairs can be calculated as follows. 
primer efficiency = 10^  -  1 JclOO
Primer efficiencies were similar for amplifications from TCR (93.95 %) and TfR 
(93.83 %) target cDNA. Quantities of TCR and TfR transcripts obtained from 
quadruplicate measurements of cDNA from PBMC after stimulation with PHA for 
different time periods were measured (in repeated experiments). The ratio of mean TCR 
transcripts in cells normalised to mean transcripts of the constitutive gene TfR 
(calculated from quadruplicate measurements) can be seen in Figure 4-7.
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Figure 4-7 Quantification of TCR transcript in lymphocytes after stimulation with 
PHA
The ratio o f  the mean quantities o f  TCR and TfR  transcripts (show n w ith deviations from  
quadruplicate m easurem ents) is sh ow n  for ce lls  stim ulated with PHA for the tim e periods 
show n on the x-axis.
Values obtained by qPCR were not normalised as transcripts per fixed amount of RNA 
or cDNA (compare section 2-8.9.1) but are shown as mean transcripts obtained from a 
fixed number of cells, which were stimulated with PHA. It was decided to set up the 
experiment in a way that reflects circumstances which would occur in final experiments 
(using FACS sorted CMV specific T cells after a short stimulation with PHA) to 
establish whether the balance of cells dying in culture versus activation of cells may 
result in a net increase of TCR mRNA yields from cells. The findings demonstrate that 
TCR mRNA levels were significantly increased in cells after stimulation with PHA for 
6 hours. Levels remained relatively stable during longer periods of stimulation and 
increased again after a stimulation period of 48 hours in parallel with the start of cell 
proliferation (compare Figure 4-5).
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The combined findings from experiments shown above indicate that TCR mRNA levels 
can successfully be increased without induction of proliferation of lymphocytes (which 
may potentially distort the TCR repertoire) after in vitro stimulation with PHA for 6 to 
32 hours. CMV was reported to drive expansion of CD8^ CD57^ T cells (Wang et a l, 
1993) and this T cell subset is known to be highly susceptible to activation-induced cell 
death (Brenchley et a l,  2003). Therefore CD8^ T cell stimulation with PHA is best kept 
short to avoid activation induced cell death of a subset of memory T cells, which may 
distort the TCR repertoire. Thus a time period of 6 hours was established as the 
optimum duration for stimulation of sorted CMV specific CD8^ T cells to boost TCR 
mRNA levels prior to spectratyping experiments.
Messenger RNA yields were additionally optimised by comparison of different 
RNA extraction methods (Qiagen RNeasy Mini Kit, robot based Qiagen EZl RNA Cell 
Mini Kit, Dynabeads mRNA DIRECT Micro Kit and Qiagen RNeasy Micro Kit) and 
RT-PCR methods. Best results were obtained from the latter column-based RNA 
extraction method, used with a carrier in combination with Sensiscript reverse 
transcriptase (refer to Chapter 2 for details).
4-2.1.3 Optimisation of multiplex PCR amplification of TCR VS & 
capiiiary electrophoresis based separation
The introductory chapter (section 1-8.1) outlined molecular mechanisms leading to 
diversity of T cell receptors during maturation of CD8^ T cells. During PCR 
amplifications spanning the CDR3 region between V6 and C6 rearranged gene 
segments, a single primer can anneal to both the CGI and the CG2 gene segments that 
can make up the TCR. It is, however, not possible to design a single primer that can 
anneal to all the VG gene segments that exist. TCR G variable gene segments are 
classified into VG families based on nucleotide sequence similarity (Rowen et a l, 1996, 
Wei et a l,  1994). New VG gene segments are still being discovered and new families 
being defined. Spectratyping requires multiple PCR reactions, each including a CG 
specific and a VG family specific primer (refer to section 1-8.2 for details).
Singleplex PCR covering all 24 VG families which were defined in 1991 
(Ferradini et a l, 1991) was used initially. This required 26 reactions since separate 
primers were required to cover the VG5.1 and VG5.2 subfamilies and the VG13.1 and 
VG13.2 subfamilies. Figure 4-8 demonstrates separation of PCR products from all of 
those 26 reactions using singleplex VG PCR.
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Figure 4-8 Detection of TCR VB singleplex PCR products by agarose gel 
electrophoresis
1% agarose gel electrophoresis o f  PCR products am plified  w ith  prim ers sp ec ific  for VB 
fam ilies indicated above the gels. Lane 1, 2 and 3: PCR w as perform ed on c D N A  generated  
from 2x10^ PBM C  from  healthy volunteers 15, 16 and 2 resp ective ly . Lane 4: PCR was 
perform ed on control sam ples using H2O as starting material for cD N A  generation. Lane 5: 
D N A  m olecular w eight marker (H yperladder IV, B io lin e, com pare Figure 4 -1 0  for s izes  o f  
standards)
Amplification was successful for all VB families except VBI2, for which amplification 
was eventually resolved, as addressed later. PCR,products from all other TCR VB 
families were successfully detected. PCR products of VB4 and 16 that were barely 
visible on the agarose gels shown in Figure 4-8 were subsequently detected by more 
sensitive methods. After gel electrophoresis was used to confirm successful PCR 
amplification of TCR VB templates, PCR products were separated using large 
polyacrylamide gels, which have a more uniform pore size than agarose gels and 
therefore enable highly sensitive detection and high resolution separation of DNA 
fragments as required for spectratyping. This high-resolution separation was performed 
using 6 % denaturing polyacrylamide gels on an automated DNA sequencer with 
fragment analysis option. A representative result obtained with this method is shown in 
Figure 4-9.
276
Chapter 4
g
Bc
8
§
2O3
U_
PCR product size
Figure 4-9 Detection of TCR VB singleplex PCR products by polyacrylamide gel 
electrophoresis on a DNA sequencer
Frequency histogram  o f  a typical VB PCR profile from  cD N A  generated from 5x10^ PBM C  
from a healthy volunteer.
During initial experiments using RNeasy mini kit (Qiagen) without PHA stimulation, 
followed by singleplex PCR, it was only possible to obtain the minimum amount of 
RNA necessary to perform spectratyping when using at least 2x10^ PBMC. This is 
illustrated in Figure 4-10.
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Figure 4-10 Requirement of 200,000 PBMC for spectratyping prior to optimisation
The 1 % agarose gel sh ow s separation o f  B-actin (le ft)  versus VB2 (right) PCR products o f  
cD N A  generated from 100 ,000  (lane 1), 2 0 0 ,0 0 0  (lane 2), 2 5 0 ,0 0 0  (lane 3), 5 0 0 ,0 0 0  (lane 4), 
1x10^ (lane 5) and 2x10^ (lane 6) PBM C from a healthy volunteer along with an H2O control 
used for cD N A  generation (lane 7). The 8* lane in the right gel is em pty; lanes on the far left 
and right represent Hyperladder IV (B io lin e) with relevant sizes indicated besid e the gel. The 
arrow indicates m inim um  cell num ber requirem ent for v is ib le  PCR am plification
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The finding is consistent with observations by other groups (Elizabeth K. Day, 
University of Cambridge, personal communication, December 2004). Minimum cell 
number requirements were a critical limitation factor for experiments because it was 
intended to spectratype ex vivo CMV specific CD8^ T cells, and initial sorting using 
MACS beads of these cells often yielded cell numbers not exceeding 3,000 (higher 
numbers between 3,500 and 13,870 were obtained from MACS bead sorted cells from 
four patients (Figure 4-20, page 295), and these were used for further experiments 
detailed in section 4-2.5).
To improve the lower limit of cell numbers required for spectratyping, a new 
method was adopted. Instead of conventional use of one labelled C6 primer with one of 
26 unlabelled Vfi primers in 26 single PCR reactions, an unlabelled CG primer was used 
along with VB primers that were labelled with one of three different fluorochromes and 
multiplexed into 7 reactions containing the CB and 2 to 5 VB primers per reaction (refer 
to Table 2-7 on page 165 for details). Only 24 VB primers were used because VB 
families 10 and 19 were reported to be pseudogenes (Currier et al., 1996). Multiplexing 
was based on compatibility of primers (such as similar melting temperatures) and PCR 
product sizes that needed to be sufficiently distinct from each other in order to 
distinguish between products of different VB families that were labelled with the same 
fluorochrome. The multiplex approach needed less than a third of the starting material 
for successful TCR spectratyping compared to 26 singleplex PCR reactions that were 
used initially. In addition multiplex PCR with VB primer labelling was reported to result 
in superior resolution when using small amounts of starting material (Fernandes et al.,
2005). New primer sequences also resolved VBI2 amplification problems described 
earlier. The use of a molecular size standard labelled with a fourth fluorochrome 
allowed for accurate sizing of labelled PCR products. Separation of PCR products 
labelled with three different fluorochromes was performed on a different automated 
DNA sequencer than that used for one-colour-based spectratyping. This machine used 
denaturing capillary electrophoresis with a linear polyacrylamide separation polymer, 
which resulted in a higher turnover and greater reproducibility of spectratyping.
Figure 4-11 demonstrates separation of TCR VB PCR products by capillary 
electrophoresis visualised by Gene Profiler software. Fragments from F AM, JOE or 
TAMRA labelled PCR products and an ET-ROX labelled size standard were run in the 
same capillary, resulting in separation of fragments according to size (along the x-axis), 
which can be detected as fluorescent signals according to their abundance in different
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spectral channels (shown on the y-axis). The original software output (after zooming 
onto part of the y-axis) from separation of a FAM labelled control PCR product is 
shown in Figure 4-11.
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Figure 4-11 Separation of TCR VB multiplex PCR control products along with a 
molecular size marker by capillary electrophoresis
Frequency histogram s dem onstrate the ET -R O X  m olecular size  marker in upper lanes (red) 
and FAM  labelled PCR products in low er lanes (blue). CDR3B lengths from TC R s o f  unsorted 
PBM C from a healthy control fo llo w  a classical G aussian distribution (part B: VB6 PCR was 
performed on cD N A  generated from 2x10^ PB M C ) whereas the TCR o f  ( l7 4 x C E M ) T2 ce lls  
dem onstrate a uniform CDR3B length because this human T-B  hybrid lym phoblastoid  ce ll line 
expresses a sin g le T cell receptor (part A: VB9 PCR w as performed on cD N A  generated from  
3,000  T2 ce lls).
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Initial TCR VB amplification using similar concentrations of VB specific primers in 
PCR reactions revealed that some primers amplified products at a significantly higher 
level compared to others. The high intensities of the signal from these highly amplified 
products led them to bleed into the neighbouring channels of the detector. To overcome 
this challenge and fully profit from the benefits of the new technology, extensive 
optimisation of primer concentrations was performed for each multiplex VB PCR. This 
was necessary to establish optimal signal to noise ratios in which optimal spectral 
compensation is possible. Additionally an extended period of the primer extension step 
at 72 °C for 5 minutes was applied and this gave superior amplification results (compare 
section 2-12.4).
Figure 4-12 illustrates frequency histograms obtained after optimisation of PCR 
conditions to achieve similar fluorescence intensities. The reliable range of signal 
detection on the DNA sequencer used to separate multiplex PCR products lies between 
100 and 64,000 relative fluorescence units. PCR conditions were optimised to achieve 
approximately 2,000 relative fluorescence units for all PCR amplifications of TCR VB 
families from cDNA of healthy volunteers. Ideally this would have been performed on 
cord blood samples with an unperturbed Gaussian TCR repertoire. However, due to lack 
of access to such samples optimisation was performed on pooled cDNA from different 
healthy individuals.
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Figure 4-12 Optimised separation and sizing of TCR VB multiplex PCR products 
by capillary electrophoresis
Frequency histogram s o f  TCR VB fam ilies derived from unsorted PBM C from healthy  
volunteers. Primer concentrations w ere optim ised  to ach ieve sim ilar m axim um  fluorescen ce  
intensity (y -ax is) o f  C DR3 spanning TCR VB PCR products o f  different s izes  (x -ax is) from all 
24 TCR VB fam ilies (assigned  above each histogram ).
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In contrast to original output data as shown in Figure 4-11, the units of the x-axis of 
frequency histograms in Figure 4-12 are shown as size in base pairs, calculated by 
comparison with the size of the molecular size markers.
4-2.2 Estimation of TCR diversity of ex vivo CMV specific CD8* I  
cells targeting different HLA/CMV peptide combinations
With methods optimised as described in the previous sections, spectratyping was 
successfully performed on ex vivo CMV specific CD8^ T cells. This section describes 
the clonotypic analysis of these cells in HSCT patients.
The analysis was successful on most samples with one comprising as few as 200 
cells. Sampling from low numbers of cells, however, may result in an artificially low 
TCR diversity detected, and this is discussed further in section 4-2.3 from page 292 
onwards.
Figure 4-13 shows spectratyping results for HLA-Al/pp50 specific CD8^ T cells 
that were FACS sorted with 96.4 % purity (cell yield 4,738) from patient 14 as a 
representative example. The software used for analysis did not allow for manual setting 
of the scale of fluorescence intensity to a common maximum value. An automatically 
generated scale would have resulted in illustrations with highly amplified insignificant 
peaks in cases where no fluorescent signal above background level was observed. To 
avoid this, V13 histograms (in black, blue or green depending on the fluorescent label of 
PCR products) are shown as an overlay with histograms from the molecular marker (in 
red). Signals from the size marker were consistently in the range of 500 to 2,000 
arbitrary units and therefore serve as a reference for fluorescence intensity. Figure 4-13 
was produced by alignment of screenshots of the output from the analysis program. 
Neighbouring spectral channels were considered during the analysis of VB histograms 
to spot potential artefacts where high fluorescence intensities from one amplification 
could bleed into other channels of the detector.
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Figure 4-13 Representative example of TCR spectratyping histograms of sorted 
cell populations
Frequency histogram s o f  TCR VB fam ilies derived from  cD N A  from patient 14 (black, blue or 
green curves) in overlay with peaks derived from the m olecular size  standard (red curve). A: 
Sorted tetramer binding cell fraction; B: Sorted cell fraction that did not bind tetramer.
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Spectratypes of tetramer sorted cells were analysed in comparison with spectratypes 
from the remaining PBMC sample to rule out that detection of expanded clones merely 
reflects the presence of an expanded but irrelevant (not CMV specific) T cell clone in 
the periphery.
Figure 4-13 shows spectratyping on a sample from patient 14 that was collected 
at 55 days post autologous transplantation. It illustrates that all VB families except VB21 
were used by CD8^ T cells that did not bind tetramer (Figure 4-13, B), and that the 
patient had T cells with a diverse TCR repertoire (with several size classes detected for 
most VB families) at this time point. The sorted HLA-Al/pp50 specific CD8^ T cells 
(Figure 4-13, A) used several VB families. Comparisons described later during this 
chapter will show that, CMV specific CD8^ T cells targeting this HLA/peptide 
combination demonstrate exceptionally diverse TCR usage in comparison to those 
targeting other HL A/peptide combinations. The strongest signals observed in the 
representative example were in VBI, 7, 17 and 24. Lower signals were also observed in 
a number of additional VB families. According to the MegaBACE manufacturer, signals 
are reliable above 100 units. Therefore signals below this strength were usually 
discounted. If close to the 100 unit threshold, signals were considered positive only if 
they could be clearly discriminated from the background in VB families such as VB 22 
(compare Table 4-1), which generally demonstrated low signals. Background from free 
TAMRA dye had to be considered in the analysis of VB24 amplifications. In the case of 
patient 14 only those of one size class were confirmed using unlabelled VB24 and 
labelled CB primer in tetramer binding CD8^ T cells. With these considerations, 
significant VB signals from HLA-Al/pp50 specific CD8^ T cells from this patient are 
summarised in Table 4-1.
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VB family Number of CDR3 lengths Maximum fluorescence 
intensity detected
1 1 26,965
2 2 304
3 1 101
6 3 180
7 1 4,248
8 1 312
12 1 305
13S1 1 137
14 1 181
17 2 3,960
20 2 125
22 2 85
24 1 4,947
Table 4-1 Representative example of CDR3 size classes detected using 
spectratyping of CMV specific CD8  ^T cells
List o f  the num ber o f  d ifferent TC R  VB C D R 3 lengths and flu orescen ce in tensity  detected  in 
cD N A  from  tetram er b ind ing ce lls  from  patient 14.
As shown for patient 14 above, spectratyping results were analysed for other patients. 
Findings are summarised in different sections depending on the HLA/CMV peptide 
specificity of CD8^ T cells. Since HLA-A2/pp65 specific CD8^ T cells might be 
considered as an archetype for comparison of CMV specific CD8^ T cells targeting 
other HL A/peptide combinations (compare section 3-2.4), analysis of these cells will be 
shown first.
4-2.2.1 TCR diversity of HLA-A2/pp65 specific CDS* T ceiis
HLA-A2/pp65 specific CD8^ T cells are the most studied CMV specific CD8^ T cells 
and as such might be considered as a standard for comparison with CMV specific CD8^ 
T cell responses targeting other HL A/peptide combinations. To use them as a standard 
in this study, the TCR diversity of HLA-A2/pp65 specific CD8^ T cells was studied in 
this section and findings will be compared to the TCR diversity of other cells in section 
4-3.
Spectratyping was successfully performed on HLA-A2/pp65 specific FACS 
sorted CD8^ T cells from 5 HSCT patients. Results from spectratyping histograms are 
summarised in Figure 4-14.
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Figure 4-14 CDR3 size classes detected by spectratyping of HLA-A2/pp65 specific 
CD8^ T cells
CDR3 size  classes detected  in cD N A  from tetramer binding ce lls  from different patients (y- 
axis) are illustrated by b oxes w ith different colours reflecting the number o f  different C DR3  
lengths (histogram  peaks) observed for TCRs in each VB fam ily (x-axis).
Figure 4-14 demonstrates that HLA-A2/pp65 specific CDS T cells obtained from 
different patients use VB families 1, 4, 6, 8, 9, 12, 13S1, 14, 17, 20 and 24. The mean 
number of TCR VB families used by HLA-A2/pp65 specific CDS^ T cells was 3.6 
(n = 5, range 2 - 10), which is similar to observations in CD8^ T cells that target other 
HLA/peptide combinations (sections 4-2.2.2, 4-2.2.4 and 4-2.2.5). In contrast, CD8^ T 
cells targeting HLA-Al/pp50 (section 4-2.2.3) used a significantly greater diversity of 
TCRs.
HLA-A2/pp65 specific CD8^ T cells from 4 out of 5 patients analysed used 2 
different VB families, whereas cells from the remaining patient used 10 VB families. 
The number of HLA-A2/pp65 TCR VB families detected in this study is similar to 
previous observations, which will be discussed further in section 4-3 (page 312 
onwards). Shared CDR3 lengths were observed for the TCRs of HLA-A2/pp65 specific 
CD8^ T cells for VB6 in patients 24, 29 and 30b (198 bp), for VBI2 in patients 30b and 
37 (234 bp), for VB12 in patients 29 and 30b (228 bp) and for VB20 in patients 29 and 
37 (226 bp). These CDR3 size classes may reflect public TCR repertoires.
The highest signals detected by VB spectratyping of HLA-A2/pp65 specific 
CD8^ T cells were found in patient 29. Paradoxically, this patient demonstrated the 
most diverse TCR repertoire and the highest level of these cells out of all HSCT 
patients, but was not protected against CMV reactivation (Figure 3-24, page 233).
The TCR diversity of CD8^ T cells from patient 24 and 29 (both of whom 
demonstrated high levels of HLA-A2/pp65 specific CD8^ T cells and were not
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protected against CMV reactivation) was analysed irrespective of the functionality of 
these cells in vivo (refer to section 3-3.1 for more details).
4-2.2.2 TCR diversity of HLA-A1/pp65 specific CD8* T cells
HLA-Al/pp65 specific CD8  ^ T cells were detected only in a minority of patients (refer 
to section 3-2.3). Therefore spectratyping could be performed on (FACS) sorted cells 
from 3 HSCT patients only. Findings are illustrated in Figure 4-15.
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Figure 4-15 CDR3 size classes detected by spectratyping of HLA-Al/pp65 specific 
CD8  ^T cells
CDR3 size  classes detected in cD N A  from tetramer b ind ing ce lls  from d ifferent patients are 
illustrated in a way sim ilar to that o f  Figure 4 -14  on page 287 .
The mean number of TCR VB families used by HLA-Al/pp65 specific CD8^ T cells 
was 5 (n = 3, range 1 - 11). A comparison of these cells with CMV specific CD8^ T 
cells targeting other HLA/CMV peptide combinations will be discussed in section 4-3.2 
(page 315). A size class of 234 bp in VB 12 was shared by patients 14 and 21 and may 
reflect a public TCR repertoire.
4-2.2.3 TCR diversity of HL A-A1/pp50 specific CD8* T cells
Spectratyping was successfully performed on HLA-Al/pp50 specific (FACS) sorted 
CD8^ T cells from four HSCT patients with results shown in Figure 4-16.
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Figure 4-16 CDR3 size classes detected by spectratyping of HLA-Al/pp50 specific 
CD8  ^T cells
C DR3 s iz e  c lasses detected in cD N A  from tetramer b inding ce lls  from different patients are 
illustrated in a way sim ilar to that o f  Figure 4 -14  on page 287 .
The mean number of TCR VB families used by HLA-Al/pp50 specific CDS^ T cells 
was 9.5 (n = 4, range 1-19) with three of 4 patients demonstrating TCR usage of 
exceptionally high diversity, which was significantly greater than that observed for 
CMV specific CDS^ T cells targeting other HLA/CMV peptide combinations (compare 
sections 4-2.2.1, 4-2.2.2, 4-2.2.4 and 4-2.2.5). In contrast to other CMV specific CDS^ 
T cells studied in this project, cells investigated in this section targeted a different CMV 
protein. All other HLA/CMV peptide combinations involved peptides from the CMV 
pp65 protein, whereas cells investigated in this section targeted peptides from the CMV 
pp50 protein.
Similar CDR3 lengths were observed in 5 VB families. The strongest signals 
from HLA-A*0101 restricted CMV pp50 (245-253) specific CDS T cells were 
observed for a CDR3 size class of 200 bp from TCR VBI in patients 14 and 22. Similar 
CDR3 lengths of 202 bp were also observed in VB2 in these two patients. Patients 14 
and 31 shared similar CDR3 lengths of 205 bp in VB2, 251 bp in VB8 and 231 bp in 
VB13S1. Signals from VB22 were below 100 fluorescence intensity units in tetramer 
binding cells from patients 14 (Figure 4-13) and 31. Since PCR products were generally 
of low signal strength and very low background noise was detected in this particular VB 
family, these peaks are considered genuine. Accordingly patients 14 and 31 also share a 
CDR3 length of 242 bp in VB22. These CDR3 size classes may reflect public TCR 
repertoires.
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4-2.2A TCR diversity of HLA~A24/pp65 specific CD8* T cells
HLA-A24/pp65 specific CD8^ T cells were detected only in a minority of patients (refer 
to section 3-2.2). Therefore spectratyping was successfully performed on sorted cells 
from three HSCT patients only. Cells from one of these patients were sorted with 
MACS beads (resulting in a purity of 97.3 % of CD8^ T cells, corresponding to 70.6 % 
of CD3^ cells) before optimisation as described in section 4-2.1.1 was completed. Due 
to the lower purity achieved by cell sorting with beads compared to cell sorting by 
FACS (compare Figure 4-2 and Figure 4-3 on page 266 and 268 respectively) signals 
were only considered to be genuine when the strength of fluorescence intensity in 
tetramer binding cells was similar or greater than the signal strength observed in cells 
that did not bind tetramer. Findings are illustrated in Figure 4-17.
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Figure 4-17 CDR3 size classes detected by spectratyping of HLA-A24/pp65 specific 
CD8  ^T cells
CDR3 size  classes detected in cD N A  from either FA C S sorted (upper part) or M A C S bead  
sorted (low er part) tetramer binding ce lls  from different patients (y -a x is) are illustrated by 
boxes with different colours reflecting the num ber o f  different C D R 3 lengths (histogram  
peaks) observed for TCRs in each VB fam ily (x-axis).
Two patients (patient 12 and 36) used the same VB family. However, similar CDR3 
lengths were not observed. The mean number of TCR VB families used by HLA- 
A24/pp65 specific CD8^ T cells was 2.3 (n=3, range 1 - 4). CMV specific CD8^ T cells 
targeting this HLA/CMV peptide combination used a TCR repertoire that was restricted 
to the same degree as that observed for HLA-B35/pp65 specific CD8^ T cells that will 
be shown in section 4-2.2.5. HLA-A24/pp65 tetramer sorted cells from patient 11 were 
further investigated in section 4-2.5.
Considering only those results obtained from samples that were FACS sorted 
which may therefore be more reliable due to the high purity of cells analysed, the
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number of TCR VB families used by HLA-A24/pp65 specific CD8^ T cells was 1 and 2 
respectively (n = 2).
4-2.2.S TCR diversity of HLA-B35/pp65 specific CDS* T cells
Spectratyping was successfully performed on HLA-B35/pp65 specific sorted CD8^ T 
cells from six HSCT patients. Cells from three of those were sorted with MACS beads 
before optimisation as described in section 4-2.1.1. The purity of sorted cells achieved 
was only 68.6 % of CD8^ T cells corresponding to 59.1 % of CD3^ T cells in patient 4,
96.3 % of CD8^ T cells corresponding to 56.9 % of CD3^ T cells in patient 5 and
65.3 % of CD8^ T cells corresponding to 56.6 % of CD3^ T cells in patient 9. Signals 
were therefore only considered to be genuine when the strength of fluorescence 
intensity in tetramer binding cells was similar or greater than the signal strength 
observed in cells that did not bind tetramer. The findings are illustrated in Figure 4-18.
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Figure 4-18 CDR3 size classes detected by spectratyping of HLA-B35/pp65 specific 
CDS* T cells
CDR3 size  classes detected in cD N A  from sorted tetramer binding ce lls  from different patients 
are illustrated in a way sim ilar to that o f  Figure 4 -17  on page 290 .
Similar CDR3 lengths were observed in four VB families.
• In VB6, a CDR3 size class of 194 bp was observed in patients 1, 8 and 9. 
However, the signal strength observed in tetramer binding cells was lower than 
in cells that did not bind tetramer from patients 8 and 9 and therefore this CDR3 
length was not considered genuine and is not illustrated for patients 8 and 9 in 
Figure 4-18. Also within this VB family, a CDR3 size class of 197 bp was 
observed in patients 1, 4 and 9. For this CDR3 length, lower signal strength in
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tetramer binding cells than in cells that did not bind tetramer was observed in 
patient 4 (not considered genuine). An additional VB6 CDR3 size class of 
206 bp was observed in patients 4 and 8 but not considered genuine in patient 4.
• In VB 12, a CDR3 size class of 221 bp was observed in patients 1, 9 and 31 and 
a CDR3 size class of 227 bp was observed in patients 4, 8 and 9 (the latter not 
considered genuine in patient 8).
• In V63, a CDR3 size class of 200 bp was observed in patients 4, 8, 9 and 35. 
This was considered genuine in patients 8 and 35 only and will be further 
discussed in section 4-3.
• In V624, a CDR3 size class of 243 bp was observed in patients 4 and 8.
These CDR3 size classes reflect potentially public TCR repertoires and some of them 
(VB6 and VBI2) were further investigated in section 4-2.5.
The mean number of TCR VB families used by HLA-B35/pp65 specific CD8^ T 
cells was 4 (n = 6, range 2 - 7). Considering only those results obtained from samples 
that were FACS sorted and which may therefore be more reliable due to high purity of 
cells analysed, the number of TCR VB families used by HLA-B35/pp65 specific CD8^
T cells was 2 (n = 3).
4-2.3 Potential artefacts affecting the TCR VB analysis of CMV 
specific CD8* I  cells
TCR diversity analysis described in the previous sections demonstrated that most CMV 
specific CD8^ T cells used VB families 6 and/or 12. This is summarised in Figure 4-19.
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Figure 4-19 CDR3 size classes detected by spectratyping of CMV specific CD8 T 
cells targeting different HLA/peptide combinations
CDR3 size  classes detected in cD N A  from F A C S or bead (* ) sorted tetram er b ind ing ce lls  
from HSCT patients (patient num bers indicated on the left). D ifferent colours reflect the 
number o f  different C DR3 lengths (histogram  peaks) observed  for TC R s in each VB fam ily.
This finding is surprising. As mentioned in section 1-8.1, CDRl and CDR2 encoded in 
the germline V segment genes are thought to interact primarily with the MHC. 
Therefore, it may be expected that CMV peptides presented by different HLA may be 
recognised by T cell receptors with different CDRl and CDR2, and therefore different 
VB families.
The common usage of VB6 and VBI2 in different responses raises the question 
of whether this finding may have resulted from an artefact introduced by variable 
efficiencies of primers specific for different VB families. Another possible explanation 
for this finding would be differential usage of VB families by PBMC from the general 
population. It is known that normal peripheral T cells use some VB families more
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frequently than others. Choi and colleagues showed that V62, 3, 6, 7, 8 and 13.1 are 
expressed by more than half of total T cells (Choi et a l,  1989). The high frequency of 
lower-numbered VB families may simply reflect the order in which they were originally 
described. Interestingly, a study aimed at analysing variations in the human TCR VB 
repertoire demonstrated predominance of VB6, 4 and 12 amongst 250 sequences from 5 
healthy volunteers (Rosenberg et a l,  1992). Importantly, this analysis was performed 
by anchored PCR, a method originally described by Loh and colleagues (Loh et a l, 
1989). It creates artificial 3’ ends on all cDNA prior to PCR to allow hybridization of a 
single complementary 3’ primer, thus avoiding any potential bias introduced by varying 
efficiencies of different 3’ VB primers. These findings argue against the hypothesis that 
prominent VB6/12 usage of CMV specific CD8^ T cells resulted from different 
efficiencies of VB primers in this study. Instead, they suggest that the use of VB6 and 
VBI2 by CMV specific CD8^ T cells merely reflects the trend in biased VB usage by 
PBMC. VB6 and 12 CDR3 sequences of HLA-B35/pp65 specific CD8^ T cells will be 
analysed further in section 4-2.5 from page 298 onwards, demonstrating private TCR 
usage. Most VB6 TCR rearrangements were found to be unproductive, which suggests 
that they did not contribute to CMV specific TCR expressed on the surface of cells.
Spectratyping analysis was performed on ex vivo CMV specific CD8^ T cells 
with different HLA/CMV peptide target specificities. Depending on the frequency of 
these cells in PBMC, cell numbers obtained by tetramer guided sorting differed 
substantially between patients. Clonotypic analysis was performed on a range of 200 to 
nearly 74,000 FACS sorted cells. This raises the possibility of a sampling artefact: 
Samples with low cell numbers may have artificially low TCR diversity. This may be 
due to lower amounts of cDNA generated from such samples, which, in turn, may 
promote weaker PCR amplification signals and therefore detection of less CDR3 size 
classes. Numbers of TCR VB families detected in tetramer sorted cells were therefore 
plotted against the number of cells used for this analysis in an attempt to test if both 
factors correlate, which may suggest a sampling artefact (Figure 4-20).
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Figure 4-20 Comparison of TCR diversity of CMV specific CD8  ^ T cells with 
different cell numbers used for analysis
This scatter graph sh ow s a plot o f  numbers o f  sorted ce lls  used for analysis versu s  num bers o f  
VB fam ilies that were detected by spectratyping o f  these sorted ce lls . D ifferently  shaped  
sym bols distinguish data points according to the target sp ecificity  o f  ce lls  (M : M A C S bead 
sorted ce lls).
Findings illustrated in Figure 4-20 demonstrate that there was no overall correlation 
between numbers of VB families detected and numbers of cells used for analysis. CMV 
specific CD8^ T cells that used the highest numbers (12 and 19) of TCR VB families 
were not derived from samples with the highest cell numbers. Instead they were derived 
from cells sorted with HLA-Al/pp50 tetramer, whereas cells sorted with other tetramers 
used ^11 TCR VB families. This suggests that usage of different numbers of VB gene 
families was dependent on HLA/peptide specificity of cells.
For HLA-B35/pp65 and HLA-A24/pp65 specific CD8^ T cells, MACS bead 
sorting resulted in detection of more VB families than FACS sorting which is likely to 
have resulted from the lower purity of cells obtained with the bead method (compare 
section 4-2.1.1, page 265). Bead or FACS sorted HLA-B35/pp65 or HLA-A24/pp65 
specific TCR VB families detected did not correlate with the quantity of starting
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material. Other target specificities demonstrate a trend towards a positive correlation but 
no direct correlation between the TCR VB families detected and the quantity of starting 
material. The same number of VB families was detected in nearly all HLA-A2/pp65 
specific CD8^ T cells ranging in numbers from 651 to 20,468. Only HLA-A2/pp65 
specific CD8^ T cells from one patient used more than 2 VB families. For this patient 10 
VB families were detected from an exceptionally high cell number of 73,977. However, 
it seems unlikely that in the sample with 20,468 cells, the number of VB families 
detected may have been biased when cell numbers below 10,000 were sufficient to 
detect a high diversity of TCRs used by HLA-Al/pp50 specific CD8^ T cells. Cells with 
the latter target specificity also demonstrated a trend towards more TCR VB families 
being detected when higher cell numbers were used for the analysis. However, this 
trend was not observed for HLA-Al/pp65 specific CD8^ T cells. This is illustrated in 
Figure 4-21.
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Figure 4-21 Comparison of TCR diversity of HLA-Al restricted CMV specific 
CD8  ^T cells with different cell numbers used for analysis
Scatter graphs sh ow  the num bers o f  sorted ce lls  used for an alysis versu s  num bers o f  VG 
fam ilies that w ere detected by spectratyping o f  sorted ce lls  that bound H L A -A l/p p 5 0  tetram er 
(left) or H L A -A l/p p 6 5  tetram er (right).
With a trend towards positive correlation observed for cells with some target 
specificities but not others, from a relatively small data set, it remains undetermined if 
this observation was merely a result of chance. Given these observations, a biased 
detection of different numbers of TCR VB families of CMV specific CD8^ T cells by
296
___________________________________________________________________ Chapter 4
analysis of different numbers of sorted cells cannot be ruled out. It may be informative 
to use cells with detectable CDR3 size classes within several VB families for an 
additional experiment in future studies. These cells could be split into two samples each, 
one representing a high cell number, a second one representing a low cell number, for 
use in spectratyping analysis in parallel. This may prove directly whether the TCR 
repertoire observed in the sample with a high cell number may be skewed in the sample 
with a lower cell number. Provided that enough material is available, a test series of 
samples with different cell numbers may be analysed to establish the threshold of cell 
numbers at which skewing of the TCR diversity can be observed. Due to restricted 
material and resources it was not feasible to perform this analysis during this project.
Consistency of results for cDNA derived from >70,000 T cells but not from 
cDNA derived from 35,000 T cells was reported by Manfras and colleagues (Manfras et 
a l,  1997). Findings from that study cannot be directly applied to the different settings 
used for spectratyping in this study but they suggest that low cell numbers can give rise 
to a sampling artefact.
4-2.4 Quantification of the constitutive gene TfR in sam ples that 
failed to produce TCR VB PCR products
TCR diversity of ex vivo CMV specific CD8^ T cells was estimated in the previous 
sections by tetramer guided sorting of CMV specific T cells followed by PCR 
amplification of the CDR3 spanning TCR VB region from their cDNA and separation of 
fiuorescently labelled PCR products of different lengths by capillary electrophoresis. A 
signal from PCR products was not obtained from all samples prepared. At least one 
sample per batch stained with a specific HLA/CMV tetramer (with a total of ten 
samples) did not result in detection of a VB amplification signal. The success rate was 
68 %. This was not dependent on the numbers of sorted cells or due to failing of a 
particular PCR reaction but was confirmed to be the result of insufficient cDNA 
quantity or quality obtained from these samples. This was shown by testing of cDNA 
for amplification of a constitutive gene by quantitative PCR as described in section 4- 
2.1.2 (page 268). Results are illustrated in Figure 4-22.
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Figure 4-22 Quantification of a constitutive gene in cDNA from sorted CMV 
specific CDS T cells that failed to produce detectable TCR VB amplification 
signals
Transferrin receptor (T fR ) transcripts w ere quantified in all cD N A  sam ples that failed  to  
produce detectable V 6 PCR products (1 -1 0 ) along w ith a p ositive  control (+ ve). T he m eans o f  
TfR cop ies detected in triplicate sam ples are show n. Errors represent the d ifferen ce to the 
highest and low est o f  the three values obtained respectively .
Figure 4-22 demonstrates that the constitutive gene was not or near to not detectable in 
cDNA samples for which spectratyping was not successful. This indicates that TCR 
analysis failed due to insufficient quantity or quality of cDNA obtained from cell 
samples. This maybe due to stress induced in cells when they were sorted off-site and 
stimulated before spectratyping.
4-2.5 TCR cloning and sequencing of CMV specific CD8* I  cells
Spectratyping can be used for initial estimation of the TCR diversity of cells. However, 
it cannot define clonality, as it does not assess the extent of heterogeneity within a 
particular CDR3 TCR VB length.
TCR repertoires of ex vivo CMV specific CD8^ T cell responses with different 
HLA/CMV peptide target specificities were shown to be restricted to a few CDR3 size 
classes in HSCT patients in the previous sections. The detection of TCR VB PCR 
products with similar CDR3 lengths, however, does not imply sequence similarity.
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The following sections describe cloning of some of the TCR VB PCR products from 
tetramer binding cells for nucleotide sequencing to determine whether the shared 
rearrangement size reflected a shared receptor. This analysis was performed to establish 
whether TCRs may have conserved junctional motifs and if the TCR repertoires of cells 
may be public (with the same TCR sequences found in different individuals) or private 
(unique to the individual). This analysis was restricted to common CDR3 lengths in 2 
VB families of three samples from HLA-B35/pp65 tetramer sorted CD8^ T cells (shown 
first) and 2 VB families of one sample from HLA-A24/pp65 tetramer sorted CD8^ T 
cells (shown thereafter).
4-2.5.1 Choice of HLA-B35/pp65 specific CD8* T cell samples for 
TCR cloning and sequencing
Two VB families (VB6 and 12) that were used by HLA-B35/pp65 specific CD8^ T cells 
from patients 4, 8 and 9 were chosen to further investigate shared class sizes.
Results from VB12 spectratyping analysis of HLA-B35/pp65 specific CD8^ T 
cells from patients 4, 8 and 9 are illustrated in Figure 4-23.
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Patient 4 Patient 8 Patient 9
A  227 bp, ,230 227 bp, ,230 bp 227,bp
t /5
Size of TCR VB PCR product in base pairs
Figure 4-23 Shared TCR VB12 size classes in patients 4, 8 and 9
Frequency histogram s o f  TCR VB 12 PCR products derived from cD N A  from  sorted ce lls  
from three patients. A: H L A /C M V  peptide tetramer b inding cell fraction; B: C ell fraction that 
did not bind H L A /C M V  peptide tetramer.
Figure 4-23 illustrates that one VB12 size class of 227 bp (indicated by blue arrow) was 
shared by patients 4, 8 and 9, whereas a second VB12 size class of 230 bp (indicated by 
red arrow) was shared by patients 4 and 8. VB PCR products of 227 bp demonstrated 
stronger fluorescent signals in cDNA obtained from the tetramer binding cell fraction 
than from the cell fraction that did not bind tetramer in patients 4 and 9. This was also 
the case for signals of the 230 bp PCR product from patient 4.
Results from VB6 spectratyping analysis of HLA-B35/pp65 specific CD8^ T 
cells from patients 4, 8 and 9 are illustrated in Figure 4-24.
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Figure 4-24 Shared TCR VB6 size classes in patients 4, 8 and 9
Frequency histogram s o f  TCR VB 6 PCR products derived from cD N A  from  sorted ce lls  from  
three patients. A: H L A /C M V  peptide tetramer binding ce ll fraction; B: C ell fraction that did 
not bind H L A/CM V  peptide tetramer. Shared C D R 3 lengths are marked by arrows (purple: 
197 bp, dark red: 206  bp).
Figure 4-24 illustrates that one V66 size class of 197 bp (indicated by purple arrow) was 
shared by patients 4 and 9. A second V66 size class of 206 bp (indicated by red arrow) 
was shared by patients 4 and 8. Both size classes demonstrated higher fluorescent 
signals in tetramer binding cell fractions than in cell fractions that did not bind tetramer. 
Patient 8 and 9 shared a third VB6 size class of 194 bp (indicated by blue arrow). 
However, this size class did not demonstrate a higher fluorescent signal in tetramer 
binding cell fractions than in cell fractions that did not bind tetramer.
VB 6 and 12 PCR products obtained from cDNA from tetramer binding cell 
fractions from patients 4, 8 and 9 were subsequently cloned and sequenced. This 
analysis demonstrated that patients shared only very limited junctional motifs within the 
size classes corresponding to spectratypes marked in blue in Figure 4-23 and Figure 
4-24. However, T cell clones were rearranged from different TCR gene segments and
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their TCR repertoire was private. These results will be described in detail in the 
following sections.
4-2.5.2 Cloning & Sequencing of HLA-B35/pp65 specific CD8* T 
cells
To amplify VB fragments suitable for cloning, cDNA from the HLA-B35/pp65 tetramer 
binding T cell fractions from patients 4, 8 and 9 was used for new PCR amplifications 
with C6 and VB specific primers of the same sequence specificity as used for 
spectratyping but without fluorescent label. Presence of PCR products was confirmed 
by gel electrophoresis as illustrated in Figure 4-25.
1 2 3 4 5 6 7 8
1,0001
Figure 4-25 PCR amplification of TCR VB fragments for bacterial cloning
A 1.5 % agarose gel is show n. H yperladder IV (B io lin e )  w as loaded in the far left lane w ith the 
m olecular w eight o f  the m arker’s standards (in bp) show n b esid e the gel p icture. TC R  PCR  
products from H L A -B 35/pp 65 tetramer b inding ce lls  w ere loaded in the rem aining lanes (3: 
patient 4, VB6; 4: patient 4 , VB12; 5: patient 8, VB6; 6: patient 8, VB12; 7: patient 9 , VB6; 8: 
patient 9, VB12). PCR products from  H L A -A 24/p p 65  tetram er b ind ing ce lls  from  patient 11 
(1: VB7; 2: VB20) are a lso  show n. C lon ing  o f  these products is described  in section s 4 -2 .5 .4  
and 4 -2 .5 .5 .
Bands of the expected size (182 - 248 bp, compare Table 2-7) were purified and ligated 
into TOPO TA pCR2.1 vector. E.coli cells were then transformed with the plasmids 
produced as described in section 2-13. Ten transformed colonies were picked for VB6 
cloning from patients 4 and 8; also ten colonies were picked for VB12 cloning from 
patients 4 and 9. Fourteen transformed colonies were picked for VB6 cloning from 
patient 9, and 14 colonies for VB12 from patient 8. Plasmid DNA was extracted and the 
presence of TCR VB inserts was confirmed by digestion of the vector with EcoRI 
followed by gel electrophoresis, which is illustrated in Figure 4-26.
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Figure 4-26 Confirmation of TCR inserts in plasmids from bacterial clones
A 1.5 % agarose gel is show n. Hyperladder IV (B io lin e ) w as loaded in lanes on the far left and 
right end (the m olecular w eigh t o f  standards is show n in bp b esid e the gel picture). Lanes I to  
18 contain representative sam ples o f  EcoRI d igested  p lasm id D N A  from  bacterial TCR VB6 
(1 -5 , 1 1-15) and V B I 2 (6 -I 0 ,  16-18) clones.
Plasmids containing inserts of an expected size between 182 and 211 bp for VB6 and 
between 219 and 248 bp for VB12 were used for DNA sequencing. Good sequencing 
results were obtained and analysed from 6 to 13 clones from each TCR VB cloning.
4-25.3 Junctional analysis of HLA-B35/pp65 specific CD8* T cells
Sequences obtained were aligned with the known sequence from the vector and those of 
the inserts were isolated. The codons obtained were translated into amino acid 
sequences.
IMGT/V-QUEST is a software program for T cell receptor V-J and V-D-J 
rearrangement analysis (Giudicelli et al., 2004). It was used to analyse which V, D and J 
segments were used by TCR B chains from tetramer binding CMV specific CD8^ T 
cells and to determine whether TCRs of these clones may have conserved junctional 
motifs. As VB primers used in this study are in accordance with the nomenclature by 
Wei and colleagues (Wei et a l, 1994) whereas IMGT/V-QUEST follows the IMGT 
TCR gene nomenclature (Lefranc, 2001a) the clones amplified with VB6 and VB12 
primers translate into TRBVIO and TRBV7 sequences respectively.
A junctional analysis of TCR VB12 clones identified in HLA-B35/pp65 tetramer 
binding cell fractions from patients 4, 8 and 9 is shown in Table 4-2.
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TCR VB12/TRBV10
Patient CDR3
(PCR size, bp) TRBV' V(D)J TRBD TRBJ length F
4 (230) 10-1*01/02 CASNPGTGTDTQYF 1*01 2-3*01 12 5/9
4 (230) 10-1*01/02 CASNPGTGADEQYF 1*01 2-7*01 12 2/9
4(227) 10-1*01/02 CASNAGTGNEQYF 1*01 2-7*01 11 1/9
4 (230) 10-1*01/02 CASNAGTGTDTQYF 1*01 2-3*01 12 1/9
9 (227) 10-3*01/02/03/04 CAISVAARGEQFF 2*01 2-1*01 11 4/9
9 (2 3 3 ) 10-3*01/02/03/04 CAISETTRGDSPLHF 1*01 1-6*02 13 2/9
9 (233) 10-3*01/02/03/04 CAISXTTRGDSPLHF 1*01 1-6*02 13 1/9
9 ( 2 2 1 ) 1()-M ()I 02 - 1-2='01 \ P 2 »)
8 (227) 10-3*01/02/03/04 CAISGRGDTEAFF 1*01 1-1*01 11 8/8
Table 4-2 Junctional analysis of TCR VB12 clones found in HLA-B35/pp65 specific 
CD8  ^T cells from patients 4, 8 and 9
T his table lists the C D R 3 seq u en ces (V (D )J ) and gen e segm en ts used by VB12 clon es. 
S im ilarities b etw een  seq u en ces from  different in d iv idu als are h igh ligh ted  in bold . The 
frequency o f  c lo n es d etected  is  sh ow n  in co lum n  F. D ifferen ces in the n om enclatu res used  for 
VB prim ers and in the an a lysis  softw are result m eant that c lo n es am plified  w ith  V B12 prim ers 
w ere assign ed  the nam e T R B V IO . T w o c lo n es  w ere found to  have unproductively  rearranged  
seq u en ces due to out o f  fram e ju n ction a l seq u en ces (N P ) and are sh ow n  in grey. ’ V  g en e  
segm en ts from  w hich  seq u en ces m ay have been  rearranged cou ld  not be determ ined  
u nam bigu ou sly  due to short PCR products.
Table 4-2 demonstrates a restricted V612 diversity of TCRs of CMV specific CD8^ T 
cells within each individual. This is especially pronounced in clones from patient 8, 
which all (n = 8) demonstrated the same sequence. PCR products amplified were too 
short to distinguish from which TRBV allele they may have been rearranged. Instead 
the IMGT blast search tool (http://imgt.cines.fr/blast/blast.html) determined several 
possible gene segments from which these sequences may have originated.
TCR rearrangements with a PCR product size of 230 bp (for which a major peak 
was observed in patient 4’s spectratype and a small peak in patient 8’s spectratype, 
compare Figure 4-23, page 300) were only detected in sequenced T cell clones from 
patient 4 but not patient 8.
TCR rearrangements with a PCR product size of 227 bp (detected in patient 4, 8 
and 9’s spectratypes. Figure 4-23) were detected in sequenced T cell clones from all 
three patients and sequence similarities of these are highlighted in bold in Table 4-2. 
Patients 8 and 9 shared only a minor junctional CDR3 motif (AIS) originating from 
TRBVIO. Public TCRs were not observed and the receptors were rearranged from 
different TCR gene segments. A sequence alignment is illustrated in Figure 4-27. This 
figure shows a comparison of the VB12 CDR3 sequences with a shared size class of
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227 bp from patients 4, 8 and 9 by the ClustalW online tool, Version 1.83 
(http://www.ebi.ac.uk/Tools/clustalw/index.html) (Chenna et a l, 2003). This is a 
multiple sequence alignment program that produces biologically meaningful 
illustrations of alignments of divergent sequences. Sequences are coloured crudely 
according to residue type as shown in Table 4-3.
A  Patient 4 CASNAGTGNEQYF
Patient 8 CAISGRGDTEAFF
Patient 9 CAISVAARGEQFF
** . * :*
B  Patient 8 CAISGRGDTEAFF
Patient 9 CAISVAARGEQFF
* * * *  *  * *
Figure 4-27 ClustalW sequence alignment of CDR3 regions of TCR VB12 clones 
with a PCR size of 227 bp found in HLA-B35/pp65 specific CDS T cells from 
patients 4, 8 and 9
A lignm ent o f  am ino acid seq u en ces. Patients from w hom  sequences originate are indicated on  
the left. S ym b ols b elow  the a ligned  sequ en ces denote the degree o f  conservation  observed at 
each position. The sym bol indicates that the residues or nucleotides in that colum n are 
identical in all sequences in the alignm ent. The sym bol indicates that substitutions have 
been observed , that are conserved  according to Table 4 -3 . The sym bol indicates that sem i­
conserved substitutions are observed .
Amino acids Colour Residue property
AVFPMILW RED Small and hydrophobic (inclusive aromatic -Y)
DE BLUE Acidic
RK MAGENTA Basic
STYHCNGQ GREEN Hydroxyl + Amine + Basic - Q
Others Gray -
Table 4-3 Colour code of protein sequence alignment
List o f  colours used to d istingu ish  different am ino acid residue types during C lustalW  
alignm ent.
Part A in Figure 4-27 demonstrates very limited similarity between aligned CDR3 
sequences of TCR rearrangements with a PCR product size of 227 bp from patients 4, 8 
and 9. Part B demonstrates that of the 11 amino acids located between the conserved 
cysteine and phenylalanine of the CDR3 region, 5 identical residues towards the ends of 
the sequence but only one semi-conserved substituted residue in the middle of the 
sequence can be observed between the aligned sequences from patients 8 and 9.
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In addition to TCR rearrangements with PCR product sizes of 227 and 230 bp described 
above, there was a productively rearranged TCR with a PCR product size of 233 bp 
detected in sequenced T-cell clones from patient 9, which had not been detected by 
spectratyping. A TCR rearrangement with a PCR product size of 221 bp, which was 
detected in the spectratype of patient 9, was found to be a non-productive rearrangement 
when junctions of sequenced T-cell clones were analysed.
Junctional analysis of TCR V66 clones is illustrated in Table 4-4.
T C R  V B 6/T R B V 7
P atient 
(P C R  
size , bp)
T R B V ' V (D )J T R B D T R B J
C D R 3
length
F
4 ( 1 9 7 ) 7-3/4/6/7/879 CASSVRLAGA#YEQYF 2*01 2-7*01 N P ( F ) 576
4 ( 2 0 0 ) 7-3'4/6 7 '8 /9 VSLCQQLRSGRSG# #EQYF 2*02 2-7*01 N P ( F ,  S) 1 6
8 (2 0 6 ) 7-476/7/8 CASSLGAGTFKTNEKLFF 1*01 1-4*01 16 9711
8 (1 9 4 ) 7-3/677 CASSLTDGDQPQHF 1*01 1-5*01 12 1711
8 ( 2 0 6 ) 7-3/4/67778 VSLC*QLRGRDF*#TNEKLFF 1*01 1-4*01 N P ( F , S ) 171 1
9 (1 9 4 ) 7-4/67778/9 CASSLVASQETQYF 2*01 2-5*01 12 1710
9 ( 1 9 7 ) 7-3,4 6/778 VSLCQHLPRGRV# ETQYF 2*01 2-5*01 N P ( F . S ) 5710
9 ( 1 9 7 ) 7-374,677/8 CASIYRGAG*ETQYF 2*01 2-5*01 N P ( S ) 2710
9 ( 1 9 4 ) 7-3/4/677 8 9 VSLCQQLSG*#QETQYF 2*01 2-5*01 N P ( F ,  S) 1710
9 ( 1 9 7 ) 7-374/6/7/8 VSLCQHLPRGRVRDPV#F 2*01 2-5*01 N P ( F ,  S) 1 1 0
Table 4-4 Junctional analysis of TCR VB6 clones found in HLA-B35/pp65 specific 
CD8  ^T cells from patients 4, 8 and 9
This table lists CD R3 seq u en ces (V (D )J ) and gene segm ents used by V 66  c lon es. S im ilarities  
betw een sequ en ces from different in div idu als are h ighlighted  in bold. The frequency o f  c lon es  
detected is show n in colum n F. D ifferen ces in the nom enclatures used for VB prim ers and in 
the an alysis softw are result m eant that c lon es am plified  w ith VB6 prim ers w ere assign ed  the 
name T R B V 7. C lon es w ith unproductively rearranged sequ en ces (ind icated  as N P  in the 
“C D R 3 length” colum n) are show n in grey. “F” indicates that c lon es dem onstrated out o f  
frame junctional sequ en ces, w hereas “ S ” indicates stop cod on s. * V  gen e  segm en ts from  
w hich sequ en ces m ay have been rearranged cou ld  not be determ ined u nam bigu ou sly  due to 
short PCR products.
A restricted diversity of TCRs of CMV specific CD8^ T cells within each individual can 
also be observed for VB6. Table 4-4 demonstrates a dominant sequence in 5 of 6 T-cell 
clones from patient 4, in 9 of 11 T-cell clones from patient 8 and in 5 of 10 T-cell 
clones from patient 9.
TCR rearrangements with a PCR product size of 206 bp (for which a major peak 
was observed in patient 8’s spectratype and a very small peak in patient 4’s spectratype, 
compare Figure 4-24, page 301) were only detected in sequenced T cell clones from 
patient 8 but not patient 4.
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TCR rearrangements with a PCR product size of 197 bp found in spectratypes from 
patients 4 and 9 (Figure 4-24, page 301) were found to be non-productive 
rearrangements when junctions of sequenced T cell clones were analysed.
TCR rearrangements with a PCR product size of 194 bp detected in patient 8 
and 9 by spectratyping (Figure 4-24) and T cell cloning shared a minor junctional 
CDR3 motif (ASSL) originating from TRBV7, which is highlighted in bold in Table 
4-4. Public TCRs were not observed and T cell clones were rearranged from different 
TRBD and TRBJ gene segments. An alignment of CDR3 sequences of these TCR 
rearrangements is illustrated in Figure 4-28.
Patient 8 CASSLTDGDQPQHF 
Patient 9 CASSLVASQETQYF 
* * * * * .  . : : . * : *
Figure 4-28 ClustalW sequence alignment of the CDR3 regions of TCR VIÎ6 clones 
with a PCR size of 194 bp found in HLA-B35/pp65 specific CD8 T cells from 
patients 8 and 9
This figure sh ow s an alignm ent o f  am ino acid sequ en ces. Patients from w hom  sequ en ces  
originate are indicated on the left. The m eaning o f  sym b ols is as explained  in Figure 4 -2 7 .
Figure 4-28 demonstrates only a limited degree of sequence similarity between aligned 
CDR3 sequences of TCR rearrangements with a PCR product size of 194 bp from 
patients 8 and 9. Of the 12 amino acids located between the conserved cysteine and 
phenylalanine of the CDR3 region, 5 identical residues can be observed at both ends of 
the sequence, whereas 3 conserved and 3 semi-conserved substituted residues can be 
observed in the middle of the sequences.
Additional small PCR amplifications of other sizes detected by spectratyping 
(for example a 188 bp amplification observed in patient 4 and 8, Figure 4-24) were not 
found by sequencing analysis of 6 to 11 T cell clones generated from each patient. 
Conversely, a non-productive TCR rearrangement with a PCR product size of 200 bp 
was observed by T cell cloning and sequencing from patient 4 although no amplification 
of the corresponding size was observed by spectratyping analysis.
These findings suggest that results from both methods, spectratyping and 
sequencing of bacterial TCR clones, can complement one another. Spectratyping results 
may need to be interpreted with care. They can indicate TCR rearrangements of similar 
CDR3 length in cells of different individuals. However, these could be non-productive 
rearrangements, as shown for VB6 clones with a shared PCR size of 197 bp detected in
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patients 4 and 9. Therefore spectratyping can provide a fast method to screen 
interindividual antigen specific cells for similarities of their TCR diversity and to 
determine which VB families should be analysed in more detail. However, only 
junctional analysis of sequences from T cell clones can determine if TCR CDR3 lengths 
observed by spectratyping are from productively rearranged T cell receptor sequences.
All T cells have the potential to rearrange the TCRB locus on both 
chromosomes. TCR mRNA from a non-productively rearranged chromosome in some T 
cells can confuse the interpretation of spectratyping results. Here, non-productive VB6 
rearrangements with a PCR product size of 197 bp in patients 4 and 9 did not contribute 
to the TCR repertoire expressed on the surface of CMV specific CD8^ T cells. They 
were present as mRNA, hitchhiking with the productively rearranged TCR mRNA that 
produced the antigen specific T cell receptor expressed on the surface of these cells.
4-2.5.4 Choice of HLA-A24/pp65 specific CD8* T ceil samples for 
TCR cloning and sequencing
Along with HLA-B35/pp65 specific CD8^ T cells from patients 4, 8 and 9 (compare 
section 4-2.5.1) HLA-A24/pp65 specific CD8^ T cells from patient 11 were also used 
for further clonotypic analysis. Patient 11 demonstrated the highest frequency of HLA- 
A24/pp65 specific CD8^ T cells (Figure 3-7, page 198). TCR PCR amplifications were 
observed in VB 3, 4,7, 14 and 20 from these cells.
Two PCR amplification peaks in VB14 were either of lower signal strength in 
cDNA obtained from the tetramer binding cell fractions compared with the cell 
fractions that did not bind tetramer or below the background level of 100 fluorescence 
units. PCR amplifications from VB3 and VB4 demonstrated fluorescent peaks of only 
100 fluorescence units, which is at the background limit of the assay. Therefore these 
signals were not considered to be genuine.
Fluorescent PCR signals in VB7 demonstrated a single peak above background 
level, which was of equal strength in cDNA obtained from the tetramer binding cell 
fraction and from the cell fraction that did not bind tetramer. Signals from VB20 
demonstrated a peak above the background level in cDNA obtained from the tetramer 
binding cell fraction but not the cell fraction that did not bind tetramer. Results from 
VB7 and 20 spectratyping analysis of HLA-A24/pp65 specific CD8^ T cells from 
patient 11 are illustrated in Figure 4-29 and were chosen for further analysis.
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Figure 4-29 CDR3 size classes detected in TCR VB7 and 20 from patient 11
Frequency histogram s o f  TCR VB7 (left) and VB20 (right) PCR products derived from  cD N A  
from sorted ce lls  from patient 11 and a healthy control. A: H L A /C M V  peptide tetramer 
binding cell fraction from patient II ;  B; cell fraction that did not bind H L A /C M V  peptide 
tetramer from patient 11; C: unsorted PBM C from healthy volunteer 19.
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4-2.5.5 Junctional analysis of HLA~A24/pp65 specific CD8* T cell 
clones & confirmation of TCR VR7 usage by flow cytometry
Cloning and sequencing of PCR VB7 and 20 PCR products from cDNA from HLA- 
A24/pp65 specific CD8^ T cells from patient 11 was performed as described in section 
4-2.5.2 (compare Figure 4-25 on page 302). 12 clones each were picked for V67 and 
VB20. TCR VB inserts, however, were only detected in plasmid DNA from three VB7 
but no VB20 clones, which may be due to the low frequency of tetramer binding T cells 
which used TCR VB20.
Good sequencing results were obtained from the three VB7 T cell clones. CDR3 
region analysis of these is shown in Table 4-5.
T C R  V D 7/T R B V 4
Patient 
(P C R  size, 
bp)
C D R 3
T R B V ' V (D )J_______________________ T R B D  T R B J length
1 1 (201 ) 
11 (2 0 1 )
4-3*01 CASSPQSGLNTEAFF 1*01 1-1*01 13 2/3
4-3*01 CASSQ DPIR ##NTEAFF 1*01 1-1*01 NP (F, S) 1/3
Table 4-5 Junctional analysis of TCR VB7 clones found in HLA-A24/pp65 specific 
CD8  ^T cells from patient 11
This table lists CDR3 seq u en ces (V (D )J ) and gen e segm ents used by VB7 c lon es. The 
frequency o f  c lon es detected is sh ow n  in colum n F. D ifferen ces in the n om enclatures used for 
VB primers and in the analysis softw are result m eant that c lon es am plified  w ith  VB7 primers 
were assigned  the nam e T R B V 4. O ne c lo n e  w as found to have an unproductively rearranged 
sequ en ce (N P ) due to out o f  fram e junctional sequ en ce (F) and stop cod on s (S ) and is sh ow n  in 
grey. * V gen e segm ents from  w hich  seq u en ces m ay have been rearranged cou ld  not be 
determ ined unam biguously due to short PCR products. Several T R B V 4 -3 /2 /I  segm ents w ere  
p ossib le  o f  w hich the reference sequ en ce w ith the best a lignm ent according to the IM G T blast 
tool is show n.
TCR rearrangements of a single PCR VB7 lengths (approximately 199 bp) were 
detected in patient l l /s  spectratypes (Figure 4-29). This was consistent with the finding 
of T cell cloning and sequencing which resulted in the detection of clones with roughly 
the same PCR product length (201 bp) in two productively rearranged VB7 clones from 
patient 11 (Table 4-5). Similar to the results obtained from HLA-B35/pp65 specific 
CD8^ T cells (4-2.5.3), there was also an unproductively rearranged clone detected in 
HLA-A24/pp65 specific CD8^ T cells from patient 11. This sequence therefore did not 
contribute to the TCR repertoire expressed on the surface of CMV specific CD8^ T 
cells.
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The TCR usage of V67 and possibly VB20 by HLA-A24/pp65 specific CD8^ T cells 
from patient 11 was additionally tested by surface staining of tetramer binding cells 
with VB7 and 20 specific monoclonal antibodies. VB specifications allocated to these 
antibodies are as described in the nomenclature by Wei and colleagues (Wei et al., 
1994) and therefore correspond to the VB specifications allocated to primers.
Staining for VB20 was undetectable, which explains why TCR VB inserts were 
not detected in plasmid DNA from VB20 clones. HLA-A24/pp65 specific CD8^ T cells 
had been isolated for spectratyping and cloning at day 588 post HSCT from patient 11. 
The next sample was obtained at day 602 at which time surface staining confirmed 
nearly 7 % of the tetramer binding population to be TCR VB7. This is demonstrated in 
Figure 4-30 on the left.
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Figure 4-30 Staining of HLA-A24/pp65 specific CD8  ^T cells from patient 11 with 
anti-VB7 monoclonal antibody
Tetramer binding ce lls  from patient 11 at day 602  post transplant are show n on the left. The 
flow  cytom etry plot on the right sh ow s CD3^ CD8^ liv e  lym phocytes from patient 11 at day 
735 post transplantation. Both plots are sorted according to their surface exp ression  o f  TCR  
VB7 on the x -ax is and H L A -A 24/p p65 tetramer stain ing on the y -ax is.
This figure also demonstrates staining at a later time point, at which VB7 staining was 
only observed in dim tetramer staining cells.
Patient 11 demonstrated a sharp increase in HLA-A24/pp65 tetramer binding 
CD8^ T cells from day 532 post HSCT onwards (compare Figure 3-7 on page 198). 
Interestingly, VB7 staining at several time points prior to day 532 was not detected in 
HLA-A24/pp65 tetramer binding CD8^ T cells. This may well have been due to the 
lower frequency of HLA-A24/pp65 specific CD8^ T cells, prohibiting detection of a 
fraction of these cells using TCR VB7.
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In conclusion the analysis of HLA-A24/pp65 specific CD8^ T cells from patient 11 
indicates that a considerable fraction of these cells used T cell receptors of the V67 
family with the same CDR3 lengths. V67 usage was confirmed by surface staining of T 
cells, and T cell clones with identical CDR3 sequences were detected in that patient. 
However, TCR V137 was not identified in HLA-A24/pp65 specific CD8^ T cells from 
two other patients from whom cells were used for spectratyping and therefore likely 
does not reflect a public T cell receptor.
4-3 Discussion
Cultured HLA-A2, HLA-B7 and HLA-B44 restricted CMV pp65 specific CD8^ T cells 
were previously reported to use a restricted TCR repertoire (Peggs et a l,  2002, Weekes 
et a l,  1999b, Wills et a l,  1996). However, clonotypic analysis was restricted to a 
limited number of CMV targets and TCR diversity may have been underrepresented in 
the past by detection of cells being limited to those able to proliferate in vitro.
This chapter shows investigations of the diversity of T cell receptors (TCRs) 
used by ex vivo CMV specific CD8^ T cell responses with different HLA/CMV peptide 
target specificities in HSCT patients.
4-3.1 Analysis of HLA-A2/pp65 specific CD8* T cells confirms 
restricted TCR diversity
During the study described here HLA-A2/pp65 specific CD8^ T cells were 
analysed for comparison with CMV specific CD8^ T cells targeting other HLA/peptide 
combinations. This analysis demonstrated that HLA-A2/pp65 specific CD8^ T cells 
from 4 out of 5 patients used only 2 different VB families whereas cells from the 
remaining patient used 10 (out of 24) VB families. In comparison a previous study 
reported 2 to 9 clonotypes using comparative denaturing gradient gel electrophoresis 
(DGGE) analysis of HLA-A2/pp65 specific CD8^ T cells that were FACS sorted from 
six nonagenarians and one middle aged healthy individual (Hadrup et a l, 2006). The 
report from that study did not list all VB families in which clonotypes of CMV specific 
CD8^ T cells were detected but demonstrated that most of them resided within VB3.
The number of VB families used by HLA-A2/pp65 specific CD8^ T cells 
analysed in this project is lower than in previous reports that also used spectratyping 
and subsequent bacterial cloning of HLA-A2/pp65 specific CD8^ T cells (Peggs et a l , 
2002) but from eight healthy virus carriers. This is not surprising given the generally
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lower TCR Vfi diversity observed post transplantation in comparison to healthy 
individuals (Peggs et a l,  2003b, Verfuerth et a l, 2000). These studies reported that 
HLA-A2/pp65 specific CD8^ T cells in healthy individuals used 5 to 20 VB families 
(median 10). These included VBl, 2, 4, 5, 6, 8, 9, 13, 14, 15 and 17 with major 
amplifications in VB6, 8 and 13. Conservation of CDR3 lengths was not observed in 
that study, in which donor PBMC were cultured with autologous DC and CMV antigen 
in vitro (Peggs et a l, 2002).
In comparison, TCR VB families that were used by HLA-A2/pp65 specific 
CD8^ T cells of five HSCT patients in the project described here included VBl, 4, 6, 8, 
9, 12, 13S1, 14, 17, 20 and 24. The diversity of the TCR repertoire of these antigen 
specific cells was restricted to 1 or 2 different CDR3 lengths in most VB families and 
did not exceed 4 different CDR3 lengths in any VB family, similar to observations by 
Peggs and colleagues (Peggs et a l,  2002).
Another study using limiting dilution of NK cell depleted PBMC from six 
healthy virus carriers after stimulation with CMV infected fibroblasts demonstrated a 
more restricted TCR VB usage than that observed here. That study reported one or two 
VB families to be predominant in CMV specific CD8^ T cells in each of the studied 
individuals. The authors used staining with VB specific mAh and detected predominant 
VB families within VB6, 13.1, 14, 17,20 and 22 (Wills et a l,  1996). The monoclonal 
antibody panel available at the time of that investigation recognised only a fraction of 
VB families. However, a later study by the same group which analysed the TCR B chain 
sequences of multiple independently derived CMV peptide specific CD8^ T cell clones 
from six healthy virus carriers also demonstrated VB gene usage to be restricted to one 
or two families in each individual which included VB6, 7 ,8 ,9 , 13.1, 14 and 17 (Weekes 
et a l,  1999b). The latter study also demonstrated a public VB8 CDR3 sequence after 
stimulation with the HLA-A2 restricted pp65 peptide in two healthy donors.
These results were similar to the results of the study described here which also 
demonstrated shared CDR3 lengths in HLA-A2/pp65 specific CD8^ T cells, which 
occurred in VB6, VB12 and VB20 and may reflect public TCR repertoires.
Findings from previous reports on the TCR diversity of HLA-A2/pp65 specific 
CD8^ T cells cited above analysed these cells after sampling from healthy virus carriers. 
A comparative analysis of HLA-A2/pp65 specific CD8^ T cell clones expanded from 
five healthy virus carriers versus patients experiencing CMV reactivation (including 
seven rheumatoid arthritis patients and one and seven recipients of kidney or bone
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marrow transplants respectively), however, demonstrated a TCR repertoire focusing 
upon chronic antigenic stimulation (Trautmann et a l, 2005). Ex vivo surface staining 
with monoclonal VB specific antibodies during that study demonstrated the use of 2-5 
VB families in healthy virus carriers in comparison to the use of only one VB family 
(VB13S1) in the bone marrow transplant recipient. However, the authors acknowledged 
that the low frequency of HLA-A2/pp65 specific CD8^ T cells likely influenced the 
accuracy of VB surface staining of cells from that patient. That study found identical 
sequences in 4 VB13S1 T cell clones derived from the bone marrow transplant patient 
and a highly restricted TCR repertoire in other patients experiencing CMV reactivation, 
in contrast to several different sequences in T cell clones derived from healthy virus 
carriers comprising the VB families VB 1, 2, 3, 6, 7, 8, 13S1, 14, 15, 20 and 23. 
Although the TCR CDR3 diversity detected in the study by Trautmann and colleagues 
may have been underrepresented by analysis of a limited number of T cell clones, it 
demonstrates that the clonotypic composition of HLA-A2/pp65 specific CD8^ T cells 
from HSCT patients in the study described here can be expected to be more restricted 
than in reports on healthy virus carriers described above.
The reduction in TCR diversity in CMV reactivating patients compared to 
healthy virus carriers in the study by Trautmann and colleagues was associated with 
selection of clones with high affinity TCRs sharing public TCR V a motifs. The same 
mechanism of focusing of a diverse primary CMV specific CD8^ T cell response by 
selection of high affinity clones (VBl3.1 in HLA-A2/pp65 specific and VBl4 in HLA- 
B7/pp65 specific CD8^ T cells) into the memory CD8^ T cell pool was also observed by 
others (Day et a l, 2007). The focusing of the response observed by Day and colleagues 
was rapid, which may suggest that it was not driven by reactivation of the virus during 
long-term carriage (reviewed in (Waller et a l,  2008)). They used limiting dilution 
assays to generate biological T cell clones from three healthy virus carriers and two 
kidney transplant patients undergoing primary CMV infections. TCR VB chains of the 
obtained T cell clones were sequenced to identify CDR3 diversity. PCR amplified 
cDNA prepared from tetramer sorted PBMC was used for bacterial cloning in parallel. 
Findings of the same sequences in multiple bacterial clones and biological T cell clones 
suggested that TCR CDR3 diversity may not be underrepresented by T cell cloning in 
comparison to ex vivo analysis of T cells.
In summary, the clonotypic analysis of HLA-A2/pp65 specific CD8^ T cells in 
HSCT patients during this project resulted in findings comparable to previous reports.
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Variations between any studies likely occur due to the dependence of detection of 
shared TCRs on the sampling effort and clonal dominance of these shared TCRs. 
Diversity was restricted to 1 or 2 CDR3 lengths in only 2 different VB families in most 
patients, but inter-individual variability was evident by the observation of 11 different 
VB families used within the patient cohort. The findings on TCR diversity of HLA- 
A2/pp65 specific CD8^ T cells were used further for comparison with CMV specific 
CD8^ T cells targeting other HLA/peptide combinations.
4-3.2 TCR diversity of CD8* T cells targeting various pp65 peptides is 
lower than that of CD8* T cells targeting ppSO (245-253)
HLA-A2, HLA-B7 and HLA-B44 restricted CMV pp65 specific T cells were reported 
to use a restricted TCR repertoire. However, the diversity of T cell receptors (TCRs) 
used by CMV specific CD8^ T cell responses with other HLA/CMV peptide target 
specificities remained unclear when initiating this project and were therefore analysed 
in this study.
Initially, CMV specific CD8^ T cells were sorted with immunomagnetic beads 
specific for the fluorochrome used for tetramer staining. The limited purity and low cell 
numbers obtained, however, necessitated a wide range of optimisation strategies for the 
separation of cells, as well as for subsequent steps to enable the analysis of the TCR 
diversity of ex vivo CMV specific CD8^ T cells from patients. Results obtained with 
TCR activated cells that were FACS sorted and analysed using optimised cDNA 
generation, PCR and separation methods allowed for highly accurate clonotypic 
analysis with more reliable results than achieved initially.
The numbers of TCR VB families found to be used by CMV specific CD8^ T 
cells targeting various HLA/peptide combinations with these optimised methods are 
shown in Table 4-6.
315
Chapter 4
CD8  ^T cell specificity Average number of VB families used
HLA-B35/pp65 2.0 ( all 2, n = 3)
HLA-A24/pp65 1.5 (range 1-2, n = 2)
HLA-Al/pp65 5.0 (range 1-11, n = 3)
HLA-Al/pp50 9.5 (range 1-19, n = 4)
HLA-A2/pp65 3.6 (range 2-10, n = 5)
Table 4-6 Number of TCR VB families used by TCRs of CMV specific CD8 T cells
The num bers o f  VB fam ilies for w hich  PCR am p lifica tion s w ere detected  in cD N A  from  F A C S  
sorted CD8^ T c e lls  b ind ing to d ifferent tetram ers are listed .
This table demonstrates that the TCR VB diversity differed substantially between 
relatively similar (1 .5 -5  numbers of VB families used on average) responses targeting 
different CMV pp65 peptides and responses targeting the peptide CMV pp50 (245-253) 
(9.5 numbers of VB families used on average). To my knowledge, this is the first study 
to analyse the TCR repertoire diversity of CD8^ T cells targeting a CMV pp50 epitope. 
The findings merit further investigation because they imply that it could be a general 
phenomenon that CMV pp50 specific CD8^ T cells have a greater TCR repertoire than 
CMV pp65 specific CD8^ T cells. Six additional CMV pp50 epitopes have been 
demonstrated to elicit CD8^ T cell responses restricted by HLA-Al, HLA-A2, HLA-A3 
or HLA-B44 (Elkington et a l, 2003). Analysis of the TCR diversity of CDS^ T cells 
targeting these peptides may be informative to determine whether CDS^ T cells 
targeting other CMV pp50 epitopes also use a less restricted TCR repertoire than those 
targeting CMV pp65, or whether the less restricted TCR repertoire is a property specific 
to CMV pp50 (245-253).
Studies on cellular responses to CMV pp50 have only recently emerged in the 
literature and knowledge of the immunogenicity of CMV pp50 is far more restricted 
than the knowledge of the properties of CMV pp65 (refer to section 1-11.2).
Since the TCR repertoire observed for CD8^ T cells targeting CMV pp50 is less 
restricted, this suggests that focusing of a diverse primary CMV pp50 specific CDS^ T 
cell response with selection of clones with high affinity TCRs into the memory CDS^ T 
cell pool (as occurs with CMV pp65 (Day et a l , 2007)) may not occur. This remains to 
be investigated in future studies.
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4-3.3 CD8* T cells for which higher cell numbers correlate with 
protection from CMV demonstrate greater TCR diversity
The number of TCR VB families used by CMV specific CD8^ T cells (Table 4-6) is 
more limited for cells targeting HLA-A24/pp65 (1.5 numbers of VB families used on 
average) and HLA-B35/pp65 (2.0 numbers of VB families used on average) than those 
targeting HLA-A2/pp65 (3.6 numbers of VB families used on average) and HLA- 
Al/pp50 (9.5 numbers of VB families used on average). In comparison, findings from 
the previous chapter demonstrated that CMV specific CD8^ T cells targeting the first 
two mentioned HLA/peptide combinations inversely correlated with the ability to detect 
CMV reactivation at significantly lower levels (7.55 and 4.44 cells/pl of peripheral 
blood respectively) than those targeting the latter HLA/peptide combinations (13.23 and 
17.15 cells/pl of peripheral blood respectively). These observations suggest that CD8^ T 
cells that inversely correlated with the ability to detect CMV reactivation at high cell 
levels appeared to use highly diverse T cell receptors, whereas CD8^ T cells that 
inversely correlated with the ability to detect CMV reactivation at low cell levels 
appeared to use less diverse T cell receptors. To address whether this finding may be a 
sampling artefact, cell numbers used for spectratyping were directly compared with 
spectratyping results (Figure 4-20) demonstrating no direct correlation.
Both cell levels that correlated with protection from CMV and the number of VB 
families used by CMV specific CD8^ T cells of certain HLA/peptide specificities, 
demonstrated substantial variability between individual patients. Most samples used for 
clonotypic analysis were derived from patients that were not included in the follow-up 
cohort (Table 2-1, page 99) which was used to determine what cell numbers inversely 
correlated with the ability to detect CMV reactivation in Chapter 3. Those that were 
(n = 5) are shown in Table 4-7, which lists the cells numbers that inversely correlated 
with the ability to detect CMV reactivation and the number of VB families used by 
CMV specific CD8^ T cells in these patients.
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CDS  ^T cell Number of VB
Patient specificity families used Protective cell level
1 HLA-B35/pp65 2 1.46
2 HLA-A24/pp65 2 6.77
21 HLA-Al/pp50 1 14.20
14 13 16.67
22 5 24.46
Table 4-7 Number of TCR VB families used by CMV specific CD8  ^ T cells in 
comparison to their cell levels correlating with protection from CMV in individual 
patients
The num bers o f  VB fam ilies for w hich  PCR am p lifica tion s w ere ob served  from  c D N A  from  
CD8^ T c e lls  b ind ing to d ifferent tetram ers (sp ec ific ity  listed  in the secon d  co lu m n ) and the 
concentration  o f  c e lls  (ce ll num ber/p l b lood ) ob served  to correlate w ith  protection  o f  C M V  in 
individual patients (“protective le v e ls”) are listed .
This table illustrates a general trend towards positive correlation between both factors 
and inter-individual variability.
4-3.4 The TCR seq u en ces used by CMV specific CD8* T cells are 
private
Spectratyping analysis estimated a restricted use of TCRs by CMV specific CD8^ T 
cells. To assess the extent of heterogeneity within particular TCR VB size classes, 
cloning and sequencing of TCRs was performed for a subset of HLA-B35/pp65 and 
HLA-A24/pp65 specific CD8^ T cells.
Junctional analysis of CMV specific CD8^ T cells was until recently confined to 
HLA-A2, HLA-B7 and HLA-B44 restricted responses (Day et a l,  2007, Khan et a l, 
2002a, Khan et a l, 2002b, Peggs et a l, 2002, Trautmann et a l, 2005, Weekes et a l,  
1999b). Findings from this project demonstrated dominant clones with conserved CDR3 
lengths in HLA-B35/pp65 specific CD8^ T cells. These cells demonstrated only very 
limited junctional similarity and no use of public TCR for V66 (TRBV7) and VBl2 
(TRBVIO).
This is in contrast to results from the first study on HLA-B35/pp65 specific 
CD8^ T cells that was published recently. In contrast to results from this project, that 
study reported skewing of the TCR repertoire of T cells towards TCR VB3 (TRBV28) 
in four of five healthy virus carriers, with surface expression ranging from 19 % to 
55 % (average 34 %) when measured by tetramer and VB antibody staining (Brennan et 
a l, 2007). Further clonal analysis by Brennan and colleagues demonstrated a conserved
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CDR3 length of 13 residues that was exclusively paired with TRBJ 1-4, with a public 
TCR VB sequence in 2 donors. Two public TRAV17/TRAJ33 sequences were shared in 
three donors each.
In comparison, TCR VB3 (TRBV28) amplifications of a 200 bp PCR product 
were shared in the spectratypes of four of the six patients analysed within this project. 
However, as HLA-B35/pp65 specific CD8^ T cells of three of these patients (patients 4, 
8, and 9) were sorted with beads (resulting in lower purity of cells before the optimised 
FACS method was used), PCR amplifications of TCR VB sequences in these cells were 
not considered genuine if the fluorescence intensity signals in tetramer binding cells 
was lower than the signal strength observed in cells that did not bind tetramer, which 
was the case for patients 4 and 9 (compare section 4-2.2.5). Accordingly the shared size 
class detected for VB3 was not considered for further analysis.
Results from VB3 spectratyping of HLA-B35/pp65 specific CD8^ T cells in 
patients 4, 8, 9 and 35 are summarised in Table 4-8.
Patient VB3 size class (in bp) Fluorescence intensity detected
4 197 1,500*
200 700*
209 250*
8 200 4,000
9 188 1,400*
194 300*
197 300*
200 800*
209 250*
35 200 500
Table 4-8 VB3 size classes detected by spectratyping of HLA-B35/pp65 specific 
CD8  ^T cells in patients 4, 8, 9 and 35
List o f  TC R  V 63 s ize  c la sses  detected  in cD N A  from  tetram er b ind in g  ce lls  that w ere sorted  
with M A C S  beads from  patients 4 , 8 and 9 or by FA C S in patient 35. in d icates s iz e  c la sses  
in M A C S  sorted tetram er b ind in g  ce lls  for w hich  the flu orescen ce intensity  w as le ss  than that 
observed  in c e lls  that did not bind tetram er.
The fluorescent strength of all VB3 PCR products with a length of 200 bp detected in 
these patients was above the detection limit (>100 fluorescent units) therefore 
confirming TCR VB3 (TRBV28) usage of HLA-B35/pp65 specific CD8^ T cells in the 
majority of the patient cohort within this study.
However, in contrast to the findings of Brennan and colleagues, observations 
from this study do not suggest skewing of the TCR repertoire of HLA-B35/pp65
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specific CD8^ T cells towards TCR V63 (TRBV28). The highest amplification signals 
were detected for TCR V612 in patient 4 (signal strength more than 6x higher than for 
VB3 PCR products of 200 bp length), for VB6 in patient 8 (signal strength more than 4x 
higher than for VB3 PCR products of 200 bp length) and for VBl4 in patient 9 (signal 
strength 25x higher than for VB3 PCR products of 200 bp length). In patient 35, the 
highest TCR amplification signal was detected for TCR VB3 and signals were detected 
in only one other VB family, which was VB8 (compare Figure 4-18 in section 4-2.2.5 on 
page 291). Low frequency T cell receptor rearrangements may be efficiently amplified 
by PCR. Therefore spectratyping results obtained from tetramer sorted cells in this 
study cannot be used to draw conclusions on the frequency of VB size classes within the 
analysed cell samples. Nevertheless, from the findings described above it is clear that 
HLA-B35/pp65 specific CD8^ T cells from the patients analysed in this study used 
several TCR VB families and VB3 was not used in all of the patients (not in patients 1 
and 31). Therefore skewing of the TCR repertoire of HLA-B35/pp65 specific CD8^ T 
cells towards TCR VB3 was not confirmed in this study.
To obtain a better understanding of how frequent particular VB size classes may 
be within the CD8^ T cell population, future studies could make use of internal 
standards. Pannetier and colleagues argued that VB-CB PCRs are competitive 
amplifications of sequences that are nearly identical except for the CDR3 part of their 
sequences, which should allow the PCR to be run in saturation while remaining 
quantitative if internal standards are used during amplification (Pannetier et al., 1992, 
Pannetier et a l, 1993).
In addition to analysis of HLA-B35/pp65 specific CD8^ T cells, junctional 
analysis was also performed on HLA-A24/pp65 specific CD8^ T cells from patient 11 
for TCR VB7. Surface staining of HLA-A24/pp65 specific CD8^ T cells with anti-VB 
antibody in this patient confirmed the findings from TCR cloning, which suggested that 
only a single VB family was used. Surface staining also demonstrated that TCR VB 
usage changed over time suggesting that the clonality of ex vivo CMV specific CD8^ T 
cells is diverse both between different individuals and at different times within the same 
patients.
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4-3.5 Limitations of the clonotypic TCR Vfi analysis
The clonotypic analysis of CMV specific CD8^ T cells performed in this study was 
limited by detection of PCR amplification of the TCR in only 68 % of samples 
analysed. Findings were, however, verified by quantification of a constitutive gene, 
which indicated that failure of PCR product detection was due to low quantity/quality of 
the cDNA in the remaining samples (Figure 4-22, section 4-2.4, page 298) rather than 
inherent to the procedure. This may have been a result of cell stress induced by the 
transport of cells required by off-site FACS sorting or the subsequent stimulation of 
cells to induce TCR mRNA levels before PCR.
As discussed in section 4-3.3, observations from this study suggest that CD8^ T 
cells that inversely correlated with the ability to detect CMV reactivation at high cell 
levels appeared to use highly diverse T cell receptors, whereas CD8^ T cells that 
inversely correlated with the ability to detect CMV reactivation at low cell levels 
appeared to use less diverse T cell receptors. It could be argued that a lower frequency 
of cells may enable selection of a lower number of cells resulting in detection of less 
TCR VB families in those cells due to the detection limits of the assays. This potential 
artefact was further analysed by plotting the numbers of VB families detected by 
clonotypic analysis against the numbers of cells originally used for that analysis. 
Although this approach cannot rule out a biased detection of TCR VB families in those 
CMV specific CD8^ T cells available in low numbers, the plot of the two variables 
(Figure 4-20 in section 4-2.3, page 295) demonstrated no overall correlation of the two 
parameters. Results suggest that detection of different numbers of VB gene families was 
dependent on HLA/peptide specificity of cells rather than the quantity of cells used for 
the analysis.
A third observation stood out to be a potential artefact. TCR usage of most 
CMV specific CD8^ T cells was detected in VB families 6 and/or 12, which may have 
resulted from variable efficiencies of primers specific for these VB families. However, 
Rosenberg and colleagues previously used a method that avoids any potential bias 
introduced by varying efficiencies of different VB primers. Their findings demonstrated 
the preferential usage of VB4, 6 and 12 amongst 250 sequences from peripheral T cells 
from 5 healthy volunteers (Rosenberg et a l,  1992). A biased use of VB6 and 12 families 
in the peripheral repertoire may therefore explain the higher probability of these VB 
families being used by peripheral T cells of any specificity.
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The clonotypic analysis performed in this study was also limited by the sorting 
purity that could be achieved by MACS bead sorting. This may have affected the 
accuracy of spectratyping results. This was addressed by the development of enhanced 
cell preparation - and spectratyping methods including the use of FACS sorting. Better 
interpretation of spectratyping results may also be achieved by the use of PCR standards 
(compare section 4-3.4) or by additional surface staining of cells with anti-VB 
antibodies, to determine the frequency of each TCR VB family within the cell 
population that is studied. This may amend spectratyping results in future studies since 
PCR (used in the latter) can amplify targets irrespectively of their frequency in the 
original population.
4-3.6 Implications of findings and final conclusions
The clonality of CMV specific CD8^ T cells present at a significant frequency in 
peripheral blood has a wide-ranging impact on patients. As will be outlined below, 
CMV drives the expansion of CD8^ T cell subsets that not only correlate with 
protection against CMV but that are also linked to immunosenescence suggesting that 
the virus accelerates the process of age-associated deterioration of immune functions.
Higher levels of CMV specific CD8^ T cells were observed in HSCT patients 
than in healthy virus carriers in the previous chapter (refer to Figure 3-28, page 246), 
which was attributed to the homeostatic drive, in addition to CMV antigen stimulus in 
conditioned patients. By aiming to contain the virus (that cannot be completely 
eliminated once it has infected the human host), the immune response leads to the 
accumulation of highly expanded oligoclonal CMV specific CD8^ T cells that result in 
detrimental effects, with changes similar to those seen in an aged immune system.
Measurement of the TCR diversity of CMV specific CD8^ T cells in HSCT 
patients may have several important implications. On the one hand, the knowledge of 
public TCRs used in the T cell response to different CMV antigens may be of clinical 
use for monitoring of CMV responses in high-risk immunodeficient patients. In this 
regard the use of clonotypic probes may be useful for enhanced detection of CMV 
specific CD8^ T cells. It may also be useful for the development of treatment modalities 
using TCR gene transfer. On the other hand, reports summarised below suggest that the 
highly restricted TCR usage of CMV specific CD8^ T cells in HSCT patients may be a 
marker of detrimental effects on the CD8^ T cell pool that accelerate the process of age-
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associated deterioration of immune functions and render the patient susceptible to other 
infections.
Clonal T cell expansions are common in the elderly and can occupy a large 
proportion of the T cell pool (Posnett et a l,  1994). These expansions are commonly 
highly differentiated effector memory CD8^ T cells of CD28’ phenotype and result in a 
change of the CD4/CD8 ratio, which was termed the immune-risk phenotype (IRP) 
because of its association with increased mortality in 80 and 90 year olds (Wikby et a l, 
2002).
The IRP was associated with CMV seropositivity. It was shown that CMV 
specific CD8^ T cells accumulate during CMV latency over time (Karrer et a l,  2003, 
Komatsu et a l,  2003) and that these are highly differentiated CD8^ T cells of a CD28 
phenotype (Vescovini et a l,  2004). In elderly CMV carriers and HSCT patients, the 
substantial accumulation of CMV specific CD8^ T cells is linked to the development of 
large clonal expansions (Khan et a l,  2002b). This memory inflation contributes to early 
immunosenescence. Previous reports (using tetramer staining on samples from a large 
number of subjects and multivariate regression analysis) demonstrated CMV 
seropositivity being associated with a marked effect on the overall phenotype of CD8^ T 
cells (at any given age) and estimated an apparent “ageing effect” of CMV on CD8^ T 
cells of 35.4 years (Northfield et a l, 2005). This can be explained as follows.
The high immunological investments against CMV may divert finite 
immunological resources away from other potential antigenic challenges and thereby 
negatively influence the immune fitness of patients by reducing the overall level of 
antigenic diversity. Shrinkage of the TCR repertoire may render individuals susceptible 
to infections other than CMV (Hadrup et a l, 2006). Furthermore the number of 
dysfunctional CMV specific CD8^ T cells that do not respond to specific antigen ex vivo 
and are considered to be anergic was reported to be increased in the elderly (Ouyang et 
a l, 2003, Ouyang et a l,  2004). Dysfunctional CMV specific CD8^ T cells were 
associated with a highly differentiated (CD28 ) and killer cell lectin-like receptor G-1 
(KLRGl)^ CD57^ phenotype (Wikby et a l, 2002) that was initially linked to reduced 
proliferative capacity (Ibegbu et a l,  2005). More recently, however, the CD28'CD57^ 
phenotype was reported to represent a highly differentiated T cell subset with unique 
functional features, well capable of proliferation (Chong et a l,  2008). Hadrup and 
colleagues found that the variety of CMV specific T cell clones increases with age but
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declines in the final years of IRP individuals correlating with survival time (Hadrup et 
a l,  2006).
The previous and this chapter showed that CD8^ T cells directed towards 
multiple CMV antigens inversely correlated with the ability to detect CMV reactivation 
at different levels and varied phenotypically and in their T cell receptor diversity. These 
results suggest that broadly directed CD8^ T cell responses may carry out divergent 
functions. Therefore, CD8^ T cell responses targeting many different CMV epitopes 
may be essential in controlling CMV replication. Consistent with this hypothesis, it was 
suggested that infected individuals with broad T cell reactivity were able to clear virus 
infections more efficiently than those with a more narrowly focused T cell response 
(Thimme et a l,  2001). Findings from this project further the prospects of the 
development of prophylactic and therapeutic anti-CMV treatments by providing the 
knowledge needed to monitor the efficiency of treatments comprising HLA-Al/pp50, 
HLA-A2/pp65, HLA-A24/pp65 and HLA-B35/pp65 CD8^ T cell responses. Data also 
provide further insight into the complexity of cellular immune responses to CMV in 
patients.
In summary, this chapter showed that the TCR diversity of ex vivo CMV 
specific CD8^ T cells targeting different pp65 peptides presented by a variety of HLA is 
similarly restricted to those targeting HLA-A2/pp65 and HLA-B7/pp65 specific CD8^ T 
cells studied previously. Findings demonstrated a restricted number of TCR V6 families 
with conservation of CDR3 lengths but no public TCR used by CD8^ T cells targeting 
HLA-Al/pp50, HLA-Al/pp65, HLA-A24/pp65 and HLA-B35/pp65. Observations 
suggest that CD8^ T cells that inversely correlated with the ability to detect CMV 
reactivation at high cell levels appeared to use highly diverse T cell receptors, whereas 
CD8^ T cells that inversely correlated with the ability to detect CMV reactivation at low 
cell levels appeared to use less diverse T cell receptors. However, heterogeneous TCR 
usage between cells from different individuals or between cells analysed at different 
time points in an individual is evident from this and other studies (Hadrup et a l,  2006). 
TCR V6 restriction differed substantially between CD8^ T cells targeting CMV pp65 
peptides and CD8^ T cells targeting the peptide CMV pp50 (245-253). This study 
represents the first clonal investigation of HLA-Al/pp50 specific CD8^ T cells. Due to 
their high TCR diversity, these cells may confer an advantage to patients in that they 
may result in a slower drive of immunosenescence than CMV specific CD8^ T cells 
with more restricted TCR repertoires, which merits further study.
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CHAPTER 5 GENERAL DISCUSSION
Current antiviral therapies are limited in that they only target replicating but not latent 
virus, are associated with significant toxicity and are counteracted by the occurrence of 
resistant viral strains. Alternative approaches, such as an adoptive therapy, are needed to 
combat the development of potentially fatal CMV related complications in 
immunosuppressed patients. The safety and proof of principle of such a therapy has 
been demonstrated in patients reconstituting their immune system after haematopoietic 
stem cell transplantation (HSCT) some years ago (Walter et a l, 1995).
The successful generation of HLA-A2/pp65 specific CD8^ T cells under GMP 
conditions has already been demonstrated (Li Pira et a l , 2006) and recovery of between 
1x10^ (Cwynarski et a l, 2001) and 2x10^ (Aubert et a l,  2001) of these cells/L of blood 
was reported to correlate with protection against CMV in patients.
Results presented in Chapter 3 demonstrate the successful detection and 
monitoring of different CMV specific CD8^ T cell populations. Numbers of CD8^ T 
cells against CMV peptides presented by the common HLA-A*0101, HLA-A*2402 and 
HLA-B*3501 alleles that inversely correlated with the ability to detect CMV 
reactivation in HSCT patients had not been shown previously. Results from this study 
demonstrate significant differences between levels of these different co-dominant CMV 
specific CD8^ T cells that, in the presence of CD4^ T cell help, inversely correlate with 
the ability to detect CMV reactivation. These differences are also apparent in 
measurements of those cells in healthy donors. Recovery of CMV specific CD8^ T cells 
was shown to reach frequencies of up to 21 % (Cwynarski et a l,  2001) and 40%  
(Ozdemir et a l , 2002) of all CD8^ T cells in HSCT patients in previous studies. This 
study demonstrates an even higher percentage of CMV specific CD8^ T cells reaching 
up to 69.4 % of all CD8^ T cells in one patient (patient 29).
The long follow-up period of some patients within this study revealed delayed 
detection of CMV replication and CMV immune responses in patients receiving 
prolonged immunosuppression, which is especially pronounced post reduced intensity 
conditioning beyond the limit of one year post HSCT reported previously (Junghanss et 
a l, 2002). The detection of CMV replication after 500 days post transplantation and 
initial detection of CMV specific CD8^ T cells at such a late time in one patient (patient 
11) suggests that prolonged surveillance of viral replication and immune status in
325
___________________________________________________________________ Chapter 5
patients receiving reduced-intensity conditioning may be advantageous beyond one 
year.
Cells were studied by the use of HLA/peptide tetramer complexes, which act as 
surrogates for HL A/peptide ligands on the surface of antigen presenting cells (to which 
T cells would respond naturally) and visualise T cells according to their antigen 
specificity. Staining with HL A/peptide tetramers is highly specific (Burrows et a l, 
2000). Accordingly tetramer guided selection and subsequent adoptive transfer of cells 
may be especially useful in the HSCT setting, where non-specific T cells can cause 
GvHD. Despite the high specificity of tetramer complexes, the possibility of 
crossreactivity of cells remains since redundancy is an intrinsic property of TCR 
recognition (Mason, 1998). Whereas occurrence of cross-reactive CMV specific CDS^ 
T cells was suggested in recipienf/donor^ HSCT pairs previously (Cwynarski et a l, 
2001, Gandhi et a l, 2003a), this study presents, for the first time, a recipient^/donor' 
HSCT case where development of cross-reactive CMV specific CD8^ T cells is 
suspected (patient 7; refer to section 3-2.1.3, page 182).
However, this phenomenon is thought to be a rare event and availability of GMP 
grade tetramer sorted CMV specific CD8^ T cells may help to provide therapy for many 
patients if adoptive therapy trials can confirm the protective capacity of these cells in 
vivo. The knowledge of protective levels of CMV peptide specific CD8^ T cells 
restricted by different HLA alleles is important to enable monitoring of the 
effectiveness of treatment modalities in patients who are likely to express a variety of 
HLA tissue types. The quantity of cells that were shown to inversely correlate with the 
ability to detect CMV reactivation in patients in this study could be used as a marker for 
monitoring patients’ immune status towards CMV even if these cells are not protective 
per se.
Results presented in Chapter 3 clearly show that CMV specific CD8^ T cell 
numbers only inversely correlated with the ability to detect CMV reactivation in 
patients that recovered at least 160 CD4^ T cells/pl blood. CD8^ T cells in any given 
individual can target at least 6 major HLA alleles, which can potentially bind many 
different CMV derived peptides. Therefore measurements using a limited panel of 
tetramers are only informative of protective levels if they reveal responses to the target 
specificity analysed. This explains recently published results demonstrating that 
monitoring CMV specific CD8^ T cell using a single tetramer (HLA-A2/pp65) cannot 
predict CMV reactivation (Morita-Hoshi et a l, 2008). In my opinion these findings
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should not be interpreted as a lack of protective capacity of CMV specific CD8^ T cell. 
Results from this and other studies show that, provided that CD8^ T cells targeting a 
specific CMV epitope can be measured in the presence of CD4^ T cells in patients, their 
numbers inversely correlate with the ability to detect CMV reactivation. Therefore the 
application of a wide range of tetramer reagents should allow for determination of a 
subgroup of patients who could be spared antiviral treatment (and its associated 
toxicity). Also adoptive therapy may help to prevent the development of CMV disease 
in the remaining patients with relevant HLA types.
The high specificity of HLA/peptide tetramers constitutes great advantages to 
their use but also limits their application to individuals possessing the relevant HLA 
molecules. This may be overcome to some extent by the selection of peptides presented 
by a variety of HLA alleles that are common in major ethnic populations. Previous 
studies suggested that 90 % coverage of some ethnic groups might be attainable with as 
few as eleven CD8^ T cell epitopes (Longmate et a l, 2001). Adoptive transfer of CD8^ 
T cells against CMV peptides presented by the common HLA-A*0101, HLA-A*0201, 
HLA-A*2402 and also HLA-B*3501 may enable therapy of more than three quarters of 
European Caucasoids and many Asians (compare section 1-11.1).
Many new CMV epitopes have been discovered during the last years (Elkington 
et a l,  2003, Burrows et a l, 2007, Khan et a l, 2007). This information could be used to 
widen the application of adoptive therapy to more patients of various other ethnic 
groups. Findings of an increasing number of CMV epitopes that are targeted during the 
naturally occurring T cell response to CMV raise the question of how diverse the total T 
cell response to CMV might be and how immunogenic each of the epitope specific T 
cell responses within that total T cell response might be. If adoptive therapy is to 
efficiently protect immunocompromised patients, these questions need to be addressed.
CMV specific CD8^ T cells with high T cell receptor diversity may counter 
immune escape mechanisms and contribute only minimally to CMV associated 
immunosenescence, thus providing an advantage over CMV specific CD8^ T cells with 
less T cell receptor diversity. The clonality of T cells may therefore aid to choose the T 
cells that are most likely to efficiently protect and benefit patients from amongst T cells 
targeting all of the known CMV epitopes.
Findings presented in Chapter 4 demonstrate significant differences between the 
diversities of TCRs used by the different CMV specific CD8^ T cells isolated from 
HSCT patients. This study is the first to describe TCR diversity of CD8^ T cells
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targeting a CMV pp50 epitope. Interindividual heterogeneity was evident but overall it 
was found that CD8^ T cells targeting HLA-Al/pp50 used significantly more diverse 
TCRs than CD8^ T cells targeting different CMV pp65 epitopes presented by HLA-Al, 
HLA-A2, HLA-A24 or HLA-B35.
The CMV pp50 protein has not been studied extensively as a target for cytotoxic 
T cells previously. Since findings presented here demonstrate an exceptionally high 
TCR diversity of T cells targeting one of the epitopes of the CMV pp50 protein, 
therapeutic use of those cells may decrease the likelihood of CMV immune escape in 
patients. Due to their high diversity of T cell receptors, CD8^ T cells targeting this 
epitope may also have less impact on the drive of immunosenescence than CMV 
specific CD8^ T cells with more restricted TCR repertoires. The CMV pp50 protein 
therefore represents an interesting antigen to be investigated in future studies to 
establish whether other epitopes derived from this protein may also elicit T cell 
responses with T cell receptors that are more diverse than those found in CMV pp65 
specific CD8^ T cells.
CMV specific CD8^ T cells were long thought to target mainly the CMV pp65 
protein, which was thought to be related to the downregulation of class 1 HLA as one of 
the immune escape strategies of CMV that prevents the presentation of proteins, which 
are not introduced during viral penetration (before the onset of expression of viral 
immune escape genes) like pp65. More recent reports, however, demonstrate that CD8^
T cell responses to CMV often contain multiple antigen reactivities, which are not 
constrained to pp65 (Elkington et a l,  2003, Sylwester et a l,  2005). This can be 
explained by CD8^ T cells being primarily induced by cross priming (Tabi et a l, 2001). 
A recent study by Sylwester and colleagues demonstrated that 33 different open reading 
frames (ORE) from CMV were recognised by CD8^ T cells from at least four out of a 
total of 33 CMV seropositive individuals (Sylwester et a l,  2005). In that study CD8^ T 
cells recognised a median of 8 ORE with considerable interindividual heterogeneity 
(range 1 to 39). Given the vast number of CD8^ T cell targets available and 
interindividual heterogeneity of T cell responses observed, it remains to be seen whether 
adoptive therapy may use T cells generated in a non-epitope specific manner in the 
future.
The highly selective nature of tetramer based cell selection makes it useful in the 
HSCT setting since it is likely associated with a low risk of GvHD development. 
Alternative cell selection methods, such as cytokine capture, however, provide the
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advantage of isolating CD4^ T cells along with CD8^ T cells and were demonstrated to 
be feasible and effective in a clinical environment (Mackinnon et a l, 2007). This study 
suggests that the presence of at least 160 CD4^ T cells/pl blood is necessary for 
efficient in vivo function of CMV specific CD8^ T cells. Therefore therapeutic trials 
using a mix of T cell specificities comprising CD4^ and CD8^ T cells targeting CMV or 
even a mix of CMV and other viruses may be preferred in the immediate future before a 
wider range of clinical grade tetramers becomes available. Consistent with that recent 
studies moved on to assess cytotoxic T cell responses against multiple viral infections 
simultaneously using ELI Spot based epitope matrices rather than tetramer based 
methods (Bihl et a l,  2005). In a recent clinical trial infusing CD8^ T cells that were 
generated against CMV, Epstein-Barr virus (EBV) and adenovirus into 14 stem cell 
recipients demonstrated recovery of immunity to CMV and EBV in all patients, and to 
adenovirus in patients with evident adenovirus infection prior to CD8^ T cell infusion 
(Leen et a l, 2006). Future studies may include other viruses that cause complications 
post HSCT including Human Herpes Virus (HHV) 6 and 7.
Despite these developments tetramer staining remains a valuable tool for highly 
specific selection and thereby therapeutic use of antigen specific T cells and for 
monitoring of those cells ex vivo. Cocktails containing a mixture of different tetramers 
should be clinically useful for the detection of antigen specific T cells. This study 
showed that they are also useful for clonal and phenotypic characterisation of selected 
cells that may aid the advancement of T cell immunotherapy. Adoptive therapy with 
cell populations selected with tetramers directly ex vivo avoids prolonged periods of 
expansion in vitro and the use of live viral antigen that may not be suitable for clinical 
applications. In vivo expansion and clinical efficiency of cells transferred in low 
numbers (median cell dosage: 8.6x10^/kg) after tetramer guided selection was 
demonstrated successfully (Cobbold et a l , 2005) and may confer an advantage over less 
specific approaches.
In the long run studies will need to address the question of how immunogenic 
CD4^ and CD8^ T cells targeting different CMV epitopes may be, to enable the 
development of a therapeutic approach comprising the epitope specific T cell 
populations that may provide maximal clinical benefit for patients. Recent advances in 
class II tetramer production comprising 16 different human HLA class II allotypes 
(Vollers and Stem, 2008) may enable tetramer guided selection of CD4^ as well CD8^ T 
cells for adoptive therapy of patients in the future.
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An important role for CD4^ T cells regarding their helper function for CD8 
cells was demonstrated by many studies. Interestingly, cytotoxic subsets of CMV 
specific CD4^ T cells that can lyse targets infected with CMV glycoprotein B (that 
accumulates in endosomes during host cell infection with CMV) were recently 
described (Hegde et a l, 2005). These cells may therefore have an important role in 
eliminating infected antigen presenting cells that express HLA class II. Furthermore a 
very recent report demonstrates high frequencies and a highly restricted TCR usage of 
these cells, which is unprecedented for CD4^ T cells, along with phenotypic and 
functional properties similar to CMV specific CD8^ T cells (Crompton et a l, 2008). 
This suggests that cytotoxic subsets of CD4^ T cells might exert functions similar to 
those of CD8^ T cells including the drive of immunosenescence in infected individuals. 
This awaits further studies to establish whether cytotoxic CD4^ T cell subsets should be 
included in antiviral therapeutic strategies.
Patients receiving HSCT grafts from CMV seronegative donors would not be 
able to benefit from donor derived adoptive cell therapy. In these cases, vaccination of 
donors may be one way to make this treatment option available to a majority of patients.
In summary, findings from this study provide a deeper understanding of CMV 
specific CD8^ T cells with previously less well studied target specificities in HSCT 
patients. Numbers of these cells that inversely correlated with the ability to detect CMV 
reactivation were shown for the first time. A significant difference in TCR diversity 
between the cells of different specificity was presented. The presence of most of these 
CMV specific CD8^ T cells in a majority of patients underlines their clinical relevance. 
Thus the findings presented here may further the prospects of the development of new 
prophylactic and therapeutic anti-CMV treatments in the future.
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CHAPTER 6 APPENDIX
6-1 Appendix for section 2-11.1
pET-3a-d V e c to rs
pET 3a DNA 
pET 3h DNA 
pET-3c DNA 
pET-3d DNA
69418-3
69419-3
69420-3
69421-3
TB026 12/98
The pET-3a-d vector* cart)' an N terminal T7*Tag* sequence and Buitài I cloning site. These 
vectors are i»w precursors to many pET family vectors; the pET-23a-<K-*-) series corresponds to 
pET-3a-d but incorporâtes several additional features. Unique sites are shown on the circle map 
Note that the sequence is numbered by the pBR322 convention, so the T7 expression region is 
reversed on the circular map. The cloning/exptessioa region of the coding strand transcribed by 
T7 RNA polymerase is shown below.
p C T - S i  I
T7 promoter 613-631
T7 iranscnption start 614
T7»Tag coding sequence 519-551 
T7 temunaior 404-450
pBR322 origin 2814
Na coding sequence 3575-4432
The maps for pET 3b. pET 3c and pET 3d 
are tfte same as pET 3a (show n) with the 
following exceptions pET 3b is a 4639bp 
plasmid, subtract I bp from each she beyond 
BamH I at 510. pET-3c is a 4638bp plasmid, 
subtract 2bp from each site beyond BaniH 1 
at 510. pET 3d is a 463Tbp plasmid; the 
0amH I d ie  is in the same reading frame as 
in pET-3c. An ACl-d I site is substituted for 
the iVde I site With a net 1 bp deletion at 
position 530 of pET-3c. A* a result. Nco 1 
cuts pET 3d at 346. For the rest of the sites, 
subtract 3bp from each she beyond position 
551 in pET-3a. Sde I tloes not cut pET-3d.
Sea 1(4125) 
Pvu K401S)
Psi 10690)
EamllOS
MgiE IK3338)
AKvN 10166)
BpulIOZ 1(456)
BamH 1(610)
EcoR 1(4630 
Apoh4638) 
e ta  1(24)
Aat 11(4667) 
Ssp 1(4449)
Ndeksso) 
Xba 1(566) 
Bgl U(646) 
SgrA 1(667)
Sph 1(643)
EcoN  1(903)
Sal 1(926)
PshA 1(893)
pET-3a
|4640bp) Eag 1(1216) 
Nm 1(1251)
ApaB K1329) 
BspM 1(1331)
BapLUl 1 1(2752)
AD 111(2752)
Sap 1(2636)
B*t1107 1(2823)
BsaA 1(2504)
T t l l l l  1(2467)
BsmB 1(2393) 
Pvu 11(2343)
Bam 1(1636) 
Ava 1(1702) 
Mac 1(1723) 
BpulO 1(1666)
BscO 1(1812)
T7 premew pm w  # 6 9 3 ^
V«.  ____ ____
*S iT C T C G 4 1 C C C 8 C S *4 *T T * ir* (S 4 C T C » C T » T *G S S 4 (U C C S C l*C S 6 T T tC C C T C T *G ***T 4 *T T T T 6 T T t* *C T ^ T M illc a A W
17-TSa_________ p£l^3» Sunny RoulKBI
T S IA C S rS T G :.
N .  I S I  o S « r S *  t  T lw O I » « 1  y S  l«a m " * t Q  I y S r q e  I y 5 * r G  I y C y s t  n d
SIK*T6*C16CrS84C*6tl**TBGeTCGt6G4TCC06CT6C1ASCAS*GtCCS4**G6A*GCT6*GTTBGCTeCT6CC*C^^MGCXA'IA*CTSGC6T*X
p E f - 3 d
NboI
TACCATCCCTA6C
I W t A l o S . r
r C 1 - 3 b  GBTCGeSAICCECC'SCTAACAAAGCCCSAAAGGAAGCTEACiraSCTCCTfiCCACtaCTSASCAATAACtAGCATAt
C I y A r ^ s p e  r  eA I aA  I s A s e l  V SA laA r gL ySG  '  uA la C  I u L su A  I oA '  oA I oT S r  AI oC  I uC  1 s C n d
p tT - 3 e  d  CGTCGeATCCCSCTGCTAACAAACCCCCAAAGGAAGCTGACnCBCTCCrCCCACCGCIEAECAATAACTSCCATtA
Gl v t r o l  I s A r o l . i A  B u T S rtv » F r? g lu A ra L v lL < > .ji» y 1 rm .» u ' p u P r o S f o L .u S s r A .n A s s tn d
T 7
CCCCITGGGGCCTtTAAAtGGGTCTTGACCGGTTTTTTG
pET-3a-d cloning/exprtssiOR region
Figure 6-1 Map of the original pET3d vector
This figure is an am endm ent o f  Figure 2 -1 6 . It sh ow s the map o f  the original pET3d vector  
(N ovagen ) used for c lon in g  o f  H L A -A 24  (adopted from  
http ://w w w .m erck biosciences.co .uk /P rod u cts).
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C C T C C A C C C T C T C C C T T A T C C C A C T C C T C C A T T A C C A A C C A C C C C A C T A C T A C C T T C A C C C C C T T C A C C A C C C C C C C C C C A A C C A A T C C T C C A T C C A A C C A
C A T C C C C C C C A A C A C T C C C C C C C C C A C C C C C C C T C C C A C C A T A C C C A C C C C C A A A C A A C C C C T C A T C A C C C C C A A C T C C C C A C C C C C A T C T T C C C C A T C C
C T C A T C T C C C C C A T A T A C C C C C C A G C A A C C C C A C C T C T C C C C C C C C T C A T C C C C C C C A C C A T C C C T C C C C C C T A C A C C A T C C A C A T C T C C A T C C C C C C A A
T 7  p r o m o te r  p r im e r  ip r im e r  1 6 1 H L A -A 2 4 b s p 2
A T T A A T A C C A C T C A C T A T A C C C A G A C C A C A A C C C T T T C C C T C T A C A A A T A A T T T T C T T T A A C T T T A A C A A C C A C A T A T A C C A T C C C C T C T C A C T C C A T C A  
- A 2 4 b s p 2
G G T A T T T C T C C A C A T C C G T G T C C C G G C C C G G C C G C G G G G A G C C C C G C T T C A T C G C C G T G G G C T A C G T G G A C G A C A C G C A G T T C G T G C G G T T C G A C A G C G A  
A 2 4 b * p 2
C G C C G C G A G C C A G A G C A T G C A G C C G C G G G C G C C G T G G A T A G A G C A G G A G G G G C C G G A G T A T T G G G A C C A G G A G A C A G G G A A A G T G A A G G C C C A C T C A C A G
,H L A -A 2 4 b sp 2
A C T G A C C G A G A G A A C C T G C G G A T C G C G C T C C G C T A C T A C A A C C A G A G C G A G G C C G G T T C T C A C A C C C T C C A G A T G A T G T T T G G C T G C G A C G T G G G G T C G G
H L A -A 2 4 b tp 2 I n t e r n a l  f o r w a r d  p r im e r  I n te rn a l  r e v e r s e  p r im e r .
A C G G G C G C T T C C T C C G C G G G T A C C A C C A G T A C G C C T A C G A C C G C A A G G A T T A C A T C G C C C T G A A A G A G G A C C T G C G C T C T T G G A C C G C G G C G A C A T G G C G
,H L A -A 2 4 b sp 2
G C T C A G A T C A C C A A G C G C A A G T G G G G A G G C G G C C C A T G T G G C G G A G C A G C A G A G A G C C T A C C T G G A G G G C A C G T G C G T G G A C G G G C T C C G C A G A T A C C T G  
,H L A -A 2 4 b sp 2
G A G A A C G G G A A G G A G A C G C T G C A G C G C A C G G A C C C C C C C A A G A C A C A T A T G A C C C A C C A C C C C A T C T C T G A C C A T G A G G C C A C T C T G A G A T G C T C G G C C C  
k A 2 4 b s p 2
T G G G C T T C T A C C C T G C G G A G A T C A C A C T G A C C T G G C A C C G G G A T G G G G A G G A C C A G A C C C A G G A C A C G G A G C T T G T G G A G A C C A G G C C T G C A G G G G A T G G  
k -A 2 4 b s p 2
A A C C T T C C A G A A G T G G G C A G C T G T G G T G G T A C C T T C T G G A G A G G A G C A G A G A T A C A C C T C C C A T G T G C A G C A T G A G G G T C T G C C C A A G C C C C T C A C C C T G
,H L A -A 2 4 b sp 2
A G A T G G G A T C C C G G C T C C G G C T C C C T G C A T C A T A T T T T T G A A G C A C A G A A A A T T G A A T G G C G C C A T C C T T A A A G A T C C G G C T G C T A A C A A A G C C C G A A A G
p r im e r  1 6 2 ,
G A A G C T G A G T T G G C T G C T G C C A C C G C T G A G C A A T A A C T A G C A T A A C C C C T T G G G G C C T C T A A A C G G G T C T T G A G G G G T T T T T T G C T G A A A G G A G G A A C T A
T A T C C G G A T A T C C A C A G G A C G G G T G T G G T C G C C A T G A T C G C G T A G T C G A T A G T G G C T C C A A G T A G C C A A G C G A G C A G G A C T G G G C G G C G G C C A A A G C G G T
C G G A C A G T G C T C C G A G A A C G G G T G C G C A T A C A A A T T G C A T C A A C G C A T A T A G C G C T A G C A G C A C G C C A T A G T G A C T G G C G A T G C T G T C G G A A T G G A C G A T
A T C C C G C A A G A G G C C C G G C A G T A C C G G C A T A A C C A A G C C T A T G C C T A C A G C A T C C A G G G T G A C G G T G C C G A G G A T G A C G A T G A G C G C A T T G T T A G A T T T C
A T A C A C G G T G C C T G A C T G C G T T A G C A A T T T A A C T G T G A T A A A C T A C C G C A T T A A A G C T T A T C G A T G A T A A G C T G T C A A A C A T G A G A A T T C T T G A A G A C G A
A A G G G C C T C G T G A T A C G C C T A T T T T T A T A G G T T A A T G T C A T G A T A A T A A T G G T T T C T T A G A C G T C A G G T G G C A C T T T T C G G G G A A A T C T G C G C G G A A C C C
C T A T T T G T T T A T T T T T C T A A A T A C A T T C A A A T A T G T A T C C G C T C A T G A G A C A A T A A C C C T G A T A A A T C C T T C A A T A A T A T T G A A A A A G G A A G A G T A T G A G
r C G C C C T T A T T C C C T T T T T T C C G G C A T T T T G C C T T C C T G T T T T T G C T C A C C C A G A A A C G C T G G T G A A A G T A A A A G A T G C T G A A
G A T C A G T T G G G T G C A C G A G T G G G T T A C A T C G A A C T G G A T C T C A A C A G C G G T A A G A T C C T T G A G A G T T T T C G C C C C G A A G A A C G T T T T C C A A T G A T G A G C A
C T T T T A A A G T T C T G C T A T G T G G C G C G G T A T T A T C C C G T G T T G A C G C C G G G C A A G A G C A A C T C G G T C G C C G C A T A C A C T A T T C T C A G A A T G A C T T G G T T G A
Continued
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C T A C T C A C C A C T C A C A G A A A A C C A T C T T A C C C A T C C C A T C A C A C T A A C A C A A T T A T C C A C T C C T C C C A T A A C C A T C A C T C A T A A C A C T C C C C C C A A C T T A
C T T C T C A C A A C C A T C C C A C C A C C C A A C C A C C T A A C C C C T T T T T T C C A C A A C A T C C C C C A T C A T C T A A C T C C C C T T C A T C C T T C C C A A C C C C A C C T C A A T C
A A C C C A T A C C A A A C C A C C A C C C T C A C A C C A C C A T C C C T C C A C C A A T C C C
Ù
C C A A C A A T T A A T A C A C T C C A T C C A C C C C C A T A A A C T T C C A C C A C C A C T T C T C C C C T C C C C C C T T C C C C C T C C C T C C T T T A T T C C T C A T A A A T C T C C A C C C
L
C C T C A C C C T C C C T C T C C C C C T A T C A T T C C A C C A C T C C C C C C A C A T C C T A A C C C C T C C C C T A T C C T A C T T A T C T A C A CIX!
A T C A A C C A A A T A C A C A C A T C C C T C A C A T A C C T C C C T C A C T C A T T A A C C A T T C C T A A C T C T C A C A C C A A C T T T A C T C A T A T A T A C T T T A C A T T C A T T T A A A
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HLA-A24^a/?2 translated:
C } S H S M R Y F S r S V S R P C j R C iE P R F I A V G Y V D D T Q F V R F D S D A A S Q R M F P R A P W l C Q E G P E Y W D E E T G K V K A I I S Q T D R E N I  RI 
A F R Y Y N Q S E A G S H T L O M M F X iC D V G S I X î R F L R G Y H O Y A Y D C j K D Y lA I  K E D l  R S \ V T A A I ) M A A G I T R R K W E A A H V A E ( X > R  
A Y L E G T C V I X iF R R Y L E N G K E T L Q R T D P P K T f lM T H H P I S D H E A T L R C W A L G F X 'P A E I T L T W Q R C K Î E I X > T Q D T E L V E T R P A G  
I X l T F g K V V A A V V V P S C iE E g R Y T C H V Q U E C iL P K P l .T L R W D P t iS t i S I .U H I F E A Q K I E W R I I R
Figure 6-2 Sequence of the HLA-A24-pET3d-bsp2 vector and its translated heavy 
chain product
This figure is an am endm ent to Figure 2 -16 . The upper part illustrates the n ucleotid e sequ en ce  
o f  the vector pET3d, after the m odified  extracellular part o f  H L A -A 24 and the b iotinylation  
target bsp2 w ere cloned  into it (Ap: am picillin  resistance gen e). The low er part sh ow s the 
translated seq u en ce o f  H L A -A 24b sp 2 , w hich  is estim ated to have a m olecular w eigh t o f  
34 kDa u sing  the on lin e tool Protein C alculator Version 3.3 availab le at 
http://scripps.edu/~cdputnam /protcalc.htm l. This figure was created u sing CLC D N A  
W orkbench softw are.
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Figure 6-3 Variation of illustration: IFNy release of cells in response to serial 
dilutions of CMV peptide pp65 (123-131)
This figure is a variation o f  Figure 3 -3 . It sh ow s IFNy release o f  PBM C in responses to 1:2 
dilutions o f  C M V  pp65 (1 2 3 -1 3 1 ) peptide that was m easured in triplicate in tw o sam ples from  
patient 7 (so lid  lines, A; sam ple taken at day 77 , B: sam ple taken at day 818 post 
transplantation) and five sam ples from other patients (dashed lines, C: patient 30b at 763 days 
post transplantation, D: patient 31 at 700  days post transplantation, E: patient 6 at 86 days post 
transplantation, F: patient 9 at 367  days post transplantation and G: patient 32 at 483 days post 
transplantation). In com parison to Figure 3-3 , this illustration sh ow s the original m edian SFU  
values above unstim ulated controls from triplicate m easurem ents with errors represented as the 
difference to 25 and 75 percentiles.
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6-3 Appendix for section S-2.2.3
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Figure 6-4 Extended statistical analysis of HLA-A24/pp65 (341-349) specific CD8 
T cell responses (may not be biologically meaningful)
This figure is a variation o f  Figure 3-11 on page 204  and illustrates the ab solu te num bers o f  
tetramer binding ce lls /p l o f  peripheral b lood in the reactivating group o f  patients m easured  
post transplantation until the last observed C M V  reactivation ( ♦  A 24/p p65 during C M V ) 
versu s  absolute numbers o f  tetramer binding ce lls  m easured from the peak o f  the last CM V  
reactivation onwards in these patients (▲  A 24/pp65 post C M V ) in com parison  to absolute  
numbers o f  tetramer b inding ce lls  in patients w ho did not reactivate C M V  (▼  A 24/p p 65  w /o  
C M V ). In contrast to Figure 3 -11 , it includes all patients o f  the study group excep t patient 20  
(C M V -/+  w ithout primary in fection ), w hich m ay not be b io log ica lly  m eaningful. Data groups 
were statistically analysed using a tw o-tailed  M ann-W hitney U test w ith the m edians and p 
values (p< 0.02  regarded sign ificant) indicated in the graph.
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Figure 6-5 Extended statistical analysis of HLA-Al/CMV specific CD8  ^T cell 
responses (may not be biologically meaningful)
This figure is a variation o f  Figure 3 -19  on page 222 and illustrates the absolute numbers o f  
tetramer binding ce lls /p l o f  peripheral b lood  in the reactivating group o f  patients measured  
post transplantation until the last observed C M V  reactivation ( ♦  during C M V ) versu s  absolute  
numbers o f  tetramer binding ce lls  m easured from the peak o f  the last C M V  reactivation  
onwards in these patients ( A  post C M V ) in com parison to absolute num bers o f  tetramer 
binding ce lls  in patients w ho did not reactivate C M V  (▼  w /o  C M V ). In contrast to  Figure 
3-19 , all patients o f  this study group, except patients 27  and 28 (C M V -/+  w ithout primary 
in fection) were included in this analysis, w hich m ay not be b io log ica lly  m eaningful. The 
com parison is extended to H L A -A l/p p 5 0  and H L A -A l/p p 6 5  sp ecific  CDS T cell responses. 
Data groups w ere statistically analysed u sing a tw o-tailed  M ann-W hitney U test with the 
m edians and p values indicated in the graph.
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Figure 6-6 Narrowed statistical analysis of HLA-Al/pp50 specific CD8 T cell 
responses
This figure is a variation o f  Figure 3 -19  on page 222  and illustrates the absolute num bers o f  
tetramer binding ce lls /p l o f  peripheral b lood in the reactivating group o f  patients measured  
post transplantation until the last observed  C M V  reactivation ( ♦  during C M V ) versu s  absolute 
numbers o f  tetramer binding ce lls  m easured from the peak o f  the last C M V  reactivation  
onwards in these patients ( A  post C M V ) in com parison to absolute num bers o f  tetramer 
binding ce lls  in patients w ho did not reactivate C M V  (▼  w /o  C M V ). In contrast to Figure 
3-19 , patients 3 and 25 , w ho dem onstrated on go in g  C M V  reactivations and never ach ieved  
m easurable levels o f  H L A -A I/p p 50  sp ecific  T ce lls , were excluded  from  this analysis. Data 
groups were statistically analysed using a tw o-tailed  M ann-W hitney U test w ith the m edians 
and p values indicated in the graph.
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Figure 6-7 Extended statistical analysis of HLA-A2/pp65 specific CDS T cell 
responses (may not be biologically meaningful)
This figure is a variation o f  Figure 3-25 on page 235  and illustrates the ab solu te num bers o f  
tetramer binding ce lls /p l o f  peripheral b lood in the reactivating group o f  patients m easured  
post transplantation until the last observed C M V  reactivation ( ♦  during C M V ) versu s  absolute  
num bers o f  tetramer b inding ce lls  m easured from the peak o f  the last C M V  reactivation  
onwards in these patients (▲  post C M V ) in com parison to absolute num bers o f  tetramer 
binding ce lls  in patients w ho did not reactivate CM V  ( T  w /o  C M V ). In contrast to  Figure 
3-25 , all patients o f  the study group (including patients 1, 2, and 26  suspected  to  be protected  
by another response and patients 24  and 29 with low  CD4^ T ce lls )  w ere included in this 
analysis, which may not be b io log ica lly  m eaningful. Data groups w ere statistica lly  analysed  
using a tw o-tailed  M ann-W hitney U test w ith the m edians and p values indicated in the graph.
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Figure 6-8 Narrowed statistical analysis of HLA-A2/pp65 specific CD8  ^T cell 
responses
This figure is a variation o f  Figure 3-25  on page 235  and illustrates the absolute numbers o f  
tetramer binding cells/|al o f  peripheral b lood  in the reactivating group o f  patients m easured  
post transplantation until the last observed  C M V  reactivation ( ♦  during C M V ) versu s  absolute  
numbers o f  tetramer binding ce lls  m easured from the peak o f  the last C M V  reactivation  
onwards in these patients ( A  post C M V ) in com parison to absolute num bers o f  tetramer 
binding ce lls  in patients w ho did not reactivate C M V  (▼  w /o  C M V ). In contrast to Figure 
3-25 , patient 30, w ho dem onstrated on go in g  C M V  reactivations and never ach ieved  
m easurable levels o f  H L A -A 2/p p65 sp ec ific  T ce lls , was excluded from this analysis. Data 
groups w ere statistically analysed  using a tw o-tailed  M ann-W hitney U test w ith  the m edians  
and p values indicated in the graph.
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